

THRU ONLINE FILING

August 5, 2017

BSE Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sirs,


Sub: Annual Report – 2016-17

We are enclosing herewith copy of our Annual Report for the financial year ended 31st March, 2017 for your perusal and record.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish P. Kamath
Corporate Counsel & Company Secretary

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Ipca Laboratories Ltd.
www.ipca.com



Ten Years' Highlights


(₹ Crores)

	2007-08	2008-09	2009-10	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17
Total Income	1059.16	1275.57	1565.50	1889.61	2342.98	2797.08	3256.25	3120.40	2870.73	3178.87
Domestic Income	522.90	595.18	759.42	864.43	941.01	1081.00	1190.23	1367.54	1440.88	1617.13
Export Income	536.26	680.39	806.08	1025.18	1401.97	1716.08	2066.02	1752.86	1429.85	1561.74
Earning before Interest, Depreciation & Tax	#186.44	#270.01	#344.65	#384.24	#526.40	#639.95	#826.66	#556.27	#341.81	#435.20
Profit before Tax	176.87	124.65	271.73	343.70	368.94	461.37	629.09	357.73	111.45	258.20
Net Profit after Tax	141.12	91.22	209.19	255.37	280.17	331.39	477.37	256.11	92.52	188.29
Share Capital	25.09	24.99	25.04	25.14	25.23	25.24	25.24	25.24	25.24	25.24
Reserves & Surplus	582.57	613.52	849.82	1028.72	1237.04	1544.61	1956.37	2196.57	2257.81	2449.88
Net Worth	607.66	638.51	874.86	1053.86	1262.27	1569.85	1981.61	2221.81	2283.05	2475.12
Net Block	541.04	579.72	674.75	792.57	1007.33	1204.50	1471.01	2019.91	2105.51	2040.84
Dividend (%)	80%	110%	140%	160%	160%	200%	250%	50%	-	50%
Earnings per share (₹)	56.38	36.33	@ 16.75	20.36	22.23	26.27	37.83	20.29	7.33	14.92
Book Value per share (₹)	242.19	255.51	@ 69.86	83.84	100.06	124.39	157.02	176.05	180.91	196.12

Before Foreign Exchange Gain /Loss

@ Post Sub-division of each equity share of ₹ 10/- into 5 equity shares of ₹ 2/- each

Contents	Page No.
Management	2
Contacts	3
Notice	4
Directors' Report	10
Report on Corporate Governance	19
Secretarial Audit Report	57
Independent Auditors' Report	59
Standalone Accounts	64
Auditors' Report on Consolidated Accounts	112
Consolidated Accounts	116
Details of Subsidiaries	163
Proxy Form / Attendance Slip	167



MANAGEMENT

Board of Directors	
Premchand Godha (DIN 00012691)	Chairman & Managing Director
Ajit Kumar Jain (DIN 00012657)	Joint Managing Director
Pranay Godha (DIN 00016525)	Executive Director
Prashant Godha (DIN 00012759)	Executive Director
Babulal Jain (DIN 00016573)	Independent Director
Anand T. Kusre (DIN 00818477)	Independent Director
Dev Parkash Yadava (DIN 00778976)	Independent Director
Dr. Ramakanta Panda (DIN 01161791)	Independent Director
Dr. (Mrs.) Manisha Premnath (DIN 05280048)	Independent Director
Corporate Management team	
Premchand Godha	Chairman & Managing Director
Ajit Kumar Jain	Joint Managing Director
Pranay Godha	Executive Director
Prashant Godha	Executive Director
Dr. Ashok Kumar	President - R&D (Chemicals)
Dr. Anil Pareek	President - Medical Affairs & Clinical Research
Sunil Ghai	President - Domestic Marketing
Harish P. Kamath	Corporate Counsel & Company Secretary
E. J. Babu	President - API Exports
A. P. Muralikrishnan Sarma	President - Generics
Sanjay Sinha	President - Operations (Formulations)
Pabitra Kumar Bhattacharya	President - Operations (API)
Dr. Sanjay Kapadia	President - Corporate Quality Assurance
Dr. Goutam Muhuri	President - R&D (Formulations)
Company Secretary	
Harish P. Kamath (ACS 6792)	
Auditors	
Natvarlal Vepari & Co., Chartered Accountants (Firm Regn. No. 106971W)	
Cost Auditors	
ABK & Associates, Cost Accountants (Firm Regn. No. 000036)	
Secretarial Auditors	
Parikh & Associates, Company Secretaries	

Registered Office

48, Kandivli Industrial Estate
Kandivli (West)
Mumbai 400 067
India
T: +91 22 6647 4444
F: +91 22 2868 6613

Research & Development Centre

48, 58-DD, 123 AB, 125 & 126 (Amalgamated)
Kandivli Industrial Estate
Kandivli (West)
Mumbai 400 067
India
T: +91 22 6210 5000
F: +91 22 6210 5439

Registrars & Share Transfer Agents

Link Intime India Pvt. Ltd.
C-101, 247 Park
L.B.S. Marg, Vikhroli (West)
Mumbai 400 083
T: +91 22 4918 6000
F: +91 22 4918 6060

Debenture Trustees

IDBI Trusteeship Services Ltd.
Asian Building, Ground Floor
17, R. Kamani Marg, Ballard Estate
Mumbai 400 001
T: +91 22 4080 7000
F: +91 22 6631 1776
E: itsl@idbitrustee.com

Bankers

Barclays Bank PLC
BNP Paribas
Citibank N.A.
Corporation Bank
DBS Bank Ltd.
HDFC Bank Ltd.
HSBC Ltd.
ICICI Bank Ltd.
Kotak Mahindra Bank
Standard Chartered Bank
United Overseas Bank Ltd.
Yes Bank Ltd.

Works

Madhya Pradesh

P.O. Sejavta 457 002, Ratlam
T: +91 7412 278000 | F: +91 7412 279083

89 A-B / 90 / 91, Industrial Estate, Pologround
Indore 452 003
T: +91 731 2421172 | F: +91 731 2422082

1, Pharma Zone
SEZ Indore, Pithampur 454 775
T: +91 7292 667777 | F: +91 7292 667020

470, 471 & 481 Sector III, Industrial Area,
Pithampur 454 775
T: +91 07292 256167

Gujarat

Plot No. 69 to 72-B, Sector II, KASEZ
Gandhidham 370 230
T: +91 2836 252385 | F: +91 2836 252313

4722, GIDC Industrial Estate
Ankleshwar 393 002
T: +91 2646 220594 | F: +91 2646 250435

23-24, GIDC Industrial Estate
Nandesari 391 340
T: +91 265 2840795 | F: +91 265 2840868

Village Ranu (Taluka Padra) 391 445
T: +91 2662 227300

Union Territory of Dadra & Nagar Haveli

Plot No. 255/1, Village Athal
Silvassa 396 230
T: +91 260 2640301 | F: +91 260 2640303

Plot No. 65, 99 & 126, Danudyog Indl. Estate
Silvassa 396 230
T: +91 260 2640850 | F: +91 260 2640646

Maharashtra

H-4, G4 to G7, MIDC, Waluj Indl. Area (Unit I and II)
Aurangabad 431 136
T: +91 240 6611501 | F: +91 240 2564113

C 89 to C 95, MIDC Industrial Area
Mahad 402 309
T: +91 2145 232058 | F: +91 2145 232055

T-139, MIDC, Tarapur, Palghar 401 506
T: +91 02525 205273

Uttarakhand

C-6, Sara Indl. Estate, Chakrata Road
Rampur, Dehradun 248 197
T: +91 135 2699195 | F: +91 135 2699171

Sikkim

393 / 394, Melli-Jorethang Road (Unit I and II)
Gom Block, Bhariikhola, South District 737 121
Telefax: +91 3595 276372

NOTICE

NOTICE is hereby given that the 67th ANNUAL GENERAL MEETING of Ipca Laboratories Limited (CIN L24239MH1949PLC007837) will be held at Shri Bhaidas Maganlal Sabhagriha, Swami Bhaktivedanta Marg, J.V.P.D. Scheme, Vile Parle (W), Mumbai 400 056 on Friday, 4th August, 2017 at 3.30 p.m. to transact the following business:

ORDINARY BUSINESS

1. To receive, consider and adopt:
 - a) the Audited Financial Statements of the Company for the financial year ended on 31st March, 2017 together with the Reports of the Board of Directors and Auditors thereon; and
 - b) the Audited Consolidated Financial Statements of the Company for the financial year ended on 31st March, 2017 together with the Report of the Auditors thereon.
2. To declare dividend on equity shares.
3. To appoint a Director in place of Mr. Prashant Godha (DIN 00012759) who retires by rotation and being eligible, offers himself for re-appointment.
4. To appoint a Director in place of Mr. Premchand Godha (DIN 00012691) who retires by rotation and being eligible, offers himself for re-appointment.
5. To appoint Auditors and fix their remuneration and in this regard to consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 and the rules made thereunder (including any statutory modification or re-enactment thereof for the time being in force), M/s. G. M. Kapadia & Co., Chartered Accountants (Firm Registration No. 104767W) be and are hereby appointed as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the 72nd Annual General Meeting, subject to their appointment being ratified by the members at every Annual General Meeting till the 71st Annual General Meeting, at such remuneration and reimbursement of out of pocket expenses as may be determined by the Board of Directors of the Company.”

SPECIAL BUSINESS

6. To consider and, if thought fit, to pass the following Resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 148 (3) and such other applicable provisions, if any, of the Companies Act, 2013 read with rules made thereunder, M/s. ABK & Associates, Cost Accountants (Firm Registration No. 000036) who have been appointed as the Cost Auditors of the Company to conduct the audit of the cost records for the financial year 2017-18 be paid remuneration of ₹ 5,50,000/- (Rupees Five Lacs Fifty Thousand Only) plus service tax and reimbursement of traveling and other out of pocket expenses.”

NOTES

- (1) **A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of himself and a proxy need not be a member of the Company. Proxies, in order to be effective must be received at the registered office of the Company not less than 48 hours before the commencement of the meeting. A person can act as proxy on behalf of members not exceeding fifty (50) and holding in the aggregate not more than 10% of the total share capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a member holding more than 10% of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other person or shareholder. A Proxy Form is attached herewith.**

- (2) Corporate Members intending to send their authorised representative to attend the meeting are requested to send a certified true copy of the board resolution authorising their representative to attend and vote on their behalf at the meeting.
- (3) The Register of Members and Share Transfer Books of the Company will remain closed from Saturday, 29th July, 2017 to Friday, 4th August, 2017 (both days inclusive).
- (4) The dividend if declared at the meeting will be paid to those members, whose names appear in the Register of Members on Friday, 4th August, 2017 and to those beneficial owners whose names are provided by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) as at the close of business hours on Friday, 28th July, 2017.
- (5) The information required to be provided regarding the directors seeking re-appointment is furnished in the Report on Corporate Governance.
- (6) Members are requested to:
- intimate to the Company / their Depository Participant ("DP") changes, if any, in their registered address at an early date;
 - quote their Registered Folio No. and/or DP Identity and Client Identity number in their correspondence;
 - bring their copy of the Annual Report and the Attendance Slip with them at the Annual General Meeting;
 - encash the dividend warrants on their receipt as dividend remaining unclaimed for seven years is now required to be transferred to the 'Investor Education and Protection Fund' established by the Central Government under the provisions of the Companies Act, 2013. Pursuant to Section 124(5) of the Companies Act, 2013, all unclaimed dividend declared and paid upto 2nd interim dividend for the financial year 2009-10 have been transferred by the Company to the Investor Education and Protection Fund. Members who have not encashed their dividend warrants for subsequent period are requested to encash the same immediately.
 - The Ministry of Corporate Affairs (MCA) on 10th May, 2012 notified the IEPF (Uploading of information regarding unpaid and unclaimed amounts lying with companies) Rules, 2012 (IEPF Rules) which is applicable to the Company. The objective of the IEPF Rules is to help the shareholders ascertain status of the unclaimed amounts. In terms of the said IEPF Rules, the Company has uploaded the information of the unclaimed dividends in respect of the final dividend for the financial year from 2009-10 till dividend for the financial year 2014-15, on the website of the Company viz. www.ipca.com.

Pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 notified by the Ministry of Corporate Affairs effective September 7, 2016, the Company is required to transfer all shares in respect of which dividend has not been encashed by the shareholders for seven consecutive years or more in the name of Investor Education and Protection Fund (IEPF). The Company has sent the required communication to the concerned shareholders whose shares are liable to be transferred to IEPF at their latest available address with the Company under the said Rules. The Company has also published notice in this regard in the newspapers (Free Press and Navshakti) on 29th March, 2017. The Company has also uploaded the full details of such shareholders and shares due for transfer to IEPF on its website. In case the Company does not receive any communication from the concerned shareholders the Company shall, with a view to complying with the requirements set out in the Rules, transfer the shares to IEPF by the due date as per procedure stipulated in the Rules.
- (7) All documents referred in the notice will be available for inspection by the members at the Registered Office of the Company from 11.00 a.m. to 1.00 p.m. on all working days (excluding Saturday) upto the date of the Annual General Meeting and shall also be placed before the members at the said Annual General Meeting.
- (8) Statement setting out material facts under Section 102 of the Companies Act, 2013 in respect of special business is annexed hereto.

(9) Electronic copy of the Notice of the 67th Annual General Meeting of the Company inter alia indicating the process and manner of remote e-voting along with Attendance Slip and Proxy Form is being sent to all the members whose e-mail IDs are registered with the Company / Depository Participant(s) for communication purpose unless any member has requested for a hard copy of the same. For members who have not registered their email address, physical copies of the notice of the 67th Annual General Meeting of the Company, inter-alia, indicating the process and manner of remote e-voting alongwith Attendance Slip and Proxy Form is being sent in the permitted mode.

(10) Members may also note that the Notice of 67th Annual General Meeting will also be available on the Company's website www.ipca.com for their download. Even after registering for e-communication, members are entitled to receive such communication in physical form upon making a request for the same. For any communication, shareholders may also send requests to the Company's investor e-mail id investors@ipca.com.

(11) Voting through electronic means:

- I. In compliance with provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 (Amended Rules 2015) and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is pleased to provide members facility to exercise their right to vote on resolutions proposed to be considered at the 67th Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting Services. The facility of casting the votes by the members using an electronic voting system from a place other than venue of the AGM ("remote e-voting") will be provided by National Securities Depository Limited (NSDL).
- II. The facility for voting through ballot paper shall be made available at the AGM and the members attending the meeting who have not cast their vote by remote e-voting shall be able to exercise their right at the meeting through ballot paper. The shareholders who do not have access to remote e-voting or who do not wish to cast the vote electronically may request the Company for physical ballot paper for casting their vote, which will be provided by the Company upon request. Such ballot paper duly filled in may be sent to The Scrutinizer c/o Ipca Laboratories Limited, 48, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067 so as to reach the scrutinizer on or before 5.00 p.m. on 3rd August, 2017.
- III. The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
- IV. The remote e-voting period commences on Tuesday, 1st August, 2017 (9:00 am) and ends on Thursday, 3rd August, 2017 (5:00 pm). During this period members of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 28th July, 2017, may cast their vote by remote e-voting. The remote e-voting module shall be disabled by NSDL for voting thereafter. Any person who is not a Member as on the cut off date should treat this notice for information purpose only. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently.
 A Member can opt for only one mode of voting, i.e. either through e-voting or by Ballot. If a Member cast vote by both modes, then voting done through e-voting shall prevail and Ballot shall be treated as invalid.
- V. The process and manner for remote e-voting is as under:
 - A. In case a Member receives an email from NSDL [for members whose email IDs are registered with the Company/Depository Participants]:
 - (i) Open email and open PDF file viz; "Ipca Laboratories remote e-voting.pdf" with your Client ID or Folio No. as password. The said PDF file contains your user ID and password/PIN for remote e-voting. Please note that the password is an initial password.
 NOTE: Shareholders already registered with NSDL for e-voting will not receive the PDF file "remote e-voting.pdf".
 - (ii) Launch internet browser by typing the following URL: <https://www.evoting.nsdl.com/>
 - (iii) Click on Shareholder – Login
 - (iv) Put user ID and password as initial password/PIN noted in step (i) above. Click Login.

- (v) Password change menu appears. Change the password/PIN with new password of your choice with minimum 8 digits/characters or combination thereof. Note new password. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
 - (vi) Home page of remote e-voting opens. Click on remote e-Voting: Active Voting Cycles.
 - (vii) Select "EVEN" (E-Voting Event Number) of Ipca Laboratories Ltd.
 - (viii) Now you are ready for remote e-voting as Cast Vote page opens.
 - (ix) Cast your vote by selecting appropriate option and click on "Submit" and also "Confirm" when prompted.
 - (x) Upon confirmation, the message "Vote cast successfully" will be displayed.
 - (xi) Once you have voted on the resolution, you will not be allowed to modify your vote.
 - (xii) Institutional shareholders (i.e. other than individuals, HUF, NRI, etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer through e-mail to scrutinizer@ipca.com with a copy marked to evoting@nsdl.co.in.
- B. In case a Member receives physical copy of the Notice of AGM [for members whose email IDs are not registered with the Company / Depository Participants or who request physical copy of notice]:
- (i) Initial password is provided as below / at the bottom of the Attendance Slip for the AGM :

<u>EVEN (Remote E-Voting Event Number)</u>	<u>USER ID</u>	<u>PASSWORD/PIN</u>
--	----------------	---------------------
 - (ii) Please follow all steps from Sl. No. (ii) to Sl. No. (xii) above, to cast vote.
- VI. In case of any queries, you may refer the frequently asked questions (FAQs) for members and remote e-voting user manual for members available at the downloads section of www.evoting.nsdl.com or call on toll free No. 1800 222 990.
- VII. If you are already registered with NSDL for remote e-voting, then you can use your existing user ID and password/PIN for casting your vote.
- NOTE: Shareholders who forgot the User Details/Password can use "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com.
- In case Shareholders are holding shares in demat mode, USER-ID is the combination of (DPID+ClientID).
- In case Shareholders are holding shares in physical mode, USER-ID is the combination of (Even No+Folio No).
- VIII. You can also update your mobile number and e-mail ID in the user profile details of the folio which may be used for sending future communication(s).
- IX. The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date of 28th July, 2017.
- X. Any person, who acquires shares of the Company and becomes member of the Company after despatch of notice and holding shares as of the cut-off date i.e., 28th July, 2017 may obtain the login ID and password by sending a request at evoting@nsdl.co.in or Company / Registrars by mentioning their Folio No. / DP ID and Client ID No. However, if you are already registered with NSDL for remote e-voting, then you can use your existing User ID and password for casting your vote. If you forget your password, you can reset your password by using "Forgot User Details / Password" or "Physical User / Reset Password" option available on www.evoting.nsdl.com or contact NSDL at the following Toll Free No: 1800 222 990.
- XI. A person whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as voting at the AGM through ballot paper.

- XII. Mr. P. N. Parikh (Membership No. FCS327 CP1228) or failing him Ms. Jigyasa N. Ved (Membership No. FCS6488 CP6018) or failing them Mr. Mitesh Dhabliwala (Membership No. FCS8331 CP9511) of M/s. Parikh & Associates, Practising Company Secretaries have been appointed as the Scrutinizer to scrutinize the remote e-voting process (including voting at the meeting) in a fair and transparent manner.
- XIII. The Chairman shall, at the AGM, at the end of discussion on resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of ballot paper for all those members who are present at the AGM but have not cast their votes by availing the remote e-voting/physical ballot facility.
- XIV. The Scrutinizer shall after the conclusion of voting at the AGM, first count the votes cast through physical ballot facility and at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than 48 hours of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- XV. The Results declared alongwith the report of the Scrutinizer shall be displayed at the Registered Office of the Company and placed on the website of the Company www.ipca.com and on the website of NSDL immediately after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be immediately forwarded to BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE).

Registered Office:

48, Kandivli Industrial Estate,
Kandivli (West), Mumbai 400 067.
Tel : 022 – 6210 6050
E-mail: investors@ipca.com
Website: www.ipca.com
CIN: L24239MH1949PLC007837
Mumbai, 28th May, 2017

By Order of the Board

For **Ipca Laboratories Ltd**

Harish P. Kamath

Corporate Counsel & Company Secretary
ACS 6792

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

Item No. 5

M/s. Natvarlal Vepari & Co, Firm Registration No. 106971W, Chartered Accountants retire as Auditors of the Company at the conclusion of the 67th Annual General Meeting of the Company scheduled to be held on Friday, 4th August, 2017.

Pursuant to the provisions of Section 139(2) of the Companies Act, 2013 they are not eligible to be re-appointed as the Auditors of the Company.

In their place, it is proposed by the Company to appoint M/s. G. M. Kapadia & Co., Chartered Accountants (Firm Registration No. 104767W) as the Statutory Auditors of the Company for a period of 5 years till the conclusion of the Company's 72nd Annual General Meeting and the necessary resolution in this regard is proposed to be passed by the members of the Company at the ensuing Annual General Meeting.

None of the Directors and Key Managerial personnel of the Company and their relatives are concerned or interested, financially or otherwise, in the resolution set out at Item No. 5.

The Board of Directors accordingly recommend the resolution set out at Item No. 5 of the accompanying Notice for the approval of the members.

Item No. 6

The Board of Directors on the recommendation of the Audit Committee have appointed M/s ABK & Associates, Cost Accountants (Firm Registration No. 000036), as the Cost Auditors of the Company for the financial year 2017-18. A Certificate issued by the above firm regarding their eligibility for appointment as Cost Auditors will be available for inspection at the registered office of the Company during normal business hours on all working days, excluding Saturday.

As per Rule 14 of the Companies (Audit and Auditors) Rules 2014, the remuneration payable to the Cost Auditors is to be ratified by the shareholders. The Board has decided the remuneration payable to M/s. ABK & Associates as Cost Auditors as mentioned in the resolution on the recommendation of the Audit Committee. Hence this resolution is put for the consideration of the shareholders.

None of the Directors and Key Managerial personnel of the Company and their relatives are concerned or interested, financially or otherwise, in the resolution set out at Item No. 6.

The Board of Directors accordingly recommend the resolution set out at Item No. 6 of the accompanying Notice for the approval of the members.

Registered Office:

48, Kandivli Industrial Estate,
Kandivli (West), Mumbai 400 067.

Tel : 022 – 6210 6050

E-mail: investors@ipca.com

Website: www.ipca.com

CIN: L24239MH1949PLC007837

Mumbai, 28th May, 2017

By Order of the Board
For **Ipca Laboratories Ltd**

Harish P. Kamath

Corporate Counsel & Company Secretary
ACS 6792

ROUTE MAP OF THE AGM VENUE

📍 Shri Bhaidas Maganlal Sabhagriha - AGM Venue

TO THE MEMBERS

Your Directors have pleasure in presenting the 67th Annual Report and Audited Financial Statements for the year ended 31st March, 2017.

STANDALONE FINANCIAL RESULTS		
	(₹ crores)	
	For the year ended 31.3.2017	For the year ended 31.3.2016
Total Income	3178.87	2870.73
Profit before finance cost & depreciation	452.54	301.28
Less : Finance cost	23.34	28.60
Depreciation and Amortisation	171.00	161.23
Profit before tax	258.20	111.45
Less : Provision for taxation		
Current Tax	56.95	21.64
Deferred Tax	13.00	(2.71)
Short / Excess provision of earlier years	(0.04)	-
Net Profit	188.29	92.52

FINANCIAL STATEMENTS

The standalone and consolidated financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

In accordance with Indian Accounting Standard (Ind AS-110), the audited consolidated financial statements are provided in the Annual Report.

MANAGEMENT DISCUSSION AND ANALYSIS

a) Industry Structure and Development

The global pharmaceutical market is now estimated to be just over US \$ 1.1 trillion and is expected to grow at a CAGR of about 5% over next few years to reach US\$ 1.5 trillion by 2021. A move to value based outcomes in drug research, increased penetration of speciality drugs, greater patient access to medicines and continued rise of emerging markets will be primary drivers behind increase in global medicine spending through 2021.

Thanks to advances in science and technology, the research based pharmaceutical industry is entering an exciting new era in medicine development. The research methods are evolving and the innovative pharmaceutical industry aims to turn fundamental research into innovative treatments that are widely available and accessible to patients.

b) Outlook, Risks and Concerns

Although economic woes of certain regions are impeding the pharma sales growth, long term outlook for the pharmaceutical industry remains positive. The pharma industry growth will be driven mainly by population growth, ageing population and increased healthcare spending in pharmerging countries. It is expected that new drug launches will reach a historically high level in the next few years with launches of new medicines that will address a wide range of disease areas including cancer, auto immune, metabolic and nervous system disorders. Biotech drugs have also steadily carved a niche for themselves, though they can be prohibitively expensive for many countries healthcare systems. However, the expanding development of biosimilars is expected to address some of the cost burden.

The Indian pharmaceutical market is the third largest in terms of volume and thirteenth largest in terms of value. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 percent of global exports in terms of volume. The Indian pharma industry is expected to outperform the global pharma industry in growth and reach to a size of about US\$ 60 billions by 2021.

India enjoys an important position in the global pharmaceuticals sector. Indian pharmaceutical exports have significantly increased from US\$ 2 billion in 2006 to about US\$ 15 billion in 2016. USA with about 30% is India's largest pharma export destination followed by European Union. It is estimated that 40% of the generics drugs sold in the USA are manufactured in India. Indian pharmaceutical manufacturing facilities registered with US FDA at 500 plus is also highest for any country outside USA. The country also has a large pool of scientists and engineers who have the potential to steer this industry ahead to an even higher level.

Indian pharma companies are focusing on global generic and API business, R&D activities, contract research and manufacturing alliances. India is also fast emerging as a preferred pharmaceuticals manufacturing location. Increasing use of pharmaceutical generics in developed markets to reduce healthcare cost will provide attractive growth opportunities to generics manufacturers and thus Indian pharmaceutical industry is poised for an accelerated growth in the coming years.

However, poor public healthcare funding and infrastructure, low per capita consumption of medicines in developing and under developed countries including India, currency fluctuations, regulatory issues, government mandated price controls, inflation and resultant all round increase in input costs are few causes of concern.

During the year under report, there was no change in the nature of Company's business.

c) Financial Performance and Operations Review

During the financial year under report, the Company registered a total income of ₹ 3178.87 crores as against ₹ 2870.73 crores in the previous year, a growth of 11%.

The ongoing US FDA regulatory issues adversely impacted the Company's business. The Company's generic formulations business in the European market also suffered due to Brexit and resultant significant currency fluctuations.

The Company has implemented comprehensive remedial measures at all its manufacturing sites to ensure quality and regulatory compliances. These remedial measures included review of all processes and procedures, revamping of training system, recruitment of senior quality personnel as well as automation of quality control laboratories. Your Company is committed in resolving the regulatory challenges faced at the earliest. The Company is also committed to its philosophy of highest quality in manufacturing, operations, systems, integrity and cGMP culture. Your management is confident that implementation of remedial measures will ensure that the Company will regain all its regulatory approvals in due course of time.

During the financial year under report, the Earnings before interest and depreciation amounted to ₹ 452.54 crores as against ₹ 301.28 crores in the previous financial year. The operations have resulted in a net profit of ₹ 188.29 crores during the financial year under report as against ₹ 92.52 crores in the previous financial year, a growth of 104%.

Break-up of Sales								(₹ Crores)
	2016-17				2015-16			
	Domestic	Exports	Total	Growth	Domestic	Exports	Total	Growth
Formulations	1388.55	995.89	2384.44	11%	1222.15	923.51	2145.66	-10%
APIs & Intermediates	144.41	565.85	710.26	8%	151.79	506.34	658.13	-7%
Total Sales	1532.96	1561.74	3094.70	10%	1373.94	1429.85	2803.79	-9%
Growth	12%	9%	10%		3%	-18%	-9%	

d) International Business

The products of the Company are now exported to nearly 120 countries across the globe. During the financial year under report, the international business amounted to ₹ 1561.74 crores as against ₹ 1429.85 crores in the previous year, a growth of 9%. Formulation exports of the Company increased by 8% to ₹ 995.89 crores and exports of APIs and Drug Intermediates increased by 12% to ₹ 565.85 crores.

Continent-wise Exports								(₹ Crores)
	2016-17				2015-16			
Continent	Formulations	APIs and Intermediates	Total	% to exports	Formulations	APIs and Intermediates	Total	% to exports
Europe	381.25	221.92	603.17	39%	373.50	174.77	548.27	38%
Africa	239.92	22.45	262.37	17%	198.82	20.10	218.92	15%
Americas	107.26	136.48	243.74	16%	113.30	151.96	265.26	19%
Asia	70.78	171.22	242.00	15%	55.87	148.03	203.90	14%
CIS	100.57	9.08	109.65	7%	94.45	6.63	101.08	7%
Australasia	96.11	4.70	100.81	6%	87.57	4.85	92.42	7%
Total	995.89	565.85	1561.74	100%	923.51	506.34	1429.85	100%

Formulation Exports - Therapeutic Contribution		
Therapeutic Group	2016-17	2015-16
Cardiovasculars & Anti-diabetics	32%	31%
Non steroidal Anti-inflammatory drugs (NSAID)	23%	25%
Anti-malarials	16%	17%
Anti-bacterials	13%	12%
Central Nervous System (CNS) products	5%	5%
Anthelmintics	6%	3%
Gastro Intestinal (G.I) products	2%	3%

Formulation Exports - Therapeutic Contribution		
Therapeutic Group	2016-17	2015-16
Cough Preparations	1%	2%
Others	2%	2%
Total	100%	100%

Europe

In spite of Brexit and resultant currency fluctuations in the European market, the Company achieved European export sales of ₹ 603.17 crores during the financial year under report as against sales of ₹ 548.27 crores in the previous year, a growth of 10% from this continent.

The Company has developed and submitted 62 generic formulation dossiers for registration in Europe out of which 61 dossiers are registered. The Company has also obtained certificate of suitability (COS) of 48 APIs from European Directorate for Quality Medicines.

Africa

The Company achieved export sales of ₹ 262.37 crores to Africa during the financial year under report as against ₹ 218.92 crores in the previous year, a growth of 20%.

The Company exports branded and generic formulations as well as APIs to many African countries. The Company markets branded formulations in countries like Uganda, Ghana, Ivory Coast, Burkina Faso, Sudan, Tanzania, Kenya, Ethiopia and Nigeria through dedicated field force. The Company also supplies generics formulations to South Africa.

The Company is expanding its branded formulations business in this continent through expansion of geographical coverage and increase in the number of branded formulations marketed. The Company is also continuously filing new formulation dossiers for registration in the African countries.

The Company has filed 62 dossiers of generic formulations for registration in South Africa out of which 42 dossiers are registered till date.

Americas

The Company exports its APIs to USA, Canada, Brazil, Mexico and generic formulations to USA, Canada and branded formulations to Panama, West Indies, Peru and Colombia in this sub-continent.

The Company achieved sales of ₹ 243.74 crores in this continent as against ₹ 265.26 crores in the previous year. As reported earlier, the US formulations and APIs business was impacted due to ongoing US FDA import alert for three of the Company's manufacturing facilities.

The Company has signed agreements with marketing partners for sale / distribution of generic formulations on a profit sharing arrangement in the US market. 44 ANDA applications of generic formulations developed by the Company are filed with US FDA out of which 18 ANDA applications are granted till date. 54 DMFs of the Company are also currently filed with US FDA.

Asia

The Asian business (excluding India) recorded sales of ₹ 242.00 crores as against ₹ 203.90 crores in the previous year, a growth of 19%. The Company exports formulations as well as APIs to several Asian countries. In countries like Nepal, Sri Lanka, Myanmar, Philippines and Vietnam, the Company markets its branded formulations through dedicated field force.

Confederation of Independent States (CIS)

The Company's CIS business recorded sales of ₹ 109.65 crores as against ₹ 101.08 crores in the previous year, a growth of 8%. Most of the business is from branded formulation sales in Russia, Ukraine, Kazakhstan and Belarus. The Company's branded formulations are marketed in this continent by its own field force appointed through its non-trading offices.

Australasia

The Company exports APIs to Australia and formulations to Australia and New Zealand in this sub-continent. The business from this continent was ₹ 100.81 crores during the financial year under report as against ₹ 92.42 crores in the previous year, a growth of 9%.

The steep depreciation of Australian and New Zealand dollars impacted the business growth of the Company in this market during the financial year under report.

The Company has developed and submitted 68 generic formulation dossiers for registration in this market out of which 61 dossiers are registered.

e) Domestic Formulations Business

The Company's formulations business in India now comprises of 13 marketing divisions focusing on key therapeutic segments.

During the financial year under report, the domestic formulations business recorded a growth of 14% at ₹ 1388.55 crores as against ₹ 1222.15 crores in the previous year.

Domestic Branded Formulations - Therapeutic Contribution		
Therapeutic segment	2016-17	2015-16
	% to sales	% to sales
Non steroidal anti-inflammatory drugs (NSAID)	41%	39%
Cardiovasculars & Anti-diabetics	21%	23%
Anti-malarials	12%	12%
Anti-bacterials	6%	6%
Gastro Intestinal (G I) products	4%	5%
Cough Preparations	5%	4%
Dermatology	4%	4%
Neuro Psychiatry	3%	3%
Urology	2%	2%
Neutraceuticals	1%	1%
Others	1%	1%
Total	100%	100%

f) Active Pharmaceutical Ingredients (APIs) and Intermediates Business

During the financial year under report, the APIs and Intermediates business recorded sales of ₹ 710.26 crores as against ₹ 658.13 crores in the previous financial year, a growth of 8%. Nearly 80% of the APIs and Intermediates business is from exports.

The Company exports its APIs across the globe. Most of the international customers of the Company are end user formulations manufacturers including several multinational companies.

Your Company is in the process of commercializing several new APIs for the global market.

g) Intellectual Property Protection

The Company has created intellectual property management group within the Research and Development centers to deal with management and protection of intellectual property. The Company has filed many patent applications till date in India, USA and other countries. These applications relate to novel and innovative manufacturing processes for the manufacture of APIs and pharmaceutical formulations.

h) Manufacturing Facilities

The Company's new formulations manufacturing unit at Melli Jorethang Road, Gom Block, Bhari khola, South District, Sikkim (Unit II) commenced manufacturing operations during the financial year.




i) Internal Control Systems and its adequacy

The Company has adequate internal control systems including suitable monitoring procedures commensurate with its size and the nature of the business. The internal control systems provide for all documented policies, guidelines, authorisation and approval procedures. The Company has an internal audit department which carries out audits throughout the year. The statutory auditors while conducting the statutory audit, review and evaluate the internal controls and their observations are discussed with the Audit committee of the Board.

j) Human Resources

The human resource plays a vital role in the growth and success of an organization. The Company has maintained cordial and harmonious relations with employees across various locations.

During the year under review, various training and development workshops were conducted to improve the competency level of employees with an objective to improve the operational performance of individuals. The Company has built a competent team to handle



challenging assignments. The Company strives to enhance the technical, work related and general skills of employees through dedicated training programs on a continuous basis.

The Company has 13,303 permanent employees as on 31st March, 2017 out of which 5856 employees are engaged in the marketing and distribution activities.

k) Cautionary Statement

Certain statement in the management discussion and analysis may be forward looking within the meaning of applicable securities laws and regulations and actual results may differ materially from those expressed or implied. Factors that would make differences to Company's operations include competition, price realisation, currency fluctuations, regulatory issues, changes in government policies and regulations, tax regimes, economic development within India and the countries in which the Company conducts business and other incidental factors.

MATERIAL CHANGES AND COMMITMENTS AFTER THE END OF THE FINANCIAL YEAR

No material changes or commitments affecting the financial position of the Company have occurred between the end of the financial year to which financial statements in this report relate and the date of this report.

SHARE CAPITAL

The paid-up equity share capital of the Company as at 31st March, 2017 is ₹ 25.24 crores. The Company currently has no outstanding shares issued with differential rights, sweat equity or ESOS as at the end of the financial year ended 31st March, 2017.

The Company has issued 1,65,000 options under Ipca Laboratories Ltd. Employees Stock Option Scheme – 2014 to selected permanent Employees of the Company including one Wholetime Non-Promoter Director on 25th April, 2017.

Each option granted gives a right but not an obligation to the Option Grantee to apply for 1 equity share of ₹ 2/- each fully paid up of the Company at a price of ₹ 300/- per share upon completion of 1 year from the date of grant of options.

SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES

There has been no material change in the nature of the business of the subsidiaries. The Company has no subsidiary which can be considered as material within the meaning of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with the provisions of Section 136(1) of the Companies Act, 2013, the following have been placed on the website of the Company www.ipca.com:




- Annual Report of the Company containing therein its standalone and the consolidated financial statements; and
- Audited annual accounts of each of the subsidiary companies.

As required, the financial data of the subsidiaries, joint venture and associate companies is furnished in the prescribed Form AOC-1 as an Annexure to the consolidated financial statements.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013, the consolidated financial statements of the Company are attached.

RESEARCH & DEVELOPMENT (R&D)

The Company has always considered Research and Development (R&D) as crucial for the sustained growth of the Company. In the recent years, the Company has stepped-up investments in R&D to keep pace with the changing domestic and global scenario.



The Company has R&D centers at Mumbai, Ratlam, Athal and Ranu duly recognized by the Government of India, Ministry of Science and Technology, Department of Scientific & Industrial Research (DSIR). These R&D centers are also approved by the prescribed authority under Section 35 (2AB) of the Income Tax Act, 1961 for availing weighted tax benefit on the R&D expenditure.

The R&D expenditure of the Company during the financial year was ₹ 125.67 crores (4.06% of the turnover) as against ₹ 137.67 crores (4.91% of the turnover) in the previous year.

With qualified and experienced research scientists and engineers manning the research and development activities, the Company has focused its thrust on new and innovative process and product development for the manufacture of APIs with non-infringing processes. Apart from development of new dosage forms and drug delivery systems, improvement in processes and yield as well as cost reduction are also focus areas.

DIVIDEND

Your Directors had not declared any interim equity dividend during the year. Your directors are now pleased to recommend a equity dividend of ₹ 1/- per share (50%) for the financial year under report. The dividend will be tax free in the hands of the shareholders.

The dividend amounting to ₹ 12.62 crores and dividend tax amounting to ₹ 2.57 crores, if approved at the ensuing Annual General Meeting, will be appropriated and paid out of the profits for the year.

DIRECTORS

Mr. Prashant Godha and Mr. Premchand Godha retire by rotation at the ensuing Annual General Meeting and, being eligible, offer themselves for re-appointment.

Mr. Babulal Jain, Mr. Anand Kusre, Mr. Dev Parkash Yadava, Dr. Ramakanta Panda and Dr. (Mrs.) Manisha Premnath, who are independent directors, have submitted declaration that each of them meets the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and there has been no change in the circumstances which may affect their status as independent directors during the year.

In the opinion of the Board, the independent directors possess appropriate balance of skills, experience and knowledge, as required.

A brief note on Directors retiring by rotation and eligible for re-appointment is furnished in the Report on Corporate Governance.

KEY MANAGERIAL PERSONNEL

During the year under report, the following persons were Key Managerial Personnel of the Company:

Mr. Premchand Godha	-	Chairman & Managing Director/CEO
Mr. Ajit Kumar Jain	-	Joint Managing Director / CFO
Mr. Pranay Godha	-	Executive Director
Mr. Prashant Godha	-	Executive Director
Mr. Harish P. Kamath	-	Corporate Counsel & Company Secretary

There was no change in the Key Managerial Personnel during the financial year.

POLICY ON DIRECTORS APPOINTMENT, REMUNERATION AND OTHER DETAILS

The Nomination and Remuneration Committee has laid down the criteria for Directors appointment and remuneration including criteria for determining qualification, positive attributes and independence of a Director. The following attributes/criteria for selection have been laid by the Board on the recommendation of the Committee:

- the candidate should possess the positive attributes such as leadership, entrepreneurship, business advisor or such other attributes which in the opinion of the Committee are in the interest of the Company;
- the candidate should be free from any disqualification as provided under Sections 164 and 167 of the Companies Act, 2013;
- the candidate should meet the conditions of being independent as stipulated under the Companies Act, 2013 and Listing Agreement entered into with Stock Exchanges, in case of appointment as an independent director; and
- the candidate should possess appropriate educational qualification, skills, experience and knowledge in one or more fields of finance, law, management, sales, marketing, administration, research, corporate governance, technical operations, infrastructure, medical, social service, professional teaching or such other areas or disciplines which are relevant for the Company's business.

BOARD EVALUATION

The Nomination and Remuneration Committee lays down the criteria for performance evaluation of independent directors, Board of Directors and Committees of the Board. The criteria for performance evaluation is based on the various parameters like attendance and participation at meetings of the Board and Committees thereof, contribution to strategic decision making, review of risk assessment and risk mitigation, review of financial statements, business performance and contribution to the enhancement of brand image of the Company.

The Board has carried out evaluation of its own performance as well as that of the Committees of the Board and all the Directors.

The annual evaluation was carried out in the following manner:

Sr. No.	Performance evaluation of	Performance evaluation performed by
1.	Board and individual directors	Board after seeking inputs from all directors
2.	Board Committees	Board seeking inputs from all committee members
3.	Individual Directors	Nomination and Remuneration committee
4.	Non-independent directors, Board as a whole and the Chairman	Separate meeting of independent directors after taking views from executive directors
5.	Board, its Committees and individual Directors	At the board meeting based on evaluation carried out as above.

REMUNERATION POLICY

The objective and broad framework of the Company's Remuneration Policy is to consider and determine the remuneration based on the fundamental principles of payment for performance, for potential and for growth. The Remuneration Policy reflects on certain guiding principles of the Company such as aligning remuneration with the longer term interests of the Company and its shareholders, promoting a culture of meritocracy and creating a linkage to corporate and individual performance and emphasising on line expertise and market competitiveness so as to attract the best talent. It also ensures the effective recognition of performance and encourages a focus on achieving superior operational results. The Nomination and Remuneration Committee recommends the remuneration of Directors and Key Managerial Personnel which is approved by the Board of Directors, subject to the approval of shareholders, where necessary. The level and composition of remuneration shall be reasonable and sufficient to attract, retain and motivate the directors, key managerial personnel and other employees of the quality required to run the Company successfully. The relationship of remuneration to performance should be clear and meet appropriate performance benchmarks. The remuneration to directors, key managerial personnel and senior management personnel should also involve a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the Company and its goals. The Remuneration Policy is placed on the Company's website www.ipca.com.

Information about elements of remuneration package of individual directors is provided in the extract of the Annual Return as provided under Section 92(3) of the Companies Act, 2013 which is annexed.

FAMILIARISATION PROGRAM FOR INDEPENDENT DIRECTORS

Details of the familiarisation program for independent directors is disclosed on the website of the Company www.ipca.com.

MEETINGS OF THE BOARD AND COMMITTEES THEREOF

This information has been furnished under Report on Corporate Governance, which is annexed.

DIRECTORS' RESPONSIBILITY STATEMENT

Your Directors confirm:

- that in the preparation of the annual accounts, the applicable accounting standards have been followed alongwith proper explanation relating to material departures;
- that your Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year March 31, 2017 and of the profit of the Company for the financial year;
- that your Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- that your Directors have prepared the annual accounts on a going concern basis;
- that your Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and
- that your Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CORPORATE GOVERNANCE

As per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has complied with the requirements of Corporate Governance in all material aspects.

A report on Corporate Governance (Annexure 1) together with a certificate of its compliance from a Practising Company Secretary, forms part of this report.

FIXED DEPOSITS

During the year under review, the Company has not accepted any fixed deposits and as such no amount of principal or interest on deposits from public was outstanding as on the date of the balance sheet.

AUDIT COMMITTEE

Details of the Audit Committee along with its constitution and other details are provided in the Report on Corporate Governance.

AUDITORS, AUDIT REPORT AND AUDITED ACCOUNTS

M/s. Natvarlal Vepari & Co., Chartered Accountants (Firm Registration No. 106971W), retire as auditors of the Company under the provisions of Section 139 of the Companies Act, 2013. They are not eligible for re-appointment as the auditors of the Company under the provisions of Section 139 (2) of the Companies Act, 2013. The Board places on record its appreciation for the services rendered by M/s. Natvarlal Vepari & Co., Chartered Accountants as the Statutory Auditors of the Company for all these years.

In their place, it is proposed by the Company to appoint M/s. G.M. Kapadia & Co., Chartered Accountants (Firm Registration No. 104767W) as the Statutory Auditors of the Company for a period of 5 years till the conclusion of the Company's 72nd Annual General Meeting and the necessary resolution in this regard is proposed to be passed by the members of the Company at the ensuing Annual General Meeting.

The Auditors' Report read with the notes to the accounts referred to therein are self-explanatory and therefore, do not call for any further comments. There are no qualifications, reservations or adverse remarks made by the Auditors.

COST AUDIT

Pursuant to the provisions of Section 148 of the Companies Act, 2013, M/s. ABK & Associates, Cost Accountants (Firm Registration No. 000036) were appointed as the Cost Auditors to conduct audit of cost records of the Company for the financial year 2016-17.

The Cost Audit Report for the financial year 2015-16, which was due to be filed with the Ministry of Corporate Affairs by 26th October, 2016 was filed on 25th October, 2016.

SECRETARIAL AUDIT

Pursuant to the provisions of Section 204 and other applicable provisions, if any, of the Companies Act, 2013, M/s. Parikh & Associates, Practising Company Secretaries were appointed as the Secretarial Auditors for auditing the secretarial records maintained by the Company for the financial year 2016-17.

The Secretarial Auditors' Report is annexed hereto. There are no qualifications, reservations or adverse remarks made by the Secretarial Auditors.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

The Company is committed to good corporate citizenship. As a part of its corporate social responsibility, the Company continues to undertake a range of activities including healthcare and education to improve living conditions of the needy people. The CSR policy of the Company is placed on the website of the Company (http://www.ipca.com/pdf/corporate_policy/Corporate_Social_Responsibility_Policy.pdf).

During the year under report, the Company has also supported healthcare and educational projects undertaken by charitable institutions and organizations.

In accordance with the provisions of Section 135 of the Companies Act, 2013, an abstract on Company's CSR activities is furnished as Annexure 2 to this report.

SAFETY, ENVIRONMENT AND HEALTH

The Company considers safety, environment and health as the management responsibility. Regular employee training programmes are carried out in the manufacturing facilities on safety, environment and health.

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

The Company has not given any loans or guarantees or made any investments in contravention of the provisions of the Section 186 of the Companies Act, 2013. The details of the loans and guarantees given and investments made by the Company are provided in the notes to the financial statements.

RELATED PARTY TRANSACTIONS

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of Company's business. The Company has not entered into any contract, arrangement or transaction with any related party which could be considered as material as defined under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board has approved a policy for related party transactions which has been uploaded on the website of the Company (http://www.ipca.com/pdf/corporate_policy/Related_Party_Transactions.pdf).

All the related party transactions are placed before the Audit Committee as well as the Board for approval on a quarterly basis. Omnibus approval was also obtained from the Audit Committee and the Board on an annual basis for repetitive transactions.

Related party transactions under Accounting Standard – IND AS24 are disclosed in the notes to the financial statements. Prescribed Form No. AOC-2 pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014 is furnished as Annexure 3 to this report.

EMPLOYEES

Pursuant to the provisions of Section 197 of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement showing the names and other particulars of the employees drawing remuneration and other details as set out in the said Rules is furnished under Annexure 4 to this report.

However, having regard to the provisions of the first proviso to Section 136(1) of the Act and as advised, the Annual Report excluding the aforesaid information is being sent to the members of the Company. The said information is available for inspection at the registered office of the Company during working hours excluding Saturdays and any member interested in obtaining such information may write to the Company Secretary and the same will be furnished on request. The full Annual Report including the aforesaid information is available on the Company's website www.ipca.com.

CODE OF CONDUCT

The Board has laid down a code of conduct for board members and senior management personnel of the Company. The code incorporates the duties of independent directors as laid down in the Companies Act, 2013. The said code of conduct is posted on Company's website www.ipca.com. The Board members and senior management personnel have affirmed compliance with the said code of conduct. A declaration in this regard signed by the Chairman & Managing Director / CEO is given at the end of the Corporate Governance Report.

WHISTLE BLOWER POLICY / VIGIL MECHANISM

There is a Whistle Blower Policy in the Company and that no personnel have been denied access to the Chairman of the Audit Committee. The policy provides for adequate safeguards against victimization of persons who use vigil mechanism. The Whistle Blower Policy is posted on the website of the Company www.ipca.com.

PREVENTION OF INSIDER TRADING

The Board at its meeting held on 30th May 2015 has adopted a revised Code of Prevention of Insider Trading based on the SEBI (Prohibition of Insider Trading) Regulations, 2015. The same has been placed on the website of the Company www.ipca.com.

All the Directors, senior management employees and other employees who have access to the unpublished price sensitive information of the Company are governed by this code. During the year under Report, there has been due compliance with the said code of conduct for prevention of insider trading.

BUSINESS RISK MANAGEMENT

Pursuant to the provisions of Section 134 of the Companies Act, 2013, the Company has constituted a Risk Management Committee. The details of the Committee and its terms of reference are provided in the Report on Corporate Governance, which is annexed.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant or material orders passed by any regulator, tribunal or court that would impact the going concern status of the Company and its future operations.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

In accordance with the requirements of Section 134 of the Companies Act, 2013, statement showing particulars with respect to conservation of energy, technology absorption and foreign exchange earnings and outgo is furnished as Annexure 5 to this report.

EXTRACT OF ANNUAL RETURN

In accordance with the requirements of Section 92 (3) of the Companies Act, 2013 and rule 12 (1) of the Companies (Management and Administration) Rules, 2014, an extract of Annual Return in Form MGT-9 is furnished as Annexure 6 to this report.

BUSINESS RESPONSIBILITY REPORT

The Business Responsibility Report of the Company for the financial year ended 31st March, 2017 forms part of this Report. The same is also uploaded on the Company's website www.ipca.com.

ACKNOWLEDGEMENTS

Your Directors place on record their appreciation for the continued co-operation and support extended to the Company by the bankers and financial institutions. Your Directors also thank the medical profession, the trade and consumers for their patronage of the Company's products. Your Directors also place on record their profound admiration and sincere appreciation of the continued hard work put in by employees at all levels.

For and on behalf of the Board

Premchand Godha
Chairman & Managing Director

Mumbai
28th May, 2017

ANNEXURE 1

REPORT ON CORPORATE GOVERNANCE

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, given below is a report on the Corporate Governance in the Company:

1. Company's philosophy on Code of Corporate Governance is to ensure

- that the Board and top management of the Company are fully appraised of the affairs of the Company that is aimed at assisting them in the efficient conduct of the Company's business so as to meet Company's obligation to the stakeholders.
- that the Board exercises its fiduciary responsibilities towards shareholders and creditors so as to ensure high accountability.
- that all disclosure of information to present and potential investors are maximised.
- that the decision making process in the organisation is transparent and are backed by documentary evidences.
- that the Company is in compliance with the requirements stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to Corporate Governance.

2. Board of Directors

a) Composition and Category of directors

The present strength of the Board of Directors of the Company is nine directors of which one is promoter Chairman & Managing Director/CEO, one professional non-promoter Joint Managing Director/CFO, two promoter Executive Directors and five non-executive independent directors including one woman director comprising of at least one half of the total strength of the Board with independent judgment in the deliberation and decision of the Board. The Chairman of the Board is an Executive and Promoter Director.

b) Details of attendance of each director at the meeting of the board of directors and the last annual general meeting and shareholding held by them in the Company

Name of the Director	Category	No. of board meetings		Attendance at last AGM (11.08.2016)	No. of Equity shares held in the Company
		Held	Attended		
Mr. Premchand Godha (DIN 00012691)	Chairman & Managing Director/CEO, Promoter Director	5	5	Yes	26,81,340
Mr. Ajit Kumar Jain (DIN 00012657)	Joint Managing Director/CFO, Professional, Non-Promoter Director	5	5	Yes	66,000
Mr. Pranay Godha (DIN 00016525)	Executive Director, Promoter Director	5	5	Yes	8,25,495
Mr. Prashant Godha (DIN 00012759)	Executive Director, Promoter Director	5	5	Yes	7,59,322
Mr. Babulal Jain (DIN 00016573)	Non-Executive, Independent Director	5	5	Yes	25,500
Mr. Anand T. Kusre (DIN 00818477)	Non-Executive, Independent Director	5	5	Yes	Nil
Mr. Dev Parkash Yadava (DIN 00778976)	Non-Executive, Independent Director	5	5	Yes	14,629
Dr. Ramakanta M. Panda (DIN 01161791)	Non-Executive, Independent Director	5	3	No	Nil
Dr. (Ms) Manisha Premnath (DIN 05280048)	Non-Executive, Independent Director	5	3	Yes	Nil

The above shareholding as at 31st March, 2017 is in respect of shares which are held by Directors as a first holder and in which shares they have beneficial interest.

c) Number of other companies or committees of which the Director is Member or Chairperson

Name of the Director	No. of other companies in which Director (including private and Section 8 companies)	No. of Committees in which Member (other than Ipca)	No. of Committees of which Chairman (other than Ipca)
Mr. Premchand Godha	5	1	Nil
Mr. Ajit Kumar Jain	Nil	Nil	Nil
Mr. Pranay Godha	6	Nil	Nil
Mr. Prashant Godha	8	Nil	Nil
Mr. Babulal Jain	1	Nil	Nil
Mr. Anand T. Kusre	2	Nil	Nil
Mr. Dev Parkash Yadava	3	2	1
Dr. Ramakanta M. Panda	15	1	Nil
Dr. (Ms.) Manisha Premnath	4	Nil	Nil

Note: Directorship held by Directors mentioned above does not include Directorship of foreign companies.

Every Director informs the Company about the Committee positions he or she occupies in the other entities and any changes in them as and when they take place.

d) Number of meetings of the board of directors held during the financial year 2016-17 and dates on which held

5 (Five) board meetings were held during the Financial Year 2016-17. The dates on which the said meetings were held are as follows:

30 th May, 2016	11 th August, 2016
26 th September, 2016	11 th November, 2016
10 th February, 2017	

The last Annual General Meeting of the Company was held on 11th August, 2016.

e) Disclosure of relationships between directors inter-se

Mr. Premchand Godha, Chairman & Managing Director, Mr. Pranay Godha and Mr. Prashant Godha, Executive Directors are related to each other. None of the other Directors are related to each other.

f) Number of shares and convertible instruments held by Non-Executive Directors

The information about number of shares held by Non-Executive Directors in the Company is given in the table above. None of the Directors hold any convertible instruments of the Company except Mr. A. K. Jain, Joint Managing Director to whom 10,000 options were allotted under Ipca Laboratories Ltd. – Employees Stock Option Scheme – 2014 on 25th April, 2017. Each option represents a right but not an obligation to apply for one equity share of ₹ 2/- each of the Company at a price of ₹ 300/- per share upon completion of 1 year from the date of grant of options.

g) Web link where details of familiarisation programmes imparted to independent directors is disclosed

The Company has conducted familiarisation programmes for the Independent Directors with regards to their role, rights and responsibilities as Independent Directors. The Independent Directors are also regularly briefed on the nature of the pharmaceutical industry and the Company's business model. The familiarisation programs have been uploaded on the website of the Company at www.ipca.com.

3. Audit Committee

a) Brief description of terms of reference

The terms of reference to Audit Committee, inter-alia, covers all the matters specified under Section 177 of the Companies Act, 2013 and also all the matters listed under Part C of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 such as oversight of the Company's financial reporting process; recommending the appointment/re-appointment, remuneration and terms of appointment of statutory auditors; review and monitor the Auditors independence and performance and effectiveness of audit process; approval of transactions with related parties; sanctioning of loans and investments; evaluation of internal financial control and risk management system; reviewing with the management annual financial statements and Auditors report thereon; quarterly financial statements and other matters as covered under role of Audit Committee in Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee has powers, inter-alia, to investigate any activity within its terms of reference and to seek information from any employee of the Company / Company's subsidiaries as well as seek outside legal and professional advice.

The Audit committee reviews all the information that is required to be mandatorily reviewed by it under the corporate governance.

b) Composition, name of members and chairperson

The Audit Committee of the Company currently comprises of Mr. Babulal Jain, Chairman of the Committee, Mr. Anand T. Kusre and Mr. Dev Parkash Yadava, all being Independent Directors with independent judgment in the deliberation and decisions of the Board as well as Audit Committee and Mr. Prashant Godha, Executive Director. All members of the Audit Committee have knowledge on financial matters and the Chairman of the Audit Committee is a senior Chartered Accountant in practice having accounting and financial management expertise.

Mr. Ajit Kumar Jain, Joint Managing Director in-charge of Finance/CFO and Mr. Pranay Godha, Executive Director along with Statutory Auditors, Cost Auditors and Mr. Kavish Agrawal, General Manager (Audit) who is the Internal Auditor of the Company are invitees to the meetings of the Audit Committee. Mr. Harish P. Kamath, Corporate Counsel and Company Secretary is the Secretary of this Committee.

c) Audit Committee meetings and the attendance during the financial year 2016-17

There were 5 (Five) meetings of the Audit Committee during the Financial Year 2016-17. The gap between two meetings did not exceed four months. The dates on which the said meetings were held are as follows:

30 th May, 2016	11 th August, 2016	26 th September, 2016
11 th November, 2016	10 th February, 2017	

The attendance of each member of the Audit Committee in the committee meetings is given below:

Name of the Member	No. of meetings held	No. of meetings attended
Mr. Babulal Jain	5	5
Mr. Anand T. Kusre	5	5
Mr. Dev Parkash Yadava	5	5
Mr. Prashant Godha	5	5

The previous annual general meeting of the Company was held on 11th August, 2016 and was attended by Mr. Babulal Jain, Chairman of the Audit committee.

4. Nomination and Remuneration Committee**a) Brief description of terms of reference**

- formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to the remuneration of the directors, key managerial personnel and other employees;
- formulation of criteria for evaluation of performance of independent directors and the board of directors;
- devising a policy on diversity of board of directors;
- identifying persons who are qualified to become directors and persons who may be appointed in senior management in accordance with the criteria laid down and recommend to the board of directors their appointment and removal;
- whether to extend or continue the term of appointment of the independent directors, on the basis of the report of performance evaluation of independent directors; and
- administer and superintend the Employees Stock Option Scheme (ESOS).

b) Composition, name of members and chairperson

The Company has a Nomination and Remuneration Committee of the Board which currently comprises of Mr. Babulal Jain (Chairman of the Committee), Mr. Anand T. Kusre and Mr. Dev Parkash Yadava, all independent directors to function in the manner and to deal with the matters specified in Part D of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also to review the overall compensation structure and policies of the Company to attract, motivate and retain employees and to administer the Company's ESOS.

The Nomination and Remuneration Committee has adopted the following policies which are displayed on the website of the Company:

- formulation of the criteria relating to the remuneration of the directors, key managerial personnel and other employees (weblink http://www.ipca.com/pdf/corporate_policy/Remuneration_Policy.pdf);
- performance criteria for evaluation of Independent Directors and the Board (weblink http://www.ipca.com/pdf/corporate_policy/Evaluation_of_Directors.pdf);
- devising a policy on Board diversity (weblink http://www.ipca.com/pdf/corporate_policy/Policy_on_Board_Diversity_of_the_Company.pdf);

- iv. oversee the familiarization programs for directors (weblink http://www.ipca.com/pdf/Board_of_Directors/familiarisation-programme-2016-17.pdf); and
- v. identifying persons who are qualified to become directors and persons who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board their appointment and removal (weblink http://www.ipca.com/pdf/corporate_policy/Criteria_for_selection_of_Candidates_for_Senior_Management_and_Members_on_the_Board.pdf).

c) Meeting and attendance during the financial year 2016-17

There were 2 (Two) meetings of this Committee during the Financial Year 2016-17. The dates on which the said meetings were held are as follows:

30 th May, 2016	10 th February, 2017
----------------------------	---------------------------------

The attendance of each member of the Nomination and Remuneration Committee in the committee meetings is given below:

Name of the Member	No. of meetings held	No. of meetings attended
Mr. Babulal Jain	2	2
Mr. Anand T. Kusre	2	2
Mr. Dev Parkash Yadava	2	2

d) Performance evaluation criteria for independent directors

Performance criteria for evaluation of Independent Directors and the Board is displayed on the Company's website (weblink http://www.ipca.com/pdf/corporate_policy/Evaluation_of_Directors.pdf).

5. Remuneration of Directors

a) All pecuniary relationship or transactions of the non-executive directors vis-à-vis the listed entity shall be disclosed in the annual report

During the financial year under report, the non-executive Directors had no pecuniary relationship or transactions with the Company.

b) Criteria of making payments to non-executive directors

The non-executive Directors are paid only sitting fees and re-imbursement of out of pocket expenses incurred for attending the meetings of the Board of Directors and Committees thereof.

Details of payments made to Non-Executive Directors in the Financial Year 2016-17 are as under:

Name of the Director	Sitting fees Paid (₹)	Commission paid (₹)
Mr. Babulal Jain	5,50,000	Nil
Mr. Anand T. Kusre	4,50,000	Nil
Mr. Dev Parkash Yadava	5,50,000	Nil
Dr. Ramakanta M. Panda	1,75,000	Nil
Dr. (Mrs.) Manisha Premnath	1,75,000	Nil

None of the Independent Directors have received any remuneration or commission from Company's holding or subsidiary companies.

c) Disclosures with respect to remuneration paid / payable to Wholetime Directors for the financial year 2016-17

- i. The details of the remuneration paid/payable to Managing Director, Joint Managing Director and Executive Directors for the Financial Year 2016-17 are given below:

Name of the Director	Salary*	Benefits / Perquisites / Pension etc.*	Commission (performance linked)	Stock Options	Total (₹)
Mr. Premchand Godha (Chairman & Managing Director)	3,63,00,000	2,01,73,342	Nil	Nil	5,64,73,342
Mr. Ajit Kumar Jain (Joint Managing Director)	1,32,00,000	1,62,92,348	Nil	Nil	2,94,92,348
Mr. Pranay Godha (Executive Director)	66,00,000	70,08,011	Nil	Nil	1,36,08,011
Mr. Prashant Godha (Executive Director)	59,30,000	64,09,690	Nil	Nil	1,23,39,690

* Fixed Component

- ii. Details of fixed component and performance linked incentives, along with the performance criteria

The required details are given in the table above.

- iii. Service contracts, notice period, severance fees

The appointment of Managing Director, Joint Managing Director and Executive Directors is contractual and is generally for a period of 5 years. Either party is entitled to terminate agreement by giving not less than 60 days notice in writing to the other party. There is no separate provision for payment of severance fee in the agreements signed by the Company with them.

- iv. Stock option details, if any and whether issued at a discount as well as the period over which accrued and over which exercisable

As on 31st March, 2017, the Company has no outstanding stock options or other convertible instruments.

6. Stakeholders Relationship Committee

a) Name of Non-Executive Director heading the committee

This Committee functions under the Chairmanship of Mr. Babulal Jain, the non-executive Independent Director. Mr. Premchand Godha, Chairman & Managing Director and Mr. Ajit Kumar Jain, Joint Managing Director are the other members of this committee. This committee monitors share transfers, transmissions and other shareholders related activities including redressal of investor grievances.

Meetings held and attendance during the financial year 2016-17

There were 4 (Four) meetings of this committee during the financial year 2016-17. The dates on which the said meetings were held are as follows:

30 th May, 2016	11 th August, 2016
11 th November, 2016	10 th February, 2017

The attendance of each member of the Stakeholders Relationship Committee in the committee meetings is given below:

Name of the Member	No. of meetings held	No. of meetings attended
Mr. Babulal Jain	4	4
Mr. Premchand Godha	4	4
Mr. Ajit Kumar Jain	4	4

b) Name and designation of Compliance officer

Mr. Harish P. Kamath, Corporate Counsel & Company Secretary is the Compliance Officer of the Company.

c) Number of shareholders' complaints received

During the year, the Company received 14 complaints/communications from the shareholders, mostly regarding non-receipt of dividend warrants posted/request for revalidation of date expiry warrants, bonus shares issue / stock split share certificate related queries, etc. all of which are attended to.

d) Number not solved to the satisfaction of shareholders

The Company had no unattended request pending for transfer of its equity shares or any unattended complaints at the close of the financial year.

e) Number of pending complaints

Nil

7. General Body Meetings

- a) **Details of the location and time where the last three Annual General Meeting (AGM) and Extra-ordinary General Meeting (EGM) were held**

AGM for the financial year ended	Day, Date & Time of AGM	Place of AGM	Special Resolutions Passed
31-3-2016	Thursday, 11-08-2016 at 3.30 p.m.	Shri Bhaidas Maganlal Sabhagriha, Vile Parle (West), Mumbai	Continuation of Mr. Premchand Godha as Managing Director even after attaining age of 70 years
31-3-2015	Thursday, 30-7-2015 at 3.30 p.m.	Shri Bhaidas Maganlal Sabhagriha, Vile Parle (West), Mumbai	Adoption of new Articles of Association
31-3-2014	Thursday, 31-07-2014 at 3.30 p.m.	Shri Bhaidas Maganlal Sabhagriha, Vile Parle (West), Mumbai	- Increase in the borrowing limit of the Company u/s 180 (1) (a) and (c) from ₹400 Crores to ₹2000 Crores. - Grant of Stock Options to Employees

All the resolutions including special resolutions set out in the respective notices calling the AGM / EGM were passed by the shareholders.

There is no proposal to pass any special resolution through postal ballot at the ensuing Annual General Meeting.

- b) **Whether any special resolutions passed in the previous three annual general meetings**

Details of special resolutions passed in the previous 3 Annual General Meetings are given in the table above.

- c) **Whether any special resolution passed last year through postal ballot**

No special resolution was passed in the last financial year using postal ballot.

- d) **Person who conducted the postal ballot exercise**

Not Applicable

- e) **Whether any special resolution is proposed to be conducted through postal ballot**

No special resolution is currently proposed to be conducted through postal ballot.

- f) **Procedure for postal ballot**

Not Applicable

8. Means of communication

a) Quarterly / Annual Results	The results of the Company are submitted to the stock exchanges where the shares of the Company are listed and published in the Newspapers after the approval of the Board.
b) Newspapers wherein results normally published	The Business Standard / Financial Express, Free Press Journal and Nav Shakti.
c) Website, where displayed	At http://www.ipca.com
d) Whether website also displays official news releases	Yes
e) Presentation made to institutional investors or to the analysts	The website includes all the information on presentations made to the investors and analysts.

9. General Shareholders Information

a) AGM : Date, Time and Venue	Friday, 4 th August, 2017 at 3.30 p.m. at Shri Bhaidas Maganlal Sabhagriha, Swami Bhaktivedanta Marg, J.V.P.D. Scheme, Vile Parle (W), Mumbai 400 056.
b) Financial Year First quarter results Second quarter results Third quarter results Annual results	1 st April –31 st March last week of July* last week of October* last week of January* last week of May* * tentative
c) Dividend Payment dates	The Company has not paid any interim dividend on the equity share capital for the financial year 2016-17. It is now proposed to recommend a dividend of ₹ 1/- per share (50%) on equity share capital for the financial year 2016-17 which if sanctioned will be paid on or before 30 th August, 2017.
Date of Book closure	Saturday, 29 th July, 2017 to Friday, 4 th August, 2017 (both days inclusive).
d) The name and address of each stock exchange(s) at which the Company's securities are listed and a confirmation about payment of annual listing fee to each of such stock exchange(s)	- BSE Ltd. (BSE) Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 023. - The National Stock Exchange of India Ltd. (NSE) Exchange Plaza Bandra-Kurla Complex Bandra (E), Mumbai 400 051. Listing fees have been paid to both the stock exchanges for the financial year 2017-18 in April, 2017. The fees of the depositories for the financial year 2017-18 were also paid in April / May 2017 on receipt of their invoices.
e) Stock code – Physical and ISIN Number for NSDL and CDSL	524494 on BSE; IPCALAB on NSE INE 571A01020
Corporate Identity Number allotted by Ministry of Corporate Affairs	L24239MH1949PLC007837
f) Market price data: high, low during each month in last financial year	Please see Annexure 'A'
g) Stock performance in comparison to BSE Sensex	Please see Annexure 'B'
h) In case the securities are suspended from trading, the directors report shall explain the reason thereof	The securities of the Company are not suspended from trading by the Stock Exchanges.
i) Registrars and share transfer agents	Link Intime India Private Limited C-101, 247 Park, LBS Marg, Vikhroli (West) Mumbai – 400 083 Tel. (022) 4918 6270 Fax. (022) 4918 6060
j) Share transfer system	All share transfers subject to correctness and completion of all documents would normally be registered and returned within fifteen days from the date of receipt.
k) Distribution of shareholding/ shareholding pattern as on 31.3.2017	Please see Annexure 'C'
l) Dematerialisation of shares and liquidity	98.72% of the paid-up share capital has been dematerialised as on 31 st March, 2017.

m) Outstanding GDRs/ADRs/warrants/ convertible instruments, conversion date and likely impact on equity	No options issued under Ipca Laboratories Ltd- Employees Stock Option Scheme (ESOS) are outstanding as at 31st March, 2017. The Company has no outstanding shares issued with differential rights, GDRs/ADRs/warrants/ convertible instruments, sweat equity or ESOS as at 31st March, 2017. The Company has issued 1,65,000 options under Ipca Laboratories Ltd. Employees Stock Option Scheme – 2014 to selected permanent Employees of the Company including one Wholtime Non-Promoter Director on 25th April, 2017. Each option granted gives a right but not an obligation to the Option Grantee to apply for 1 equity share of ₹ 2/- each fully paid up of the Company at a price of ₹ 300/- per share upon completion of 1 year from the date of grant of options.
n) Commodity Price Risk or Foreign Exchange Risk and Hedging Activities	The Company is not materially exposed to commodity price risk. The Company also does not carry out any commodity hedging activities. Since about 50% of the Company's income is by way of exports with major currency exposure being in US Dollars, Pound Sterling and Euros, the Company generally does currency hedging upto a maximum period of 18 months and upto the extent of 40% - 60% of its Net Foreign Exchange Earnings (NFE). Most of the Company's borrowings are in foreign currencies, mainly in US Dollars. The Company keeps its borrowings in foreign currency exposure open and to that extent is exposed to the currency fluctuation risks.
o) Plant Locations	1. Sejavata, Ratlam, Madhya Pradesh. 2. Pologround, Indore, Madhya Pradesh. 3. SEZ Indore, Pithampur, Madhya Pradesh. 4. Sector III, Pithampur, Madhya Pradesh. 5. Gandhidham, Gujarat. 6. Nandesari, Gujarat. 7. Ankleshwar, Gujarat. 8. Village Ranu, Tehsil Padra, District Vadodara, Gujarat. 9. Athal, Silvassa (D & NH). 10. Dandudyog Industrial Estate, Silvassa (D&NH). 11. Aurangabad, Maharashtra (Unit I & Unit II). 12. Mahad, Maharashtra. 13. Tarapur, District Palghar, Maharashtra. 14. Dehradun, Uttarakhand. 15. Gom Block, Bharikhola, South Sikkim (Unit I & Unit II).
p) Address for Correspondence	Harish P Kamath Corporate Counsel & Company Secretary Ipca Laboratories Limited 125, Kandivli Industrial Estate Kandivli (W), Mumbai 400 067 Tel. (022) 6210 6050 E-mail : investors@ipca.com
q) Share transfer and other communications may be addressed to the Registrars	Link Intime India Private Limited C-101, 247 Park, LBS Marg, Vikhroli (West) Mumbai – 400 083 Tel. (022) 4918 6000

10. Other Disclosures**a) Disclosures on materially significant related party transactions that may have potential conflict with the interest of the Company at large**

The Board has approved a policy for related party transactions which has been uploaded on the website of the Company (Weblink http://www.ipca.com/pdf/corporate_policy/Related_Party_Transactions.pdf). There were no materially significant related party transactions during the year that may have potential conflict with the interest of the Company.

The Register of Contracts containing the transactions in which Directors are deemed to be concerned or interested is placed before the Board and Audit Committee regularly for its approval. Disclosures from directors and senior management staff have been obtained to the effect that they have not entered into any material, financial and commercial transactions where they have personal interest that may have potential conflict with the interest of the Company at large.

Transactions with the related parties are disclosed in the notes to the accounts forming part of this Annual Report.

b) Details of non-compliance by the Company, penalties, strictures imposed on the Company by Stock Exchange(s) or the Board or any other statutory authorities on any matter related to capital market during the last 3 financial years

None

c) Details of establishment of vigil mechanism, whistle blower policy and affirmation that no personnel has been denied access to the audit committee

There is a Whistle Blower Policy in the Company and that no personnel has been denied access to the Chairman of the Audit Committee. The policy provides for adequate safeguards against victimization of persons who use vigil mechanism. The Whistle Blowing Policy is posted on the website of the Company (weblink <http://www.ipca.com/whistleblower.html>).

d) Details of compliance with mandatory requirements and adoption of the non-mandatory requirements

The Company has complied with all the mandatory requirements of corporate governance under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The details about adoption of non-mandatory requirements are given in the table below.

e) Web link where policy for determining material subsidiaries is disclosed

The Board has approved a policy for determining material subsidiaries which has been uploaded on the website of the Company (Weblink http://www.ipca.com/pdf/corporate_policy/Policy_on_Material_Subsiaries.pdf).

f) Web link where policy on dealing with related party transactions is disclosed

The Board has approved a policy for related party transactions which has been uploaded on the website of the Company (Weblink http://www.ipca.com/pdf/corporate_policy/Related_Party_Transactions.pdf).

g) Disclosure of commodity price risks and commodity hedging activities

The Company is engaged in the manufacturing and marketing of pharmaceuticals. Since the Company does not consume large quantities of commodities in its manufacturing activities, the Company is not materially exposed to commodity price risks nor does the Company do any commodity hedging.

11. Non-Compliance of any requirement of Corporate Governance Report with reasons thereof

None

12. Adoption of Discretionary Requirements

A. The Board	The Company currently has an Executive Chairman and as such he has an office maintained by the Company.
B. Shareholders Rights	At present, the Company does not send the statement of half yearly financial performance to the household of each shareholder. The Company publishes the same in the newspapers and also uploads the same on its website.
C. Modified opinion(s) in audit report	The Company's financial statements are with unmodified audit opinion.
D. Separate posts of chairperson and chief executive officer	Currently, the Executive Chairman is also the CEO of the Company.
E. Reporting of internal auditor	The Internal Auditor reports to the Joint Managing Director / CFO as well as to the Audit Committee.

13. The disclosures of the compliance with corporate governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46

- a) The Company has a process to provide, inter-alia, the information to the Board as specified in Part A of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to Corporate Governance. The Board also periodically reviews the compliances by the Company of all applicable laws.
- b) The Board of Directors in their meeting regularly discuss and are satisfied that the Company has plans in place for orderly succession for appointment to the Board of Directors and Senior Management.
- c) Code of Conduct for Board and Senior Managerial Personnel

The Board has laid down a code of conduct for Board members and senior management personnel of the Company. The code incorporates the duties of independent directors as laid down in the Companies Act, 2013. The said code of conduct is posted on Company's website www.ipca.com.

The Board members and senior management personnel have affirmed compliance with the said code of conduct. A declaration in this regard signed by the Chairman & Managing Director / CEO is given at the end of this Report.

The Company has adopted a code of conduct for prevention of insider trading based on SEBI (Prohibition of Insider Trading) Regulations, 2015. The same has been placed on the website of the Company www.ipca.com. All the Directors, senior management employees and other employees who have access to the unpublished price sensitive information of the Company are governed by this code. During the year under Report, there has been due compliance with the said code of conduct for prevention of insider trading.

- d) The Company complies with the requirement of placing minimum information before the Board of Directors as contained in Part A of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- e) The CEO/CFO compliance certification under Part B of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of this Annual Report.
- f) The Company has a Risk Management Committee which monitors and reviews risk management plan on regular basis. The Board of Directors also periodically review and monitor the risk management plan of the Company.
- g) The Board on an annual basis evaluates the performance of independent Directors.
- h) Risk Management Committee

The Risk Management Committee was constituted by the Board of Directors at its meeting held on 21st September, 2014 consisting of the following members:

Mr. A. K. Jain, Joint Managing Director/CFO, Mr. Pranay Godha, Executive Director, Mr. Prashant Godha, Executive Director and Mr. Manish Jain, Vice President – Business Development.

The roles and responsibilities of the Risk Management Committee includes monitoring and review of risk management plan on a regular basis and reporting the same to the Board of Directors periodically as it may deem fit and any other terms as may be referred to them by the Board of Directors, from time to time.

The risk management policy is displayed on the Company's website (http://www.ipca.com/pdf/corporate_policy/Risk_Management_Policy.pdf).

There were 3 (three) meetings of this committee during the financial year 2016-17. The dates on which the said meetings were held are as follows:

30 th June, 2016	11 th November, 2016
10 th February, 2017	

The attendance of each member of the Risk Management Committee in the committee meetings is given below:

Name of the Member	No. of meetings held	No. of meetings attended
Mr. Ajit Kumar Jain	3	3
Mr. Pranay Godha	3	3
Mr. Prashant Godha	3	3
Mr. Manish Jain (Vice President – Business Development)	3	2

- i) The Company has formulated a policy on materiality of related party transactions and dealing with related party transactions which is available on the website of the Company (http://www.ipca.com/pdf/corporate_policy/policy-on-materiality.pdf).

- j) The Company has not entered into any materially significant transactions during the year under report with promoters, directors, key/senior management personnel, related parties, etc. other than the non-material transactions entered into in the ordinary course of Company's business as approved by the Audit Committee through omnibus approval valid for each financial year. Transactions with related parties are disclosed under notes forming part of the accounts. The Board and the Audit Committee periodically reviews the details of the related party transactions entered into by the Company. Omnibus approval of the Audit Committee is also obtained before entering into related party transactions.
- k) No employee including Key Managerial Personnel or Director or Promoter of the Company has entered into any agreement for himself or on behalf of other person with any shareholder or any other third party with regard to compensation or profit sharing in connection with dealings in the securities of the Company.

l) **Subsidiary Companies**

The Company has 1 non-listed, non-material Indian subsidiary company. The Company also has 5 overseas non-material wholly owned subsidiary companies and 2 non-material wholly owned subsidiary companies of wholly owned subsidiaries, the financial statements of which are regularly reviewed by the Audit Committee and the Board of Directors. The minutes of board meetings of subsidiary companies are also placed before the meetings of the Board of Directors of the Company. The Board of Directors of the Company also reviews all significant transactions and arrangements, if any, entered into by the subsidiaries.

- m) None of the Directors are directors in more than 20 companies at the same time and are also not serving as independent director in more than seven listed companies or serve as Wholetime Director in any other listed company. None of the Wholetime Directors of the Company serve as Independent Director in more than 3 listed entities.

None of the Directors on the Board is a member of more than 10 committees and Chairman of more than 5 committees across all the companies in which they are Directors. All directors have disclosed their committee positions to the Company. For determining this limit, Chairpersonship and Membership of Audit Committee and Stakeholders Relationship Committee only are considered.

The shareholders have approved the appointment of Mr. Babulal Jain, Mr. Anand T. Kusre, Mr. Dev Parkash Yadava, Dr. Ramakanta Panda and Dr. (Mrs.) Manisha Premnath as Independent directors for a term of five years. The terms and conditions of appointment of independent directors have been disclosed on the website of the Company www.ipca.com. The maximum tenure of independent directors is in accordance with the Companies Act, 2013 and the rules made thereunder.

In accordance with requirements of Section 149(6) and (7) of the Companies Act, 2013, all the independent directors have given declaration of independence in the first board meeting of the current financial year held on 25th April, 2017.

n) **Independent Directors Meeting**

During the year under review, the Independent Directors met on 10th February, 2017, without the attendance of non-independent directors and members of the management, inter-alia, to discuss:

- i. Evaluation of the performance of Non-Independent Directors and the Board of Directors as a whole;
- ii. Evaluation of the performance of the Chairman of the Company, taking into account the views of the Executive and Non Executive Directors; and
- iii. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

All the independent Directors were present at the said meeting.

- o) The Company maintains a functional website containing the basic information about the Company. The Company has disseminated all the required information on its website as required under Regulation 46 (2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- p) Information on Directors retiring by rotation and seeking appointment / re-appointment :

Mr. Prashant Godha (DIN 00012759)

Mr. Prashant Godha, aged 42 years is a graduate in Commerce and has done Post Graduate Diploma in Business Management and has experience of over 17 years in pharmaceuticals marketing and general management.

He was appointed as an Additional Director on the Board of the Company with effect from 28th July, 2011 and was first appointed as the Executive Director of the Company with effect from 16th August, 2011.

He holds 7,59,322 equity shares in the Company.

He is also a Director of the following companies:

1. Saraswati Entertainment Pvt. Ltd.	2. Mexin Medicaments Pvt. Ltd.
3. Paschim Chemicals Pvt. Ltd.	4. Kaygee Laboratories Pvt. Ltd.
5. Paranthapa Investments & Traders Pvt. Ltd.	6. Gudakesh Investment & Traders Pvt. Ltd.
7. Kaygee Investments Pvt. Ltd.	8. Ajanma Holdings Pvt. Ltd.

He is not a member of any Committee of the Board in other companies in which he is a Director.

Number of Board Meetings held and attended by him during his tenure as Director of the Company are given in the Corporate Governance Report of the respective financial year annexed with the Company's Annual Reports which are available on the Company's website www.ipca.com.

Mr. Premchand Godha, Chairman & Managing Director, Mr. Pranay Godha and Mr. Prashant Godha, Executive Directors are related to each other. He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.

Mr. Premchand Godha (DIN 00012691)

Mr. Premchand Godha aged 70 years is a qualified Chartered Accountant and a Commerce graduate. He is also a first generation entrepreneur. He is a director of the Company since 31st October, 1975 and has been the Managing Director of the Company since March, 1983. He has over 41 years of experience in the pharmaceutical industry.

He holds 26,81,340 equity shares of the Company.

He is also a Director of the following companies:

1. Kaygee Investments Pvt. Ltd	2. Vasant Investment Corporation Ltd.
3. Gudakesh Inv. & Traders Pvt. Ltd.	4. Paranthapa Inv. & Traders Pvt. Ltd.
5. AB Corp Ltd.	

Mr. Premchand Godha is a member of the Audit Committee of AB Corp Limited.

Number of Board Meetings held and attended by him during his tenure as Director of the Company are given in the Corporate Governance Report of the respective financial year annexed with the Company's Annual Reports which are available on the Company's website www.ipca.com.

Mr. Premchand Godha, Chairman & Managing Director, Mr. Pranay Godha and Mr. Prashant Godha, Executive Directors are related to each other. He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.

q) **Corporate Social Responsibility Committee**

As per Section 135 of the Companies Act, 2013, the Company has constituted a Corporate Social Responsibility (CSR) Committee of the Board of Directors comprising of Mr. Dev Parkash Yadava, Independent Director and Chairman of the Committee, Mr. Premchand Godha, Chairman & Managing Director, Mr. Ajit Kumar Jain, Joint Managing Director and Mr. Prashant Godha, Executive Director. The CSR Committee of the Board will be responsible for:

- formulating and recommending to the Board a Corporate Social Responsibility Policy which shall indicate the CSR activities to be undertaken by the Company;
- recommending the amount of expenditure to be incurred on the CSR activities; and
- monitoring the CSR Policy of the Company from time to time.

There were 4 (Four) meetings of this committee during the financial year 2016-17. The dates on which the said meetings were held are as follows:

30 th May, 2016	11 th August, 2016
11 th November, 2016	10 th February, 2017

The attendance of each member of the Corporate Social Responsibility Committee in the committee meetings is given below:

Name of the Member	No. of meetings held	No. of meetings attended
Mr. Dev Parkash Yadava	4	4
Mr. Premchand Godha	4	4
Mr. Ajit Kumar Jain	4	4
Mr. Prashant Godha	4	4

The CSR policy of the Company is placed on the website of the Company www.ipca.com.

r) **Reconciliation of Share Capital Audit:**

A qualified practising Company Secretary carries out a share capital audit to reconcile the total admitted equity share capital with NSDL and CDSL and the total issued and listed equity share capital of the Company. The audit report confirms that

the total issued/ paid-up capital is in agreement with the total number of shares in physical form and the total number of dematerialized shares held with NSDL and CDSL.

s) Dividend Distribution Policy

In terms of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Second Amendment) Regulations, 2016, the Company has formulated a Dividend Distribution Policy which has been uploaded on the website of the Company (http://www.ipca.com/pdf/corporate_policy/dividend_distribution_policy.pdf).


Annexure A

High/low of market price of the Company's shares traded on BSE Ltd (BSE) and National Stock Exchange of India Ltd. (NSE) during the financial year 2016-17 is furnished below:

Year	Month	Highest (₹)		Lowest (₹)	
		BSE	NSE	BSE	NSE
2016	April	581.70	583.05	480.00	478.60
	May	500.80	503.00	424.50	422.10
	June	502.65	502.80	402.00	404.00
	July	518.55	518.80	459.00	459.00
	August	559.40	559.90	493.75	493.10
	September	619.50	618.95	534.00	532.20
	October	643.00	644.00	601.00	599.55
	November	621.20	621.00	524.20	457.00
	December	588.00	589.40	512.20	512.95
2017	January	575.00	574.00	526.70	526.60
	February	573.60	574.00	514.10	514.05
	March	631.10	631.85	539.00	538.10

Annexure B

Graph of share price/ BSE Sensex



Annexure C

The distribution of shareholding as on 31 st March, 2017 is as follows :						
No. of equity shares held			No. of shareholders	%	No. of shares	%
Upto		500	57475	89.14	5219189	4.14
501	to	1000	4913	7.62	4454149	3.53
1001	to	2000	1004	1.56	1540245	1.22
2001	to	3000	301	0.47	780579	0.62
3001	to	4000	145	0.22	530278	0.42
4001	to	5000	125	0.19	594981	0.47
5001	to	10000	214	0.33	1551870	1.23
10001	and	above	303	0.47	111527818	88.37
Grand Total			64480	100.00	126199109	100.00
No. of shareholders in Physical Mode			4922	7.63	1619372	1.28
No. of shareholders in Electronic Mode			59558	92.37	124579737	98.72

Shareholding pattern as on 31 st March, 2017 is as follows :			
Categories of shareholders	No. of shareholders	No. of shares	% holding
Indian Promoters	17	58216236	46.13
Banks and Insurance Companies	5	292858	0.23
Mutual Funds / Foreign Mutual Funds	78	27783099	22.02
FII's / Foreign Portfolio Investors	109	18936627	15.00
NRI's	1568	612952	0.49
Domestic Companies / Other Bodies Corporates	1061	4059154	3.22
Resident Individuals/Others	61642	16298183	12.91
	64480	126199109	100.00

CEO/CFO CERTIFICATION

The Board of Directors

Ipca Laboratories Limited

48, Kandivli Industrial Estate,

Kandivli - West, Mumbai – 400 067.

We hereby certify that:

- We have reviewed financial statements and the cash flow statement for the year ended 31st March, 2017 and that to the best of our knowledge and belief:
 - these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- No transaction is entered into by the Company during the year which is fraudulent, illegal or violative of the Company's code of conduct.
- We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of the internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- We have indicated to the Auditors and the Audit Committee:
 - significant changes in internal control over financial reporting during the year;
 - significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For Ipca Laboratories Ltd.

Premchand Godha

Chairman & Managing Director / CEO

Ajit Kumar Jain

Joint Managing Director / CFO

Mumbai

28th May, 2017

CEO CERTIFICATION

To,
The Members of
Ipca Laboratories Ltd.

It is hereby certified and confirmed in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the Board members and the Senior Management personnel of the Company have affirmed compliance with the Code of Conduct of the Company for the financial year ended 31st March, 2017.

28th May, 2017

For Ipca Laboratories Limited
Premchand Godha
Chairman & Managing Director / CEO

PRACTISING COMPANY SECRETARIES' CERTIFICATE ON CORPORATE GOVERNANCE

To
The Members of
Ipca Laboratories Limited

We have examined the compliance of the conditions of Corporate Governance by Ipca Laboratories Limited (the Company) for the year ended on March 31, 2017, as stipulated in Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para C, D & E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

The compliance of the conditions of Corporate Governance is the responsibility of the management. Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us and the representations made by the Directors and the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the Listing Agreement and the Listing Regulations applicable for the respective periods as mentioned above.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **Parikh & Associates**
Practising Company Secretaries
Jigyasa N. Ved
Partner
FCS: 6488 CP: 6018

Mumbai
28th May, 2017

DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT		
a)	Aggregate number of shareholders and the outstanding shares in the suspense account lying at the beginning of the year	None
b)	Number of shareholders who approached listed entity for transfer of shares from suspense account during the year	None
c)	Number of shareholders to whom shares were transferred from suspense account during the year	None
d)	Aggregate number of shareholders and the outstanding shares in the suspense account lying at the end of the year	None
e)	That the voting rights on these shares shall remain frozen till the rightful owner of such shares claims the shares	Not Applicable

Note: The Company has sent three reminder letters, last one being 31st March, 2017 to the addresses of the shareholders whose unclaimed shares/share certificates, which were returned undelivered, are lying with the Company's Registrar's and Share Transfer Agents, requesting such shareholders to immediately claim their share certificate(s) by submitting the required proof. They have been informed about the requirement of transferring the unclaimed shares / share certificate(s) to the share suspense account to be created by the Company in respect of such unclaimed shares.

ANNEXURE 2

ANNUAL REPORT ON CSR ACTIVITIES

1. A brief outline of the Company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs

The Company believes that contributing to the overall health and wellness of our world starts with lessening our impact on the environment and we remain committed to the highest ethical standards in everything we do - right from research and development to sales and marketing.

The Company's Corporate Social Responsibility involves initiatives on a micro level to include patient health, employee and public safety, nurturing of environment and building sustainable communities. The Company also engages with external stakeholders including healthcare professionals, investors, customers, non-governmental organisations and suppliers in this endeavour.

The Company is committed to operate its business with emphasis on CSR in all areas of its operation. The Company integrates its business values and operations to meet the expectations of its shareholders, customers, employees, regulators, investors, suppliers, the community and take care of environment with best interest.

A definite and well structured Corporate Social Responsibility (CSR) policy has been framed by the Company and is available on its website (weblink http://www.ipca.com/pdf/corporate_policy/Corporate_Social_Responsibility_Policy.pdf). The CSR policy forms a part of the Company's corporate vision and defines its approach on key responsibility issues.

2. The Composition of the CSR Committee of the Board

Mr. Dev Parkash Yadava	-	Independent Director and Chairman of the Committee
Mr. Premchand Godha	-	Chairman & Managing Director
Mr. Ajit Kumar Jain	-	Joint Managing Director
Mr. Prashant Godha	-	Executive Director

3. Average net profit of the company for last three financial years: ₹ 357.15 Crores.

4. Prescribed CSR Expenditure (two percent of the amount as in item 3 above)

The Company was required to spend an amount of ₹ 7.14 crores as CSR expenditure for the financial year ended 31st March, 2017.

5. Details of CSR spent during the financial year:

- Total amount to be spent for the financial year: ₹ 7.14 crores.
Amount spent: ₹ 4.28 crores
- Amount unspent, if any: ₹ 2.86 crores.
- Manner in which the amount spent during the financial year is detailed below:

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Sr. No	CSR project or activity identified	Sector in which the Project is covered	Projects or Programs 1. Local area or other 2. Specify the State and district where projects or programs were undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or programs Sub-heads: 1. Direct expenditure on projects or programs 2. Overheads	Cumulative expenditure upto the reporting period (₹ Crores)	Amount spent: Direct or through implementing agency
1.	Promotion of Education, Vocational Training and Skill Enhancement Projects	Promotion of Education, Vocational Training and Skill Enhancement Projects	Rajasthan	Budgeted by Charitable Trust	Direct expenditure on projects or programs	3.00	Thru Charitable Trust
2.	Education/ Healthcare / Vocational Training & Skill Enhancement	Healthcare/ Vocational Training & Skill enhancement	Maharashtra	Budgeted by Charitable Trust	Direct expenditure on projects or programs	0.55	Thru Charitable Trust
3.	Education / Healthcare / Rural Development and Sports/Animal Welfare/Natural resource conservation/ drinking water/ sanitation/ national heritage, art and culture	Education / Healthcare / Rural Development and Sports/Animal Welfare/Natural resource conservation/ drinking water/ sanitation/ national heritage, art and culture	Madhya Pradesh, Maharashtra, Orissa, Gujarat, Sikkim, Uttarakhand, U.T. of D&NH, etc.	Budgeted by Company	Direct expenditure on approved CSR projects or programs	0.73	Directly by Company
	Total					4.28	

6. In case the company has failed to spend the two per cent of the average net profit of the last three financial years or any part thereof, the company shall provide the reasons for not spending the amount in its Board report

There is a deficit of ₹ 2.86 crores in the Company's CSR spent during the financial year under report. In view of the ongoing US FDA regulatory issues faced by the Company coupled with pricing pressure on products sold by the Company due to Governmental pharma policy changes across the globe as well as increased competition in the market place, there is profitability and margin pressure on Company's business which has impacted the Company's ability to spend the required amount under its CSR activities.

7. A responsibility statement of the CSR Committee that the implementation and monitoring of CSR Policy, is in compliance with CSR objectives and Policy of the Company

The CSR Committee of the Board confirms that it has implemented and monitored the CSR activities in accordance with and in compliance of CSR objectives and CSR Policy of the Company.

Mumbai
28th May, 2017

For and on behalf of the Board
Premchand Godha
Managing Director / CEO

Dev Parkash Yadava
Chairman CSR Committee

ANNEXURE 3

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:
 - (a) Name(s) of the related party and nature of relationship: Not Applicable
 - (b) Nature of contracts/arrangements/transactions: Not Applicable
 - (c) Duration of the contracts / arrangements/transactions: Not Applicable
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any: Not Applicable
 - (e) Justification for entering into such contracts or arrangements or transactions: Not Applicable
 - (f) Date(s) of approval by the Board: Not Applicable
 - (g) Amount paid as advances, if any: Not Applicable
 - (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188: Not Applicable
2. Details of material contracts or arrangement or transactions at arm's length basis:
 - (a) Name(s) of the related party and nature of relationship: Not Applicable
 - (b) Nature of contracts/arrangements/transactions: Not Applicable
 - (c) Duration of the contracts / arrangements/transactions: Not Applicable
 - (d) Salient terms of the contracts or arrangements or transactions including the value, if any: Not Applicable
 - (e) Date(s) of approval by the Board, if any: Not Applicable
 - (f) Amount paid as advances, if any: Not Applicable

Note: All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of Company's business. The Company has not entered into any contract, arrangement or transaction with any related party which could be considered as material within the meaning of Regulation 23(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All the related party transactions are disclosed in the notes to the financial statements.

Mumbai
28th May, 2017

For and on behalf of the Board
Premchand Godha
Chairman & Managing Director

ANNEXURE 4

DETAILS OF REMUNERATION AS REQUIRED UNDER SECTION 197(12) OF THE COMPANIES ACT, 2013 READ WITH RULE 5 (1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

- i. The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2016-17, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2016-17 is as under:

Sr. No.	Name of the Director / Key Managerial Person (KMP) and Designation	Remuneration of Director / KMP for the financial year 2016-17 (₹)	% increase/ (decrease) in remuneration in the financial year 2016-17	Ratio of remuneration of each Director to median remuneration of employees
1.	Mr. Premchand Godha (Chairman & Managing Director/CEO)	5,64,73,342	16%	263
2.	Mr. A. K. Jain (Joint Managing Director/CFO)	2,94,92,348	20%	137
3.	Mr. Pranay Godha (Executive Director)	1,36,08,011	15%	63
4.	Mr. Prashant Godha (Executive Director)	1,23,39,690	53%	57
5.	Mr. Babulal Jain (Independent Director)	5,50,000	-	3
6.	Mr. A. T. Kusre (Independent Director)	4,50,000	-	2
7.	Mr. Dev Parkash Yadava (Independent Director)	5,50,000	-	3
8.	Dr. Ramakanta Panda (Independent Director)	1,75,000	(36%)	-
9.	Dr. (Mrs.) Manisha Premnath (Independent Director)	1,75,000	(22%)	-
10.	Mr. Harish P. Kamath (Corporate Counsel & Company Secretary)	96,30,596	21%	45

- ii. The median remuneration of the employees of the Company during the financial year was ₹ 2,14,862/-.
- iii. In the financial year, there was an increase of 7.4% in the median remuneration of employees.
- iv. There were 13,303 permanent employees on the rolls of Company as on March 31, 2017.
- v. Average percentage increase made in the salaries of employees other than the managerial personnel in the financial year 2016-17 was 18.70% whereas there is an increase of 19.41% in the managerial remuneration for the same financial year.
- vi. It is hereby affirmed that the remuneration paid is as per the Remuneration Policy for Directors, Key Managerial Personnel and other Employees.

Mumbai
28th May, 2017

For and on behalf of the Board
Premchand Godha
Chairman & Managing Director

ANNEXURE 5

1. CONSERVATION OF ENERGY

(i) The steps taken or impact on conservation of energy :

The Company continues its policy of giving priority to energy conservation measures including regular review of energy generation and consumption and effective control on utilisation of energy.

The following energy conservation measures were implemented during the financial year:

- Close monitoring of cooling water and vacuum pumps.
- Optimization of pressure for compressed air and nitrogen line.
- Operational efficiency of chiller and brine plant.
- Leakage survey and plugging of compressed air network.
- Maintaining unity power factor.
- Impeller coating on all chilling, cooling and brine pumps of utilities section.
- Replacement of conventional lighting with LED lighting.
- Improvement in condensate recovery.

(ii) The steps taken by the Company for utilizing of alternate sources of energy :

The Company is evaluating all possibilities of utilizing alternate sources of energy in its operations, wherever possible, especially solar energy.

(iii) The capital investment on energy conservation equipments :

All the necessary capital and revenue expenditures were incurred by the Company on energy conservation equipments and consumables.

2. TECHNOLOGY ABSORPTION**Research & Development****(A) Specific areas in which R & D work was carried out by the Company:**

The Company's R & D Centres at Mumbai, Ratlam, Athal and Ranu are approved by Department of Scientific and Industrial Research, Government of India. These centres are also approved under Section 35 (2AB) of Income Tax Act, 1961 for the purposes of weighted tax deduction. The Company carries out R & D in several areas including:

- (i) Development of indigenous technologies for major drugs and intermediates, process improvements, technology absorption and optimisation of basic drugs, process simplification, etc.
- (ii) Improvement of existing processes to improve yields and quality, reduce cost and lead to eco friendly process.
- (iii) Development of newer dosage forms and new drug delivery systems.
- (iv) Development of non-infringing processes for APIs.

(B) Benefits derived as a result of the above R & D :

- (i) R & D efforts have helped bring out an improvement in processes, product design and operating efficiencies.
- (ii) Development of new formulations and line extensions.
- (iii) Development of various APIs and Intermediates.
- (iv) Development of new markets, adaptation to meet export requirements, quality upgradation and cost reduction.

(C) Future Plan of Action :

- (i) Development of various APIs/intermediates having good potential for exports and local market.
- (ii) Additional investment in manpower, latest instrumentation to upgrade and strengthen R & D facilities.
- (iii) Development of newer drug delivery systems.
- (iv) Development of formulations for developed market and bio-equivalence studies of the same.

(D) Expenditure on R & D:

	2016-17 (₹ Crores)	2015-16 (₹ Crores)
a) Capital	6.12	17.20
b) Revenue	119.55	120.47
c) Total	125.67	137.67
d) R & D expenditure as a percentage of turnover	4.06%	4.91%

(E) Imported technology (imported during last 5 years):

The Company has not imported any technology during the last 5 years.

3. FOREIGN EXCHANGE EARNINGS AND OUTGO**A) Earnings**

The CIF value of exports of the Company during the year aggregated to ₹ 1561.74 crores as against ₹ 1429.85 crores in the previous year.

B) Outgo

The foreign exchange outgo of the Company during the year aggregated to ₹ 457.10 crores as against ₹ 444.53 crores in the previous year.

Mumbai
28th May, 2017

For and on behalf of the Board
Premchand Godha
Chairman & Managing Director

ANNEXURE 6

Form No. MGT-9

EXTRACT OF ANNUAL RETURN

as on the financial year ended 31st March, 2017

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

- i) CIN: L24239MH1949PLC007837
- ii) Registration Date: 19.10.1949
- iii) Name of the Company: Ipca Laboratories Limited
- iv) Category / Sub-Category of the Company: Company limited by shares
- v) Address of the Registered office and contact details:
48, Kandivli Industrial Estate, Kandivli (W),
Mumbai – 400067. Tel: 022 – 6210 5000; e-mail: investors@ipca.com; website: www.ipca.com
- vi) Whether listed company: Yes
- vii) Name, Address and Contact details of Registrar and Transfer Agent, if any:
Link Intime India Private Limited
C 101, 247 Park, L B S Marg, Vikhroli West,
Mumbai 400 083. Tel No: 022 4918 6270; e-mail: rnt.helpdesk@linkintime.co.in

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

Sr. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
1.	Pharmaceuticals	21002	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

Sr. No.	Name And Address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1	Ipca Pharma Nigeria Ltd. 17, Osolo way, Ajao Estate Isolo, Lagos, Nigeria.	N.A.	Subsidiary	100% Subsidiary of Ipca Laboratories Ltd.	2(87)(ii)
2	Ipca Pharmaceuticals Inc. 51, Cragwood Road, Suite No.203, South Plainfield, NJ 07080, USA.	N.A.	Subsidiary	100% Subsidiary of Ipca Laboratories Ltd.	2(87)(ii)
3	Ipca Laboratories (UK) Ltd. Units 97-98, Silverbriar, Sunderland Enterprise Park East, Sunderland, SR5 2TQ UK	N.A.	Subsidiary	100% Subsidiary of Ipca Laboratories Ltd.	2(87)(ii)
4	Onyx Scientific Limited Silverbriar, Sunderland Enterprise Park East, Sunderland SR5 2TQ, UK	N.A.	Subsidiary	100% Subsidiary of Ipca Laboratories (UK) Ltd.	2(87)(ii)
5	Ipca Pharma (Australia) Pty. Ltd. 6, Morotai Avenue, Ashburton, VIC 3147, Melbourne, Australia.	N.A.	Subsidiary	100% Subsidiary of Ipca Laboratories Ltd.	2(87)(ii)
6	Ipca Pharma (NZ) Pty. Ltd 3-A, St. Oswalds Road, Greenland, Auckland 1061, New Zealand	N.A.	Subsidiary	100% Subsidiary of Ipca Pharma (Australia) Pty Ltd.	2(87)(ii)
7	Ipca Pharmaceuticals Limited, S.A de CV Presa La Angostura 116, Colonia Irrigacion Delegacion Miguel Hidalgo, C.P. 11500, Alvaro Obregon, Mexico D.F.	N.A.	Subsidiary	100% Subsidiary of Ipca Laboratories Ltd.	2(87)(ii)

Sr. No.	Name And Address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
8	Tonira Exports Ltd. 142AB, Kandivli Industrial Estate, Kandivli (W), Mumbai – 400067.	U51909MH1995PLC248308	Subsidiary	100% Subsidiary of Ipca Laboratories Ltd.	2(87)(ii)
9	Avik Pharmaceutical Ltd. Arvind Chambers, Gauri Compound, 188 Kurla Road, Ground Floor, Western Express Highway, Andheri (E), Mumbai - 400069	U99999MH1979PLC021711	Associate	49 %	2(6)
10	CCPL Software Private Ltd. 3, Sangam, 1st Floor, Opp. Traffic Police Chowki, Khar (West), Mumbai - 400052	U74999MH1995PTC092000	Associate	28.95%	2(6)
11	Trophic Wellness Pvt. Ltd. 142AB, Kandivli Industrial Estate, Kandivli (W), Mumbai – 400067.	U24100MH2010PTC206526	Associate	19.26%	2(6)
12	Krebs Biochemicals & Industries Ltd. Kothapalli village, Kasimkota Mandal, Anakapalli, Hyderabad 531 031	L24110AP1991PLC103912	Associate	29.83%	2(6)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year (01.04.2016)				No. of Shares held at the end of the year (31.03.2017)				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual/HUF	10497946	--	10497946	8.32	10746027	--	10746027	8.51	0.19
b) Central Govt.	--	--	--	--	--	--	--	--	--
c) State Govt. (s)	--	--	--	--	--	--	--	--	--
d) Bodies Corp.	47420209	--	47420209	37.57	47470209	--	47470209	37.62	0.05
e) Banks / FI	--	--	--	--	--	--	--	--	--
f) Any Other....	--	--	--	--	--	--	--	--	--
Sub-total (A) (1):-	57918155	--	57918155	45.89	58216236	--	58216236	46.13	0.24
(2) Foreign									
a) NRIs - Individuals	--	--	--	--	--	--	--	--	--
b) Other -Individuals	--	--	--	--	--	--	--	--	--
c) Bodies Corp.	--	--	--	--	--	--	--	--	--
d) Banks / FI	--	--	--	--	--	--	--	--	--
e) Any Other....	--	--	--	--	--	--	--	--	--
Sub-total (A) (2):-	--	--	--	--	--	--	--	--	--
Total shareholding of Promoter (A) = (A)(1) + (A)(2)	57918155	--	57918155	45.89	58216236	--	58216236	46.13	0.24
B. Public Shareholding									
(1) Institutions									
a) Mutual Funds	20813774	5000	20818774	16.50	27096515	5000	27101515	21.48	4.98
b) Banks / FI	156883	1000	157883	0.13	291858	1000	292858	0.23	0.10
c) Central Govt.	--	--	--	--	--	--	--	--	--
d) State Govt. (s)	--	--	--	--	--	--	--	--	--
e) Venture Capital Funds	--	--	--	--	--	--	--	--	--
f) Insurance Companies	--	--	--	--	--	--	--	--	--

Category of Shareholders	No. of Shares held at the beginning of the year (01.04.2016)				No. of Shares held at the end of the year (31.03.2017)				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
g) FII's	12417273	16500	12433773	9.85	1212405	16500	1228905	0.97	(8.88)
h) Foreign Venture Capital Funds	--	--	--	--	--	--	--	--	--
i) Others (specify)									
Foreign Mutual Fund	673453	--	673453	0.53	681584	--	681584	0.54	0.01
Sub-total (B)(1):-	34061383	22500	34083883	27.01	29282362	22500	29304862	23.22	(3.79)
(2) Non-Institutions									
a) Bodies Corp.									
i) Indian	3993013	12620	4005633	3.18	4046534	12620	4059154	3.22	0.04
ii) Overseas	--	--	--	--	--	--	--	--	--
b) Individuals									
i) Individual shareholders holding nominal share capital upto ₹ 1 lakh	12092181	1670124	13762305	10.91	12936559	1579622	14516181	11.50	0.59
ii) Individual shareholders holding nominal share capital in excess of ₹ 1 lakh	1108524	--	1108524	0.88	1042436	--	1042436	0.83	(0.05)
c) Others (specify)									
(c-i) Clearing Member	89063	--	89063	0.07	199387	--	199387	0.16	0.09
(c-ii) Market Maker	3914	--	3914	0.00	11757	--	11757	0.01	0.01
(c-iii) HUF	491396	--	491396	0.39	528422	--	528422	0.42	0.03
(c-iv) Foreign Holding									
NRI (Repatriate)	297620	4630	302250	0.24	391852	4630	396482	0.32	0.08
NRI (Non Repatriate)	256233	--	256233	0.20	216470	--	216470	0.17	(0.03)
(c-v) Foreign Portfolio Investor (Corporate)	14177753	--	14177753	11.23	17707722	--	17707722	14.03	2.80
Sub-total (B)(2):-	32509697	1687374	34197071	27.10	37081139	1596872	38678011	30.65	3.55
Total Public Shareholding (B)=(B)(1) + (B)(2)	66571080	1709874	68280954	54.11	66363501	1619372	67982873	53.87	(0.24)
C. Shares held by Custodian for GDRs & ADRs	--	--	--	--	--	--	--	--	--
Grand Total (A+B+C)	124489235	1709874	126199109	100.00	124579737	1619372	126199109	100.00	--

ii) Shareholding of Promoters

Sr. No	Shareholder's Name	Shareholding at the beginning of the year (01.04.2016)			Share holding at the end of the year (31.03.2017)			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	Kaygee Investments Pvt. Ltd.	27018195	21.41	--	27018195	21.41	--	--
2	Chandurkar Investments Pvt. Ltd.	6978005	5.53	--	6978005	5.53	--	--

Sr. No	Shareholder's Name	Shareholding at the beginning of the year (01.04.2016)			Share holding at the end of the year (31.03.2017)			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
3	Kaygee Laboratories Pvt. Ltd. (Formerly Exon Laboratories Pvt. Ltd.)	8271000	6.55	--	8321000	6.59	--	0.04
4	Paschim Chemicals P. Ltd.	5029000	3.99	--	5029000	3.99	--	--
5	Paranthapa Investments and Traders P. Ltd.	15500	0.01	--	15500	0.01	--	--
6	Makers Laboratories Ltd	101480	0.08	--	101480	0.08	--	--
7	M. R. Chandurkar	2151000	1.70	--	2151000	1.70	--	--
8	Usha M. Chandurkar	2000000	1.59	--	2000000	1.59	--	--
9	Sameer M. Chandurkar	1000000	0.79	--	1000000	0.79	--	--
10	Premchand Godha	2681340	2.13	--	2681340	2.13	--	--
11	Usha P. Godha	1209370	0.96	--	1209370	0.96	--	--
12	Prashant Godha	731800	0.58	--	759322	0.60	--	0.02
13	Pranay Godha	606936	0.48	--	825495	0.65	--	0.17
14	Nirmal Jain	115000	0.09	0.03	115000	0.09	0.01	--
15	Bhawna Godha	2500	0.00	--	2500	0.00	--	--
16	Neetu Godha	--	--	--	2,000	0.00	--	--
17	Mexin Medicaments Private Limited	7029	0.00	--	7029	0.01	--	--
	Total	57918155	45.89	0.03	58216236	46.13	0.01	0.24

iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sr. No	Name of the Promoter	Date	Shareholding at the beginning of the year (01.04.2016)		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Pranay Godha					
	At the beginning of the year	01.04.2016	606936	0.48	--	--
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	06.06.2016	2081	0.00	609017	0.48
		13.07.2016	100000	0.08	709017	0.56
		15.07.2016	7000	0.01	716017	0.57
		26.09.2016	12478	0.01	728495	0.58
		03.10.2016	82000	0.06	810495	0.64
		16.11.2016	15000	0.01	825495	0.65
	At the End of the year	31.03.2017		--	825495	0.65
2	Prashant Godha					
	At the beginning of the year	01.04.2016	731800	0.58	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	23.09.2016	27522	0.02	759322	0.60
	At the End of the year	31.03.2017	--	--	759322	0.60

Sr. No	Name of the Promoter	Date	Shareholding at the beginning of the year (01.04.2016)		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
3	Neetu Godha					
	At the beginning of the year	01.04.2016	--	--	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	06.06.2016	2000	0.00	2000	0.00
	At the End of the year	31.03.2017	--	--	2000	0.00
4	Kaygee Laboratories Pvt. Ltd.					
	At the beginning of the year	01.04.2016	8271000	6.55	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	19.10.2016	50000	0.04	8321000	6.59
	At the End of the year	31.03.2017	--	--	8321000	6.59

Note: Except for the above, there is no change in the shareholding of other promoters.

iv) **Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):**

Sr. No.	For Each of the Top 10 Shareholders	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	ICICI Prudential					
	At the beginning of the year	01.04.2016	4255598	3.37	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	08.04.2016	10064	0.01	4265662	3.38
		15.04.2016	914278	0.72	5179940	4.10
		22.04.2016	1109423	0.88	6289363	4.98
		29.04.2016	465041	0.37	6754404	5.35
		06.05.2016	199506	0.16	6953910	5.51
		13.05.2016	7592	0.01	6961502	5.51
		20.05.2016	1285377	1.02	8246879	6.53
		27.05.2016	24341	0.02	8271220	6.55
		03.06.2016	120302	0.10	8391522	6.65
		10.06.2016	34298	0.03	8425820	6.68
		11.11.2016	243136	0.19	8668956	6.87
		18.11.2016	18030	0.01	8686986	6.88
		25.11.2016	72032	0.06	8759018	6.94
		16.12.2016	30823	0.02	8789841	6.96
		03.02.2017	24095	0.02	8813936	6.98
		17.02.2017	20000	0.01	8833936	7.00
		24.03.2017	26439	0.02	8860375	7.02
		31.03.2017	(273268)	(0.22)	8587107	6.80
	At the End of the year	31.03.2017	--	--	8587107	6.80
2.	HDFC Trustee Company					
	At the beginning of the year	01.04.2016	5242021	4.15	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	15.04.2016	(240000)	(0.19)	5002021	3.96
		05.08.2016	20000	0.02	5022021	3.98
		24.02.2017	142000	0.11	5164021	4.09
		03.03.2017	350000	0.28	5514021	4.37
		31.03.2017	387093	0.31	5901114	4.68
	At the End of the year	31.03.2017	--	--	5901114	4.68

Sr. No.	For Each of the Top 10 Shareholders	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
3.	Lavender Investments Limited					
	At the beginning of the year	01.04.2016	4989773	3.95	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	--	--	--	--	--
	At the End of the year	31.03.2017	--	--	4989773	3.95
4.	DSP Blackrock					
	At the beginning of the year	01.04.2016	3067788	2.43	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	15.04.2016	70000	0.06	3137788	2.49
		22.04.2016	74794	0.06	3212582	2.54
		29.04.2016	232382	0.18	3444964	2.73
		20.05.2016	(150725)	(0.12)	3294239	2.61
		03.06.2016	(40565)	(0.03)	3253674	2.58
		24.06.2016	(21311)	(0.02)	3232363	2.56
		30.06.2016	(57891)	(0.05)	3174472	2.51
		01.07.2016	(22733)	(0.02)	3151739	2.50
		08.07.2016	(17029)	(0.01)	3134710	2.48
		22.07.2016	721948	0.57	3856658	3.06
		29.07.2016	82461	0.07	3939119	3.12
		05.08.2016	34218	0.03	3973337	3.15
		19.08.2016	146643	0.12	4119980	3.26
		26.08.2016	50162	0.04	4170142	3.30
		09.09.2016	10000	0.01	4180142	3.31
		30.09.2016	(120427)	(0.10)	4059715	3.22
		21.10.2016	13965	0.01	4073680	3.23
		28.10.2016	(8221)	(0.01)	4065459	3.22
		04.11.2016	(31412)	(0.02)	4034047	3.20
		11.11.2016	(1701)	0.00	4032346	3.19
		25.11.2016	74000	0.06	4106346	3.25
		13.01.2017	(51276)	(0.04)	4055070	3.21
		27.01.2017	(7500)	(0.01)	4047570	3.21
		03.02.2017	(15531)	(0.01)	4032039	3.19
		17.02.2017	(110186)	(0.09)	3921853	3.11
		24.02.2017	(178270)	(0.14)	3743583	2.97
		03.03.2017	8712	0.01	3752295	2.97
		10.03.2017	(23969)	(0.02)	3728326	2.95
		17.03.2017	249533	0.20	3977859	3.15
		24.03.2017	9356	0.01	3987215	3.16
	At the End of the year	31.03.2017	--	--	3987215	3.16

Sr. No.	For Each of the Top 10 Shareholders	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
5.	Axis Mutual Fund Trustee Limited					
	At the beginning of the year	01.04.2016	2520412	2.00	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	08.04.2016	10000	0.01	2530412	2.00
		15.04.2016	200000	0.16	2730412	2.16
		06.05.2016	(40000)	(0.03)	2690412	2.13
		13.05.2016	(50000)	(0.04)	2640412	2.09
		20.05.2016	(20000)	(0.02)	2620412	2.08
		27.05.2016	(20000)	(0.02)	2600412	2.06
		03.06.2016	(160000)	(0.13)	2440412	1.93
		10.06.2016	(70000)	(0.06)	2370412	1.88
		05.08.2016	456213	0.36	2826625	2.24
		09.12.2016	(222396)	(0.18)	2604229	2.06
		16.12.2016	(27604)	(0.02)	2576625	2.04
		13.01.2017	(30000)	(0.02)	2546625	2.02
		03.02.2017	(35227)	(0.03)	2511398	1.99
		10.02.2017	(64765)	(0.05)	2446633	1.94
		17.02.2017	(126214)	(0.10)	2320419	1.84
	At the End of the year	31.03.2017	--	--	2320419	1.84
6.	Saif India IV FII Holdings Limited/Saif Advisors Mauritius Limited					
	At the beginning of the year	01.04.2016	2010533	1.59	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	2010533	1.59
7.	Unit Trust of India					
	At the beginning of the year	01.04.2016	1744278	1.38	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	15.04.2016	1000	0.00	1745278	1.38
		06.05.2016	13000	0.01	1758278	1.40
		20.05.2016	13000	0.01	1771278	1.40
		07.10.2016	(10000)	(0.01)	1761278	1.39
		28.10.2016	(10000)	(0.01)	1751278	1.39
		18.11.2016	(10000)	(0.01)	1741278	1.38
		06.01.2017	(10000)	(0.01)	1731278	1.37
	At the End of the year	31.03.2017	--	--	1731278	1.37
8.	Government Pension Fund Global					
	At the beginning of the year	01.04.2016	1206935	0.96	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	22.07.2016	106000	0.08	1312935	1.04
		05.08.2016	250155	0.20	1563090	1.24
		21.10.2016	(2737)	0.00	1560353	1.24
	At the End of the year	31.03.2017	--	--	1560353	1.24

Sr. No.	For Each of the Top 10 Shareholders	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
9.	T. Rowe Price International Discovery Fund					
	At the beginning of the year	01.04.2016	1413585	1.12	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	--		--	--	--
	At the End of the year	31.03.2017	--	--	1413585	1.12
10.	Goldman Sachs India Limited					
	At the beginning of the year	01.04.2016	1255657	0.99	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	31.03.2017	22187	0.02	1277844	1.01
	At the End of the year	31.03.2017	--	--	1277844	1.01
11.	Reliance Capital Trustee Co. Ltd					
	At the beginning of the year	01.04.2016	1598851	1.27	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	10.06.2016	50000	0.04	1648851	1.31
		17.06.2016	681600	0.54	2330451	1.85
		09.09.2016	(135000)	(0.11)	2195451	1.74
		23.09.2016	(194000)	(0.15)	2001451	1.58
		30.09.2016	(41700)	(0.03)	1959751	1.55
		07.10.2016	(208100)	(0.16)	1751651	1.39
		21.10.2016	(40000)	(0.03)	1711651	1.36
		28.10.2016	(26000)	(0.02)	1685651	1.33
		04.11.2016	(14800)	(0.01)	1670851	1.32
		11.11.2016	(22000)	(0.02)	1648851	1.31
		02.12.2016	(50000)	(0.04)	1598851	1.27
		27.01.2017	(35911)	(0.03)	1562940	1.24
		03.02.2017	(99436)	(0.08)	1463504	1.16
		10.02.2017	(113951)	(0.09)	1349553	1.07
		17.02.2017	(187300)	(0.15)	1162253	0.92
		24.02.2017	(207896)	(0.16)	954357	0.76
		03.03.2017	(100000)	(0.08)	854357	0.68
		31.03.2017	(50000)	(0.04)	804357	0.64
	At the End of the year	31.03.2017	--	--	804357	0.64
12.	Franklin Templeton Investment Funds					
	At the beginning of the year	01.04.2016	3237807	2.57	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	15.04.2016	(301700)	(0.24)	2936107	2.33
		22.04.2016	(14000)	(0.01)	2922107	2.31
		29.04.2016	(556500)	(0.44)	2365607	1.87
		06.05.2016	(193460)	(0.15)	2172147	1.72
		30.06.2016	(700)	(0.00)	2171447	1.72
		01.07.2016	(2937)	(0.00)	2168510	1.72
		22.07.2016	(692300)	(0.55)	1476210	1.17
		29.07.2016	(518200)	(0.41)	958010	0.76
		05.08.2016	(958010)	(0.76)	0	0.00
	At the End of the year	31.03.2017	--	--	0	0.00

Sr. No.	For Each of the Top 10 Shareholders	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
13.	Dendana Investments (Mauritius) Limited					
	At the beginning of the year	01.04.2016	2826855	2.24	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	22.04.2016	(451000)	(0.36)	2375855	1.88
		13.05.2016	(4998)	(0.00)	2370857	1.88
		20.05.2016	(1169295)	(0.93)	1201562	0.95
		27.05.2016	(36836)	(0.03)	1164726	0.92
		03.06.2016	(291841)	(0.23)	872885	0.69
		10.06.2016	(872885)	(0.69)	0	0.00
	At the End of the year	31.03.2017	--	--	0	0.00

v) Shareholding of Directors and Key Managerial Personnel:

Sr. No.	For Each of the Directors and KMP	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Mr. Premchand Godha Chairman and Managing Director/CEO					
	At the beginning of the year	01.04.2016	2681340	2.13	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	2681340	2.13
2.	Mr. Ajit Kumar Jain Joint Managing Director/CFO					
	At the beginning of the year	01.04.2016	66000	0.05	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	66000	0.05
3.	Mr. Pranay Godha Executive Director					
	At the beginning of the year	01.04.2016	606936	0.48	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	06.06.2016	2081	0.00	609017	0.48
		13.07.2016	100000	0.08	709017	0.56
		15.07.2016	7000	0.01	716017	0.57
		26.09.2016	12478	0.01	728495	0.58
		03.10.2016	82000	0.06	810495	0.64
		16.11.2016	15000	0.01	825495	0.65
	At the End of the year	31.03.2017	--	--	825495	0.65

Sr. No.	For Each of the Directors and KMP	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
4.	Mr. Prashant Godha Executive Director					
	At the beginning of the year	01.04.2016	731800	0.58	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	23.09.2016	27522	0.02	759322	0.60
	At the End of the year	31.03.2017	--	--	759322	0.60
5.	Mr. Babulal Jain Independent Director					
	At the beginning of the year	01.04.2016	25500	0.02	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	25500	0.02
6.	Mr. Dev Parkash Yadava Independent Director					
	At the beginning of the year	01.04.2016	4629	0.00	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	21.06.2016	5000	0.00	9629	0.01
		24.06.2016	5000	0.00	14629	0.01
	At the End of the year	31.03.2017	--	--	14629	0.01
7.	Mr. Anand T Kusre Independent Director					
	At the beginning of the year	01.04.2016	--	--	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	--	--
8.	Dr. Ramakanta Panda Independent Director					
	At the beginning of the year	01.04.2016	--	--	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	--	--

Sr. No.	For Each of the Directors and KMP	Date	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
			No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
9.	Dr. (Mrs) Manisha Premnath Independent Director					
	At the beginning of the year	01.04.2016	--	--	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	--	--
10.	Mr. Harish Kamath Company Secretary					
	At the beginning of the year	01.04.2016	7500	0.01	--	--
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):		--	--	--	--
	At the End of the year	31.03.2017	--	--	7500	0.01

V) INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

(₹ Lacs)

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year (01.04.2016)				
i) Principal Amount	73662.46	12857.91	0.00	86520.37
ii) Interest due but not paid	0.00	0.00	0.00	0.00
iii) Interest accrued but not due	213.25	60.12	0.00	273.37
Total (i+ii+iii)	73875.71	12918.03	0.00	86793.74
Change in Indebtedness during the financial year				
i) Addition	101606.26	98.60	0.00	101704.86
ii) Reduction	108732.54	8018.50	0.00	116751.04
Net Change	(7126.28)	(7919.90)	0.00	(15046.18)
Indebtedness at the end of the financial year (31.03.2017)				
i) Principal Amount	66631.56	4945.06	0.00	71576.62
ii) Interest due but not paid	0.00	0.00	0.00	0.00
iii) Interest accrued but not due	117.87	53.07	0.00	170.94
Total (i+ii+iii)	66749.43	4998.13	0.00	71747.56

VI) REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sr. no.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total (₹)
		Mr. Premchand Godha (Chairman & Managing Director /CEO)	Mr. Ajit Kumar Jain (Joint Managing Director/ CFO)	Mr. Pranay Godha (Executive Director)	Mr. Prashant Godha (Executive Director)	
1.	Gross salary					
	a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	3,63,00,000	1,32,00,000	66,00,000	59,30,000	6,20,30,000
	b) Value of perquisites u/s 17(2) Income-tax Act, 1961	2,01,73,342	1,62,92,348	70,08,011	64,09,690	4,98,83,391
	c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	-	-
2.	Stock Option	-	-	-	-	-
3.	Sweat Equity	-	-	-	-	-
4.	Commission					
	as % of profit/others, specify (as approved by Board)	-	-	-	-	-
5.	Others, please specify	-	-	-	-	-
	Total (A)	5,64,73,342	2,94,92,348	1,36,08,011	1,23,39,690	11,19,13,391
	Ceiling as per the Act	₹ 26.90 crores (being 10% of the profits of the Company calculated as per Section 197 and 198 of the Companies Act, 2013)				

B. Remuneration to other directors:

Sr. no.	Particulars of Remuneration	Name of Directors					Total (₹)
		Mr. Babulal Jain	Mr. Anand T Kusre	Mr. Dev Parkash Yadava	Dr. Ramakanta Panda	Dr. Manisha Premnath	
1.	Independent Directors						
	Fee for attending board / committee meetings	5,50,000	4,50,000	5,50,000	1,75,000	1,75,000	19,00,000
	Commission	-	-	-	-	-	-
	Others, please specify	-	-	-	-	-	-
	Total (1)	5,50,000	4,50,000	5,50,000	1,75,000	1,75,000	19,00,000
2.	Other Non-Executive Directors						
	Fee for attending board / committee meetings	-	-	-	-	-	-
	Commission	-	-	-	-	-	-
	Others, please specify	-	-	-	-	-	-
	Total (2)	-	-	-	-	-	-
	Total (B)=(1+2)	-	-	-	-	-	-
	Total Managerial Remuneration (A+B)	-	-	-	-	-	11,38,13,391
	Overall Ceiling as per the Act	₹ 29.59 crores (being 11% of the profits of the Company calculated as per Section 197 and 198 of the Companies Act, 2013)					

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Sr. no.	Particulars of Remuneration	Key Managerial Personnel	
		Mr. Harish P Kamath (Company Secretary)	Total (₹)
1.	Gross salary		
	a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	94,53,587	94,53,587
	b) Value of perquisites u/s 17(2) Income-tax Act, 1961	1,77,009	1,77,009
	c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-
2.	Stock Option	-	-
3.	Sweat Equity	-	-
4.	Commission - as % of profit - others, specify (as decided by Board)	-	-
5.	Others, please specify	-	-
	Total	96,30,596	96,30,596

Remuneration of CEO and CFO who are also Wholetime Directors is given in Item No. VI (A) above.

VII) PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
Penalty			NIL		
Punishment					
Compounding					
OTHER OFFICERS IN DEFAULT					
Penalty			NIL		
Punishment					
Compounding					

Mumbai
28th May, 2017

For and on behalf of the Board
Premchand Godha
Chairman & Managing Director

Business Responsibility (BR) Report

SECTION A: GENERAL INFORMATION ABOUT THE COMPANY

Sr. No.	Particulars	Details
1.	Corporate Identity Number	L24239MH1949PLC007837
2.	Name of the Company	Ipca Laboratories Limited
3.	Registered address	48, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067
4.	Website	www.ipca.com
5.	E-mail id	investors@ipca.com
6.	Financial Year reported	1 st April, 2016 to 31 st March, 2017
7.	Sector(s) that the Company is engaged (industrial activity code-wise)	Pharmaceuticals. NIC Code - 21002
8.	List of key products/services that the Company manufactures/provides (as in balance sheet)	The Company is engaged in the manufacturing and marketing of pharmaceuticals. Key products are : 1. Hydroxychloroquine Sulphate 2. Artemether & Lumefantrine 3. Aceclofenac and its combinations
9.	Total number of locations where business activity is undertaken by the Company	
	(a) Number of International Locations (provide details of major 5)	The Company has non-trading offices in several countries in South East Asia, CIS and Africa. The Company's wholly owned subsidiary has a contract research and manufacturing centre in the United Kingdom.
	(b) Number of National Locations –	The Company has 17 manufacturing facilities details of which are provided in the Annual Report. The Company's R&D Centres are located at Mumbai, Ranu, Ratlam & Silvassa. The Registered and Corporate offices of the Company are at Mumbai. The Company has pan India Distribution network.
10.	Markets served by the Company - Local/ State/National/International	The Company's products are sold across the globe.

SECTION B: FINANCIAL DETAILS OF THE COMPANY

Sr. No.	Particulars	Details
1.	Paid up Capital (INR)	₹ 25.24 crores
2.	Total Turnover (INR)	₹ 3178.87 crores
3.	Total profit after taxes (INR)	₹ 188.29 crores
4.	Total Spending on Corporate Social Responsibility (CSR) as percentage of profit after tax (%)	₹ 4.28 crores. 2.27% of the net profit for the financial year 2016-17.
5.	List of activities in which expenditure in 4 above has been incurred	Mainly in the field of education, medical relief and poverty elevation.

SECTION C: OTHER DETAILS

Sr.No.	Particulars	Details
1	Does the Company have any Subsidiary Company/ Companies?	The Company has 6 wholly owned subsidiaries and 2 wholly owned subsidiaries of the wholly owned subsidiaries.
2	Do the Subsidiary Company/Companies participate in the BR Initiatives of the parent Company? If yes, then indicate the number of such subsidiary company(s)	Most of the subsidiaries are incorporated mainly to hold product registrations and therefore, do not generate material revenue and do not directly participate in the BR initiatives of the parent Company.
3	Do any other entity/entities (e.g. suppliers, distributors etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity/entities?	There is no direct participation in the Company's BR initiatives by Company's suppliers, distributors, etc.

SECTION D: BR INFORMATION

1. Details of Director/Directors responsible for BR

(a) Details of the Director/Directors responsible for implementation of the BR policy :

Sr.No.	Particulars	Details
1	DIN Number	00012657
2	Name	Mr. Ajit Kumar Jain
3	Designation	Joint Managing Director

(b) Details of the BR head

Sr.No.	Particulars	Details
1	DIN Number	00012657
2	Name	Mr. Ajit Kumar Jain
3	Designation	Joint Managing Director
4	Telephone No.	022-6210 6020
5	E-mail id	ajit.jain@ipca.com

2. Principle-wise (as per NVGs) BR Policy/policies

(a) Details of compliance

Sr. No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
1	Do you have a policy/ policies for	Yes, wherever necessary.								
2	Has the policy being formulated in consultation with the Relevant Stakeholders?	The policies have been formulated in consultation with the Company's Corporate Management Team and are approved by the Board of Directors.								
3	Does the policy conform to any national / international standards? If yes, specify?	All the policies are framed keeping in mind the compliances with the national standards/requirements.								
4	Has the policy being approved by the Board? If yes, has it been signed by MD/ owner/ CEO/ appropriate Board Director?	The policies are approved by the Board, signed by the Managing Director/CEO and many of which are also placed on the website of the Company, www.ipca.com								
5	Does the company have a specified committee of the Board/ Director/ Official to oversee the implementation of the policy?	The implementation of the policies are periodically reviewed by the Corporate Management Team of the Company.								
6	Indicate the link for the policy to be viewed online?	www.ipca.com								
7	Has the policy been formally communicated to all relevant internal and external Stakeholders?	Many of the Company's policies are placed on the website of the Company and can be viewed by the Company's internal and external stakeholders. The other relevant policies are made available upon request by any stakeholder.								

Sr. No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
8	Does the company have in-house structure to implement the policy/ policies?	Yes								
9	Does the Company have a grievance redressal mechanism related to the policy/ policies to address Stakeholders' grievances related to the policy/ policies?	Yes								
10	Has the company carried out independent audit/ evaluation of the working of this policy by an internal or external agency?	Effectiveness of the policies are periodically reviewed/evaluated by the Company's Corporate Management Team. However, the Company has not carried out any independent evaluation/audit of the working of these policies by external agency.								

(b) If answer to the question at serial number 1 against any principle, is 'No', please explain why: (Tick up to 2 options)

No.	Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
1.	The company has not understood the Principles	NOT APPLICABLE								
2.	The company is not at a stage where it finds itself in a position to formulate and implement the policies on specified principles									
3.	The company does not have financial or manpower resources available for the task									
4.	It is planned to be done within next 6 months									
5.	It is planned to be done within the next 1 year									
6.	Any other reason (please specify)									

3. Governance related to BR

Sr.No.	Particulars	Details
1	Frequency with which the Board of Directors, Committee of the Board or CEO to assess the BR Performance of the Company. (Within 3 months, 3-6 months, Annually, More than 1 year)	All the policies of the Company are reviewed on a quarterly basis by the Company's Corporate Management Team consisting of all Wholetime working Directors and other senior managerial employees of the Company.
2	Does the Company publish a BR or a Sustainability Report?	The Company does not propose to publish a Business Responsibility or Sustainability Report.
	What is the hyperlink for viewing this report?	Business responsibility report will be placed on the website of the Company as and when prepared.
	How frequently it is published?	Please see the answer above.

SECTION E: PRINCIPLE-WISE PERFORMANCE

Principle 1 – Businesses should conduct and govern themselves with Ethics, Transparency and Accountability	
1	Does the policy relating to ethics, bribery and corruption cover only the company? Yes/ No. Does it extend to the Group/Joint Ventures/ Suppliers/Contractors/NGOs /Others? The policy covers all the stakeholders of the Company, internal as well as external.
2	How many stakeholder complaints have been received in the past financial year and what percentage was satisfactorily resolved by the management? Other than normal business related complaints in the ordinary course of the Company's business, no other material complaint has been received from any of the stakeholder in the financial year under report. All the complaints received are satisfactorily resolved.

Principle 2 - Businesses should provide goods and services that are safe and contribute to sustainability throughout their life cycle

1	List up to 3 of your products or services whose design has incorporated social or environmental concerns, risks and/or opportunities.
(a)	All the pharmaceuticals manufactured by the Company meet the pharmacopeial requirements.
(b)	Pharmacovigilance activities are carried out in the markets serviced by the Company.
(c)	Safety/Stability of the products are continuously monitored as per the standard operating procedures of the Company.
2	For each such product, provide the following details in respect of resource use (energy, water, raw material etc.) per unit of product(optional)
(a)	Reduction during sourcing/production/ distribution achieved since the previous year throughout the value chain? The Company monitors these activities on a continuous basis. However, in view of varied nature of products and packs, the compilation of accurate information is not feasible.
(b)	Reduction during usage by consumers (energy, water) has been achieved since the previous year? Please see the information furnished under (a) above.
3	Does the company have procedures in place for sustainable sourcing (including transportation)? The philosophy of the Company is to continuously work on the indigenization of its key raw materials to reduce dependence on imports and to reduce cost in order to be competitive as well as to have alternate source of dependable supply for uninterrupted supply chain.
(a)	If yes, what percentage of your inputs was sourced sustainably? Also, provide details thereof, in about 50 words or so. Due to the Company's policy as stated above, the consumption of imported raw materials have come down in the current year under report.
4	Has the company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work? Yes
(a)	If yes, what steps have been taken to improve their capacity and capability of local and small vendors? The Company provides necessary regulatory and technical support to small vendors providing goods and services to the Company. Regular Vendor Audits are carried out and reports are shared with small vendors for improvement in their quality systems.
5	Does the company have a mechanism to recycle products and waste? If yes what is the percentage of recycling of products and waste (separately as <5%, 5-10%, >10%). Also, provide details thereof, in about 50 words or so. Being in the highly regulated industry, re-cycling of products is not possible/permissible. However, wherever possible, industrial solvents are recovered and reused. Similarly, catalysts used in the processes are regenerated and reused.

Principle 3 - Businesses should promote the wellbeing of all employees

1	Total number of employees	13,303
2	Total number of employees hired on temporary/ contractual/casual basis.	5,737
3	Number of permanent women employees.	877
4	Number of permanent employees with disabilities	This information is being compiled
5	Do you have an employee association that is recognized by management?	Yes
6	What percentage of your permanent employees is members of this recognized employee association?	About 20%
7	Number of complaints relating to child labour, forced labour, involuntary labour, sexual harassment in the last financial year and pending, as on the end of the financial year.	
	Category	No of complaints filed during the financial year
(a)	Child labour/forced labour/involuntary labour	None
(b)	Sexual harassment	9
(c)	Discriminatory Employment	None
	The Company has adopted a policy in line with the requirements of Prevention of Sexual Harassment of Women at the Workplace and a Committee has been set-up to redress sexual harassment complaints received. The necessary annual report has been submitted to the competent authority in this regard.	

8	What percentage of your under mentioned employees were given safety & skill upgradation training in the last year?	
(a)	Permanent Employees	All employees are trained on safety and job skills before their induction in the organization. Also need based regular safety and job skills trainings as well as re-trainings are imparted based on requirements and observations.
(b)	Permanent Women Employees	
(c)	Casual/Temporary/Contractual Employees	
(d)	Employees with Disabilities	

Principle 4 - Businesses should respect the interests of, and be responsive towards all stakeholders, especially those who are disadvantaged, vulnerable and marginalized.

1	Has the company mapped its internal and external stakeholders?
	Yes. The Company has mapped its internal and external stakeholders.
2	Out of the above, has the company identified the disadvantaged, vulnerable & marginalized stakeholders
	Yes.
3	Are there any special initiatives taken by the company to engage with the disadvantaged, vulnerable and marginalized stakeholders. If so, provide details thereof, in about 50 words or so
	Company generally provides its highest attention to the needs of disadvantaged and marginalized stakeholders.

Principle 5 - Businesses should respect and promote human rights

1	Does the policy of the company on human rights cover only the company or extend to the Group/Joint Ventures/Suppliers/Contractors/NGOs/Others?
	The Company's policy on human rights extends to subsidiaries and group companies / ventures.
2	How many stakeholder complaints have been received in the past financial year and what percent was satisfactorily resolved by the management?
	No complaints were received in the financial year under report in respect of violation of human rights.

Principle 6 - Business should respect, protect, and make efforts to restore the environment

1	Does the policy related to Principle 6 cover only the company or extends to the Group/Joint Ventures/Suppliers/Contractors/NGOs/others.
	Extends to Company as well as Company's subsidiaries and group companies.
2	Does the company have strategies/ initiatives to address global environmental issues such as climate change, global warming, etc? Y/N. If yes, please give hyperlink for webpage etc.
	The Company has strategies / initiatives to address global environmental issues. The approach includes use of renewable power supply like solar energy, sourcing of power from wind mills, replacement of coal with agri waste briquettes for boilers, enhanced solvent recovery, water conservation thru 3R (reduce, recycle, replenish) water management principles, etc.
3	Does the company identify and assess potential environmental risks?
	Yes
4	Does the company have any project related to Clean Development Mechanism? If so, provide details thereof, in about 50 words or so. Also, if Yes, whether any environmental compliance report is filed?
	No
5	Has the company undertaken any other initiatives on – clean technology, energy efficiency, renewable energy, etc. Y/N. If yes, please give hyperlink for web page etc.
	Please see answer to item 2 above.
6	Are the Emissions/Waste generated by the company within the permissible limits given by CPCB/SPCB for the financial year being reported?
	Yes. All manufacturing plants comply with the permissible limits for air emissions, effluent quality and discharge, solid and hazardous waste generation and disposal as per consents / authorizations.
7	Number of show cause/ legal notices received from CPCB/SPCB which are pending (i.e. not resolved to satisfaction) as on end of Financial Year.
	None pending unattended / unresolved as at the financial year end.

Principle 7 - Businesses, when engaged in influencing public and regulatory policy, should do so in a responsible manner

1	Is your company a member of any trade and chamber or association? If Yes, Name only those major ones that your business deals with:
	The Company is a member of Indian Drugs Manufacturers Association (IDMA), Indian Pharmaceuticals Association (IPA), etc.
2	Have you advocated/lobbied through above associations for the advancement or improvement of public good? Yes/No; if yes specify the broad areas
	The Company has lobbied through the associations in respect of the policies passed / to be passed by the Government and relating to pharmaceuticals industry sector for advancement of pharmaceutical industry as well as for advancement of economy and public good.

Principle 8 - Businesses should support inclusive growth and equitable development

1	Does the company have specified programmes/initiatives/projects in pursuit of the policy related to Principle 8? If yes details thereof.
	Yes. The Company's initiatives and programs are in the activities such as promotion of education, vocational training & skill improvement, healthcare, rural development, etc.
2	Are the programmes/projects undertaken through in-house team/own foundation/ external NGO/government structures/any other organization?
	The programs and projects undertaken through in-house teams as well as through other charitable organizations.
3	Have you done any impact assessment of your initiative?
	Impact assessment is not done through any independent agency.
4	What is your company's direct contribution to community development projects- Amount in INR and the details of the projects undertaken?
	This information has been provided under CSR Report of the Company. The total amount spent in the financial year under report is ₹ 4.28 crores.
5	Have you taken steps to ensure that this community development initiative is successfully adopted by the community?
	The company generally monitors its CSR spent towards community development initiatives.

Principle 9 - Businesses should engage with and provide value to their customers and consumers in a responsible manner

1	What percentage of customer complaints/consumer cases are pending as on the end of financial year.
	There are no material consumer cases pending against the Company.
2	Does the company display product information on the product label, over and above what is mandated as per local laws?
	No. Being in a highly regulated industry, the Company has to strictly follow mandated laws.
3	Is there any case filed by any stakeholder against the company regarding unfair trade practices, irresponsible advertising and/ or anti-competitive behaviour during the last five years and pending as on end of financial year. If so, provide details thereof
	None
4	Did your company carry out any consumer survey/ consumer satisfaction trends?
	Yes. The Company carries out pharmacovigilance activities and the reports are filed with the regulators on a regular basis.

Mumbai
28th May, 2017

For and on behalf of the Board
Premchand Godha
Chairman & Managing Director

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

(Pursuant to Section 204 (1) of the Companies Act, 2013 and rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

To

The Members

Ipca Laboratories Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Ipca Laboratories Limited (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company, the information provided by the Company, its officers, agents and authorised representatives during the conduct of secretarial audit, the explanations and clarifications given to us and the representations made by the Management, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2017, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records made available to us and maintained by the Company for the financial year ended on 31st March, 2017 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contract (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 and amendments from time to time;
 - (d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
 - (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
 - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client (Not applicable to the Company during the audit period);
 - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Not applicable to the Company during the audit period); and
 - (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 (Not applicable to the Company during the audit period).
- (vi) Other laws applicable specifically to the Company namely :
 - (1) Pharmacy Act, 1948;
 - (2) Drugs and Cosmetics Act, 1940;
 - (3) Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954;
 - (4) Narcotic Drugs and Psychotropic Substances Act, 1985; and
 - (5) Drug Pricing Control Order, 2013.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India with respect to board and general meetings.
- (ii) The Listing Agreements entered into by the Company with BSE Limited and National Stock Exchange of India Limited read with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, standards etc. mentioned above. However, the Company has spent an amount of ₹ 4.28 crores against the amount of ₹ 7.14 crores to be spent during the year towards Corporate Social Responsibility.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice was given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Decisions at the Board Meetings were taken unanimously.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period the Company had following events which had bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.

- (i) The Company has made 3rd redemption amounting to ₹ 5 crores on 9.25% 2017 Non-Convertible Debentures and the Face Value of the NCDs have now been reduced from ₹ 5,00,000/- each to ₹ 2,50,000/- each.
- (ii) The Company's manufacturing units situated at Ratlam (M.P.), Indore SEZ, Pithampur (M.P.) and Piparia (Silvassa) are currently under USFDA import alert. Till these USFDA import alert/warning letters issues are resolved, the Company's business will continue to get adversely impacted.

For **Parikh & Associates**
Company Secretaries

Jigyasa N. Ved
Partner
FCS: 6488 CP: 6018

Mumbai
28th May, 2017

This Report is to be read with our letter of even date which is annexed as Annexure A and Forms an integral part of this report.

'Annexure A'

To
The Members
Ipca Laboratories Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the process and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, we have obtained the Management Representation about the Compliance of laws, rules and regulations and happening of events etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For **Parikh & Associates**
Company Secretaries

Jigyasa N. Ved
Partner
FCS: 6488 CP: 6018

Mumbai
28th May, 2017

INDEPENDENT AUDITORS' REPORT

To
The Members of
Ipca Laboratories Limited

Report on the Standalone Ind AS Financial Statements

We have audited the accompanying standalone Ind AS financial statements of Ipca Laboratories Limited ("the Company"), which comprises the Balance Sheet as at March 31, 2017, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Cash Flow and Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "Standalone Ind AS Financial Statement").

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these Standalone Ind AS Financial Statements that give a true and fair view of the financial position, financial performance including other comprehensive income and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Act, read with relevant rules thereon.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records relevant to the preparation and presentation of the Standalone Ind AS Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these Standalone Ind AS Financial Statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Standalone Ind AS Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Standalone Ind AS Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the Standalone Ind AS Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Company's directors, as well as evaluating the overall presentation of the Standalone Ind AS Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Standalone Ind AS Financial Statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Ind AS Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including the Ind AS, of the state of affairs of the Company as at March 31, 2017, its financial performance including other comprehensive income, its cash flows and the statement of changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure A, a statement on the matters Specified in paragraphs 3 and 4 of the said Order.
2. As required by section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;

- (b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid Standalone Ind AS Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with relevant rules thereon.
- (e) On the basis of written representations received from the directors as on March 31, 2017 and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2017 from being appointed as a director in terms of section 164(2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"; and
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its Standalone Ind AS Financial Statement - Refer Note 35 to the Standalone Ind AS Financial Statement.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There are no delays in payment of amounts to the Investor Education and Protection Fund during the year.
 - iv. The Company has provided requisite disclosures in its Standalone Ind AS Financial Statements as to holdings as well as dealings in Specified Bank Notes during the period from November 08, 2016 to December 30, 2016 and these are in accordance with the books of accounts maintained by the Company. Refer Note 8 to the Standalone Ind AS Financial Statements.

For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No. 106971W

N. Jayendran
Partner
M. No. 40441

Mumbai,
28th May, 2017

ANNEXURE A TO AUDITORS' REPORT

- (i) (a) The Company has generally maintained proper records showing full particulars including quantitative details and situation of its fixed assets.
- (b) Fixed assets have been physically verified by the management during the year and no material discrepancies were identified on such verification.
- (c) We have verified the title deeds of immovable properties forming part of Fixed Assets produced before us by the management and based on such verification we confirm that the same are held in the name of the company.
- (ii) The management has conducted physical verification of inventory at reasonable intervals during the year. The discrepancies noticed between the book stock and the physical stocks were not material and they have been properly dealt with in the books of accounts.
- (iii) During the year the Company has granted loan to its associates covered in the register maintained u/ s 189 of the Companies Act 2013.
 - (a) The terms and conditions of the grant of such loans are not prejudicial to the company's interest;
 - (b) The loan is not due for repayment presently and therefore there is no default in its repayment and there is no overdue. Hence, the clause 3(iii)(c) of the Companies (Auditors Report) Order, 2016 is not applicable to the Company.
- (iv) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 with respect to loans, investments, guarantees and security given.

- (v) The Company has not accepted any deposit from the public pursuant to sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and rules framed thereunder. As informed to us, there is no order that has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal in respect of the said sections.
- (vi) As informed to us, the maintenance of the cost records under the sub-section (1) of section 148 of the Companies Act, 2013 has been prescribed and we are of the opinion that prima facie, the prescribed accounts and records have been maintained. We have not, however, carried out a detailed examination of the records to ascertain whether they are accurate or complete.
- (vii) (a) The Company has been regular in depositing undisputed statutory dues including Provident fund, Employees State Insurance, Income Tax, Sales Tax, Service Tax, Custom Duty, Excise Duty, Cess and other statutory dues with the appropriate authorities during the year. According to the information and explanations given to us, no undisputed amount payable in respect of the aforesaid dues were outstanding as at March 31, 2017 for a period of more than six months from the date of becoming payable.
- (b) According to the information and explanations given to us, there are no dues of Sales Tax, Income Tax, Service Tax, Duty of Customs or Duty of Excise or Value Added Tax which have not been deposited on account of any dispute except as given in the statement attached herewith.
- (viii) According to the information and explanations given to us and based on the documents and records produced to us, the Company has not defaulted in repayment of dues to the financial institution or banks or to the debenture holders.
- (ix) The Company has not raised any money by way of public issue / follow-on offer (including debt instruments). On the basis of the documents submitted to the bankers and the other records perused by us, we have to state that the term loans which are in the nature of External Commercial Borrowings and the buyers credit for purchase of fixed assets taken during the year have been applied for the purpose for which the loans were obtained.
- (x) According to the information and explanations given to us and to the best of our knowledge and belief no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- (xi) The managerial remuneration has been paid/ provided in accordance with the requisite approvals mandated by the provisions of section 197 read with schedule V to the Companies Act, 2013.
- (xii) The Company is not a Nidhi Company hence clause 3(xii) of Companies (Auditors Report) Order, 2016 is not applicable to the Company.
- (xiii) All transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act, 2013 in so far as our examination of the proceedings of the meetings of the Audit Committee and Board of Directors are concerned. The details of related party transactions have been disclosed in the Standalone Ind AS Financial Statements as required by the applicable Accounting Standard.
- (xiv) The Company has not made any preferential allotment / private placement of shares or fully or partly convertible debentures during the year under review and hence the clause 3(xiv) of the Companies (Auditors Report) Order, 2016 is not applicable to the Company.
- (xv) The Company has not entered into any non-cash transactions with directors or persons connected with him and hence the clause 3(xv) of the Companies (Auditors Report) Order, 2016 is not applicable to the Company.
- (xvi) The nature of business and the activities of the Company are such that the Company is not required to obtain registration under section 45-IA of the Reserve Bank of India Act 1934.

For Natvarlal Vepari & Co.
Chartered Accountants
Firm Registration No. 106971W

N. Jayendran
Partner
M. No. 40441

Mumbai,
28th May, 2017

Statement of Statutory Dues Outstanding on account of disputes as on March 31, 2017, Referred to in Para (vii)(b) of Annexure A to the Auditors' Report

Name of the Statute	Nature of Dues	Amount (₹ crores)	Period to which the amount relates	Forum where dispute is pending
Excise Duty	Valuation of as such clearance of RM/ PM on 115%	0.12	Apr'01 to Feb'03	Commissioner, Central Excise, Ujjain
Excise Duty	Wrong availment of PLA recredit in respect of education cess and secondary & higher education cess at Ipca Sikkim	0.68	Dec'11 to Dec'13	Commissioner (Appeals), Kolkata
Excise Duty	Wrong availment of PLA recredit in respect of education cess and secondary & higher education cess at Ipca Sikkim	0.49	Jan'14 to Dec'14	Commissioner (Appeals), Kolkata
Excise Duty	Wrong availment of PLA recredit in respect of education cess and secondary & higher education cess at Ipca Sikkim	0.09	Jan'15 & Feb'15	Commissioner (Appeals), Kolkata
Excise Duty	Differential Excise duty on WIP on Debonding	0.23	2009-10	CESTAT, Ahmedabad
Excise Duty	Rebate claim rejected due to late filed	0.03	2013-14	Asst Commissioner Central Excise, Customs & Service tax, Silvassa
Excise Duty	Interest and penalty on past anti-dumping duty & excise duty	4.15		High Court, Gujarat
Service Tax	Service Tax Credit on Garden Maintenance charges disallowed during EA-2000 audit	0.07	2012-13 to 2016-17	Asst Commissioner Central Excise, Customs & Service tax, Silvassa
Service Tax	Availment of credit of Service Tax on H.O. Invoices	0.64	2006-07 & 2007-08	Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on H.O. Invoices	0.23	Apr'08 to Nov'08	Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on H.O. Invoices	0.04	Dec'08 to Sept'09	Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on Telephone/ Cell Phone/ Taxi Hire charges & Insurance	0.03	2006-07 & 2007-08	Commissioner/ Dy. Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on Telephone/ Cell Phone/ Taxi Hire charges & Insurance	0.01	April'08 to Dec'08	Commissioner/ Dy. Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on Telephone/ Cell Phone/ Taxi Hire charges & Insurance	0.01	Jan'09 to Sept'09	Asst. Commissioner/ Dy. Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on H.O. Invoices	1.42	2006-07 & 2007-08	Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on H.O. Invoices	0.34	April'08 to Nov'08	Commissioner, Central Excise
Service Tax	Availment of credit of Service Tax on H.O. Invoices	0.30	Dec'08 to Sept'09	Commissioner, Central Excise
Service Tax	Non reversal of proportionate amount of Service Tax credit on GTA against input credit reversal on short received and destruction of RM/ PM	0.01	2005-06 to 2007-08	Asst. Commissioner, Central Excise & Service Tax
Service Tax	Availment of credit of Service Tax on outward Freight based on CERA audit query	0.02	2009-10 & 2010-11	Commissioner, (Appeals) Central Excise & Service Tax
Service Tax	Availment of credit of Service Tax on Garden Maintenance Based on EA-2000 audit query	0.28	2012-13 & 2014-15	Dy. Commissioner, Central Excise & Service Tax, DIVISION, RATLAM
Service Tax	Availment of Cenvat Credit on Service Tax	0.01	2006-07	Asst. Commissioner/ Dy. Commissioner, Central Excise
Service Tax	Non - Payment of Service tax on import of Service	0.61	2006-2007 & 2007-2008	CESTAT, Mumbai
Service Tax	Non - payment of Service tax under RCM on remittances in foreign currency for product/ patent registration and facility fees to US FDA	2.49	July'12 to Sept'13	Commissioner Service Tax -VI, Mumbai
Sales Tax	Jammu & Kashmir Value added tax Act, (2011-12) - Disputed Demand	0.05	2011-2012	Dy. Commissioner of Commercial Tax (Appeal), Srinagar
Sales Tax	Gujarat Value Added Tax Act (2006-07) - Disputed demand	0.07	2006-07	Gujarat VAT Tribunal, Ahmedabad
Sales Tax	Gujarat Value Added Tax Act (2007-2008) - Disputed demand	0.02	2007-08	Jt. Commissioner of Commercial Tax, Rajkot
Sales Tax	Gujarat Value Added Tax Act (2006-2007) - Disputed demand	0.28	2006-07	Additional Commercial Commissioner Ahmedabad
Sales Tax	Central Sales Tax - Assessment Demand	0.22	2012-13	Commercial Tax
Sales Tax	Central Sales Tax - Assessment Demand	0.37	2013-14	Commercial Tax
Sales Tax	VAT - Assessment Demand	0.10	2013-14	Commercial Tax
Sales Tax	Demand after Assessment	0.52	2014-15	The Dy. Commissioner Commercial Tax Ratlam Division-Ratlam (M.P.)
Sales Tax	Demand after Assessment	0.01	2014-15	The Add. Commissioner Commercial Tax Indore (M.P.)
Entry Tax	Entry Tax	4.70	2013-14	Sales Tax Department
Sales Tax	Duburdih Check Post Penalty	0.01	2014-15	Deputy Commissioner, Sales Tax, West Bengal
	Total	18.65		

Annexure - B to the Auditors' Report**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of Ipca Laboratories Limited ("the Company") as of March 31, 2017 in conjunction with our audit of the Standalone Ind AS Financial Statement of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No. 106971W

N. Jayendran
Partner
M. No. 40441

Mumbai,
28th May, 2017

Particulars	Note Ref.	As at Mar 31, 2017 (₹ Crores)	As at Mar 31, 2016 (₹ Crores)	As at Apr 01, 2015 (₹ Crores)
ASSETS				
1. Non-current assets				
(a) Property, plant & equipment	1	1,899.69	1,927.88	1,706.39
(b) Capital work-in-progress		62.33	93.80	236.29
(c) Goodwill	1A	23.61	23.61	23.61
(d) Other intangible assets	1B	22.67	25.09	22.96
(e) Intangible assets under development		32.54	35.13	30.66
(f) Financial assets				
(i) Investments in Subsidiary/ Joint Venture/ Associate	2	97.96	97.38	79.48
(ii) Other investments	2A	0.05	0.05	2.88
(iii) Loans	3	96.67	71.65	61.60
(iv) Others	4	2.24	2.49	15.55
(g) Other non-current assets	5	26.26	27.78	51.59
		2,264.02	2,304.86	2,231.01
2. Current assets				
(a) Inventories	6	873.54	831.93	916.98
(b) Financial assets				
(i) Investments	2B	113.57	-	-
(ii) Trade receivables	7	501.98	441.45	629.06
(iii) Cash and cash equivalents	8	11.10	155.31	87.09
(iv) Bank balances other than (iii) above	9	6.43	6.67	26.11
(v) Loans	3	2.08	2.85	2.78
(vi) Others	4	29.85	15.63	39.22
(c) Current tax assets (net)		-	-	-
(d) Other current assets	5	165.38	145.93	166.51
		1,703.93	1,599.77	1,867.75
Total Assets		3,967.95	3,904.63	4,098.76
EQUITY & LIABILITIES				
Equity				
(a) Equity share capital		25.24	25.24	25.24
(b) Other equity	11	2,449.88	2,257.81	2,196.57
Total Equity		2,475.12	2,283.05	2,221.81
Liabilities				
1. Non-current liabilities				
(a) Financial liabilities				
(i) Borrowings	12	351.74	484.28	498.70
(ii) Other financial liabilities	13	-	-	-
(b) Provisions	14	24.55	20.22	17.66
(c) Deferred tax liabilities (net)	15	168.64	155.64	158.35
(d) Other non-current liabilities	16	1.56	1.56	1.56
		546.49	661.70	676.27
2. Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	17	177.30	182.86	597.31
(ii) Trade payables	18	449.22	415.24	302.56
(iii) Other financial liabilities	13	212.41	250.49	171.29
(b) Other current liabilities	16	36.12	45.60	64.20
(c) Provisions	14	66.07	62.17	55.33
(d) Current tax liabilities (net)	19	5.22	3.52	9.99
		946.34	959.88	1,200.68
Total Equity and Liabilities		3,967.95	3,904.63	4,098.76

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.

As per our report of even date attached

For **Natvarlal Vepari & Co.**

Chartered Accountants

Firm Registration No. 106971W

N. Jayendran

Partner

M.No. 40441

Mumbai,

28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director (DIN 00012691)

Ajit Kumar Jain

Joint Managing Director & CFO (DIN 00012657)

Prashant Godha

Executive Director (DIN 00012759)

Harish P. Kamath

Company Secretary (ACS - 6792)

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837
Statement of Profit and Loss for the year ended March 31, 2017

Particulars	Note Ref.	2016-17 (₹ Crores)	2015-16 (₹ Crores)
I. Revenue from operations	20	3,156.66	2,843.06
II. Other income	21	22.21	27.67
III. Total income (I + II)		3,178.87	2,870.73
IV. Expenses:			
Cost of materials consumed	22	947.31	886.01
Purchase of Stock-in-trade	23	161.84	138.33
Changes in inventories of finished goods, work-in-progress and stock-in-trade	24	(1.73)	22.26
Employee benefit expenses	25	674.93	603.35
Finance cost	26	23.34	28.60
Depreciation & amortisation	27	171.00	161.23
Other expenses	28	943.98	919.50
Total expenses (IV)		2,920.67	2,759.28
V. Profit before exceptional and extraordinary items and tax (III-IV)		258.20	111.45
VI. Exceptional items		-	-
VII. Profit before extraordinary items and tax (V-VI)		258.20	111.45
VIII. Extraordinary items		-	-
IX. Profit before tax (VII-VIII)		258.20	111.45
X. Tax expense			
1. Current tax		56.95	21.64
2. Short/ (excess) provision of earlier years		(0.04)	-
3. Deferred tax liability/ (asset) incl. MAT credit		13.00	69.91
			(2.71)
XI. Profit for the period from Continuing Operations (IX-X)		188.29	92.52
XII. Profit/ (loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/ (loss) from discontinuing operations after tax		-	-
XV. Profit for the period (XIV+XI)		188.29	92.52
Other comprehensive income			
A (i) Items that will not be reclassified to profit or loss			
Actuarial gain and loss		(4.44)	1.70
(ii) Income tax relating to items that will not be reclassified to profit or loss		0.95	(0.36)
B (i) Items that will be reclassified to profit or loss			
Exchange difference in translating the financial statement of foreign operation		(0.40)	-
Gain/ (loss) on cash flow hedge		7.67	(17.42)
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
Other comprehensive income for the year, net of tax		3.78	(16.08)
Total comprehensive income for the year		192.07	76.44
XVI. Earnings per equity share (for continuing operations):	30		
Basic (in ₹)		14.92	7.33
Diluted (in ₹)		14.92	7.33

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.

As per our report of even date attached

For **Natvarlal Vepari & Co.**

Chartered Accountants

Firm Registration No. 106971W

N. Jayendran

Partner

M.No. 40441

Mumbai,

28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director (DIN 00012691)

Ajit Kumar Jain

Joint Managing Director & CFO (DIN 00012657)

Prashant Godha

Executive Director (DIN 00012759)

Harish P. Kamath

Company Secretary (ACS - 6792)

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837

Cash Flow Statement for the year ended 31st March, 2017

	2016-17 (₹ Crores)	2015-16 (₹ Crores)
A. Cash Flow from Operating Activities		
1) Net profit before taxation and extraordinary item	258.20	111.45
Adjustments for :		
Depreciation, amortisation and impairment expense	171.00	161.23
(Profit)/ loss on sale of property, plant & equipment	1.50	0.54
(Profit)/ loss on sale of investment (net)	-	0.32
(Profit)/ loss on mutual fund investments	(5.31)	(5.36)
Property, plant & equipment scrapped	1.54	0.34
Sundry balances written (back)	(2.51)	(2.72)
Bad debts w/off	2.68	3.30
Bad Debts (recovered)/ write off	(0.68)	(0.80)
Provision for doubtful debts/ advances	0.51	(0.18)
Reversal of provision for diminution in value of investments	-	(6.62)
Unrealised foreign exchange (gain)/ loss	(17.42)	35.58
Interest income	(14.28)	(12.93)
Dividend income	-	(0.03)
Interest expense	23.34	28.60
2) Operating profit before working capital changes	418.57	312.72
Decrease/ (increase) in receivables	(71.42)	190.64
Decrease/ (increase) in loans and advances	(11.93)	28.93
Decrease/ (Increase) in inventories	(41.61)	85.04
Increase/ (decrease) in liabilities & provisions	26.36	107.73
3) Cash generated from operation	319.97	725.06
Income tax paid (net)	(54.32)	(29.06)
Net cash from operating activities	265.65	696.00
B. Cash Flow from Investing Activities		
Purchase of property, plant & equipment including capital WIP	(134.53)	(241.76)
Investment in subsidiaries	-	(0.69)
Disposal of investment in subsidiary	-	0.14
Redemption of preference shares in subsidiary	2.22	-
Repayment of loan by subsidiary	1.98	-
Investment in associate	(3.40)	-
Loan to associate	(23.57)	(11.40)
Sale of investment - others	-	4.19
(Profit)/ loss on mutual fund investments	5.31	5.36
Proceeds from sale of plant, property and equipment	1.67	1.56
Movement in other bank balances	0.45	20.12
Interest received	9.97	8.83
Dividend received	-	0.03
Net cash from/ (used) in investing activities	(139.90)	(213.62)
C. Cash Flow from Financing Activities		
Increase/ (decrease) in short term borrowings	(2.66)	(415.77)
Proceeds from long-term borrowings	67.70	151.83
Repayment of long-term borrowings	(193.35)	(101.43)
Repayment of debentures	(5.00)	(5.00)
Interest paid	(22.84)	(28.45)
Dividend & dividend tax paid	(0.24)	(15.34)
Net cash from (used in) financing activities	(156.39)	(414.16)
Net increase/ (decrease) in cash and cash equivalents (A + B + C)	(30.64)	68.22
Cash and cash equivalents at beginning of year	155.31	87.09
Cash and cash equivalents at end of year	124.67	155.31
Components of cash & cash equivalents :		
Cash and cheques on hand	1.54	1.83
Balance with banks	9.56	153.48
Mutual funds	113.57	-
	124.67	155.31

As per our report of even date attached
For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No. 106971W

N. Jayendran
Partner
M.No. 40441
Mumbai,
28th May, 2017

For and on behalf of the Board of Directors
Premchand Godha
Chairman & Managing Director (DIN 00012691)
Ajit Kumar Jain
Joint Managing Director & CFO (DIN 00012657)
Prashant Godha
Executive Director (DIN 00012759)
Harish P. Kamath
Company Secretary (ACS - 6792)

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837**Statement of changes in equity for the year ended March 31, 2017****Equity Share Capital**

Equity share capital of face value ₹ 2.00 each	No. of shares	(₹ Crores)
Balance as at April 1, 2015	12,61,99,109	25.24
Changes in equity share capital during the year	-	-
Balance as at March 31, 2016	12,61,99,109	25.24
Changes in equity share capital during the year	-	-
Balance as at March 31, 2017	12,61,99,109	25.24

Other equity**(₹ Crores)**

Particulars	Other equity									Total
	Reserves and surplus						Other comprehensive income			
							Not Reclassified to P&L	Reclassified to P&L		
	Capital reserve	Securities premium	Capital redem. reserve	Debenture redem. reserve	General reserve	Retained earnings		Remea- surement of employee benefit	Effective portion of cash flow hedges	
As at 1 April 2015	0.59	43.99	0.26	10.00	1,300.00	840.24	(12.09)	13.58	-	2,196.57
Profit for the period	-	-	-	-	-	92.52	-	-	-	92.52
Gain/ (loss) on cash flow hedge	-	-	-	-	-	-	-	(17.42)	-	(17.42)
Actuarial gain/ (loss) on gratuity (net of tax thereon)	-	-	-	-	-	-	1.34	-	-	1.34
Dividend	-	-	-	-	-	(12.62)	-	-	-	(12.62)
Tax on dividend	-	-	-	-	-	(2.57)	-	-	-	(2.57)
Transfer to General reserve	-	-	-	(5.00)	-	-	-	-	-	(5.00)
Transfer from Debenture Redem. Reserve	-	-	-	-	5.00	-	-	-	-	5.00
Balance as on March 31, 2016	0.59	43.99	0.26	5.00	1,305.00	917.56	(10.75)	(3.84)	-	2,257.81
Profit for the period	-	-	-	-	-	188.29	-	-	-	188.29
Gain/ loss on cash flow hedge	-	-	-	-	-	-	-	7.67	-	7.67
Actuarial gain / (loss) on gratuity (net of tax thereon)	-	-	-	-	-	-	(3.49)	-	-	(3.49)
Foreign currency translation reserve	-	-	-	-	-	-	-	-	(0.40)	(0.40)
Balance as on March 31, 2017	0.59	43.99	0.26	5.00	1,305.00	1,105.85	(14.25)	3.83	(0.40)	2,449.88

As per our report of even date attached

For **Natvarlal Vepari & Co.**

Chartered Accountants

Firm Registration No. 106971W

N. Jayendran

Partner

M.No. 40441

Mumbai,

28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director (DIN 00012691)

Ajit Kumar Jain

Joint Managing Director & CFO (DIN 00012657)

Prashant Godha

Executive Director (DIN 00012759)

Harish P. Kamath

Company Secretary (ACS - 6792)

Statement of Significant Accounting policies and Other Explanatory Notes

(A) Corporate Information

Incorporated in the year 1949, Ipca Laboratories Limited is a integrated pharmaceutical company manufacturing and marketing over 350 formulations and 80 APIs covering various therapeutic segments. The products of the Company are now sold in over 120 countries across the globe. The Company has 17 manufacturing units in India manufacturing APIs and formulations for the world market.

(B) Significant Accounting Policies

I) Basis of Preparation

These financial statements are Separate Financial Statements as per Ind AS 27 - Separate Financial Statements and are prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

For all periods upto and including the year ended March 31, 2016 the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act, 2013 read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP).

The year ended March 31, 2017 is the first period for which the Company has prepared its financial statements in accordance with Ind AS. The previous period comparatives for the period ended March 31, 2016 which were earlier prepared as per the aforesaid Companies (Accounts) Rules, 2014 have been restated as per Ind AS to make them comparable. The date of transition to Ind AS is therefore April 1, 2015 for which the Opening Balance Sheet is prepared.

These financial Statements are prepared under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

II) Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of circumstances surrounding the estimates. Changes in estimates are reflected in the financial statement in the period in which changes are made and if material, their effects are disclosed in the notes to the financial statements.

III) Summary of significant accounting policies

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

(a) Current and non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

An asset is current when :

- It is expected to be realised or intended to be sold or consumed in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is expected to be realised within twelve months after the reporting period, or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when :

- It is expected to be settled in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for atleast twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

(b) Property, Plant and Equipment

- i) Leasehold land is carried at historical cost. All other items of property, plant and equipment are stated at historical cost less depreciation. Cost of acquisition comprises its purchase price including import duties and other non-refundable taxes or levies and any directly attributable cost of bringing the asset to its working condition for its intended use; any trade discount and rebates are deducted in arriving at the purchase price. Revalued assets are recorded at revalued amounts.
- ii) Capital Work In Progress represents expenditure incurred on capital assets that are under construction or are pending capitalisation and includes Project expenses pending allocation. Project expenses pending allocation are apportioned to the property, plant and equipment of the project proportionately on capitalisation.
- iii) Cost of borrowing for assets taking substantial time to be ready for use is capitalised for the period up to the time the asset is ready for its intended use.
- iv) Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.
- v) The residual useful life of property, plant & equipment is reviewed at each balance sheet date and adjusted if required in the depreciation rates.
- vi) The Property, plant and equipment existing on the date of transition are accounted on deemed cost basis by applying para D7AA in accordance with the exemption provided in Ind AS 101 "First-time Adoption of Indian Accounting Standards" at previous GAAP carrying value.
- vii) Depreciation methods, estimated useful lives and residual value

Depreciation on all assets of the Company is charged on straight-line method over the useful life of assets mentioned in Schedule II to the Companies Act, 2013 or the useful life previously assessed by the management based on technical review whichever is lower for the proportionate period of use during the year. Intangible assets are amortised over the economic useful life estimated by the management.

The management's estimated useful life/ useful life as per schedule II whichever is lower for the various tangible assets are as follows.

Assets	Estimated useful life (Years)
Leasehold land	Period of Lease
Buildings	28 to 58
Roads	3 to 10
Plant and equipment and R&D equipments	9 to 20
Office and other equipments	5
Computers	3 to 6
Furniture and fixtures	10
Vehicles	6 to 8
Leasehold improvements	Period of Lease

c) Goodwill

Goodwill represents excess of consideration paid for acquisition of business over the fair value of net assets. Goodwill is not amortised but is tested for impairment at each reporting date.

d) Intangible assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition, and other economic factors (such as the stability of the industry, and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.

The Intangible assets existing on the date of transition are accounted on deemed cost basis by applying para D7AA in accordance with the exemption provided in Ind AS 101 "First-time Adoption of Indian Accounting Standards" at previous GAAP carrying value.

Research costs are expensed as incurred. The costs which can be capitalized include the cost of material, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use. Research and development

costs incurred under contractual arrangements with customers are accounted as expenses in the Statement of Profit and Loss.

The management has estimated the economic useful life for the various intangible assets as follows.

Assets	Estimated useful life (Years)
Brands and Trademarks	4
Technical Know how	4
Software for internal use	4

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the Statement of Profit or Loss when the asset is derecognised.

e) Borrowings

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. Other borrowing costs are expensed in the period in which they are incurred.

f) Impairment Loss

Assets subject to amortization/ depreciation are tested for impairment provided that an event or change in circumstances indicates that their carrying amount might not be recoverable. An impairment loss is recognized in the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher between an asset's fair value less sale costs and value in use. For the purposes of assessing impairment, assets are grouped together at the lowest level for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill for which impairment losses have been recognized are tested at each balance sheet date in the event that the loss has reversed.

g) Inventories

Items of inventories are valued lower of cost or estimated net realisable value as given below.

Raw Materials and Packing Materials	Lower of cost and Net realisable value. However materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost is determined on First-in-First-out basis.
Work-in-process and Finished Goods	At lower of cost including material cost net of CENVAT, labour cost and all overheads other than selling and distribution overheads and net realisable value. Excise duty is considered as cost for finished goods wherever applicable.
Stores and Spares	Stores and spare parts are valued at lower of purchase cost computed on First-in-First-out method and net realisable value.
Traded Goods	Traded Goods are valued at lower of purchase cost and net realisable value.

h) Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits in banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within bank borrowings in current liabilities on the balance sheet.

i) Provisions

The Company recognizes a provision when: it has a present legal or constructive obligation as a result of past events; it is likely that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Provisions are not recognized for future operating losses.

j) Retirement and other benefits

Provident Fund

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than the contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as an expense, when an employee renders the related service.

Gratuity

Gratuity, a defined benefit obligation is provided on the basis of an actuarial valuation made at the end of each year/ period on projected unit credit method.

The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method.

Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset.

Compensated Absences

The Company has a policy on compensated absences which are both accumulating and non-accumulating in nature. The expected cost of accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at each balance sheet date using projected unit credit method on the additional amount expected to be paid/ availed as a result of the unused entitlement that has accumulated at the balance sheet date. Expense on non-accumulating compensated absences is recognized in the period in which the absences occur.

k) Foreign Currencies**Transactions and Balances**

- i. The functional currency of the company is the Indian rupee. These financial statements are presented in Indian rupees.
- ii. Transactions denominated in foreign currency are recorded at the exchange rate on the date of transaction. The exchange gain/ loss on settlement/ negotiation during the year is recognised in the Statement of Profit and Loss.
- iii. Foreign currency monetary transactions remaining unsettled at the end of the year are converted at year-end rates. The resultant gain or loss is accounted for in the Statement of Profit and Loss.
- iv. Non Monetary items that are measured at historical cost denominated in foreign currency are translated using exchange rate at the date of transaction.
- v. The overseas trading offices are non-integral operations and the overseas non trading offices are integral operations and are accounted accordingly.

l) Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
 - In the absence of a principal market, in the most advantageous market for the asset or liability
- The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

m) Financial Instruments**(i) Financial Assets & Financial Liabilities****Initial recognition and measurement**

All financial assets and liabilities are recognised initially at fair value.

In the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset is treated as cost of acquisition. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent Measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit and loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Impairment of financial assets

The Company assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. Note 7 details how the entity determines whether there has been a significant increase in credit risk. For trade receivables only, the Company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

De-recognition of financial instruments

A financial asset is de-recognised only when

- The Company has transferred the rights to receive cash flows from the financial asset or
- Retains the contractual rights to receive the cash flows of the financial asset, but assumes a contractual obligation to pay the cash flows to one or more recipients.

Where the entity has transferred an asset, the group evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is de-recognised. Where the entity has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not de-recognised.

Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is de-recognised if the group has not retained control of the financial asset. Where the group retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

A financial liability (or a part of a financial liability) is de-recognised from the Company's Balance Sheet when the obligation specified in the contract is discharged or cancelled or expires.

(ii) Investments in Subsidiaries/ Associates/ Joint ventures

Investments in subsidiaries/ associates/ joint ventures are carried at cost in the Separate Financial Statements.

(iii) Derivative financial instruments and hedge accounting

Initial recognition and subsequent measurement

The Company uses derivative financial instruments, such as forward currency contracts, interest rate swaps and forward commodity contracts, to hedge its foreign currency risks, interest rate risks and commodity price risks, respectively.

Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

The purchase contracts that meet the definition of a derivative under Ind AS 109 are recognised in the Statement of Profit and Loss.

Cash flow Hedge

The Company designates certain foreign exchange forward and options contracts as cash flow hedges to mitigate the risk of foreign exchange exposure on highly probable forecast cash transactions.

When a derivative is designated as a cash flow hedging instrument, the effective portion of changes in the fair value of the derivative is recognized in other comprehensive income and accumulated in the cash flow hedging reserve. Any ineffective portion of changes in the fair value of the derivative is recognized immediately in the

net profit in the Statement of Profit and Loss. If the hedging instrument no longer meets the criteria for hedge accounting, then hedge accounting is discontinued prospectively. If the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss on the hedging instrument recognized in cash flow hedging reserve till the period the hedge was effective remains in cash flow hedging reserve until the forecasted transaction occurs. The cumulative gain or loss previously recognized in the cash flow hedging reserve is transferred to the net profit in the Statement of Profit and Loss upon the occurrence of the related forecasted transaction. If the forecasted transaction is no longer expected to occur, then the amount accumulated in cash flow hedging reserve is reclassified to net profit in the Statement of Profit and Loss.

n) Revenue Recognition

- i) Revenue from sale of goods is recognised net of returns, product expiry claims and trade discount, on transfer of significant risk and rewards in respect of ownership to the buyer which is generally on dispatch of goods. Sales include excise duty but exclude sales tax and value added tax.
- ii) In respect of incentives attributable to the export of goods, the Company following the accounting principle of matching revenue with the cost has recognised export incentive receivable when all conditions precedent to the eligibility of benefits have been satisfied and when it is reasonably certain of deriving the benefit. Since these schemes are meant for neutralisation of duties and taxes on inputs pursuant to exports, the same are grouped under material costs.
- iii) The other export incentives that do not arise out of neutralisation of duties and taxes are disclosed under other operating revenue.
- iv) Revenue from services is recognised when all relevant activities are completed and the right to receive income is established.
- v) Revenue in respect of insurance/ other claims, commission, etc. are recognised only when it is reasonably certain that the ultimate collection will be made.
- vi) For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR).
- vii) Dividend from subsidiaries/ associates/ joint ventures is recognised in the Statement of Profit and Loss in separate financial statements when the parent company's right to receive the dividend is established.

o) Taxes

Tax expenses comprise Current Tax and Deferred Tax.:

i) Current Tax:

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

ii) Deferred Tax:

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the standalone financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting profit nor taxable profit (tax loss). Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

For items recognised in OCI or equity, deferred/ current tax is also recognised in OCI or equity.

iii) **MAT Credit**

Minimum Alternate Tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognises MAT credit available as an asset only to the extent that there is reasonable certainty that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. The MAT credit to the extent there is reasonable certainty that the Company will utilise the credit is recognised in the Statement of Profit and Loss and corresponding debit is done to the Deferred Tax Asset as unused tax credit.

p) **Leases**

Operating lease

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease. All other leases are operating lease. Operating lease payments, as per terms of the agreement, are recognised as an expense in the Statement of Profit and Loss on a straight-line basis in accordance with Ind AS 17.

q) **Excise Duty and CENVAT/ Service Tax Credit**

The excise duty expenses are bifurcated into two components: excise duty expenses related to sales and the un-recovered excise duty is recognized under other expenses and excise duty relating to the difference between the closing and opening stock of finished goods is recognized in the material cost and inventory adjustments. CENVAT / Service Tax credit utilised during the year is accounted in excise duty and unutilised CENVAT / Service Tax credit at the year end is considered as duties and taxes refundable.

r) **Research and Development**

Revenue expenditure on research and development is charged to Statement of Profit and Loss in the year in which it is incurred. Capital expenditure on research and development is considered as an addition to property, plant & equipment/ intangible assets.

s) **Earnings Per Share**

Earnings per share is calculated by dividing the net profit or loss before OCI for the year by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss before OCI for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

t) **Dividend Distribution**

Dividend distribution to the Company's equity holders is recognized as a liability in the Company's annual accounts in the year in which the dividends are approved by the Company's equity holders.

Notes to financial statements as at and for the year ended March 31, 2017

1. Property, Plant & Equipment

Particulars	Freehold Land	Leasehold Land	Building	Plant & Equipment	Plant & Equipment (Given on Lease)	Office & Other Equipment	Eff. Treatment Plant	Fur. & Fix.	Vehicles	R&D Building	R&D Eqpts.	R&D Furniture	Total
Gross Block													
As on 01/04/2015	49.66	47.16	414.20	973.63	3.54	12.02	50.85	34.46	13.91	14.30	91.27	1.39	1,706.39
Additions	0.62	0.63	61.43	263.88	-	4.13	19.43	10.10	1.90	0.03	14.95	0.95	378.05
Adjustments	-	-	0.49	(4.79)	0.06	(0.08)	(0.31)	0.04	(0.58)	-	0.20	-	(4.97)
As on 31/03/2016	50.28	47.79	476.12	1,232.72	3.60	16.07	69.97	44.60	15.23	14.33	106.42	2.34	2,079.47
Additions	-	-	34.28	83.06	-	2.51	7.68	3.21	1.33	-	5.28	0.33	137.68
Adjustments	-	-	(1.82)	(4.32)	0.10	(0.07)	-	(0.02)	(0.59)	-	(0.20)	-	(6.92)
As on 31/03/2017	50.28	47.79	508.58	1,311.46	3.70	18.51	77.65	47.79	15.97	14.33	111.50	2.67	2,210.23

Accumulated Depreciation													
As on 01/04/2015	-	-	-	-	-	-	-	-	-	-	-	-	-
For the year 2015-16	-	0.96	16.81	101.16	0.45	3.72	5.07	5.13	3.75	0.62	14.18	0.25	152.10
Adjustments	-	-	-	(0.39)	-	(0.01)	-	-	(0.10)	-	(0.01)	-	(0.51)
As on 31/03/2016	-	0.96	16.81	100.77	0.45	3.71	5.07	5.13	3.65	0.62	14.17	0.25	151.59
For the year 2016-17	-	0.96	17.11	106.75	0.43	3.70	6.36	5.41	3.53	0.62	14.53	0.30	159.70
Adjustments	-	-	(0.05)	(0.37)	-	(0.03)	-	(0.01)	(0.22)	-	(0.07)	-	(0.75)
As on 31/03/2017	-	1.92	33.87	207.15	0.88	7.38	11.43	10.53	6.96	1.24	28.63	0.55	310.54

Net Block as on 31/03/2016	50.28	46.83	459.31	1,131.95	3.15	12.36	64.90	39.47	11.58	13.71	92.25	2.09	1,927.88
Net Block as on 31/03/2017	50.28	45.87	474.71	1,104.31	2.82	11.13	66.22	37.26	9.01	13.09	82.87	2.12	1,899.69

Note : In view of the adoption of para D7AA of Ind AS 101 relating to Deemed Cost, the net block as at March 31, 2015 as follows has been shown as gross block as on April 01, 2015.

Particulars	Freehold Land	Leasehold Land	Building	Plant & Equipment	Plant & Equipment (Given on Lease)	Office & Other Equipment	Eff. Treatment Plant	Fur. & Fix.	Vehicles	R&D Building	R&D Eqpts.	R&D Furniture	Total
Gross Block as on 31/03/2015	49.69	48.70	486.74	1,451.49	5.83	21.27	61.79	55.64	25.00	18.41	161.83	2.97	2,389.36
Accumulated Depreciation till 31/03/2015	0.03	1.54	72.54	477.86	2.29	9.25	10.94	21.18	11.09	4.11	70.56	1.58	682.97
Net Block as on 31/03/2015	49.66	47.16	414.20	973.63	3.54	12.02	50.85	34.46	13.91	14.30	91.27	1.39	1,706.39

Notes:

- Buildings include cost of shares in Co-operative societies.
- Out of depreciation and amortisation for the year of ₹ 171.03 crores (previous year ₹ 161.25 crores), depreciation of ₹ 0.03 crore (previous year ₹ 0.02 crore) relating to project under execution for the period before start of production is transferred to project expenses pending allocation.
- Cost of Borrowing of ₹ 0.50 crore (previous year ₹ 0.65 crore) is capitalised to the project at the weighted average cost of borrowing @ 2.77% (previous year 2.80%)

Notes to financial statements as at and for the year ended March 31, 2017

1A : Goodwill

The Goodwill represents the excess of the consideration paid over the fair value of assets and liabilities of industrial undertaking situated at Mahad, Aurangabad and Pithampur acquired by the company before the transition date. This Goodwill was being amortised over 5 years as per the previous GAAP. The same is carried at the previous GAAP value and is being tested for impairment at each balance sheet date.

1B : Other Intangible Assets

(₹ Crores)

Particulars	Software	Brand/ Trade Mark	Know-How	Software - R&D	Total
Gross Block					
As on 01/ 04/ 2015	12.87	5.90	3.54	0.65	22.96
Additions	9.05	-	0.97	1.27	11.29
Adjustments	(0.01)	-	-	-	(0.01)
As on 31/ 03/ 2016	21.91	5.90	4.51	1.92	34.24
Additions	3.19	-	5.21	0.51	8.91
Adjustments	-	-	-	-	-
As on 31/ 03/ 2017	25.10	5.90	9.72	2.43	43.15
Accumulated Amortisation					
As on 01/ 04/ 2015	-	-	-	-	-
For the year 2015-16	5.87	1.76	1.06	0.46	9.15
Adjustments	-	-	-	-	-
As on 31/ 03/ 2016	5.87	1.76	1.06	0.46	9.15
For the year 2016-17	6.77	1.76	2.24	0.56	11.33
Adjustments	-	-	-	-	-
As on 31/ 03/ 2017	12.64	3.52	3.30	1.02	20.48
Net Block as on 31/ 03/ 2016	16.04	4.14	3.45	1.46	25.09
Net Block as on 31/ 03/ 2017	12.46	2.38	6.42	1.41	22.67

Note : In view of the adoption of para D7AA of Ind AS 101 relating to Deemed Cost, the net block as at March 31, 2015 as follows has been shown as gross block as on April 01, 2015.

	Software	Brand/ Trade Mark	Know-How	Software - R&D	Total
Gross Block as on 31/ 03/ 2015	23.86	9.22	7.74	1.74	42.56
Accumulated amortisation till 31/ 03/ 2015	10.99	3.32	4.20	1.09	19.60
Net Block as on 31/ 03/ 2015	12.87	5.90	3.54	0.65	22.96

2. Financial Assets - Investments

Investments in Subsidiary/ Joint Venture/ Associate at Cost

(₹ Crores)

Sr. No.	Particulars	As at 31/ 03/ 2017	As at 31/ 03/ 2016	As at 01/ 04/ 2015
1	Equity instrument in Subsidiary	21.63	21.63	22.77
2	Equity instrument in Joint Venture	6.51	6.51	6.51
3	Equity instrument in Associates	34.30	30.90	18.48
4	Investment in Preference shares	38.20	41.02	41.02
5	Provision for diminution in the value of Investments	(2.68)	(2.68)	(9.30)
Total		97.96	97.38	79.48

Notes to financial statements as at and for the year ended March 31, 2017

(₹ Crores)

Particulars	As at 31/03/2017	As at 31/03/2016	As at 01/04/2015
2A Other Non-Current Investments			
Investment in Equity	-	-	2.83
Investment in Preference shares	0.05	0.05	0.05
Total	0.05	0.05	2.88
2B Current Investments			
Investment in Mutual fund	113.57	-	-
Total	113.57	-	-

2 Investment in Subsidiary/ Joint Venture/ Associate

Sr. No.	Name of the Body Corporate	Relationship	Extent of Holding (%) / No. of shares			(₹ Crores)		
			31/03/2017	31/03/2016	01/04/2015	31/03/2017	31/03/2016	01/04/2015
Non-Current Investment								
Investments at cost								
(1)	Unquoted equity shares							
i)	Investment in Equity Instruments (At cost)							
1	Ipca Pharmaceuticals, Inc. USA	Subsidiary	100.00%	100.00%	100.00%	9.31	9.31	8.65
			1,000	1,000	1,000			
2	Ipca Laboratories (U.K.) Ltd.,U.K.	Subsidiary	100.00%	100.00%	100.00%	8.08	8.08	8.08
			9,14,186	9,14,186	9,14,186			
3	Ipca Pharma Nigeria Ltd. Nigeria	Subsidiary	100.00%	100.00%	100.00%	2.82	2.82	2.82
			5,15,89,190	5,15,89,190	5,15,89,190			
4	National Druggist (Pty) Ltd. South Africa	Subsidiary	-	-	100.00%	-	-	0.64
					10,59,732			
5	Ipca Pharma (Australia) Pty Ltd. Australia	Subsidiary	100.00%	100.00%	100.00%	0.17	0.17	0.17
			26,944	26,944	26,944			
6	Ipca Pharmaceuticals (Shanghai) Ltd.China	Subsidiary	-	-	100.00%	-	-	1.19
			-	-	No par value			
7	Ipca Pharmaceuticals Ltd. SA de CV. Mexico	Subsidiary	100.00%	100.00%	100.00%	1.15	1.15	1.12
			No par value	No par value	No par value			
8	Tonira Exports Limited	Subsidiary	100.00%	100.00%	100.00%	0.10	0.10	0.10
			1,00,000	1,00,000	1,00,000			
9	Avik Pharmaceutical Ltd.	Joint Venture	49%	49%	49%	6.51	6.51	6.51
			5,00,000	5,00,000	5,00,000			
10	CCPL Software Pvt.Ltd. #	Associate	28.95%	28.95%	28.95%	-	-	-
			55,000	55,000	55,000			
11	Trophic Wellness Pvt. Ltd. (Previous year 1,00,000 shares fully paid & 6,80,000 partly paid - ₹ 7.50)	Associate	19.26%	19.26%	19.26%	12.34	8.94	8.94
			7,80,000	7,80,000	7,80,000			
Total (i)						40.48	37.08	38.22

Notes to financial statements as at and for the year ended March 31, 2017

ii) Investment in Preference Shares (At cost)

Sr. No.	Name of the Body Corporate	Relationship	Extent of Holding (%) No. of shares			(₹ Crores)		
			31/03/2017	31/03/2016	01/04/2015	31/03/2017	31/03/2016	01/04/2015
1	Ipca Laboratories (U.K.) Ltd., U.K.	Subsidiary	100.00%	100.00%	100.00%	38.20	41.02	41.02
			37,25,000	40,00,000	40,00,000			
	Total (ii)					38.20	41.02	41.02
	Total unquoted investments					78.68	78.10	79.24
(2)	Quoted equity shares							
	Investment in Equity Instruments (At cost)							
1	Krebs Biochemicals & Industries Ltd.	Associate	29.83%	31.38%	18.92%	21.96	21.96	9.54
			41,00,100	41,00,100	18,00,000			
	Total quoted investments					21.96	21.96	9.54
	Total Investments (1+2)					100.64	100.06	88.78
	Less : Provision for Diminution in value (Refer table (iii) below)					(2.68)	(2.68)	(9.30)
	Total FVTPL Non-Current Investments (net of provision)					97.96	97.38	79.48
	# Cost fully written off in books							

iii) Provision for diminution in the value of Investments till date in shares in respect of the above companies is as follows:-

(₹ Crores)

Sr. No.	Name of the Body Corporate	Relationship	31/03/2017	31/03/2016	01/04/2015
1	Ipca Pharmaceuticals Inc., USA	Subsidiary	2.68	2.68	7.61
2	National Druggist (Pty) Ltd. South Africa	Subsidiary	-	-	0.64
3	Ipca Pharmaceuticals(Shanghai) Ltd. China	Subsidiary	-	-	1.05
Total			2.68	2.68	9.30

iv) Aggregate value of investments

(₹ Crores)

Particulars	31/03/2017	31/03/2016	01/04/2015
Aggregate book value of quoted investments	21.96	21.96	9.54
Aggregate market value of quoted investments	41.06	43.05	16.01
Aggregate book value of unquoted investments	78.68	78.10	79.24

Notes to financial statements as at and for the year ended March 31, 2017

v) Details of investments Subsidiary/ Joint Venture/ Associate at Cost

a) **Ipca Pharmaceuticals, Inc. USA**

This wholly owned subsidiary company was incorporated under the laws of the State of New Jersey in the United States on July 10, 2003. This subsidiary company is coordinating the development and registration of formulations developed by the Company in United States of America as well as distribution of Active Pharmaceutical Ingredients (APIs) manufactured by the Company in the US market.

b) **Ipca Laboratories (U.K.) Ltd., U.K.**

During the financial year 2003-04, Company incorporated this wholly owned subsidiary to apply and obtain product registrations in the United Kingdom. During the year 2011-12, this subsidiary acquired 100% share capital of Onyx Research Ltd., holding company of Onyx Scientific Ltd. During the year 2015-16, Onyx Research Chemicals Ltd., U.K. merged with its holding company Ipca Laboratories (U.K.) Ltd. and consequent to this, Onyx Scientific Ltd. has now become wholly owned subsidiary of this Company.

c) **Ipca Pharma Nigeria Ltd. Nigeria**

During the year 2006-07, the Company acquired the entire share capital of its stepdown subsidiary Ipca Pharma Nigeria Ltd. Thus, Ipca Pharma Nigeria Ltd. became wholly owned subsidiary of the Company with effect from 31st January, 2007. The company was incorporated as a private company in Nigeria. It commenced commercial operations in December 2001. It is engaged in importation and marketing of formulations and APIs in the Nigerian market.

d) **Ipca Pharma (Australia) Pty Ltd. Australia**

This subsidiary company was acquired by the Company in the year 2007-08 and is engaged in the activities of holding formulations dossier registrations with TGA, Australia and sale of pharmaceuticals manufactured by the Company in Australia. This subsidiary company has a wholly owned subsidiary in New Zealand - Ipca Pharma (NZ) Pty Ltd.

e) **Ipca Pharma (NZ) Pty Ltd., New Zealand**

The Company was incorporated to hold formulation dossier registrations in New Zealand and to distribute formulations manufactured by the Company in the New Zealand market. This company is wholly owned subsidiary of Ipca Pharma (Australia) Pty Ltd.

f) **Ipca Pharmaceuticals Ltd. SA de CV. Mexico**

This subsidiary company was setup during the year 2008-09 as wholly owned subsidiary of the Company to hold formulations dossier registrations and promotion of pharmaceuticals manufactured by the Company in the Mexican market. This Company is currently in the process of registration of dossiers in Mexico.

g) **Tonira Exports Limited**

Tonira Exports Ltd. was incorporated as a wholly owned subsidiary of Tonira Pharma Ltd. The Company acquired management control of Tonira Pharma Ltd. in May 2008. Upon merger of Tonira Pharma Ltd. with the Company in the year 2011-12, Tonira Exports Ltd. has become wholly owned subsidiary of the Company. This Company is presently not into any business.

h) **Avik Pharmaceutical Ltd.**

During the year 2013-14, the Company had acquired 49.02% of shares in Avik Pharmaceutical Ltd. Avik is manufacturing APIs, primarily Cortico Steroids and Hormones since 1980. Avik is pioneer in the manufacturing of steroids in India. Avik's two manufacturing facilities are located at Vapi, Gujarat.

i) **Trophic Wellness Pvt. Ltd.**

Trophic Wellness Pvt. Ltd. was incorporated in 2010 and is headquartered in Mumbai, India. The Company has acquired shareholding to the extent of 19.26 % in Trophic Wellness Pvt. Ltd. during the year 2010-11. Trophic Wellness Pvt. Ltd. is engaged in the manufacturing and marketing of nutraceuticals with its manufacturing unit situated in Sikkim.

j) **Krebs Biochemicals & Industries Ltd.**

Krebs Biochemicals and Industries Ltd. was established in 1991. During the financial year 2014-15, Krebs Biochemicals and Industries Ltd. became an associate company. The Company is presently holding 29.83% shares in this company. Krebs undertakes both contract manufacturing for large pharmaceutical and multinational companies and develops products for sale in global markets. Krebs is listed on NSE and BSE and is headquartered in Vishakapatnam, India with manufacturing plants in Nellore and Vizag. Expertise and infrastructure in the areas of chemical synthesis, fermentation and enzymatic technologies along with a focus on cost and quality makes Krebs a logical partner of the Company for the development and supply of products made using one or more of these technologies.

Notes to financial statements as at and for the year ended March 31, 2017

2A Other Long term Investments

Other Long term investments								
Sr. No.	Name of the Body Corporate	Relationship	No. of Shares			(₹ Crores)		
			31/ 03/ 2017	31/ 03/ 2016	01/ 04/ 2015	31/ 03/ 2017	31/ 03/ 2016	01/ 04/ 2015
	Investments at fair value through P&L (fully paid)							
	Unquoted equity shares							
1	Gujarat Industrial Co-Op Bank Ltd.	Others	140	140	140	-	-	-
2	Narmada Clean Tech Ltd. (NCTL) (formerly known as Bharuch Eco Aqua Infrastructure Ltd.)	Others	35,000	35,000	35,000	-	-	-
	Unquoted preference shares							
3	Enviro Infrastructure Company Limited	Others	45,000	45,000	45,000	0.05	0.05	0.05
	Quoted equity shares							
4	Mangalam Drugs & Organics Ltd.	Others	-	-	10,67,939	-	-	2.83
Total						0.05	0.05	2.88

Aggregate value of investments

(₹ Crores)

Particulars	31/03/2017	31/03/2016	01/04/2015
Aggregate book value of quoted investments	-	-	2.83
Aggregate market value of quoted investments	-	-	2.83
Aggregate book value of unquoted investments	0.05	0.05	0.05

2B Current Investment

Sr. No.	Name of the Mutual Fund Scheme	No. Of Units			(₹ Crores)		
		31/03/2017	31/03/2016	01/04/2015	31/03/2017	31/03/2016	01/04/2015
	Quoted investment						
	Investments at fair value through P&L (fully paid)						
A.	Investment in Mutual Fund						
	Kotak Low Duration Fund	1,48,069	-	-	30.07	-	-
	Kotak Floater Short Term Fund	1,25,499	-	-	33.43	-	-
	Reliance Liquid Fund	75,908	-	-	30.01	-	-
	Reliance Medium Term Fund	57,82,392	-	-	20.06	-	-
	Total Current Investments	61,31,868	-	-	113.57	-	-

Aggregate value of investments

(₹ Crores)

Particulars	31/03/2017	31/03/2016	01/04/2015
Aggregate book value of quoted investments	113.57	-	-
Aggregate market value of quoted investments	113.57	-	-

Notes to financial statements as at and for the year ended March 31, 2017

Details of loans given, investments made & guarantee given covered under section 186(4) of the Companies Act, 2013 are given hereunder:

(₹ Crores)						
Sr. No.	Name of the party	Nature	Relation	Purpose	31/03/2017	31/03/2016
1	Ipca Pharmaceuticals, Inc (USA)	Investment	Subsidiary	Equity contribution to Subsidiary	-	0.66
2	Ipca Pharmaceuticals Ltd., SA de CV, Mexico	Investment	Subsidiary	Equity contribution to Subsidiary	-	0.03
3	Krebs Biochemicals & Industries Ltd.	Investment	Associate	Equity contribution to Associate - Share allotment	-	12.42
4	Krebs Biochemicals & Industries Ltd.	Loan Given	Associate	Loan (ICD) given to Associate for business purpose	23.57	11.40
5	Avik Pharmaceutical Ltd.	Loan Given	Joint Venture	Loan (ICD) given to Joint Venture for business purpose	-	1.87
6	Trophic Wellness Pvt. Ltd.	Investment	Associate	Partly paid up shares converted to fully paid up shares	3.40	-
Total					26.97	26.38

The disclosure under section 186(4) is made at transaction value before Ind AS effects.

3. Financial Assets - Loans

Financial Assets - Loans						(₹ Crores)	
	Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
		Non Current	Current	Non Current	Current	Non Current	Current
(a)	Deposits with others:						
	Considered good	46.13	0.82	41.27	0.56	33.98	0.36
	Considered doubtful	0.02	-	0.02	-	0.02	-
		46.15	0.82	41.29	0.56	34.00	0.36
	Less : Provision for doubtful deposits	(0.02)	-	(0.02)	-	(0.02)	-
		46.13	0.82	41.27	0.56	33.98	0.36
(b)	Loans to related parties:						
	(Unsecured, considered good)	50.03	-	29.68	0.64	26.59	0.78
(c)	Others (Unsecured, considered good):						
	Loans given to :						
	- Employees	0.51	1.26	0.70	1.65	1.03	1.64
Total		96.67	2.08	71.65	2.85	61.60	2.78

Disclosures:

- a) Details of loans and advances in the nature of loan to subsidiaries, associates etc. as required under Schedule V(A)(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 :

(₹ Crores)					
Sr. No.	Name of the company and relationship	Balance as at Mar 31, 2017	Maximum outstanding during the year 2016-17	Balance as at Mar 31, 2016	Maximum outstanding during the year 2015-16
i)	Ipca Laboratories (U.K.) Ltd. U.K.- 100% Subsidiary	-	2.88	2.88	9.23
ii)	Krebs Biochemicals & Industries Limited - Associate	34.97	34.97	11.40	11.40
iii)	Avik Pharmaceutical Limited - Joint Venture	15.06	16.19	16.19	16.19

Loans and advances to subsidiary company is interest free and there is no repayment schedule fixed.

The disclosure in this para is made of transaction value and not the figures after application of Ind AS.

Notes to financial statements as at and for the year ended March 31, 2017

b) Investment by the loanee in the shares of the company:

None of the loanees have, per se, made investments in the shares of the company.

c) Details of Loans and advances to Related Parties.

(₹ Crores)

Sr. No.	Name of the company and relationship	Balance as at Mar 31, 2017	Balance as at Mar 31, 2016
i)	Ipca Laboratories (U.K.) Ltd. U.K.- 100% Subsidiary	-	2.88
ii)	Krebs Biochemicals & Industries Limited - Associate	34.97	11.40
iii)	Avik Pharmaceutical Limited - Joint Venture	15.06	16.19
Total		50.03	30.47

d) Deposit includes ₹ 45.00 crores (previous year ₹ 45.00 crores) given as lease deposit for two manufacturing facilities of Krebs Biochemicals & Industries Limited taken on lease by the Company. The figures stated are at transaction value before Ind AS effects.

4. Financial Assets - Others

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Advances to employees						
- Considered good	-	0.79	-	1.55	-	0.68
- Considered doubtful	-	0.60	-	0.29	-	0.43
	-	1.39	-	1.84	-	1.11
Less : Provision for doubtful advances	-	(0.60)	-	(0.29)	-	(0.43)
	-	0.79	-	1.55	-	0.68
Share application money pending allotment	-	-	-	-	12.42	-
Other income receivables	-	3.39	0.04	2.90	-	2.66
Gratuity and other claim receivables	-	1.65	-	3.56	-	7.06
Unbilled revenue	-	11.86	-	4.30	-	8.25
Forward contract gain receivable	-	8.33	-	3.32	-	6.09
Hedging gain receivable	-	3.83	-	-	-	14.48
Term Deposits with banks kept as margin money	2.24	-	2.45	-	3.13	-
Total	2.24	29.85	2.49	15.63	15.55	39.22

5. Other Non-Financial Assets

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
(i) Capital advances (Unsecured, considered good)	6.86	-	4.49	-	26.66	-
(ii) Other advances						
(a) Prepaid expenses	8.99	13.35	12.87	13.56	15.14	13.18
(b) Duties & taxes refundable	7.72	103.49	6.59	80.11	6.91	98.46
(iii) Deposits with Govt. departments						
- Considered good	-	3.81	-	3.27	-	1.26
(iv) Advance to suppliers	-	6.14	-	4.55	-	8.44
(v) Export benefits receivables	-	35.40	-	40.62	-	39.98
(vi) Advances to employees	-	2.83	-	3.57	-	4.24
(vii) Others	0.24	0.36	0.36	0.25	-	0.95
(viii) Prepaid taxes (net of provisions)	2.45	-	3.47	-	2.88	-
Total	26.26	165.38	27.78	145.93	51.59	166.51

Notes to financial statements as at and for the year ended March 31, 2017

6. Inventories

(₹ Crores)

Particulars		As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
i)	Raw Materials						
	In hand	299.73		278.85		315.72	
	In transit	31.61	331.34	15.42	294.27	15.58	331.30
ii)	Packing Materials						
	In hand	31.13		32.33		39.11	
	In transit	0.12	31.25	0.35	32.68	0.28	39.39
iii)	Work-in-progress		185.10		198.14		172.16
iv)	Finished goods						
	In hand						
	Own	257.05		253.18		316.99	
	Traded	40.03	297.08	28.83	282.01	30.00	346.99
	In transit						
	Own	10.47		9.78		10.63	
	Traded	3.94	14.41	2.28	12.06	3.85	14.48
v)	Stores and spares		14.36		12.77		12.66
Total			873.54		831.93		916.98

All the above inventory other than stores & spares are hypothecated to the lenders as security towards short term borrowings.

The disclosure of inventories recognised as an expense in accordance with paragraph 36 of Ind AS 2 is as follows:

(₹ Crores)

Particulars		As at March 31, 2017	As at March 31, 2016
(i)	Amount of inventories recognised as an expense during the period.	1,131.07	1,049.38
(ii)	Amount of write - down of inventories recognised as an expense during the period.	9.07	30.33
Total		1,140.14	1,079.71

7. Financial Assets - Trade receivables (Unsecured, at amortised cost)

(₹ Crores)

Particulars		As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Considered good	502.54		442.08		629.87	
	Considered doubtful	0.02	502.56	0.10	442.18	0.23	630.10
	Less: Allowance for doubtful debts	(0.56)		(0.63)		(0.81)	
	Less: Provision for doubtful debts (lifetime credit loss)	(0.02)	(0.58)	(0.10)	(0.73)	(0.23)	(1.04)
Total			501.98		441.45		629.06

The Company uses a provision matrix to determine impairment loss on portfolio of its trade receivable. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in forward-looking estimates are analysed. The Company estimates the following matrix at the reporting date which is calculated on overdue amounts.

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Default rate - Local	0.12%	0.03%	0.03%
Default rate - Export	0.74%	0.14%	0.14%

Notes to financial statements as at and for the year ended March 31, 2017

Movement in the expected credit loss allowance

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016
Balance at the beginning of the period	0.63	0.81
Movement in expected credit loss allowance on trade receivables calculated at lifetime expected credit losses	(0.07)	(0.18)
Provision at the end of the period	0.56	0.63

8. Financial Assets - Cash & Cash Equivalents

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Balances with banks	9.56	13.48	8.03
Cheques, drafts on hand	1.34	1.56	1.72
Cash on hand	0.20	0.27	0.34
Fixed deposit with bank	-	140.00	77.00
Total	11.10	155.31	87.09

Disclosure of Specified Bank Notes (SBN)

During the year, the Company had specified bank notes or other denomination note as defined in the MCA notification G.S.R. 308(E) dated March 30, 2017 of Specified Bank Note (SBN) held and transacted during the period November 8, 2016 to December 30, 2016. The denomination wise SBNs and other notes as per the notification is given below:

(In ₹)

Particulars	SBNs	Other Denomination Notes	Total
Closing cash on hand as on 08 Nov 2016	55,66,500	23,82,607	79,49,107
(+) Non Permitted receipts	-	-	-
(+) Permitted receipts	-	55,05,856	55,05,856
(-) Permitted payments	56,500	51,88,833	52,45,333
(-) Amounts Deposited in Banks	55,10,000	12,035	55,22,035
Closing cash on hand as on 30 Dec 2016	-	26,87,595	26,87,595

9. Financial Assets - Bank balances other than (8) above

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Unpaid dividend accounts	1.43	1.67	1.82
Fixed Deposits	5.00	5.00	5.00
Open offer Escrow account	-	-	19.29
Total	6.43	6.67	26.11

10. Equity Share Capital

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
Face Value	Equity Shares	₹2.00 each	Equity Shares	₹2.00 each	Equity Shares	₹2.00 each
Class of Shares	28,50,00,000	57.00	28,50,00,000	57.00	28,50,00,000	57.00
Authorised Capital						
Issued, Subscribed and Paid up Capital						
Issued & Subscribed	12,74,80,204	25.50	12,74,80,204	25.50	12,74,80,204	25.50
Paid up	12,61,99,109	25.24	12,61,99,109	25.24	12,61,99,109	25.24

Of the above :

- 3,22,704 Equity shares of ₹ 2/- each of the Company have been allotted during 2012-13 without payment being received in cash under the scheme of amalgamation of erstwhile Tonira Pharma Limited with the Company.

Notes to financial statements as at and for the year ended March 31, 2017

Disclosures:

i) Reconciliation of Shares

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Numbers	(₹ Crores)	Numbers	(₹ Crores)	Numbers	(₹ Crores)
Shares outstanding at the beginning of the year	12,61,99,109	25.24	12,61,99,109	25.24	12,61,99,109	25.24
Shares Issued during the year	-	-	-	-	-	-
Shares outstanding at the end of the year	12,61,99,109	25.24	12,61,99,109	25.24	12,61,99,109	25.24

ii) Details of Shareholding in excess of 5%

Name of Shareholder	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Number of shares held	%	Number of shares held	%	Number of shares held	%
Kaygee Investments Pvt. Ltd.	2,70,18,195	21.41%	2,70,18,195	21.41%	2,70,18,195	21.41%
Kaygee Laboratories Pvt. Ltd. (Formerly Exon Laboratories Pvt. Ltd.)	83,21,000	6.59%	82,71,000	6.55%	82,71,000	6.55%
Chandurkar Investments Pvt. Ltd.	69,78,005	5.53%	69,78,005	5.53%	69,78,005	5.53%

iii) Rights and obligations of shareholders

The Company has only one class of share referred as Equity shares having a par value of ₹ 2/- per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after payment of external liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders. The dividend is recommended by management which is subject to shareholder's approval at the General Meeting.

11. Other Equity

(₹ Crores)

Particulars		As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
(a)	Capital Reserve		0.59		0.59		0.59
(b)	Securities Premium		43.99		43.99		43.99
(c)	Capital Redemption Reserve		0.26		0.26		0.26
(d)	Debenture Redemption Reserve		5.00		5.00		10.00
(e)	General Reserve		1,305.00		1,305.00		1,300.00
(f)	Retained Earnings		1,105.85		917.56		840.24
(g)	OCI Reserve						
	- Remeasurement of employee benefits	(14.25)		(10.75)		(12.09)	
	- Cash flow hedging reserve	3.83		(3.84)		13.58	
	- Foreign currency translation reserve	(0.40)	(10.82)	-	(14.59)	-	1.49
Total			2,449.88		2,257.81		2,196.57

*The Board of Directors in their meeting held on May 28, 2017 have recommended a dividend of ₹ 1/- per equity share (previous year- Nil) to be approved by the shareholders in the ensuing general meeting. On approval, this will result in an outflow of ₹ 15.19 crores including dividend tax.

Notes to financial statements as at and for the year ended March 31, 2017

12. Financial Liabilities - Borrowings

a) Long-term Borrowings - Secured

(₹ Crores)

Particulars	Non - Current Portion As at			Current Maturities as at		
	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
i. Debentures	-	4.99	9.98	4.99	4.99	4.98
ii. Foreign currency term loan	340.42	413.84	435.41	130.00	180.36	100.94
iii. Buyers credit	6.80	14.80	-	6.79	1.64	-
Total (a)	347.22	433.63	445.39	141.78	186.99	105.92

Details of above:-

(₹ Crores)

Sr. No.	Name of the Instruments/ Institutions	Non - Current Portion As at			Current Maturities as at		
		Mar 31, 2017	Mar 31, 2016	Apr 01, 2015	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
i. Debentures							
1	9.25% Secured Redeemable Non-Convertible Debentures	-	4.99	9.98	4.99	4.99	4.98
	Total (i)	-	4.99	9.98	4.99	4.99	4.98
ii. Foreign Currency Term Loans							
1	a) BNP PARIBAS, Singapore Branch	44.90	66.20	-	19.96	-	-
	b) BNP PARIBAS, Singapore Branch	-	-	62.35	-	66.26	-
2	DBS BANK, Singapore Branch	7.64	23.40	36.78	15.20	15.48	14.55
3	Barclays Bank PLC, London Branch	-	-	-	-	-	6.56
4	a) HSBC Bank Mauritius Ltd.	-	-	15.61	-	16.55	37.40
	b) HSBC Bank Mauritius Ltd.	14.31	44.03	62.27	28.87	22.09	-
	c) HSBC Bank Mauritius Ltd.	-	15.28	33.61	14.96	20.35	19.17
	d) HSBC Bank Mauritius Ltd.	40.49	74.41	101.30	32.33	33.00	23.26
	e) HSBC Bank Mauritius Ltd.	107.71	124.68	123.49	14.63	6.63	-
5	Standard Chartered Bank- London	60.80	-	-	4.05	-	-
6	United Overseas Bank Ltd.	64.57	65.84	-	-	-	-
	Total (ii)	340.42	413.84	435.41	130.00	180.36	100.94
iii. Buyers Credit							
1	Standard Chartered Bank	6.80	14.80	-	6.79	1.64	-
	Total (iii)	6.80	14.80	-	6.79	1.64	-
	Total (i + ii + iii)	347.22	433.63	445.39	141.78	186.99	105.92

b) Long-term Borrowings - Unsecured

(i) Buyers credit	4.52	50.65	53.31	44.93	11.07	-
Grand Total (a+b)	351.74	484.28	498.70	186.71	198.06	105.92

c) Details of securities and repayment terms of secured loans stated above

(i) Debentures

Secured by first mortgage and pari-passu charge over Company's office premises at Ahmedabad, Gujarat and first charge by way of equitable mortgage charge on immovable properties being land and building situated at Sejavata, Ratlam and Polo Ground, Indore, both in the state of Madhya Pradesh; Village Athal & Village Piparia (Silvassa); plot no.48, plot no.142-AB, plot no.123, plot no.125 & plot no.126ABCD at Kandivli Industrial Estate in Mumbai and at Dehradun in the state of Uttarakhand.

Redeemable in 4 equal annual installments of ₹ 5.00 crores at the end of 2nd year, 3rd year, 4th year and 5th year from the date of issue i.e. December 12, 2012.

Notes to financial statements as at and for the year ended March 31, 2017

(ii) Foreign Currency Term Loans

1 BNP PARIBAS, Singapore Branch

- a. Secured by first pari-passu charge by way of hypothecation of movable fixed assets both present and future including Pithampur Plant (Indore).
Repayable in 13 equal quarterly instalments from June 30, 2017.
- b. Secured by first pari-passu charge by way of hypothecation of movable fixed assets both present and future except on movable fixed assets at Pithampur, Indore.
Bullet repayment at the end of 5th year on October 07, 2016.

2 DBS BANK, Singapore Branch

Secured by first pari-passu charge by way of hypothecation of all the movable fixed assets both present and future.
Repayable in 17 equal quarterly instalments from September 16, 2014.

3 Barclays Bank PLC, London Branch

Secured by first pari-passu charge on the plant & machinery of the Company except assets at Pithampur, Indore.
Repayable in 13 quarterly instalments from May 31, 2012.

4 HSBC Bank Mauritius Ltd.

- a. Secured by first pari-passu charge on the plant & machinery of the Company except assets at Pithampur, Indore.
Repayable in 7 half yearly instalments from July 31, 2013.
- b. Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Pithampur, Indore and at Baroda.
Repayable in 9 equal quarterly instalments from September 26, 2016.
- c. Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Pithampur, Indore and at Baroda.
Repayable in 13 equal quarterly instalments from November 19, 2014.
- d. Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Pithampur, Indore and at Baroda.
Repayable in 16 equal quarterly instalments from September 30, 2015.
- e. Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Baroda (Gujarat).
Repayable in 11 half yearly un-equal instalments from December 08, 2016.

5 Standard Chartered Bank- London

Secured by first pari-passu charge on movable fixed assets at company's API plant at Baroda and Formulation plant at SEZ Pithampur and the specific and exclusive charge on the unit II at Sikkim.
Repayable in 16 quarterly equal instalments from February 15, 2018.

6 United Overseas Bank Ltd.

Secured by first pari-passu charge by way of hypothecation on movable fixed assets both present and future including Pithampur plant (Indore).
Repayable in 4 equal half yearly instalments from June 29, 2018.

(iii) Buyer's Credit - Standard Chartered Bank

Exclusive Charge by way of hypothecation on specific movable fixed assets financed through this Buyers' credit.
Repayable 10% at end of 12 months, 45% at end of 24 months and balance 45% at end of 36 months from the date of drawdown.

d) Maturity Profile of Borrowings other than Debentures is as per the original sanction terms without Ind AS effects.

(₹ Crores)

Particulars	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
Installment payable between 1 to 2 years	152.30	182.06	224.15
Installment payable between 2 to 5 years	200.86	259.71	201.62
Installment payable beyond 5 years	-	39.75	65.63
Total	353.16	481.52	491.40

e) The long term loans other than non convertible debentures are taken at the following rates.

Particulars	Interest Band
i) Foreign currency loan	Libor + 0.55% to 2.45%

Notes to financial statements as at and for the year ended March 31, 2017

13. Other Financial Liabilities

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Deposits from customers	-	1.07	-	1.10	-	1.33
Current maturities of long term debt	-	186.71	-	198.06	-	105.92
Interest accrued but not due on borrowings	-	1.71	-	2.73	-	2.62
Unpaid dividends	-	1.43	-	1.67	-	1.82
Amount payable on hedging transactions	-	0.02	-	3.84	-	1.27
Payable for capital goods	-	21.47	-	43.09	-	58.33
Total	-	212.41	-	250.49	-	171.29

14. Provisions

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Gratuity	-	3.39	-	1.92	-	2.79
Provision for leave encashment	24.55	2.67	20.22	2.32	17.66	1.99
Provision for leave travel assistance (LTA)	-	5.66	-	4.84	-	4.17
Other employee related provision	-	2.16	-	5.74	-	1.31
Provision for breakage / damage	-	2.38	-	3.45	-	4.61
Provision for product expiry	-	43.46	-	37.28	-	34.12
Provision for sales return	-	6.35	-	6.62	-	6.34
Total	24.55	66.07	20.22	62.17	17.66	55.33

The disclosure of provisions movement as required by Ind AS 37 is as follows:-

(₹ Crores)

Particulars		Mar 31, 2017	Mar 31, 2016
(i)	Provision for breakage/ damage		
	Balance at the beginning of the period	3.45	4.61
	Provisions made during the period	2.49	2.95
	Utilisations during the period	(3.56)	(4.11)
	Provision at the end of the period	2.38	3.45
(ii)	Provision for product expiry		
	Balance at the beginning of the period	37.28	34.12
	Provisions made during the period	30.79	26.24
	Utilisations during the period	(24.61)	(23.08)
	Provision at the end of the period	43.46	37.28
(iii)	Provision for sales return		
	Balance at the beginning of the period	6.62	6.34
	Provisions made during the period	17.81	16.18
	Utilisations during the period	(18.08)	(15.90)
	Provision at the end of the period	6.35	6.62
(iv)	Provision for wage arrears under negotiation		
	Balance at the beginning of the period	5.74	1.32
	Provisions made during the period	8.32	4.60
	Utilisations during the period	(11.90)	(0.18)
	Provision at the end of the period	2.16	5.74

Notes to financial statements as at and for the year ended March 31, 2017

(v) Disclosure in accordance with Ind AS – 19 “Employee Benefits”, of the Companies (Indian Accounting Standards) Rules, 2015.

Gratuity

The company provides for gratuity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement/ termination is the employees last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service. The gratuity plan is a funded plan and the company makes contributions to recognised funds in India. The company does not fully fund the liability and maintains a target level of funding to be maintained over a period of time based on estimations of expected gratuity payments.

The following table summarizes the components of net benefit expense recognized in the Statement of Profit and Loss and the funded status and amounts recognized in the balance sheet.

(₹ Crores)		
Particulars	Mar 31, 2017	Mar 31, 2016
Expense recognised in Statement of Profit & Loss		
Current Service cost	6.13	5.02
Interest expense	3.24	3.02
Expected Return on Plan Assets	(3.49)	(2.79)
Benefit paid but pending claim	-	2.29
Total	5.88	7.54
Expense recognised in Other Comprehensive Income		
Return on plan assets (Greater)/ Less than Discount Rate	(0.17)	(0.54)
Actuarial (Gain)/ Loss due to Experience on DBO	4.61	(1.16)
Total	4.44	(1.70)
Present value of funded defined benefit obligation	54.49	43.20
Fair value of Plan assets	(51.10)	(41.28)
Funded Status	3.39	1.92
Net defined benefit (Asset)/ Liability	3.39	1.92
Movements in present value of defined benefit obligation		
Present value of defined benefit obligation at the beginning of the year	43.20	37.79
Current Service Cost	6.13	5.01
Interest Cost	3.24	3.02
Actuarial (Gain)/ Loss	4.61	(1.16)
Benefits paid	(2.69)	(1.46)
Present value of defined benefit obligation at the end of the year	54.49	43.20
Movements in fair value of the plan assets are as follows.		
Opening fair value of plan assets	41.28	35.01
Expected returns on plan assets	3.49	2.79
Remeasurement (Gains)/ Losses:		
Actuarial (Gain)/ Loss on plan assets	0.17	0.54
Contribution from Employer	8.85	6.69
Benefits paid	(2.69)	(1.46)
Benefit paid but pending claim	-	(2.29)
Closing fair value of the plan asset	51.10	41.28
Remeasurement effect recognised on Other Comprehensive Income		
Actuarial (Gain)/ Loss arising from experience adjustments	4.61	(1.16)
Actuarial (Gain)/ Loss on plan assets	(0.17)	(0.54)
Total Actuarial (Gain)/ Loss included in OCI	4.44	(1.70)

Notes to financial statements as at and for the year ended March 31, 2017

The principal assumptions used as at the balance sheet date are used for purpose of actuarial valuations were as follow

Particulars	March 31, 2017	March 31, 2016
Financial Assumptions		
Discount Rate	7.25%	8.00%
Salary Increase Rate	6.00%	6.00%
Demographic Assumptions		
Mortality Rate	IALM (2006-08) Ultimate	IALM (2006-08) Ultimate
Withdrawal Rate	5%	Age Based: Upto 30 years - 3% 31 to 45 years - 2% 46 years and above - 1%
Retirement age	58 Years	58 Years

The rate used to discount post-employment benefit obligations is determined by reference to market yields at the end of the reporting period on government bonds.

Significant actuarial assumptions for the determination of the defined obligation are discount rate, expected salary increase and mortality.

The sensitivity analyses below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of reporting period, while holding all other assumptions constant.

Defined Benefit Obligation

Discount rate

a. Discount rate - 100 basis points	60.75	47.78
b. Discount rate + 100 basis points	50.56	39.14

Salary increase rate

a. Rate - 100 basis points	51.99	39.03
b. Rate + 100 basis points	58.74	47.83

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would clear in isolation of one another as some of the assumptions may be correlated.

Further more, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

15. Deferred Tax Liabilities (Net)

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
Deferred tax liabilities on account of:						
Depreciation including on R&D Assets, Amortisation and impairment		226.54		211.29		183.80
Deferred tax asset on account of:						
Leave encashment	9.42		7.80		6.80	
Bonus	2.42		2.77		0.69	
MAT Credit available	28.00					
Unabsorbed Depreciation as per IT	-		28.48		-	
Provision for revenue and credit loss	18.06		16.60		15.88	
Other tax disallowance	-	57.90	-	55.65	2.08	25.45
Net deferred tax liability		168.64		155.64		158.35

Notes to financial statements as at and for the year ended March 31, 2017

16. Other Non-financial liabilities

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Security Deposit	1.56	-	1.56	-	1.56	-
Revenue received in advance	-	9.85	-	20.43	-	21.70
Duties & Taxes Payable	-	21.73	-	21.27	-	39.21
Other Payables	-	4.54	-	3.90	-	3.29
Total	1.56	36.12	1.56	45.60	1.56	64.20

17. Financial Liabilities - Borrowings

(₹ Crores)

Particulars		As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
(i)	Secured Loans:*			
	Working capital loan from banks	167.30	116.00	476.96
(ii)	Unsecured Loans:			
	Short term loans from banks	10.00	66.26	120.35
	Short term loans from others	-	0.60	-
Total Short term Borrowings (i)+(ii)		177.30	182.86	597.31

* Secured loans are secured by first charge by way of hypothecation of all the stocks, book debts and all other movable current assets of the Company and second charge by way of mortgage of the immovable properties of the Company and hypothecation of plant & machinery of the Company.

18. Financial Liabilities - Trade Payables

(₹ Crores)

Particulars		As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
a)	Trade Payables for goods and services:			
	Total outstanding dues of Micro and small enterprises	2.63	3.67	2.51
	Others	408.45	397.74	283.17
b)	Acceptances	38.14	13.83	16.88
Total		449.22	415.24	302.56

Trade payables and acceptances are non-interest bearing and are normally settled between 0-120 days.

Details of dues to micro and small enterprises as defined under MSMED Act, 2006

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Principal amount due	2.63	3.67	2.51
Interest due on above	-	-	-
Amount paid in terms of Sec 16 of the Micro, Small and Medium Enterprise Development Act, 2006			
- Principal amount paid beyond appointed day	2.98	1.59	1.68
- Interest paid thereon	0.02	0.01	0.06
Amount of interest due and payable for the period of delay	-	-	-
Amount of interest accrued and remaining unpaid as at year end	0.02	0.01	0.01
Amount of further interest remaining due and payable in the succeeding year	-	-	-

The company has compiled the above information based on written confirmations from suppliers and have been determined to the extent such parties have been identified on the basis of the information available with the company. This has been relied upon by the auditors.

Notes to financial statements as at and for the year ended March 31, 2017

19. Current Tax Liabilities (Net)

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Provision for taxation (Net of taxes paid)	5.22	3.52	9.99
Total	5.22	3.52	9.99

20. Revenue from Operations (Gross)

(₹ Crores)

Particulars	2016-17		2015-16	
Sale of products		3,090.72		2798.74
Sale of services		3.98		5.05
Other operating revenues				
Export incentives	47.03		26.98	
Sundry balances w/back	2.51		2.72	
Bad debts recovered	0.68		0.80	
Miscellaneous income	11.74	61.96	8.77	39.27
Total		3,156.66		2,843.06

21. Other Income

(₹ Crores)

Particulars	2016-17	2015-16
Interest income	10.35	9.35
Interest income on financial asset at amortised cost	3.93	3.58
Dividend income - from current investments	-	0.03
Profit on sale of investments - current (net)	5.15	5.36
Net gain on financial asset through FVTPL	0.16	-
Remeasurement of Financial Assets	0.11	0.52
Profit on sale of property, plant & equipment	0.43	0.38
Reversal of provision for diminution in value of non-current investments	-	6.62
Miscellaneous income	2.08	1.83
Total	22.21	27.67

22. Cost of Materials Consumed

(₹ Crores)

Particulars	2016-17		2015-16	
Raw Materials Consumed				
Opening stock	294.27		331.30	
Add : Purchases (Net of discount)	802.17		683.09	
Add : Raw material conversion charges	11.42		10.53	
	1,107.86		1,024.92	
Less : Closing stock	331.34	776.52	294.27	730.65
Packing Materials Consumed				
Opening stock	32.68		39.39	
Add : Purchases (Net of discount)	187.89		167.07	
	220.57		206.46	
Less : Closing stock	31.25	189.32	32.68	173.78
Neutralisation of duties and taxes on inputs on exports - Drawback benefits		(18.53)		(18.42)
Total		947.31		886.01

Notes to financial statements as at and for the year ended March 31, 2017

23. Purchases of Traded Goods

(₹ Crores)

Particulars	2016-17	2015-16
Formulations	142.37	111.17
Active Pharmaceutical ingredients/ Intermediates	16.64	15.85
Others	2.83	11.31
Total	161.84	138.33

24. Changes in inventories of Finished Goods(FG), Work-in-progress(WIP) and Traded Goods

(₹ Crores)

Particulars	2016-17	2015-16
Inventory Adjustments - WIP		
Stock at commencement	198.14	172.16
Less: Stock at closing	185.10	198.14
Inventory Adjustments - FG		
Stock at commencement	262.96	327.62
Less : Stock at closing	267.52	262.96
Inventory Adjustments - Traded Goods		
Stock at commencement	31.12	33.85
Less : Stock at closing	43.97	31.12
Variation in Excise duty on		
Closing stock of finished goods	24.68	22.04
Less: Opening stock of finished goods	22.04	41.19
Total	(1.73)	22.26

25. Employee Benefits Expenses

(₹ Crores)

Particulars	2016-17	2015-16
Salaries , bonus , perquisites , etc.	597.46	535.18
Contribution to provident and other funds	32.63	29.98
Leave encashment	11.17	8.02
Leave travel assistance	3.86	3.34
Gratuity fund contributions	5.88	7.54
Staff welfare expenses	21.32	15.34
Recruitment & training	2.61	3.95
Total	674.93	603.35

26. Finance Cost

(₹ Crores)

Particulars	2016-17	2015-16
Interest expense	19.33	21.79
Other borrowing cost	3.01	6.80
Interest on Income tax	1.00	0.01
Total	23.34	28.60

27. Depreciation & Amortisation

(₹ Crores)

Particulars	2016-17	2015-16
Depreciation on tangible assets	159.67	152.08
Amortisation on intangible assets	11.33	9.15
Total	171.00	161.23

Notes to financial statements as at and for the year ended March 31, 2017

28. Other Expenses

(₹ Crores)

Particulars	2016-17	2015-16
Consumption of stores and spares	32.72	33.11
Power and fuel	143.60	134.74
Water charges	5.33	5.29
Freight, forwarding and transportation	74.72	73.22
Outside manufacturing charges	19.94	18.04
Repairs and maintenance	85.18	84.49
Loss on sale of property, plant & equipment	1.93	0.92
Loss on sale of investments - non-current (net)	-	0.32
Property, plant & equipment scrapped	1.54	0.34
Commission on sales and brokerage	19.31	15.54
Field staff expenses	84.13	72.66
Sales and marketing expenses	168.06	128.05
Product information catalogue	19.24	25.55
Expenditure on scientific research	41.68	40.46
Laboratory expenses and analytical charges	31.27	30.98
Rent	18.32	16.77
Rates and taxes	17.14	15.37
Travelling expenses	31.23	26.37
Professional charges	35.49	28.00
Printing and stationery	7.71	7.49
Books, subscription and software	13.47	17.61
Product registration expenses	10.79	10.10
Excise duty	56.01	39.40
Communication expenses	6.18	6.72
Insurance	11.02	11.30
Intellectual property right expenses	1.83	4.13
Remuneration to auditors	0.62	0.56
Bank charges	2.65	2.51
Provision for doubtful debts / advances	0.51	(0.18)
Bad debts and other balance w /off	2.68	3.30
CSR expenses	4.28	4.80
Compensation towards failure to supply of goods/ services	1.79	10.13
Foreign exchange (gain) / Loss-net	(17.34)	40.53
Miscellaneous expenses (none of which individually forms more than 1% of the operating revenue)	10.95	10.88
Total	943.98	919.50
Details of:		
1. Repairs and Maintenance:		
Building	13.50	16.23
Machinery	70.16	67.18
Others	1.52	1.08
	85.18	84.49
2. Remuneration To Auditors:		
Audit fees including Limited Review	0.42	0.41
Tax matters	0.10	0.06
Certification and other services	0.07	0.06
Out of pocket expenses	0.03	0.03
	0.62	0.56

Notes to financial statements as at and for the year ended March 31, 2017

Disclosures:

Total expenditure on R & D is included in respective heads of accounts as under:

(₹ Crores)

Particulars	2016-17	2015-16
Expenditure on Scientific Research (Includes stores and chemicals, Bio-availability, Bio-equivalence and Toxicity Studies)	41.68	40.46
Cost of materials consumed	0.94	0.97
Employee benefits expenses	51.38	50.50
Other expenses	25.55	28.54
Depreciation	16.02	15.51
Total	135.57	135.98

29. Tax Expense

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016
Current Tax	56.95	21.64
Tax expense of previous year	(0.04)	-
Deferred Tax	13.00	(2.71)
Total	69.91	18.93
i. Reconciliation of current rate of tax and effective rate of tax:		
Profit before Income taxes	258.20	111.45
Enacted tax rates in India (%)	34.61%	34.61%
Computed expected tax expenses	89.36	38.57
Tax effect due to incentives	(1.93)	-
Accelerated Depreciation	(45.66)	(15.64)
Effect of exempt income	-	(0.49)
Effect of non- deductible expenses	10.99	24.77
Additional deduction on Research and Development Expenses	(38.27)	(40.16)
Others	(14.49)	(7.05)
Income tax expenses - Net	-	-
Tax liability as per Minimum Alternate Tax on book profits		
Minimum Alternate Tax rate	21.34%	21.34%
Computed tax liability on book profits	55.10	23.79
Tax effect on adjustments:		
Provision for diminution disallowed	0.01	0.35
Adjustment of OCI	0.95	(0.36)
Others	0.89	(2.14)
Minimum Alternate Tax on Book Profit	56.95	21.64

ii. Reconciliation of Deferred Tax

Deferred tax (assets)/ liabilities in relation to:

(₹ Crores)

Particulars	As at March 31, 2017	Recognised in profit / (loss)	As at March 31, 2016	Recognised in profit / (loss)	As at April 01, 2015
Property, Plant & Equipment	226.54	(15.25)	211.29	(27.49)	183.80
Unabsorbed Depreciation as per Income Tax	-	(28.48)	(28.48)	28.48	-
MAT Credit available	(28.00)	28.00	-	-	-
Compensated absences	(9.42)	1.62	(7.80)	1.00	(6.80)
Revenue Losses	(18.06)	1.46	(16.60)	0.72	(15.88)
Accrued compensation to employees	(1.73)	(0.35)	(2.08)	-	(2.08)
Expenses	(0.69)	-	(0.69)	-	(0.69)
Total	168.64	(13.00)	155.64	2.71	158.35

Notes to financial statements as at and for the year ended March 31, 2017

30. Disclosure as required by Accounting Standard – Ind AS 33 “Earning Per Share” of the Companies (Indian Accounting Standards) Rules 2015.

The earning per share is calculated by dividing the profit after tax by weighted average number of shares outstanding for basic & diluted EPS.

Particulars	2016-17		2015-16	
i Profit after tax		188.29		92.52
ii Profit after tax and exceptional Items		188.29		92.52
iii Closing equity shares outstanding (Nos.)				
Opening equity shares outstanding (Nos.)	12,61,99,109		12,61,99,109	
Add:- issued during the year (Nos.)	-		-	
Closing equity shares outstanding (Nos.)		12,61,99,109		12,61,99,109
iv Weighted avg no. of shares outstanding (Nos.) (Basic)		12,61,99,109		12,61,99,109
v Weighted avg no. of shares outstanding (Nos.) (Diluted)		12,61,99,109		12,61,99,109
vi Nominal value of equity share (₹)		2.00		2.00
vii Basic EPS (i / iv) (₹)		14.92		7.33
viii Diluted EPS (i / v) (₹)		14.92		7.33

31. Disclosure in accordance with Ind AS – 17 “Leases”, of the Companies (Indian Accounting Standards) Rules, 2015.

The Company has taken various residential/ godowns/ offices premises (including Furniture and Fittings if any) under leave and license agreements. These generally range between 11 months to 3 years under leave and license basis. These arrangements are renewable by mutual consent on mutually agreed terms. Under some of these arrangements the Company has given refundable security deposits. The lease payments are recognized in the Statement of Profit and Loss under Rent.

32. Segment Reporting

Disclosure as required by Ind AS 108 “Operating Segment”, of the Companies (Indian Accounting Standards) Rules, 2015.

Based on the “management approach” as defined in Ind AS 108, the Chief Operating Decision Maker (CODM) evaluates the Company’s performance In accordance with Ind AS “Operating Segment”, the Company has only one reportable operating segment i.e. Pharmaceuticals. The additional disclosure is being made in the consolidated financial statements.

33. Disclosure in accordance with Ind AS - 24 “Related Party Disclosures”, of the Companies (Indian Accounting Standards) Rules, 2015

A. List of related parties

Relationships	Country
i. Entities where control exists	
Shareholders of Ipca Laboratories Ltd	
Kaygee Investments Pvt.Ltd.	India
Subsidiaries	
Ipca Pharmaceuticals, Inc.	USA
Ipca Laboratories (U.K.) Ltd.	United Kingdom
Ipca Pharma (Australia) Pty Ltd.	Australia
Ipca Pharma Nigeria Ltd.	Nigeria
Ipca Pharmaceuticals Ltd.SA de CV	Mexico
National Druggists (Pty) Ltd. (Liquidated during previous year)	South Africa
Ipca Pharmaceuticals (Shanghai) Ltd, China (Liquidated during previous year)	Peoples Republic of China
Tonira Exports Limited	India

Notes to financial statements as at and for the year ended March 31, 2017

Relationships		Country
Step-down Subsidiaries		
Ipca Pharma (NZ) Pty. Ltd.		New Zealand
Onyx Scientific Limited		United Kingdom
ii. Associates		
Trophic Wellness Pvt.Ltd.		India
Krebs Biochemicals & Industries Ltd.		India
iii. Joint Venture		
Avik Pharmaceutical Ltd.		India
iv. Key Management Personnel		
Mr. Premchand Godha	Chairman & Managing Director	Indian
Mr. Ajit Kumar Jain	Joint Managing Director & CFO	Indian
Mr. Pranay Godha	Executive Director	Indian
Mr. Prashant Godha	Executive Director	Indian
Mr. Babulal Jain	Independent Director	Indian
Mr. Anand T. Kusre	Independent Director	Indian
Mr. Dev Parkash Yadava	Independent Director	Indian
Dr. Ramakanta M. Panda	Independent Director	Indian
Mrs. Manisha Premnath	Independent Director	Indian
v. Other Related Parties (Entities in which Directors or their relatives have significant influence)		
Nipra Industries Pvt.Ltd.		India
Nipra Packaging Pvt. Ltd.		India
Prabhat Foundation		India
Vandhara Resorts Pvt. Ltd.		India
Mexin Medicaments Pvt. Ltd.		India
Makers Laboratories Ltd.		India

(Details of related party transaction are given in statement 1 attached to the financial statement.)

34. CSR expenditure:

- Gross amount required to be spent by the Company during the year ₹ 7.14 crores (previous year ₹ 9.51 crores).
- i) Amount spent by the Company during the year is as follows :

		(₹ Crores)		
Particulars	Paid in cash	Yet to be paid in cash	Total	
1 Eradication of poverty, promotion of healthcare, sanitation, drinking water etc.	0.38	-	0.38	
2 Promotion of education, vocational training & skill enhancement etc.	3.67	-	3.67	
3 Environmental sustainability, animal welfare, natural resource conservation etc.	0.01	-	0.01	
4 Promoting of gender equality and empowering women	0.02	-	0.02	
5 Protection of national heritage, art, culture etc.	-	-	-	
6 Promotion of rural sports	0.03	-	0.03	
7 Rural development	0.17	-	0.17	
Total	4.28	-	4.28	

Notes to financial statements as at and for the year ended March 31, 2017

ii) Amount spent by the Company during the previous year is as follows :

(₹ Crores)

Particulars	Paid in cash	Yet to be paid in cash	Total
1 Eradication of poverty, promotion of healthcare, sanitation, drinking water etc.	0.44	-	0.44
2 Promotion of education, vocational training & skill enhancement etc.	4.08	-	4.08
3 Environmental sustainability, animal welfare, natural resource conservation etc.	0.03	-	0.03
4 Protection of national heritage, art, culture etc.	0.05	-	0.05
5 Promotion of rural sports	0.06	-	0.06
6 Rural development	0.14	-	0.14
Total	4.80	-	4.80

35. Contingent liabilities and Commitments

A. Contingent Liabilities

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016
Other moneys for which the Company is contingently liable for tax, excise, customs and other matters not accepted by the Company *	20.43	17.03
Amount deposited under protest	(1.80)	(3.51)
Claims against the Company not acknowledged as debts	13.25	13.22
Corporate guarantee given to others	2.28	4.27
Guarantees given by banks in favor of Govt. & others *	11.31	15.14
Total	45.47	46.15

*Note:- It includes ₹4.38 crores (Previous year ₹4.38 crores) towards interest and penalty demanded by excise department, Ankleshwar relating to erstwhile Tonira Pharma Limited since amalgamated with the Company and is not payable in accordance with the order passed by the Hon'ble Central Excise and Service Tax Appellate Tribunal (CESTAT), Ahmedabad. The Department had moved the Hon'ble Gujarat High Court against the said CESTAT order and as per the order of the said Hon'ble High Court, the Company has furnished a Bank Guarantee of ₹2.00 crores (Previous year ₹2.00 crores) to the Department.

B. Commitments

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016
(a) Estimated amount of contracts remaining to be executed on capital account and not provided for:		
Tangible Assets	14.89	41.08
Intangible Assets	27.68	29.71
	42.57	70.79
(b) Uncalled liability on partly paid shares and other investment partly paid	-	3.40
	-	3.40
(c) Other Commitments		
Purchase orders backed by LC opened by bankers.	34.40	7.73
	34.40	7.73
Total	76.97	81.92

36. Significant accounting judgments, estimates and assumptions

The financial statements require management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosures of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods .

Notes to financial statements as at and for the year ended March 31, 2017**a. Judgments**

In the process of applying the company's accounting policies, management has made judgments, which have significant effect on the amounts recognised in the separate financial statements.

b. Taxes

Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Significant management judgment is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

c. Defined benefit plans (gratuity benefits)

The cost of the defined benefit gratuity plan and the present value of the gratuity obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds in currencies consistent with the currencies of the post-employment benefit obligation. For plans operated outside India, the management considers the interest rates of high quality corporate bonds in currencies consistent with the currencies of the post-employment benefit obligation with at least an 'AA' rating or above, as set by an internationally acknowledged rating agency, and extrapolated as needed along the yield curve to correspond with the expected term of the defined benefit obligation. The underlying bonds are further reviewed for quality. Those having excessive credit spreads are excluded from the analysis of bonds on which the discount rate is based, on the basis that they do not represent high quality corporate bonds.

The mortality rate is based on publicly available mortality tables for the specific countries. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates for the respective countries.

37. First-time adoption of Ind AS

These financial statements, for the year ended March 31, 2017, are the first financial statements the Company has prepared in accordance with Ind AS. For periods up to and including the year ended March 31, 2016, the Company prepared its financial statements in accordance with accounting standards notified under section 133 of the Companies Act, 2013 read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP).

Accordingly, the Company has prepared financial statements which comply with Ind AS applicable for periods ending on March 31, 2017, together with the comparative period data as at and for the year ended March 31, 2016, as described in the summary of significant accounting policies. In preparing these financial statements, the Company's opening balance sheet was prepared as at April 1, 2015, the Company's date of transition to Ind AS. This note explains the principal adjustments made by the Company in restating its previous GAAP financial statements, including the balance sheet as at April 1, 2015 and the financial statements as at and for the year ended March 31, 2016.

A. Exemptions applied

Ind AS 101 allows first-time adopters certain exemptions from the retrospective application of certain requirements under Ind AS. The Company has applied the following exemptions:

- i. The Company has elected to apply the exemption for deemed cost of property, plant and equipment contained in D7AA of Ind AS 101 by considering the previous GAAP carrying values as deemed costs. Accordingly the Net block as at March 31, 2015 as per the previous GAAP have been considered as the deemed cost as at April 1, 2015 and are being depreciated over the residual useful life on a straight line basis.
- ii. Ind AS 101 permit cumulative translating gains and losses to be reset to zero at the transition date. This provides relief from determining cumulative currency translation difference in accordance with Ind AS 21.
- iii. The Company has designated unquoted equity instruments held at April 01, 2015 as fair value through P&L.

Notes to financial statements as at and for the year ended March 31, 2017

38. Reconciliation between previous GAAP and Ind AS

(₹ Crores)

A Effect of Ind AS adoption on the Balance Sheet as on March 31, 2016 and April 01, 2015.

Particulars	Notes to first time adoption	As at March 31, 2016 (End of Last Period presented under previous GAAP)			As at April 01, 2015 (Date of Transition)		
		Previous GAAP	Effect of Transition to Ind AS	March 31, 2016	Previous GAAP	Effect of Transition to Ind AS	As per Ind AS Balance Sheet
ASSETS							
(1) Non-current assets							
(a) Property, plant and equipment		1,927.88	-	1,927.88	1,706.39	-	1,706.39
(b) Capital work-in-progress		93.80	-	93.80	236.29	-	236.29
(c) Goodwill	xi	15.12	8.49	23.61	23.61	-	23.61
(d) Other intangible assets		25.09	-	25.09	22.96	-	22.96
(e) Intangible assets under development		35.13	-	35.13	30.66	-	30.66
(f) Financial assets							
i. Investments in Subsidiary/ Joint venture/ Associate		96.38	1.00	97.38	78.48	1.00	79.48
ii. Other Investments	i	0.09	(0.04)	0.05	3.38	(0.50)	2.88
iii. Loans	xii	89.45	(17.80)	71.65	80.94	(19.34)	61.60
iv. Other financial assets		2.49	-	2.49	15.55	-	15.55
(g) Other non-current assets	xii	15.73	12.05	27.78	37.14	14.44	51.59
Total non-current assets		2,301.16	3.70	2,304.86	2,235.40	(4.40)	2,231.01
(2) Current assets							
(a) Inventories		831.93	-	831.93	916.98	-	916.98
(b) Financial assets							
i. Investments		-	-	-	-	-	-
ii. Trade receivables	ii	442.07	(0.62)	441.45	629.87	(0.81)	629.06
iii. Cash and cash equivalents		155.81	(0.50)	155.31	87.09	-	87.09
iv. Bank balances other than (iii) above		6.67	-	6.67	26.11	-	26.11
v. Loans		2.85	-	2.85	2.78	-	2.78
vi. Other financial assets		15.63	-	15.63	39.22	-	39.22
(c) Current tax assets (net)		-	-	-	-	-	-
(d) Other current assets	xii	141.58	4.35	145.93	162.62	3.89	166.51
Total current assets		1,596.54	3.23	1,599.77	1,864.66	3.07	1,867.75
Total assets		3,897.70	6.93	3,904.63	4,100.08	(1.32)	4,098.76
EQUITY AND LIABILITIES							
Equity							
(a) Equity share capital		25.24	-	25.24	25.24	-	25.24
(b) Other equity	xiii	2,280.85	(23.04)	2,257.81	2,208.10	(11.53)	2,196.57
Total equity		2,306.09	(23.04)	2,283.05	2,233.34	(11.53)	2,221.81

Notes to financial statements as at and for the year ended March 31, 2017

Particulars	Notes to first time adoption	As at March 31, 2016 (End of Last Period presented under previous GAAP)			As at April 01, 2015 (Date of Transition)		
		Previous GAAP	Effect of Transition to Ind AS	March 31, 2016	Previous GAAP	Effect of Transition to Ind AS	As per Ind AS Balance Sheet
LIABILITIES							
(1) Non-current liabilities							
(a) Financial liabilities							
i. Borrowings	v	486.52	(2.24)	484.28	501.40	(2.70)	498.70
ii. Other financial liabilities		-	-	-	-	-	-
(b) Provisions		20.22	-	20.22	17.66	-	17.66
(c) Deferred tax liabilities (Net)	vii	169.30	(13.66)	155.64	174.23	(15.88)	158.35
(d) Other non-current liabilities		-	1.56	1.56	-	1.56	1.56
Total non-current liabilities		676.04	(14.34)	661.70	693.29	(17.02)	676.27
(2) Current liabilities							
(a) Financial liabilities							
i. Borrowings	v	183.35	(0.49)	182.86	597.31		597.31
ii. Trade payables		415.24	-	415.24	302.56	-	302.56
iii. Other financial liabilities	v	252.77	(2.28)	250.49	173.68	(2.39)	171.29
(b) Other current liabilities		45.86	(0.26)	45.60	64.46	(0.26)	64.20
(c) Provisions	vi	14.83	47.34	62.17	25.45	29.88	55.33
(d) Current tax liabilities		3.52	-	3.52	9.99	-	9.99
Total current liabilities		915.57	44.31	959.88	1,173.45	27.23	1,200.68
Total liabilities		1,591.61	29.97	1,621.58	1,866.74	10.21	1,876.95
Total equity and liabilities		3,897.70	6.93	3,904.63	4,100.08	(1.32)	4,098.76

* The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

B Effect of Ind AS adoption on the Statement of Profit and Loss for the year ended March 31, 2016 (₹ Crores)

Particulars	Notes to first time adoption	Previous GAAP	Effect of Transition to Ind AS	2015-16
(I) Income				
Revenue from operations	vi & viii	2,814.11	28.95	2,843.06
Other income	xii	23.06	4.61	27.67
Total income		2,837.17	33.56	2,870.73
(II) Expenses				
Cost of materials consumed		886.00	-	886.01
Purchases of stock in trade		138.33	-	138.33
Change in inventories of work-in-progress, stock-in-trade and finished goods		22.27	-	22.26
Employee benefit expense	iii	601.64	1.70	603.35
Finance costs	v	27.91	0.69	28.60
Depreciation and amortisation expense	xi	169.72	(8.49)	161.23
Other expenses	xii	882.78	36.73	919.50
Total expenses		2,728.65	30.63	2,759.28
Profit before exceptional items and tax		108.52	2.93	111.45

Notes to financial statements as at and for the year ended March 31, 2017

(₹ Crores)				
Particulars	Notes to first time adoption	Previous GAAP	Effect of Transition to Ind AS	2015-16
Exceptional items		-	-	-
Profit before tax from continuing operations		108.52	2.93	111.45
Income tax expense				
- Current tax		22.00	(0.36)	21.64
- Deferred tax	vii	(4.93)	2.22	(2.71)
Total tax expense		17.07	1.86	18.93
Profit from continuing operations		91.45	1.07	92.52
Profit from discontinued operation		-	-	-
Profit for the year		91.45	1.07	92.52
Other comprehensive income		-	(16.08)	(16.08)
Total comprehensive income		91.45	(15.01)	76.44

* The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

C Reconciliation of total Equity as at March 31, 2016 and April 01, 2015

(₹ Crores)			
Particulars	Notes to first time adoption	March 31, 2016	April 01, 2015
Total equity (shareholder's funds) as per previous GAAP		2,306.09	2,233.34
Adjustments:			
FCTR transfer to retained earning	(iv)	1.28	-
Proposed dividend and tax on dividend	(x)	-	15.19
Exchange gain / (loss)	(iv)	(0.90)	0.41
Depreciation and amortisation expense	(xi)	8.49	-
Effect of Ind AS 109		2.43	2.88
Effect of Ind AS 18	(vi)	(48.00)	(45.88)
Tax effects of adjustments	(vii)	13.66	15.88
Total adjustments		(23.04)	(11.53)
Total equity as per Ind AS		2,283.05	2,221.81

D Notes to effect of first time adoption

i) FVTPL Financial assets

Under Indian GAAP, the Company accounted for long term investments and mutual funds in unquoted and quoted equity shares as investment measured at cost less provision for other than temporary diminution in the value of investments. Under Ind AS, the Company has designated such investments other than investments in subsidiaries/ joint ventures and associates as FVTPL investments. Ind AS requires FVTPL investments to be measured at fair value. At the date of transition to Ind AS, difference between the instruments fair value and previous GAAP carrying amount has been recognised under retained earnings.

On this account of this adjustment the retained earning increased by ₹ 0.46 crore as at March 31, 2016 and is decreased by ₹ 0.50 crore as at April 01, 2015.

ii) Trade Receivables

As per Ind AS 109, the Company is required to apply expected credit loss model for recognising the allowance for doubtful debts. As a result, the allowance for doubtful debts is ₹ (0.18) crore as at March 31, 2016 and ₹ 0.81 crore as at April 01, 2015.

Notes to financial statements as at and for the year ended March 31, 2017

iii) Defined benefit liabilities

Under Ind AS, remeasurements i.e. actuarial gains and losses and the return on plan assets, excluding amounts included in the net interest expense on the net defined benefit liability are recognised in other comprehensive income instead of profit or loss. Accordingly ₹ (12.09) crores net of tax thereon has been adjusted in other comprehensive income from retained earnings as at April 01, 2015. The adjustment for the year ended March 31, 2016 is ₹ 1.35 crores net of the tax effect thereon. As a result of this change, the retained earnings as at April 01, 2015 and profit for the year ended March 31, 2016 has been adjusted. There is no impact on the total equity as at March 31, 2016.

iv) Foreign currency translation reserve

Under Indian GAAP, the Company recognised translation differences on foreign operations in a separate component of equity. Under Ind AS, the balance appearing in the foreign currency reserve has been reset to zero as at April 1, 2015 by transferring the same to retained earnings. Accordingly, foreign currency translation reserve balance under previous GAAP has been transferred to retained earnings. There is no impact on total equity as a result of this adjustment.

v) Borrowings

Ind AS 109 requires transaction costs incurred towards origination of borrowing to be deducted from carrying amount of borrowings on initial recognition. These cost are recognised in the profit and loss over the tenure of the borrowing as part of the interest expenses by applying the effective interest rate method.

Accordingly, the upfront fees has been amortised over the loan period as against charge to the profit and loss statement in the initial year. On account of this change, retained earnings as at April 01, 2015 has been increased by ₹ 3.22 crores with consequent adjustment of the upfront fees as prepaid expenses to be amortised over the period of the loan.

vi) Provisions for expiry, returns and breakage/ damage

The Company has estimated probable expiry, returns and breakage/ damage based on past trends and has made provision thereon as required by Ind AS 18 "Revenue recognition". On account of this change, the retained earnings as at April 01, 2015 has been decreased by ₹ 45.07 crores with consequent increase in provision. The impact for the year ended March 31, 2016 is ₹ 2.28 crores on the profit for the year with corresponding effect on the balance of provisions.

vii) Deferred tax

Consequent impact on deferred tax arising out of various adjustments under Ind AS has been given in accordance with Ind AS 12 "Income Taxes". On the date of transition the net impact of deferred tax is ₹ 15.88 crores which is adjusted against retained earnings. For the year ended March 31, 2016 the impact on profit arising out of deferred tax changes is ₹ 2.22 crores.

viii) Excise duty

Under Indian GAAP, sale of goods was presented as net of excise duty. However, under Ind AS, sale of goods includes excise duty. Excise duty on sale of goods is accounted as a cost under other expenses. Thus sale of goods under Ind AS has increased by ₹ 31.74 crores in March 2016 with a corresponding increase in other expense. There is no impact on total equity.

ix) Statement of cash flows

The transition from Indian GAAP to Ind AS has not had a material impact on the statement of cash flows.

x) Proposed Dividend

Under the previous GAAP, dividends proposed by the board of directors after the balance sheet date but before the approval of the financial statements were considered as adjusting events. Accordingly, provision for proposed dividend was recognised as a liability as at March 31, 2015. Under Ind AS, such dividends are recognised when the same is approved by the shareholders in the general meeting. Accordingly, the liability for proposed dividend of ₹ 12.62 crores and ₹ 2.57 crores tax liability as at March 31, 2015 has been reversed back to retained earnings. The same is charged to retained earnings during the year ended March 31, 2016 on approval by the shareholders. There is no impact on equity as at March 31, 2016.

Notes to financial statements as at and for the year ended March 31, 2017

xi) Goodwill

Under Ind AS goodwill on business acquisition is not required to be amortised but is to be tested for impairment. Accordingly, amortisation of goodwill during March 31, 2016 has been reversed and the goodwill is carried at April 01, 2015 values. On account of this profit for the year March 31, 2016 is higher by ₹ 8.49 crores.

xii) Security deposits

Under the previous GAAP, interest free lease security deposits (that are refundable in cash on completion of the lease term) are recorded at their transaction value. Under Ind AS, all financial assets are required to be recognised at fair value. Accordingly, the group has fair valued these security deposits under Ind AS. Difference between the fair value and transaction value of the security deposit has been recognised as prepaid rent. Consequent to this change, the amount of security deposits increased by ₹ 0.80 crores as at March 31, 2016 and decreased by ₹ 18.45 crores as at April 01, 2015. The prepaid rent decreased by ₹ 1.76 crores as at March 31, 2016 and increased by ₹ 18.17 crores as at April 01, 2015. The net impact on retained earnings as at April 01, 2015 is decrease of ₹ 0.27 crores and the impact on profit for the year ended March 31, 2016 is decrease of ₹ 0.96 crores.

xiii) Retained earning

Retained earnings as at April 1, 2015 has been adjusted consequent to the above Ind AS transition adjustments.

39. Standards issued but not yet effective

In March 2017, the Ministry of Corporate Affairs issued the Companies (Indian Accounting Standards) (Amendments) Rules, 2017, notifying amendments to Ind AS 7, 'Statement of cash flows' and Ind AS 102, 'Share-based payment.' These amendments are in accordance with the recent amendments made by International Accounting Standards Board (IASB) to IAS 7, 'Statement of cash flows' and IFRS 2, 'Share-based payment', respectively. The amendments are applicable to the Company from April 1, 2017.

Amendment to Ind AS 7:

The amendment to Ind AS 7 requires the entities to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes, suggesting inclusion of a reconciliation between the opening and closing balances in the balance sheet for liabilities arising from financing activities, to meet the disclosure requirement.

The Company is currently evaluating the requirements of the amendment and has not yet determined the impact on the financial statements.

Amendment to Ind AS 102:

The amendment to Ind AS 102 provides specific guidance to measurement of cash-settled awards, modification of cash-settled awards and awards that include a net settlement feature in respect of withholding taxes.

It clarifies that the fair value of cash-settled awards is determined on a basis consistent with that used for equity-settled awards. Market-based performance conditions and non-vesting conditions are reflected in the 'fair values', but non-market performance conditions and service vesting conditions are reflected in the estimate of the number of awards expected to vest. Also, the amendment clarifies that if the terms and conditions of a cash-settled share-based payment transaction are modified with the result that it becomes an equity-settled share-based payment transaction, the transaction is accounted for as such from the date of the modification. Further, the amendment requires the award that include a net settlement feature in respect of withholding taxes to be treated as equity-settled in its entirety. The cash payment to the tax authority is treated as if it was part of an equity settlement. The Company is currently evaluating the requirements of the amendment and has not yet determined the impact on the financial statements.

Notes to financial statements as at and for the year ended March 31, 2017

40. Financial Instruments

The carrying value and fair value of financial instruments by categories as at March 31, 2017, March 31, 2016 and April 1, 2015 is as follows:

Particulars	Carrying Value			Fair Value		
	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
Financial assets						
Amortised Cost						
Investments						
- Equity Instruments	-	-	-	-	-	-
- Preference Shares	0.05	0.05	0.05	0.05	0.05	0.05
Loans	98.75	74.50	64.38	98.75	74.50	64.38
Others	19.93	14.80	34.20	19.93	14.80	34.20
Trade receivables	501.98	441.45	629.06	501.98	441.45	629.06
Cash and cash equivalents	17.53	161.98	113.20	17.53	161.98	113.20
FVTPL						
Equity Instruments	-	-	2.83	-	-	2.83
Mutual funds considered as Cash and cash equivalents	113.57	-	-	113.57	-	-
FVTOCI						
Derivative Assets	12.16	3.32	20.57	12.16	3.32	20.57
Total Financial Assets	763.97	696.10	864.29	763.97	696.10	864.29
Financial liabilities						
Amortised Cost						
Borrowings	529.04	667.14	1,096.01	529.04	667.14	1,096.01
Trade payables	449.22	415.24	302.56	449.22	415.24	302.56
Others	212.39	246.65	170.02	212.39	246.65	170.02
FVTOCI						
Derivative Liabilities	0.02	3.84	1.27	0.02	3.84	1.27
Total Financial Liabilities	1,190.67	1,332.87	1,569.86	1,190.67	1,332.87	1,569.86

The management assessed that fair value of cash and short-term deposits, trade receivables, trade payables, book overdrafts and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

41. Fair Value Hierarchy

This section explains the judgments and estimates made in determining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

Notes to financial statements as at and for the year ended March 31, 2017

(₹ Crores)

Particulars	Date of Valuation	Fair Value measurement using			
		Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Financial assets measured at fair value					
Mutual funds - Growth plan	31/03/2017	113.57	-	-	113.57
Mutual funds - Dividend plan	31/03/2017	-	-	-	-
Derivative financial assets	31/03/2017	-	12.16	-	12.16
Total financial assets		113.57	12.16	-	125.73
Financial liabilities					
Derivatives designated as hedges	31/03/2017	-	-	-	-
Derivative financial liabilities	31/03/2017	-	0.02	-	0.02
Total financial liabilities		-	0.02	-	0.02
Financial assets measured at fair value					
Listed Equity investments	31/03/2016	-	-	-	-
Derivative financial assets	31/03/2016	-	3.32	-	3.32
Total financial assets		-	3.32	-	3.32
Financial liabilities					
Derivative financial liabilities	31/03/2016	-	3.84	-	3.84
Total financial liabilities		-	3.84	-	3.84
Financial assets measured at fair value					
Listed Equity investments	01/04/2015	2.83	-	-	2.83
Derivative financial assets	01/04/2015	-	20.57	-	20.57
Total financial assets		2.83	20.57	-	23.40
Financial liabilities					
Derivative financial liabilities	01/04/2015	-	1.27	-	1.27
Total financial liabilities		-	1.27	-	1.27

42. Financial Risk Factors

The Company's business activities are exposed to a variety of financial risks: Market/ Business risk, credit risk, Exchange risk, etc. The Company's focus is to foresee the unpredictability of financial and business risks and seek to minimize potential adverse effects of these risks on its business and financial performance.

i. Business/ Market Risk

The primary business/ market risk to the Company is the price risk and its ability to pass on the same to its customers. The Company's operations extend to a number of countries across the globe and its products pricing competitiveness is a primary factor for the acceptability of Company's products in those markets. The Company has a robust procurement process, which ensures that its pricing power is not adversely affected by price changes in the market place for its raw – materials. The backward integration into manufacturing of several API's for its own use in the formulations manufacturing also works as a mitigating strategy for price risk faced by the Company.

Notes to financial statements as at and for the year ended March 31, 2017

The other business risk is regulatory risk and regulatory audits of its manufacturing facilities by the regulators to ensure that the manufacturing facilities meet the current Good Manufacturing Practices (cGMP) requirements. The Company is already exposed to certain audit observations from the US FDA for 3 of its manufacturing plants and has taken the necessary corrective measures to redress those US FDA audit observations so as to be able to market all its products once again in the US market. While the stringent regulatory requirements and audits works as a business risk, the successful audit of its facilities by regulators coupled with price competitiveness results in higher business and margins for the Company.

The Company's products are also subjected to product liability claims/ litigations. To mitigate these risks, the Company has obtained adequate Product Liability Insurance.

The Company, however, has a reduced risk from dependence on any single customer as no single customer or customer group accounts for more than 10% of Company's annual revenue. The Company also continuously forays into different markets/ countries to reduce its dependence on any particular country or customer group. The Company also has a diversified therapeutic product portfolio and therefore no single product account for more than 10% of Company's annual revenue.

ii. Credit Risk

The Company has exposure to credit risks associated with sales to various developing markets/ countries. To mitigate these credit risks arising out of this, the Company obtains credit insurance on a regular basis after evaluating the credit risk associated with a country/ customer. Country/ customer where no credit insurance is available, the Company monitors such risk by continuously monitoring its exposure to such country/ customer. There was no historically significant credit risk in the domestic market for the Company. Based on the historical data, the Company has made adequate provisions for expected loss because of credit risk, which is neither significant nor material.

iii. Interest Risk

The Company has borrowings mainly in foreign currencies which is linked to Libor. The Company mitigates these risks associated with floating Libor rates by entering into interest rate swaps to move them to fixed Libor rates. The domestic interest risk is exposed to the changes in the RBI bank rate. The Company manages this risk by managing its working capital effectively.

iv. Foreign Currency Risk

The company continuously manages its risks associated with foreign currency by adopting various hedging strategies in consultation with internal and external experts. The Company has a system of regularly monitoring its currency wise exposures. The significant part of Company's receivables and borrowings are in US Dollars which operates as a natural hedge against each other. The Company has a policy not to borrow in a currency where it has no business exposure.

v. The unhedged foreign currency exposure is as follows:

Particulars	Currency	Mar 31, 2017		Mar 31, 2016	
		Amount in foreign currency (in millions)	Amount (₹ crores)	Amount in foreign currency (in millions)	Amount (₹ crores)
I) Unhedged foreign exchange liability					
a. ECB Term Loan & Interest	USD	72.91	472.86	90.28	598.22
b. Buyers Credit & Interest	USD	7.01	45.43	8.67	57.44
	EURO	2.64	18.27	2.86	21.56
c. Packing Credit & Interest	USD	1.00	6.49	6.24	41.37
	AUD	3.47	17.23	-	-
	GBP	2.00	16.19	-	-
d. FCNR Working Capital Loan	USD	-	-	10.01	66.36
e. Trade & Other Payables Incl. advances received	USD	14.93	96.83	12.77	84.64
	EURO	0.09	0.65	0.22	1.69
	GBP	0.00	0.03	0.01	0.09
	NZD	0.00	0.01	-	-
	AUD	-	-	0.01	0.05
	JPY	0.14	0.01	-	-
	CAD	-	-	0.06	0.31

Notes to financial statements as at and for the year ended March 31, 2017

Particulars	Currency	Mar 31, 2017		Mar 31, 2016	
		Amount in foreign currency (in millions)	Amount (₹ crores)	Amount in foreign currency (in millions)	Amount (₹ crores)
II) Unhedged receivables in foreign currency					
a. Long Term Loan	GBP	-	-	0.24	2.24
b. Short Term Loan & Interest Receivable	EURO	-	-	0.09	0.64
c. Trade & Other receivables incl. advances given	USD	42.83	277.75	38.70	256.42
	EURO	5.03	34.88	3.42	25.79
	GBP	3.76	30.46	3.51	33.49
	AUD	1.50	7.44	0.96	4.87
	CAD	0.44	2.15	0.62	3.15
	NZD	0.64	2.92	0.99	4.54
	COP	649.63	1.46	954.77	2.10
d. Unbilled Revenue	USD	1.79	11.59	0.65	4.30
	CAD	0.04	0.27	-	-

III) The Company has entered into various derivatives transactions, which are not intended for trading or speculative purpose but to hedge the export receivables including future receivables and foreign currency loan interest rate risks.

The Company has following derivatives instruments/ forward cover outstanding.

Type of transaction	Purpose	Amount Outstanding in millions	
		Mar 31, 2017	Mar 31, 2016
a. USD interest rate swap	To hedge the USD LIBOR risk by moving from Floating LIBOR rate to Fixed LIBOR Rate.	USD 49.20 Notional O/ s	USD 68.38 O/ s
b. Forward cover	To hedge export receivables	STG 2.00	Nil

43. Capital Management

For the purpose of the Company's capital management, capital includes paid-up equity share capital, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Company's capital management is to maximise the shareholders' value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust its dividend payment ratio to shareholders, return capital to shareholders or issue fresh shares. The Company monitors capital using a gearing ratio, which is net debt divided by its total capital. The Company includes within its net debt the interest bearing loans and borrowings, trade and other payables less cash and cash equivalents.

Particulars	(₹ Crores)		
	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Borrowings other than convertible preference shares	529.04	667.14	1,096.01
Trade payables	449.22	415.24	302.56
Other payables	212.41	250.49	171.29
Less: Cash and Cash Equivalents (C&CE)	(17.53)	(161.98)	(113.20)
Less: Investment in MF (part of C&CE)	(113.57)	-	-
Net debt	1,059.57	1,170.89	1,456.66
Total Equity	2,475.12	2,283.05	2,221.81
Capital and net debt			
Gearing ratio	42.81%	51.29%	65.56%

Notes to financial statements as at and for the year ended March 31, 2017

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets the financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the lending institutions to immediately call back the loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

No changes were made in the objectives, policies or processes for managing the capital during the years ended March 31, 2017 and March 31, 2016.

- 44.** The Balance Sheet, Statement of Profit and Loss, Cash Flow Statement, Statement of changes in equity, Statement of significant accounting policies and the other explanatory notes forms an integral part of the financial statements of the Company for the year ended March 31, 2017.

As per our report of even date attached
For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No. 106971W

N. Jayendran
Partner
M.No. 40441
Mumbai,
28th May, 2017

For and on behalf of the Board of Directors
Premchand Godha
Chairman & Managing Director (DIN 00012691)
Ajit Kumar Jain
Joint Managing Director & CFO (DIN 00012657)
Prashant Godha
Executive Director (DIN 00012759)
Harish P. Kamath
Company Secretary (ACS - 6792)

Statement 1 (refer Note No. 33)

Related Party Disclosure as required by Indian Accounting Standard – Ind AS 24 “Related Party Transactions” of the Companies (Accounting Standards) Rule 2015.

Transactions with Related Parties

(₹ Crores)

Description	Entities where control exists Subsidiaries		Key Management Personnel		Associates		Joint Venture		Other Related Parties		Total	
	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16
Purchase of goods and services												
Makers Laboratories Ltd.	-	-	-	-	-	-	-	-	8.18	13.12	8.18	13.12
Ipca Pharmaceuticals, Inc. USA	4.96	5.75	-	-	-	-	-	-	-	-	4.96	5.75
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	18.02	17.31	-	-	18.02	17.31
Krebs Biochemicals & Industries Limited	-	-	-	-	5.87	4.15	-	-	-	-	5.87	4.15
Others	-	-	-	-	-	-	-	-	5.76	5.51	5.76	5.51
TOTAL	4.96	5.75	-	-	5.87	4.15	18.02	17.31	13.94	18.63	42.79	45.84
Sales of goods and services												
Ipca Pharma Nigeria Ltd.	10.41	6.08	-	-	-	-	-	-	-	-	10.41	6.08
Makers Laboratories Ltd.	-	-	-	-	-	-	-	-	2.52	2.24	2.52	2.24
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	0.81	16.07	-	-	0.81	16.07
Others	-	-	-	-	0.59	0.60	-	-	-	0.15	0.59	0.75
TOTAL	10.41	6.08	-	-	0.59	0.60	0.81	16.07	2.52	2.39	14.33	25.14
Rent income												
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	0.41	0.46	-	-	0.41	0.46
Trophic Wellness Pvt. Ltd.	-	-	-	-	0.13	0.04	-	-	-	-	0.13	0.04
TOTAL	-	-	-	-	0.13	0.04	0.41	0.46	-	-	0.54	0.50
Interest income												
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	1.78	1.58	-	-	1.78	1.58
Krebs Biochemicals & Industries Limited	-	-	-	-	6.20	4.01	-	-	-	-	6.20	4.01
Others	0.05	0.21	-	-	-	-	-	-	-	-	0.05	0.21
TOTAL	0.05	0.21	-	-	6.20	4.01	1.78	1.58	-	-	8.03	5.81
Other income												
Ipca Pharmaceuticals, Inc. USA	-	0.01	-	-	-	-	-	-	-	-	-	0.01
TOTAL	-	0.01	-	-	-	-	-	-	-	-	-	0.01
Purchase of fixed assets												
Makers Laboratories Ltd.	-	-	-	-	-	-	-	-	-	0.06	-	0.06
TOTAL	-	-	-	-	-	-	-	-	-	0.06	-	0.06
Sale of fixed assets												
Trophic Wellness Pvt. Ltd.	-	-	-	-	0.33	-	-	-	-	-	0.33	-
TOTAL	-	-	-	-	0.33	-	-	-	-	-	0.33	-
Rent and other expenses												
Ipca Pharma (Australia) Pty Ltd. Australia	0.28	0.89	-	-	-	-	-	-	-	-	0.28	0.89
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	(0.02)	(0.25)	-	-	(0.02)	(0.25)
Ipca Pharmaceuticals, Inc. USA	-	0.19	-	-	-	-	-	-	-	-	-	0.19
Krebs Biochemicals & Industries Limited	-	-	-	-	5.58	5.23	-	-	-	-	5.58	5.23
Others	0.02	0.01	-	-	0.02	-	-	-	0.20	0.21	0.24	0.22
TOTAL	0.30	1.09	-	-	5.60	5.23	(0.02)	(0.25)	0.20	0.21	6.08	6.28
Excise duty Reimbursements												
Makers Laboratories Ltd.	-	-	-	-	-	-	-	-	0.65	0.30	0.65	0.30
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	0.65	(0.68)	-	-	0.65	(0.68)
Krebs Biochemicals & Industries Limited	-	-	-	-	(0.75)	(0.51)	-	-	-	-	(0.75)	(0.51)
TOTAL	-	-	-	-	(0.75)	(0.51)	0.65	(0.68)	0.65	0.30	0.55	(0.89)
Net loans and advances given/ (Recovered)												
Ipca Laboratories (U.K.) Ltd.	(2.88)	(6.49)	-	-	-	-	-	-	-	-	(2.88)	(6.49)
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	-	1.87	-	-	-	1.87
Krebs Biochemicals & Industries Limited	-	-	-	-	23.57	16.23	-	-	-	-	23.57	16.23
TOTAL	(2.88)	(6.49)	-	-	23.57	16.23	-	1.87	-	-	20.69	11.61
Deposit given												
Krebs Biochemicals & Industries Limited	-	-	-	-	-	5.56	-	-	-	-	-	5.56
TOTAL	-	-	-	-	-	5.56	-	-	-	-	-	5.56
Investments made												
Trophic Wellness Pvt. Ltd.	-	-	-	-	3.40	-	-	-	-	-	3.40	-
Krebs Biochemicals & Industries Limited	-	-	-	-	-	12.42	-	-	-	-	-	12.42
Others	-	0.70	-	-	-	-	-	-	-	-	-	0.70
TOTAL	-	0.70	-	-	3.40	12.42	-	-	-	-	3.40	13.12
Money received on Liquidation												
Ipca Trading (Shanghai) Co. Ltd.	-	0.14	-	-	-	-	-	-	-	-	-	0.14
TOTAL	-	0.14	-	-	-	-	-	-	-	-	-	0.14

(₹ Crores)

Description	Entities where control exists Subsidiaries		Key Management Personnel		Associates		Joint Venture		Other Related Parties		Total	
	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16
Guarantee given/ (released) against standby letter of credit issued by Company's banker												
Ipca Pharmaceuticals, Inc. USA	-	(2.39)	-	-	-	-	-	-	-	-	-	(2.39)
TOTAL	-	(2.39)	-	-	-	-	-	-	-	-	-	(2.39)
Remuneration to Directors												
Mr. Premchand Godha	-	-	5.21	4.48	-	-	-	-	-	-	5.21	4.48
Mr. Ajit Kumar Jain	-	-	2.56	2.32	-	-	-	-	-	-	2.56	2.32
Mr. Pranay Godha	-	-	1.19	1.11	-	-	-	-	-	-	1.19	1.11
Mr. Prashant Godha	-	-	1.08	0.76	-	-	-	-	-	-	1.08	0.76
TOTAL	-	-	10.04	8.67	-	-	-	-	-	-	10.04	8.67
Provident Fund to Directors												
Mr. Premchand Godha	-	-	0.44	0.40	-	-	-	-	-	-	0.44	0.40
Mr. Ajit Kumar Jain	-	-	0.16	0.14	-	-	-	-	-	-	0.16	0.14
Mr. Pranay Godha	-	-	0.08	0.07	-	-	-	-	-	-	0.08	0.07
Mr. Prashant Godha	-	-	0.07	0.05	-	-	-	-	-	-	0.07	0.05
TOTAL	-	-	0.75	0.66	-	-	-	-	-	-	0.75	0.66
Post employment benefits of Directors												
Mr. Ajit Kumar Jain	-	-	0.23	0.19	-	-	-	-	-	-	0.23	0.19
Mr. Pranay Godha	-	-	0.09	0.03	-	-	-	-	-	-	0.09	0.03
Mr. Prashant Godha	-	-	0.09	0.02	-	-	-	-	-	-	0.09	0.02
TOTAL	-	-	0.41	0.24	-	-	-	-	-	-	0.41	0.24
Sitting Fee to Non-executive Director												
Mr. Anand T Kusre	-	-	0.05	0.05	-	-	-	-	-	-	0.05	0.05
Mr. Babulal Jain	-	-	0.05	0.06	-	-	-	-	-	-	0.05	0.06
Mr. Dev Prakash Yadava	-	-	0.05	0.06	-	-	-	-	-	-	0.05	0.06
Mrs. Manisha Premnath	-	-	0.02	0.02	-	-	-	-	-	-	0.02	0.02
Dr. Ramakanta M. Panda	-	-	0.02	0.03	-	-	-	-	-	-	0.02	0.03
TOTAL	-	-	0.19	0.22	-	-	-	-	-	-	0.19	0.22
Donation												
Prabhat Foundation	-	-	-	-	-	-	-	-	-	0.15	-	0.15
TOTAL	-	-	-	-	-	-	-	-	-	0.15	-	0.15
Balance at year end												
Receivables												
Avik Pharmaceutical Ltd.	-	-	-	-	-	-	15.18	17.74	-	-	15.18	17.74
Krebs Biochemicals & Industries Limited	-	-	-	-	56.69	58.06	-	-	-	-	56.69	58.06
Others	7.63	9.45	-	-	0.50	-	-	-	-	-	8.13	9.45
TOTAL	7.63	9.45	-	-	57.19	58.06	15.18	17.74	-	-	80.00	85.25
Payables												
Ipca Pharmaceuticals, Inc. USA	0.15	1.24	-	-	-	-	-	-	-	-	0.15	1.24
Mr. Premchand Godha	-	-	0.89	0.51	-	-	-	-	-	-	0.89	0.51
Makers Laboratories Ltd.	-	-	-	-	-	-	-	-	1.89	5.22	1.89	5.22
Others	-	0.02	0.64	1.04	-	-	-	-	0.84	1.03	1.48	2.09
TOTAL	0.15	1.26	1.53	1.55	-	-	-	-	2.73	6.25	4.41	9.06
Guarantees outstanding against standby letter of credit issued by Company's banker												
Ipca Pharmaceuticals, Inc. USA	-	1.99	-	-	-	-	-	-	-	-	-	1.99
TOTAL	-	1.99	-	-	-	-	-	-	-	-	-	1.99

INDEPENDENT AUDITORS' REPORT ON CONSOLIDATED ACCOUNTS

To
The Members of
Ipca Laboratories Limited

Report on the Consolidated Ind AS Financial Statements

We have audited the accompanying consolidated Ind AS financial statements of Ipca Laboratories Limited (hereinafter referred to as "the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), (as defined in the Companies (Indian Accounting Standards) Rules, 2015, comprising of the Consolidated Balance Sheet as at March 31, 2017, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, the Consolidated Cash Flow Statement and Consolidated Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated Ind AS financial statements").

Management's Responsibility for the Consolidated Ind AS financial statements

The Holding Company's Board of Directors is responsible for the preparation of these consolidated Ind AS financial statements in terms of the requirements of the Companies Act, 2013 (hereinafter referred to as "the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated cash flows and consolidated changes in equity of the Group in accordance with the accounting principles generally accepted in India, including the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Act, read with relevant rules thereon. The respective Governing Bodies of the entities included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated Ind AS financial statements by the Board of Directors of the Holding Company, as aforesaid.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated Ind AS financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters, which are required to be included in the audit, report under the provisions of the Act and the Rules made thereunder. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated Ind AS financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated Ind AS financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation of the consolidated Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Board of Directors, as well as evaluating the overall presentation of the consolidated Ind AS financial statements.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in sub-paragraph (a) of the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group, as at March 31, 2017, their consolidated profit, their consolidated cash flows and their consolidated changes in equity for the year ended on that date.

Other Matters

- (a) We did not audit the financial statements of 5 subsidiaries, whose financial statements reflect total assets of ₹ 106.01 crores as at March 31, 2017, total revenues of ₹ 75.68 crores and net cash flows amounting to ₹ 4.49 crores for the year ended on that date, as considered in the preparation of the consolidated Ind AS financial statements. The consolidated Ind AS financial statements also includes the Group's share of net loss of ₹ 4.28 crores for the year ended March 31, 2017, as considered in the consolidated Ind AS

financial statements, in respect of 1 associate and 1 Jointly controlled entity, whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated Ind AS financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, jointly controlled entities and associates, and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries, jointly controlled entities and associates in India, is based solely on the reports of the other auditors.

- (b) We did not audit the financial statements of 3 subsidiaries, whose financial statements reflect total assets of ₹ 0.94 crores as at March 31, 2017, total revenues of ₹ 0.49 crores and net cash flows amounting to ₹ 0.27 crores for the year ended on that date, as considered in the preparation of the consolidated Ind AS financial statements. The consolidated Ind AS financial statements also include the Group's share of net loss of ₹ 2.70 crores for the year ended March 31, 2017, as considered in the consolidated Ind AS financial statements, in respect of 1 associate. These financial statements are unaudited and have been furnished to us by the Management and our opinion on the consolidated Ind AS financial statements, in so far as it relates to the amounts and disclosures included in respect of these associates, and our report in terms of sub-sections (3) and (11) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries and associates, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management, these financial statements are not material to the Group.

Report on Other Legal and Regulatory Requirements

1. As required by sub-section (3) of Section 143 of the Act, we report, to the extent applicable, that:
 - (a) We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated Ind AS financial statements.
 - (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated Ind AS financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.
 - (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account and working/ records maintained for the purpose of preparation of the consolidated Ind AS financial statements.
 - (d) In our opinion, the aforesaid consolidated Ind AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with relevant rules thereon.
 - (e) On the basis of the written representations received from the directors of the Holding Company as on March 31, 2017 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary company incorporated in India, none of the directors of the Group Companies incorporated in India is disqualified as on March 31, 2017 from being appointed as a director in terms of Section 164 (2) of the Act. Since the provisions of Section 164(2) of the Act do not apply to entities incorporated outside India no comments are made in respect of such overseas entities.
 - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure A"; and
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The consolidated Ind AS financial statements disclose the impact of pending litigations on the consolidated financial position of the Group— Refer Note 35 to the consolidated Ind AS financial statements.
 - ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company and its subsidiary company incorporated in India.
 - iv. The Company has provided requisite disclosures in its Consolidated Ind AS Financial Statements as to holdings as well as dealings in Specified Bank Notes during the period from November 08, 2016 to December 30, 2016 and these are in accordance with the books of accounts maintained by the Company and its Indian subsidiaries. Refer Note 8 to the Consolidated Ind AS Financial Statements.

For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No.106971W

N. Jayendran

Partner

Membership No. 40441

Mumbai,
28th May, 2017

Annexure - A to the Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of consolidated Ind AS financial statements of Ipca Laboratories Limited (hereinafter referred to as "the Holding Company") and its subsidiary companies, which are companies incorporated in India as of March 31, 2017 in conjunction with our audit of the Consolidated Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding company and its subsidiary companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters paragraph below is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiary companies, which are companies incorporated in India, have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Other Matters

Our aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting in so far as it relates to one subsidiary company which is a company incorporated in India, is based on the corresponding reports of the auditors' of such company.

For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No.106971W

Mumbai,
28th May, 2017

N. Jayendran
Partner
Membership No. 40441

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837
CONSOLIDATED ACCOUNTS
Consolidated Balance Sheet as at March 31, 2017

Particulars	Note Ref.	As at Mar 31, 2017 (₹ Crores)	As at Mar 31, 2016 (₹ Crores)	As at Apr 01, 2015 (₹ Crores)
ASSETS				
1. Non-current assets				
(a) Property, plant & equipment	1	1,913.40	1,941.89	1,716.96
(b) Capital work-in-progress		62.10	93.61	236.25
(c) Goodwill on consolidation		23.59	23.59	23.59
(d) Goodwill on acquisition	1A	23.61	23.61	23.61
(e) Other intangible assets	1B	22.67	25.09	22.96
(f) Intangible assets under development		32.54	35.13	30.66
(g) Non-current asset held for sale		0.01	-	-
(h) Financial assets				
(i) Investments in joint venture/associate	2	22.19	25.77	16.37
(ii) Other investments	2A	0.05	0.05	2.88
(iii) Loans	3	96.72	70.35	49.22
(iv) Others	4	2.24	2.49	15.55
(i) Other non-current assets	5	26.40	28.21	51.92
		2,225.52	2,269.79	2,189.97
2. Current Assets				
(a) Inventories	6	882.22	837.42	925.84
(b) Financial assets				
(i) Investments	2B	113.57	-	-
(ii) Trade receivables	7	500.16	445.87	630.35
(iii) Cash and cash equivalents	8	29.42	168.87	140.06
(iv) Bank balances other than (iii) above	9	6.43	6.67	26.11
(v) Loans	3	2.10	1.75	6.46
(vi) Others	4	29.87	14.29	37.86
(c) Current tax assets (net)		-	-	-
(d) Other current assets	5	170.22	147.05	168.11
		1,733.99	1,621.92	1,934.79
Total Assets		3,959.51	3,891.71	4,124.76
EQUITY & LIABILITIES				
Equity				
(a) Equity share capital	10	25.24	25.24	25.24
(b) Other equity	11	2,430.02	2,233.95	2,171.30
Total equity		2,455.26	2,259.19	2,196.54
Liabilities				
1. Non-current liabilities				
(a) Financial liabilities				
(i) Borrowings	12	351.74	484.27	498.70
(ii) Other financial liabilities	13	-	0.06	0.15
(b) Provisions	14	24.55	20.22	17.66
(c) Deferred tax liabilities (net)	15	170.47	156.46	158.41
(d) Other non-current liabilities	16	1.56	1.56	1.56
		548.32	662.57	676.48
2. Current liabilities				
(a) Financial liabilities				
(i) Borrowings	17	177.30	184.85	643.33
(ii) Trade payables	18	457.67	421.11	305.96
(iii) Other financial liabilities	13	212.46	250.59	171.39
(b) Other current liabilities	16	37.16	46.91	65.45
(c) Provisions	14	66.07	62.22	55.33
(d) Current tax liabilities (net)	19	5.27	4.27	10.28
		955.93	969.95	1,251.74
Total Equity and Liabilities		3,959.51	3,891.71	4,124.76

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.

As per our report of even date attached

For **Natvarlal Vepari & Co.**

Chartered Accountants

Firm Registration No. 106971W

N. Jayendran

Partner

M.No. 40441

Mumbai,

28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director (DIN 00012691)

Ajit Kumar Jain

Joint Managing Director & CFO (DIN 00012657)

Prashant Godha

Executive Director (DIN 00012759)

Harish P. Kamath

Company Secretary (ACS - 6792)

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837

Consolidated Statement of Profit and Loss for the year ended March 31, 2017

Particulars	Note Ref	2016-17 (₹ Crores)	2015-16 (₹ Crores)
I Revenue from operations	20	3,210.64	2,906.51
II Other Income	21	22.57	22.22
III Total income (I + II)		3,233.21	2,928.73
IV Expenses:			
Cost of materials consumed	22	953.87	893.31
Purchase of stock-in-trade	23	161.84	139.24
Changes in inventories of finished goods, work-in-progress and stock-in-trade	24	(5.52)	25.85
Employee benefit expenses	25	695.98	625.58
Finance cost	26	24.08	31.91
Depreciation & amortisation	27	172.95	163.26
Other expenses	28	959.69	932.94
Total expenses (IV)		2,962.89	2,812.09
V Profit before exceptional and extraordinary items and tax (III-IV)		270.32	116.64
VI Exceptional items		-	-
VII Profit before extraordinary items and tax (V-VI)		270.32	116.64
VIII Extraordinary items		-	-
IX Profit before tax (VII-VIII)		270.32	116.64
X Tax expense			
1. Current tax		53.30	22.39
2. Short/(excess) provision of earlier years		(0.04)	-
3. Deferred tax liability/(asset) incl. MAT credit		14.26	(1.95)
XI Profit for the period from continuing operations (IX-X)		202.80	96.20
XII Profit/(loss) from discontinuing operations		-	-
XIII Tax expense of discontinuing operations		-	-
XIV Profit/(loss) from discontinuing operations after tax		-	-
XV Profit for the period (XI+XIV)		202.80	96.20
Share of profits/(loss) from investment in associates		(8.26)	(3.06)
Net profit after tax, minority interest and share of profits/(loss) of associates		194.54	93.14
XVI Other comprehensive income			
A (i) Items that will not be reclassified to profit or loss			
Actuarial gain and loss		(4.44)	1.70
(ii) Income tax relating to items that will not be reclassified to profit or loss		0.95	(0.36)
B (i) Items that will be reclassified to profit or loss			
Exchange difference in translating the financial statement of foreign operation		(3.93)	0.19
Gain/(loss) on cash flow hedge		7.67	(17.42)
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
(iii) Share of OCI from investment in associates		1.28	0.02
Other comprehensive income for the year, net of tax		1.53	(15.87)
Total comprehensive Income for the year		196.07	77.27
XVII Earnings per equity share (for continuing operations):	30		
Basic (in ₹)		15.42	7.38
Diluted (in ₹)		15.42	7.38

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.

As per our report of even date attached

For **Natvarlal Vepari & Co.**

Chartered Accountants

Firm Registration No. 106971W

N. Jayendran

Partner

M.No. 40441

Mumbai,

28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director (DIN 00012691)

Ajit Kumar Jain

Joint Managing Director & CFO (DIN 00012657)

Prashant Godha

Executive Director (DIN 00012759)

Harish P. Kamath

Company Secretary (ACS - 6792)

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837
Consolidated Cash Flow Statement for the year ended March 31, 2017

	2016-17 (₹ Crores)	2015-16 (₹ Crores)
A. Cash Flow from Operating Activities		
1) Net profit before taxation and extraordinary item	270.32	116.64
Adjustments for :		
Depreciation, amortisation and impairment expense	172.95	163.26
(Profit)/loss on sale of property, plant & equipment	1.48	0.53
(Profit)/loss on sale of investments	-	(1.36)
(Profit)/loss on mutual fund investments	(5.31)	(5.36)
Property, plant & equipment scrapped	1.53	0.34
Sundry balances written (back)	(2.51)	(2.72)
Provision for doubtful debts/ advances	0.51	(0.13)
Bad debts w/off	2.68	3.30
Bad debts recovered	(0.68)	(0.85)
Loss on liquidation of subsidiary	-	0.68
Unrealised foreign exchange (gain)/ loss	(15.30)	34.25
Interest income	(14.28)	(12.71)
Dividend income	-	(0.03)
Interest expense	24.08	31.91
2) Operating profit before working capital changes	435.47	327.75
Decrease/(increase) in receivables	(74.49)	189.17
Decrease/(increase) in loans and advances	(16.90)	22.34
Decrease/(Increase) in inventories	(44.80)	88.42
Increase/(decrease) in liabilities & provisions	28.42	110.37
3) Cash generated from operation	327.70	738.05
Income tax paid (net)	(51.28)	(29.40)
Net cash from operating activities	276.42	708.65
B. Cash Flow from Investing Activities		
Purchase of property, plant & equipment including capital WIP	(136.33)	(247.13)
Loan to associate	(23.57)	(11.40)
Investment in associate	(3.40)	-
Sale of other investment	-	4.19
Profit/(loss) on mutual fund investments	5.31	5.36
Proceeds from sale of property, plant & equipment	1.88	1.62
Movement in other bank balances	0.45	20.12
Interest received	12.49	8.88
Dividend received	-	0.03
Net cash used in investing activities	(143.17)	(218.33)
C. Cash Flow from Financing Activities		
(Decrease)/increase in short term borrowings	(4.65)	(459.80)
Proceeds from long-term borrowings	67.70	151.83
Repayment of long-term borrowings	(193.35)	(101.44)
Repayment of debentures	(5.00)	(5.00)
Interest paid	(23.59)	(31.76)
Dividend & dividend tax paid	(0.24)	(15.34)
Net cash from/(used in) financing activities	(159.13)	(461.51)
Net increase in cash and cash equivalents (A + B + C)	(25.88)	28.81
Cash and cash equivalents at beginning of year	168.87	140.06
Cash and cash equivalents at end of year	142.99	168.87
Components of cash & cash equivalents :		
Cash and cheques on hand	1.56	1.85
Balance with banks	27.86	167.02
Mutual funds	113.57	-
	142.99	168.87

As per our report of even date attached
For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No. 106971W

N. Jayendran
Partner
M.No. 40441
Mumbai,
28th May, 2017

For and on behalf of the Board of Directors
Premchand Godha
Chairman & Managing Director (DIN 00012691)
Ajit Kumar Jain
Joint Managing Director & CFO (DIN 00012657)
Prashant Godha
Executive Director (DIN 00012759)
Harish P. Kamath
Company Secretary (ACS - 6792)

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837
Consolidated Statement of Changes in Equity for the year ended March 31, 2017
Equity Share Capital

Equity Share Capital of face value ₹ 2 each	No. of shares	(₹ Crores)
Balance as at April 1, 2015	12,61,99,109	25.24
Changes in equity share capital during the year	-	-
Balance as at March 31, 2016	12,61,99,109	25.24
Changes in equity share capital during the year	-	-
Balance as at March 31, 2017	12,61,99,109	25.24

Other Equity		Other equity										₹ Crores		
Particulars	Reserves and surplus										Other comprehensive income			Total
	Capital reserve	Securities premium	Capital redem. reserve	Debenture redem. reserve	General reserve	Retained earnings	Not reclassified to P&L		Reclassified to P&L					
							Other items of other comprehensive income	Foreign currency translation reserve	Hedging reserve	Remeasurement of employee benefit				
As at April 1, 2015	0.59	43.99	0.26	10.00	1,300.48	814.45	(12.05)	13.58	-	-	-	2,171.30		
Profit for the period	-	-	-	-	-	96.20	-	-	0.19	-	-	96.39		
Gain/ (loss) on cash flow hedge	-	-	-	-	-	-	-	(17.42)	-	-	-	(17.42)		
Actuarial gain/(loss) on gratuity (net of tax thereon)	-	-	-	-	-	-	1.34	-	-	-	-	1.34		
Dividend	-	-	-	-	-	(12.62)	-	-	-	-	-	(12.62)		
Share of Profits/(loss) from investment in associates	-	-	-	-	-	(3.06)	0.02	-	-	-	-	(3.04)		
General reserve transfer on liquidation of subsidiary	-	-	-	-	0.57	-	-	-	-	-	-	0.57		
Tax on dividend	-	-	-	-	-	(2.57)	-	-	-	-	-	(2.57)		
Transfer to general reserve	-	-	-	(5.00)	-	-	-	-	-	-	-	(5.00)		
Transfer from debenture redem. reserve	-	-	-	-	5.00	-	-	-	-	-	-	5.00		
Balance as on March 31, 2016	0.59	43.99	0.26	5.00	1,306.05	892.40	(10.69)	(3.84)	0.19	-	-	2,233.95		
Profit for the period	-	-	-	-	-	202.80	-	-	(3.93)	-	-	198.87		
Share of Profits/(loss) from investment in associates	-	-	-	-	-	(8.26)	-	-	-	-	-	(8.26)		
Gain/ (loss) on cash flow hedge	-	-	-	-	-	-	-	7.67	-	-	-	7.67		
Actuarial gain/(loss) on gratuity (net of tax thereon)	-	-	-	-	-	-	(3.49)	-	-	-	-	(3.49)		
Share of OCI from investment in associates	-	-	-	-	-	-	1.28	-	-	-	-	1.28		
Balance as on March 31, 2017	0.59	43.99	0.26	5.00	1,306.05	1,086.94	(12.90)	3.83	(3.74)	-	-	2,430.02		

As per our report of even date attached
For **Natvarlal Vepari & Co.**
Chartered Accountants
Firm Registration No. 106971W

N. Jayendran
Partner
M.No. 40441
Mumbai,
28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha
Chairman & Managing Director (DIN 00012691)
Ajit Kumar Jain
Joint Managing Director & CFO (DIN 00012657)
Prashant Godha
Executive Director (DIN 00012759)
Harish P. Kamath
Company Secretary (ACS - 6792)

IPCA LABORATORIES LIMITED. CIN L24239MH1949PLC007837

Statement of Significant Accounting policies and Other Explanatory Notes

(A) Corporate Information

Incorporated in the year 1949, Ipca Laboratories Limited is a integrated pharmaceutical company manufacturing and marketing over 350 formulations and 80 APIs covering various therapeutic segments. The products of the Company are now sold in over 120 countries across the globe. The Company has 17 manufacturing units in India manufacturing APIs and formulations for the world market.

(B) Principles of Consolidation

The consolidated financial statements relates to Ipca Laboratories Ltd. and its Subsidiary Companies, Associates and Joint Ventures (referred to as Group). The consolidated financial statements have been prepared in accordance with Indian Accounting Standard - 110 "Consolidated Financial Statement", Indian Accounting Standard - 28 "Investment in Associate and Joint Ventures" of the Companies (Indian Accounting Standard) Rules 2015. The Consolidated Financial Statements have been prepared on the following basis: -

The financial statements of the Group companies are consolidated on a line-by-line basis and intra-group balances and transactions including unrealized gain/loss from such transactions are eliminated upon consolidation. These financial statements are prepared by applying uniform accounting policies in use at the Group. Non-controlling interests which represent part of the net profit or loss and net assets of subsidiaries that are not, directly or indirectly, owned or controlled by the company, are excluded.

In case of foreign subsidiaries, revenue items are consolidated at average rate prevailing during the year. All Assets and Liabilities are converted at the rates prevailing at the end of the year. Exchange gain or loss on conversion arising on consolidation is recognized under foreign currency translation reserve.

Associates are entities over which the Group has significant influence but not control. Investments in associates are accounted for using the equity method of accounting as per Indian Accounting Standard - 28 "Investment in Associate and Joint venture". The investment is initially recognized at cost, and the carrying amount is increased or decreased to recognize the investor's share of the profit or loss of the investee after the acquisition date. The Group's investment in associates includes goodwill identified on acquisition.

The financial statements of the Subsidiaries, Associate and Joint Ventures used in consolidation are drawn up to the same reporting date as that of the Company i.e. 31st March.

The difference between the cost to the Company of its investments in the subsidiary/ associates/ joint ventures over the Company's portion of equity is recognized in the financial statement as Goodwill on consolidation or Capital Reserve.

The list of subsidiary companies, associates and joint ventures included in consolidation and Company's holding therein are as under: -

Name of the Companies	Relationship	Country of Incorporation	% of ultimate holding	
			2016-17	2015-16
Ipca Pharmaceuticals, Inc. USA	Subsidiary	USA	100.00	100.00
Ipca Laboratories (U.K.) Ltd.	Subsidiary	UK	100.00	100.00
National Druggists (Pty) Ltd. *	Subsidiary	South Africa	-	-
Ipca Pharma Nigeria Ltd.	Subsidiary	Nigeria	100.00	100.00
Ipca Pharma (Australia) Pty.Ltd.	Subsidiary	Australia	100.00	100.00
Ipca Pharmaceuticals (Shanghai) Ltd. *	Subsidiary	China	-	-
Ipca Pharmaceuticals Ltd.,SA de CV	Subsidiary	Mexico	100.00	100.00
Tonira Exports Ltd.	Subsidiary	India	100.00	100.00
Onyx Scientific Ltd. (Subsidiary of Ipca Laboratories (U.K.) Ltd.)	Step down subsidiary	UK	100.00	100.00
Ipca Pharma (NZ) Pty. Ltd. (Subsidiary of Ipca Pharma (Australia) Pty.Ltd.)	Step down subsidiary	New Zealand	100.00	100.00
Avik Pharmaceutical Ltd.	Joint Venture	India	49	49
CCPL Software Private Ltd.	Associate	India	28.95	28.95
Trophic Wellness Pvt. Ltd.	Associate	India	19.26	19.26
Krebs Biochemicals & Industries Ltd.	Associate	India	29.83	31.38

* Liquidated during the previous year.

(C) Significant Accounting Policies**(I) Basis of Preparation**

These financial statements are prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. For all periods upto and including the year ended March 31, 2016 the Company prepared its financial statements in accordance with accounting standards notified under the section 133 of the Companies Act, 2013 read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP).

The year ended March 31, 2017 is the first period for which the Company has prepared its financial statements in accordance with Ind AS. The previous period comparatives for the period ended March 31, 2016 which were earlier prepared as per the aforesaid Companies (Accounts) Rules, 2014 have been restated as per Ind AS to make them comparable. The date of transition to Ind AS is therefore April 1, 2015 for which the Opening Balance Sheet is prepared.

These financial Statements are prepared under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values.

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

(II) Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of circumstances surrounding the estimates. Changes in estimates are reflected in the financial statement in the period in which changes are made and if material, their effects are disclosed in the notes to the financial statements.

(III) Summary of Significant Accounting Policies

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

(a) Current and Non-current Classification

The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is current when :

- It is expected to be realised or intended to be sold or consumed in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is expected to be realised within twelve months after the reporting period, or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when :

- It is expected to be settled in normal operating cycle or
- It is held primarily for the purpose of trading or
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for atleast twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

(b) Property, Plant and Equipment

- (i) Leasehold land is carried at historical cost. All other items of property, plant and equipment are stated at historical cost less depreciation. Cost of acquisition comprises its purchase price including import duties and other non-refundable taxes or levies and any directly attributable cost of bringing the asset to its working condition for its intended use; any trade discount and rebates are deducted in arriving at the purchase price. Revalued assets are recorded at revalued amounts.

- (ii) Capital Work In Progress represents expenditure incurred on capital assets that are under construction or are pending capitalisation and includes Project expenses pending allocation. Project expenses pending allocation are apportioned to the property, plant and equipment of the project proportionately on capitalisation.
- (iii) Cost of borrowing for assets taking substantial time to be ready for use is capitalised for the period up to the time the asset is ready for its intended use.
- (iv) Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.
- (v) The residual useful life of property, plant & equipment is reviewed at each balance sheet date and adjusted if required in the depreciation rates.
- (vi) The Property, plant and equipment existing on the date of transition are accounted on deemed cost basis by applying para D7AA in accordance with the exemption provided in Ind AS 101 "First-time Adoption of Indian Accounting Standards" at previous GAAP carrying value.

(vii) Depreciation Methods, Estimated Useful Lives and Residual Value

Depreciation on all assets of the Company is charged on straight line method over the useful life of assets mentioned in Schedule II to the Companies Act, 2013 or the useful life previously assessed by the management based on technical review whichever is lower for the proportionate period of use during the year. Intangible assets are amortised over the economic useful life estimated by the management.

The management's estimated useful life/useful life as per schedule II whichever is lower for the various tangible assets are as follows.

Assets	Estimated useful life (Years)
Leasehold land	Period of Lease
Buildings	28 to 58
Roads	3 to 10
Plant and equipment and R&D equipments	9 to 20
Office and other equipments	5
Computers	3 to 6
Furniture and fixtures	10
Vehicles	6 to 8
Leasehold improvements	Period of Lease

(c) Goodwill

Goodwill on Acquisition

Goodwill on acquisition represents excess of consideration paid for acquisition of business over the fair value of net assets. Goodwill is not amortised but is tested for impairment at each reporting date.

Goodwill on Consolidation

Goodwill on consolidation represents excess cost of investment over the company's share of equity that is carried in balance sheet and is tested for impairment at each reporting date.

(d) Intangible Assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition, and other economic factors (such as the stability of the industry, and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.

The Intangible assets existing on the date of transition are accounted on deemed cost basis by applying para D7AA in accordance with the exemption provided in Ind AS 101 "First-time Adoption of Indian Accounting Standards" at previous GAAP carrying value.

Research costs are expensed as incurred. The costs which can be capitalized include the cost of material, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use. Research and development costs incurred under contractual arrangements with customers are accounted as expenses in the Statement of Profit and Loss.

The management has estimated the economic useful life for the various intangible assets as follows.

Assets	Estimated useful life (Years)
Brands and Trademarks	4
Technical Know how	4
Software for internal use	4

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss when the asset is derecognised.

(e) Borrowings

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. Other borrowing costs are expensed in the period in which they are incurred.

(f) Impairment Loss

Assets subject to amortization/depreciation are tested for impairment provided that an event or change in circumstances indicates that their carrying amount might not be recoverable. An impairment loss is recognized in the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher between an asset's fair value less sale costs and value in use. For the purposes of assessing impairment, assets are grouped together at the lowest level for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill for which impairment losses have been recognized are tested at each balance sheet date in the event that the loss has reversed.

(g) Inventories

Items of inventories are valued lower of cost or estimated net realisable value as given below.

Raw Materials and Packing Materials	Lower of cost and Net realisable value. However materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost is determined on First-in-First-out basis.
Work-in-process and Finished Goods	At lower of cost including material cost net of CENVAT, labour cost and all overheads other than selling and distribution overheads and net realisable value. Excise duty is considered as cost for finished goods wherever applicable.
Stores and Spares	Stores and spare parts are valued at lower of purchase cost computed on First-in-First-out method and net realisable value.
Traded Goods	Traded Goods are valued at lower of purchase cost and net realisable value.

(h) Cash and Cash Equivalents

Cash and cash equivalents include cash in hand, demand deposits in banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within bank borrowings in current liabilities on the balance sheet.

(i) Provisions

The Company recognizes a provision when: it has a present legal or constructive obligation as a result of past events; it is likely that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Provisions are not recognized for future operating losses.

(j) Retirement and Other Benefits

Provident Fund/ Pension Scheme

Retirement benefit in the form of provident fund/ pension is a defined contribution scheme. The Company has no obligation, other than the contribution payable to the provident fund/ pension scheme. The company recognizes contribution payable to the fund schemes as an expense, when an employee renders the related service.

Gratuity

Gratuity, a defined benefit obligation is provided on the basis of an actuarial valuation made at the end of each year/ period on Projected Unit Credit Method.

The cost of providing benefits under the defined benefit plan is determined using the Projected Unit Credit Method. Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included

in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset.

Compensated Absences

The Company has a policy on compensated absences which are both accumulating and non-accumulating in nature. The expected cost of accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at each balance sheet date using Projected Unit Credit Method on the additional amount expected to be paid/availed as a result of the unused entitlement that has accumulated at the balance sheet date. Expense on non-accumulating compensated absences is recognized in the period in which the absences occur.

(k) Foreign Currencies

Transactions and Balances

- (i) The functional currency of the company is the Indian rupee. These financial statements are presented in Indian rupees.
- (ii) Transactions denominated in foreign currency are recorded at the exchange rate on the date of transaction. The exchange gain/loss on settlement/ negotiation during the year is recognised in the Statement of Profit and Loss.
- (iii) Foreign currency monetary transactions remaining unsettled at the end of the year are converted at year-end rates. The resultant gain or loss is accounted for in the Statement of Profit and Loss.
- (iv) Non Monetary items that are measured at historical cost denominated in foreign currency are translated using exchange rate at the date of transaction.
- (v) The overseas trading offices are non-integral operations and the overseas non trading offices are integral operations and are accounted accordingly.

(l) Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

(m) Financial Instruments

(i) Financial Assets & Financial Liabilities Initial Recognition and Measurement

All financial assets and liabilities are recognised initially at fair value.

In the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset is treated as cost of acquisition. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent Measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit and loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Impairment of Financial Assets

The Company assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. Note 7 details how the entity determines whether there has been a significant increase in credit risk. For trade receivables only, the Company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

De-recognition of Financial Instruments

A financial asset is de-recognised only when

- The Company has transferred the rights to receive cash flows from the financial asset or
- Retains the contractual rights to receive the cash flows of the financial asset, but assumes a contractual obligation to pay the cash flows to one or more recipients.

Where the entity has transferred an asset, the group evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is de-recognised. Where the entity has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not de-recognised.

Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is de-recognised if the group has not retained control of the financial asset. Where the group retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

A financial liability (or a part of a financial liability) is de-recognized from the Company's Balance Sheet when the obligation specified in the contract is discharged or cancelled or expires.

(ii) Derivative Financial Instruments and Hedge Accounting**Initial Recognition and Subsequent Measurement**

The Company uses derivative financial instruments, such as forward currency contracts, interest rate swaps and forward commodity contracts, to hedge its foreign currency risks, interest rate risks and commodity price risks, respectively. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

The purchase contracts that meet the definition of a derivative under Ind AS 109 are recognised in the Statement of Profit and Loss.

Cash Flow Hedge

The company designates certain foreign exchange forward and options contracts as cash flow hedges to mitigate the risk of foreign exchange exposure on highly probable forecast cash transactions.

When a derivative is designated as a cash flow hedging instrument, the effective portion of changes in the fair value of the derivative is recognized in other comprehensive income and accumulated in the cash flow hedging reserve. Any ineffective portion of changes in the fair value of the derivative is recognized immediately in the net profit in the Statement of Profit and Loss. If the hedging instrument no longer meets the criteria for hedge accounting, then hedge accounting is discontinued prospectively. If the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss on the hedging instrument recognized in cash flow hedging reserve till the period the hedge was effective remains in cash flow hedging reserve until the forecasted transaction occurs. The cumulative gain or loss previously recognized in the cash flow hedging reserve is transferred to the net profit in the Statement of Profit and Loss upon the occurrence of the related forecasted transaction. If the forecasted transaction is no longer expected to occur, then the amount accumulated in cash flow hedging reserve is reclassified to net profit in the Statement of Profit and Loss.

(n) Revenue Recognition

- (i) Revenue from sale of goods is recognised net of returns, product expiry claims and trade discount, on transfer of significant risk and rewards in respect of ownership to the buyer which is generally on dispatch of goods. Sales include excise duty but exclude sales tax and value added tax.
- (ii) In respect of incentives attributable to the export of goods, the Company following the accounting principle of matching revenue with the cost has recognised export incentive receivable when all conditions precedent to the eligibility of benefits have been satisfied and when it is reasonably certain of deriving the benefit. Since these schemes are meant for neutralisation of duties and taxes on inputs pursuant to exports, the same are grouped under material costs.
- (iii) The other export incentives that do not arise out of neutralisation of duties and taxes are disclosed under other operating revenue.
- (iv) Revenue from services is recognised when all relevant activities are completed and the right to receive income is established.
- (v) Revenue in respect of insurance/other claims, commission, etc. are recognised only when it is reasonably certain that the ultimate collection will be made.

- (vi) For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR).
- (vii) Dividend from subsidiaries/ associates/ joint ventures is recognised in the Statement of Profit and Loss in separate financial statements when the parent company's right to receive the dividend is established.

(o) Taxes

Tax expenses comprise Current Tax and Deferred Tax:

(i) Current Tax:

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

(ii) Deferred Tax:

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the standalone financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting profit nor taxable profit (tax loss). Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

For items recognised in OCI or equity, deferred/ current tax is also recognised in OCI or equity.

(iii) MAT Credit:

Minimum Alternate Tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognises MAT credit available as an asset only to the extent that there is reasonable certainty that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. The MAT credit to the extent there is reasonable certainty that the Company will utilise the credit is recognised in the Statement of Profit and Loss and corresponding debit is done to the Deferred Tax Asset as unused tax credit.

(p) Leases

Operating Lease

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease. All other leases are operating lease. Operating lease payments, as per terms of the agreement, are recognised as an expense in the Statement of Profit and Loss on a straight-line basis in accordance with Ind AS 17.

(q) Excise Duty and CENVAT/ Service Tax Credit

The excise duty expenses are bifurcated into two components: excise duty expenses related to sales and the un-recovered excise duty is recognized under other expenses and excise duty relating to the difference between the closing and opening stock of finished goods is recognized in the material cost and inventory adjustments. CENVAT/ Service Tax credit utilised during the year is accounted in excise duty and unutilised CENVAT/ Service Tax credit at the year end is considered as duties and taxes refundable.

(r) Research and Development

Revenue expenditure on research and development is charged to Statement of Profit and Loss in the year in which it is incurred. Capital expenditure on research and development is considered as an addition to property, plant & equipment/ intangible assets.

(s) Government Grants

Grants relating to revenue items are credited to the Statement of Profit and Loss in the same accounting period as the expenditure to which the grant relates. Grants in respect of capital items are credited to the Statement of Profit and Loss over the same period as the asset to which the grant relates is written off.

(t) Earnings Per Share

Earnings per share is calculated by dividing the net profit or loss before OCI for the year by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss before OCI for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

(u) Dividend Distribution

Dividend distribution to the Company's equity holders is recognized as a liability in the Company's annual accounts in the year in which the dividends are approved by the Company's equity holders.

Notes to financial statements as at and for the year ended March 31, 2017

1. Property, Plant & Equipment

Particulars	Freehold Land	Leasehold Land	Building	Plant & Equipment	Plant & Equipment (Given on Lease)	Office & Other Equipment	Eff. Treatment Plant	Fur. & Fix.	Vehicles	R&D Building	R&D Eqpts.	R&D Furniture	Total
Gross Block													
As on 01/04/2015	49.66	47.25	421.52	976.10	3.54	12.07	50.86	34.78	14.22	14.29	91.28	1.39	1,716.96
Additions	0.62	0.64	62.30	267.68	-	4.20	19.43	10.16	2.01	0.03	14.95	0.95	382.97
Adjustments	-	-	0.92	(4.67)	0.06	(0.09)	(0.31)	0.06	(0.58)	-	0.19	-	(4.42)
As on 31/03/2016	50.28	47.89	484.74	1,239.11	3.60	16.18	69.98	45.00	15.65	14.32	106.42	2.34	2,095.51
Additions	-	-	34.98	85.07	-	2.51	7.68	3.28	1.46	-	5.28	0.33	140.59
Adjustments	-	-	(2.14)	(5.06)	0.10	(0.10)	-	(0.04)	(0.77)	-	(0.22)	-	(8.23)
As on 31/03/2017	50.28	47.89	517.58	1,319.12	3.70	18.59	77.66	48.24	16.34	14.32	111.48	2.67	2,227.87
Accumulated Depreciation													
As on 01/04/2015	-	-	-	-	-	-	-	-	-	-	-	-	-
For the year 2015-16	-	0.96	17.48	102.26	0.45	3.75	5.08	5.23	3.87	0.62	14.18	0.25	154.13
Adjustments	-	-	-	(0.39)	-	(0.01)	-	-	(0.10)	-	(0.01)	-	(0.51)
As on 31/03/2016	-	0.96	17.48	101.87	0.45	3.74	5.08	5.23	3.77	0.62	14.17	0.25	153.62
For the year 2016-17	-	0.96	17.72	107.88	0.43	3.73	6.35	5.51	3.62	0.62	14.52	0.31	161.65
Adjustments	-	-	(0.05)	(0.38)	-	(0.03)	-	(0.01)	(0.25)	-	(0.08)	-	(0.80)
As on 31/03/2017	-	1.92	35.15	209.37	0.88	7.44	11.43	10.73	7.14	1.24	28.61	0.56	314.47
Net Block as on 31/03/2016	50.28	46.93	467.26	1,137.24	3.15	12.44	64.90	39.77	11.88	13.70	92.25	2.09	1,941.89
Net Block as on 31/03/2017	50.28	45.97	482.43	1,109.75	2.82	11.15	66.23	37.51	9.20	13.08	82.87	2.11	1,913.40

Note : In view of the adoption of para D7AA of Ind AS 101 relating to Deemed Cost, the net block as at March 31, 2015 as follows has been shown as gross block as on April 01, 2015.

Particulars	Freehold Land	Leasehold Land	Building	Plant & Equipment	Plant & Equipment (Given on Lease)	Office Equipment	Eff. Treatment Plant	Fur. & Fix.	Vehicles	R&D Building	R&D Eqpts.	R&D Furniture	Total
Gross Block as on 31/03/2015	49.69	48.79	501.12	1,476.16	5.83	21.59	61.79	56.69	25.62	18.40	161.84	2.97	2,430.49
Accumulated Depreciation till 31/03/2015	0.03	1.54	79.60	500.06	2.29	9.52	10.93	21.91	11.40	4.11	70.56	1.58	713.53
Net Block as on 31/03/2015	49.66	47.25	421.52	976.10	3.54	12.07	50.86	34.78	14.22	14.29	91.28	1.39	1,716.96

Notes:

- Buildings include cost of shares in Co-operative societies.
- Out of depreciation and amortisation for the year of ₹ 172.98 crores (previous year ₹ 163.28 crores), depreciation of ₹ 0.03 crore (previous year ₹ 0.02 crore) relating to project under execution for the period before start of production is transferred to project expenses pending allocation.
- Cost of Borrowing of ₹ 0.50 crore (previous year ₹ 0.65 crore) is capitalised to the project at the weighted average cost of borrowing @ 2.77% (previous year 2.80%).

Notes to financial statements as at and for the year ended March 31, 2017

1A : Goodwill

The Goodwill represents the excess of the consideration paid over the fair value of assets and liabilities of industrial undertaking situated at Mahad, Aurangabad and Pithampur acquired by the company before the transition date. This Goodwill was being amortised over 5 years as per the previous GAAP. The same is carried at the previous GAAP value and is being tested for impairment at each balance sheet date.

1B : Other Intangible Assets

(₹ Crores)

Particulars	Software	Brand/ Trade Mark	Know-How	Software - R&D	Total
Gross Block					
As on 01/04/2015	12.87	5.90	3.54	0.65	22.96
Additions	9.05	-	0.97	1.27	11.29
Adjustments	(0.01)	-	-	-	(0.01)
As on 31/03/2016	21.91	5.90	4.51	1.92	34.24
Additions	3.19	-	5.21	0.51	8.91
Adjustments	-	-	-	-	-
As on 31/03/2017	25.10	5.90	9.72	2.43	43.15
Accumulated Amortisation					
As on 01/04/2015	-	-	-	-	-
For the year 2015-16	5.87	1.76	1.06	0.46	9.15
Adjustments	-	-	-	-	-
As on 31/03/2016	5.87	1.76	1.06	0.46	9.15
For the year 2016-17	6.77	1.76	2.24	0.56	11.33
Adjustments	-	-	-	-	-
As on 31/03/2017	12.64	3.52	3.30	1.02	20.48
Net Block as on 31/03/2016	16.04	4.14	3.45	1.46	25.09
Net Block as on 31/03/2017	12.46	2.38	6.42	1.41	22.67

Note : In view of the adoption of para D7AA of Ind AS 101 relating to Deemed Cost, the net block as at March 31, 2015 as follows has been shown as gross block as on April 01, 2015.

(₹ Crores)

Particulars	Software	Brand/ Trade Mark	Know-How	Software - R&D	Total
Gross Block as on 31/03/2015	23.86	9.22	7.74	1.74	42.56
Accumulated Amortisation till 31/03/2015	10.99	3.32	4.20	1.09	19.60
Net Block as on 31/03/2015	12.87	5.90	3.54	0.65	22.96

Financial Assets - Investments

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
2. Investments in Joint Venture/ Associate			
Equity instrument in joint venture	3.35	4.18	3.56
Equity instrument in Associates	18.84	21.59	12.81
Total	22.19	25.77	16.37
2A Other Non-current Investments			
Investment in Equity	-	-	2.83
Investment in Preference	0.05	0.05	0.05
Total	0.05	0.05	2.88
2B Current Investment			
Investment in Mutual fund	113.57	-	-
Total	113.57	-	-

Notes to financial statements as at and for the year ended March 31, 2017

2. Investment in Joint Venture/ Associate

Sr. No.	Name of the Body Corporate	Relationship	Extent of Holding (%) / No. of Shares			(₹ Crores)		
			31/03/2017	31/03/2016	01/04/2015	31/03/2017	31/03/2016	01/04/2015
	Non-Current Investment							
	Investment in Equity Instruments (Associate and Joint venture accounted under equity method)							
(1)	Unquoted equity shares							
1	Avik Pharmaceutical Ltd.	Joint Venture	49%	49%	49%	3.35	4.18	3.56
			5,00,000	5,00,000	5,00,000			
2	CCPL Software Pvt.Ltd. #	Associate	28.95%	28.95%	28.95%	-	-	-
			55,000	55,000	55,000			
3	Trophic Wellness Pvt. Ltd.	Associate	19.26%	19.26%	19.26%	6.59	5.90	4.42
			7,80,000	7,80,000	7,80,000			
Total unquoted investments						9.94	10.08	7.98
(2)	Quoted equity shares							
1	Krebs Biochemicals & Industries Ltd.	Associate	29.83%	31.38%	18.92%	12.25	15.69	8.39
			41,00,100	41,00,100	18,00,000			
Total quoted investments						12.25	15.69	8.39
Total Investments (1+2)						22.19	25.77	16.37
# Cost fully written off in books								

Aggregate value of investments			₹ Crores		
Particulars	31/03/2017	31/03/2016	01/04/2015		
Aggregate book value of quoted investments	21.96	21.96	9.54		
Aggregate market value of quoted investments	41.06	43.05	16.01		
Aggregate book value of unquoted investments	9.94	10.08	7.98		

Details of investments in Joint Venture/ Associate accounted under equity method.

a) Avik Pharmaceutical Ltd.

During the year 2013-14 the Company had acquired 49.02% of shares in Avik Pharmaceutical Ltd. Avik is manufacturing APIs, primarily Cortico Steroids and Hormones since 1980. Avik is pioneer in the manufacturing of steroids in India. Avik's two manufacturing facilities are located at Vapi, Gujarat.

b) Trophic Wellness Pvt. Ltd.

Trophic Wellness Pvt. Ltd. was incorporated in 2010 and is headquartered in Mumbai, India. The Company has acquired shareholding to the extent of 19.26% in Trophic Wellness Pvt. Ltd. during the year 2010-11. Trophic Wellness Pvt. Ltd. is engaged in the manufacturing and marketing of nutraceuticals with its manufacturing unit situated in Sikkim.

c) Krebs Biochemicals & Industries Ltd.

Krebs Biochemicals and Industries Ltd. was established in 1991. During the financial year 2014-15, Krebs Biochemicals and Industries Ltd. became an associate company. The Company is presently holding 29.83% shares in this company. Krebs undertakes both contract manufacturing for large pharmaceutical and multinational companies and develops products for sale in global markets. Krebs is listed on NSE and BSE and is headquartered in Vishakapatnam, India with manufacturing plants in Nellore and Vizag. Expertise and infrastructure in the areas of chemical synthesis, fermentation and enzymatic technologies along with a focus on cost and quality makes Krebs a logical partner of the Company for the development and supply of products made using one or more of these technologies.

Notes to financial statements as at and for the year ended March 31, 2017

2A Other Long term Investments

24 Other Long term investments								
Sr. No.	Name of the Body Corporate	Relati- onship	No. Of Shares			(₹ Crores)		
			31/03/2017	31/03/2016	01/04/2015	31/03/2017	31/03/2016	01/04/2015
Investments at fair value through P&L (fully paid)								
	Unquoted equity shares							
1	Gujarat Industrial Co-op Bank Ltd.	Others	140	140	140	-	-	-
2	Narmada Clean Tech Ltd. (NCTL) (formerly known as Bharuch Eco Aqua Infrastructure Ltd.)	Others	35,000	35,000	35,000	-	-	-
	Unquoted preference shares							
3	Enviro Infrastructure Company Limited	Others	45,000	45,000	45,000	0.05	0.05	0.05
	Quoted equity shares							
4	Mangalam Drugs & Organics Ltd.	Others	-	-	10,67,939	-	-	2.83
Total						0.05	0.05	2.88

Aggregate value of investments

		(₹ Crores)		
Particulars	31/03/2017	31/03/2016	01/04/2015	
Aggregate book value of quoted investments	-	-	2.83	
Aggregate market value of quoted investments	-	-	2.83	
Aggregate book value of unquoted investments	0.05	0.05	0.05	

2B Current Investment

Name of the Mutual Fund Scheme	No. Of Units			(₹ Crores)		
	31/03/2017	31/03/2016	01/04/2015	31/03/2017	31/03/2016	01/04/2015
Quoted investment						
A. Investments at fair value through P&L (fully paid)						
Investment in Mutual Fund:						
Kotak Low Duration Fund	1,48,069	-	-	30.07	-	-
Kotak Floater Short Term Fund	1,25,499	-	-	33.43	-	-
Reliance Liquid Fund	75,908	-	-	30.01	-	-
Reliance Medium Term Fund	57,82,392	-	-	20.06	-	-
Total Current Investment	61,31,868	-	-	113.57	-	-

B. Aggregate value of investments

		(₹ Crores)		
Particulars	31/03/2017	31/03/2016	01/04/2015	
Aggregate book value of quoted investments	113.57	-	-	
Aggregate market value of quoted investments	113.57	-	-	

Notes to financial statements as at and for the year ended March 31, 2017

Details of loans given, investments made & guarantee given covered under section 186(4) of the Companies Act, 2013 are given in statement 2 attached to the financial statements.

						(₹ crores)
Sr. No.	Name of the party	Nature	Relation	Purpose	31/03/2017	31/03/2016
1	Krebs Biochemicals & Industries Ltd.	Investment	Associate	Equity contribution to Associate - Share allotment	-	12.42
2	Krebs Biochemicals & Industries Ltd.	Loan Given	Associate	Loan (ICD) given to Associate for business purpose	23.57	11.40
3	Avik Pharmaceutical Ltd.	Loan Given	Joint Venture	Loan (ICD) given to Joint Venture for business purpose	-	1.87
4	Trophic Wellness Pvt. Ltd.	Investment	Associate	Partly paid up shares converted to fully paid up shares	3.40	-
Total					26.97	25.69

The disclosure under section 186(4) is made at transaction value before Ind AS effects.

The associates and Joint ventures of the Company and the ownership interest are as follows: -

Name of the Associate	CCPL Software Private Ltd.	Trophic Wellness Pvt. Ltd.	Krebs Biochemicals & Industries Ltd	Avik Pharmaceutical Ltd.	Total (₹ Crores)
% of Share held	28.95%	19.26%	31.38%	49.02%	-
Original cost of Investment	1.31	8.94	9.54	6.51	26.30
(Goodwill)/Capital Reserve	(0.79)	1.73	(16.31)	(10.84)	-
Accumulated Profit/ (Loss) up to 01/04/2015	(0.51)*	(4.52)	(1.15)	(2.99)	(8.66)
Accumulated Other comprehensive income up to 01/04/2015	-	-	-	0.04	0.04
Investment during the year	-	-	12.42	-	12.42
Share of Profit/ (Loss) for the year 2015-16 Plus Dividend	*	1.45	(5.12)	0.60	(3.07)
Share of other comprehensive income 2015-16	-	0.03	-	0.02	0.05
% of Share held for 2016-17	28.95%	19.26%	29.83%	49.02%	-
Investment during the year	-	3.40	-	-	3.40
Share of Profit/ (Loss) for the year 2016-17 Plus Dividend	-	(2.71)	(4.78)	(0.77)	(8.26)
Share of other comprehensive income 2016-17	-	-	1.34	(0.06)	1.28
Dividend received from associates	-	-	-	-	-
Less: - Disposal of Investment	-	-	-	-	-
Carrying value of Investment on 31/03/2017	NIL**	6.59	12.25	3.35	22.19

* No effect of share from CCPL is taken since April 01, 2004, as the Company has no further commitment towards its share of loss in the associate.

** Balance cost is fully written off in books.

Notes to financial statements as at and for the year ended March 31, 2017

3. Financial Assets - Loans

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
(a) Deposits with others						
Considered good	46.18	0.82	42.06	-	33.87	-
Considered doubtful	0.02	-	0.02	-	(0.02)	-
	46.20	0.82	42.08	-	33.85	-
Less : Provision for doubtful deposits	(0.02)	-	(0.02)	-	0.02	-
	46.18	0.82	42.06	-	33.87	-
(b) Loans to related parties (Unsecured, considered good)	50.03	-	27.59	-	14.32	4.80
(c) Others (Unsecured, considered good)						
Loan given to Employees	0.51	1.28	0.70	1.75	1.03	1.66
Total	96.72	2.10	70.35	1.75	49.22	6.46

Disclosures:

- (a) Details of loans and advances in the nature of loan to associates and joint venture as required under Schedule V(A)(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 :

(₹ Crores)

Sr. No.	Name of the company and relationship	Balance as at Mar 31, 2017	Maximum outstanding during the year 2016-17	Balance as at Mar 31, 2016	Maximum outstanding during the year 2015-16
(i)	Krebs Biochemicals & Industries Limited - Associate	34.97	34.97	11.40	11.40
(ii)	Avik Pharmaceutical Limited - Joint Venture	15.06	16.19	16.19	16.19

The disclosure in this para is made of transaction value and not the figures after application of Ind AS.

- (b) Investment by the loanee in the shares of the Company:

None of the loanees have, per se, made investments in the shares of the Company.

- (c) Details of Loans and advances to Related Parties.

(₹ Crores)

Sr. No.	Name of the company and relationship	Balance as at Mar 31, 2017	Balance as at Mar 31, 2016
(i)	Krebs Biochemicals & Industries Limited - Associate	34.97	11.40
(ii)	Avik Pharmaceutical Limited - Joint Venture	15.06	16.19
Total		50.03	27.59

- (d) Deposit includes ₹ 45.00 crores (previous year ₹ 45.00 crores) given as lease deposit for two manufacturing facilities of Krebs Biochemicals & Industries Limited taken on lease by the Company. The figures stated are at transaction value before Ind AS effects.

Notes to financial statements as at and for the year ended March 31, 2017

4. Financial Assets - Others

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Advances to employees						
- Considered good	-	0.79	-	1.55	-	0.68
- Considered doubtful	-	0.60	-	0.29	-	0.43
	-	1.39	-	1.84	-	1.11
Less : Provision for doubtful advances	-	(0.60)	-	(0.29)	-	(0.43)
	-	0.79	-	1.55	-	0.68
Other Income receivables	-	3.41	0.04	1.56	-	1.30
Gratuity and other claim receivables	-	1.65	-	3.56	-	7.06
Unbilled revenue	-	11.86	-	4.30	-	8.25
Forward contract gain receivable	-	8.33	-	3.32	-	6.09
Hedging gain receivable	-	3.83	-	-	-	14.48
Share application money pending allotment	-	-	-	-	12.42	-
Term Deposits with banks kept as margin money	2.24	-	2.45	-	3.13	-
Total	2.24	29.87	2.49	14.29	15.55	37.86

5. Other Non-Financial Assets

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
(i) Capital advances (Unsecured, considered good)	6.86	-	4.49	-	26.66	-
(ii) Other advances						
(a) Prepaid expenses	8.99	14.25	13.06	14.66	15.24	14.10
(b) Duties & taxes refundable	7.82	107.01	6.70	80.11	7.06	98.46
(iii) Deposits with Govt. departments						
- Considered good	-	3.70	-	3.27	-	1.88
(iv) Advance to suppliers	-	6.17	-	4.58	-	8.48
(v) Export benefits receivables	-	35.40	-	40.62	-	39.98
(vi) Advances to employees	-	2.85	-	3.57	-	4.24
(vii) Others	0.24	0.84	0.36	0.24	-	0.97
(viii) Prepaid taxes (net of provisions)	2.49	-	3.60	-	2.96	-
Total	26.40	170.22	28.21	147.05	51.92	168.11

Notes to financial statements as at and for the year ended March 31, 2017

6. Inventories

(₹ Crores)

Particulars		As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
(i.)	Raw Materials						
	In hand	300.25		279.48		316.30	
	In transit	31.61	331.86	15.42	294.90	15.58	331.88
(ii.)	Packing Materials						
	In hand	31.13		32.33		39.11	
	In transit	0.12	31.25	0.35	32.68	0.28	39.39
(iii)	Work-in-progress		187.70		201.23		173.50
(iv)	Finished goods						
	In hand						
	Own	261.45		254.64		322.68	
	Traded	40.03	301.48	28.83	283.47	30.00	352.68
	In transit						
	Own	11.63		10.08		11.88	
	Traded	3.94	15.57	2.28	12.36	3.85	15.73
(v)	Stores and spares		14.36		12.78		12.66
Total			882.22		837.42		925.84

All the above inventory other than stores & spares are hypothicated to the lenders as security towards short term borrowings.

The disclosure of inventories recognised as an expense in accordance with paragraph 36 of Ind AS 2 is as follows:

(₹ Crores)

Particulars		As at March 31, 2017	As at March 31, 2016
(i)	Amount of inventories recognised as an expense during the period.	1,134.54	1,062.35
(ii)	Amount of write - down of inventories recognised as an expense during the period.	9.64	30.33
Total		1,144.18	1,092.68

7. Financial Assets - Trade receivables (Unsecured, at amortised cost)

(₹ Crores)

Particulars		As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Considered good	500.72		446.50		631.16	
	Considered doubtful	0.03	500.75	0.52	447.02	0.23	631.39
	Less: Allowance for doubtful debts	(0.56)		(0.63)		(0.81)	
	Less: Provision for doubtful debts	(0.03)	(0.59)	(0.52)	(1.15)	(0.23)	(1.04)
Total			500.16		445.87		630.35

The Company uses a provision matrix to determine impairment loss on portfolio of its trade receivable. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in forward-looking estimates are analysed. The Company estimates the following matrix at the reporting date which is calculated on overdue amounts.

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Default rate - Local	0.12%	0.03%	0.03%
Default rate - Export	0.74%	0.14%	0.14%

Notes to financial statements as at and for the year ended March 31, 2017

Movement in the expected credit loss allowance

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016
Balance at the beginning of the period	0.63	0.81
Movement in expected credit loss allowance on trade receivables calculated at lifetime expected credit losses	(0.07)	(0.18)
Provision at the end of the period	0.56	0.63

8. Financial Assets - Cash & Cash Equivalents

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Cash on hand	0.22	0.29	0.39
Balances with banks	25.93	22.36	60.95
Cheques, drafts on hand	1.34	1.56	1.72
Fixed deposit with bank	1.93	144.66	77.00
Total	29.42	168.87	140.06

Disclosure of Specified Bank Notes (SBN)

During the year, the Company had specified bank notes or other denomination note as defined in the MCA notification G.S.R. 308(E) dated March 30, 2017 of Specified Bank Note (SBN) held and transacted during the period November 8, 2016 to December 30, 2016. The denomination wise SBNs and other notes as per the notification is given below:

(In ₹)

Particulars	SBNs	Other Denomination Notes	Total
Closing cash on hand as on November 08, 2016	55,66,500	23,82,607	79,49,107
(+) Non Permitted receipts	-	-	-
(+) Permitted receipts	-	55,05,856	55,05,856
(-) Permitted payments	56,500	51,88,833	52,45,333
(-) Amounts Deposited in Banks	55,10,000	12,035	55,22,035
Closing cash on hand as on December 31, 2016	-	26,87,595	26,87,595

9. Financial Assets - Bank balances other than (8) above

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Unpaid dividend accounts	1.43	1.67	1.82
Fixed Deposits	5.00	5.00	5.00
Open offer Escrow account	-	-	19.29
Total	6.43	6.67	26.11

10. Equity Share Capital

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
Face Value	Equity Shares	₹2.00 each	Equity Shares	₹2.00 each	Equity Shares	₹2.00 each
Class of Shares	28,50,00,000		28,50,00,000		28,50,00,000	
Authorised Capital	57.00		57.00		57.00	
Issued, Subscribed and Paid up Capital						
Issued & Subscribed	12,74,80,204	25.50	12,74,80,204	25.50	12,74,80,204	25.50
Paid up	12,61,99,109	25.24	12,61,99,109	25.24	12,61,99,109	25.24

Of the above :

- (a) 3,22,704 Equity shares of ₹ 2/- each of the Company have been allotted during 2012-13 without payment being received in cash under the scheme of amalgamation of erstwhile Tonira Pharma Limited with the Company.

Notes to financial statements as at and for the year ended March 31, 2017

Disclosures:

(i) Reconciliation of Shares

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Numbers	(₹ Crores)	Numbers	(₹ Crores)	Numbers	(₹ Crores)
Shares outstanding at the beginning of the year	12,61,99,109	25.24	12,61,99,109	25.24	12,61,99,109	25.24
Shares Issued during the year	-	-	-	-	-	-
Shares outstanding at the end of the year	12,61,99,109	25.24	12,61,99,109	25.24	12,61,99,109	25.24

ii. Details of Shareholding in excess of 5%

Name of Shareholder	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Number of shares held	%	Number of shares held	%	Number of shares held	%
Kaygee Investments Pvt. Ltd.	2,70,18,195	21.41%	2,70,18,195	21.41%	2,70,18,195	21.41%
Kaygee Laboratories Pvt. Ltd. (Formerly Exon Laboratories Pvt. Ltd.)	83,21,000	6.59%	82,71,000	6.55%	82,71,000	6.55%
Chandurkar Investments Pvt. Ltd.	69,78,005	5.53%	69,78,005	5.53%	69,78,005	5.53%

iii) Rights and obligations of shareholders

The Company has only one class of share referred as Equity shares having a par value of ₹2/- per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after payment of external liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders. The dividend is recommended by management which is subject to shareholder's approval at the General Meeting.

11. Other Equity

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
a. Capital Reserve		0.59		0.59		0.59
b. Securities Premium Account		43.99		43.99		43.99
c. Capital Redemption Reserve		0.26		0.26		0.26
d. Debenture Redemption Reserve		5.00		5.00		10.00
e. General Reserve		1,306.05		1,306.05		1,300.48
f. Retained Earnings		1,086.94		892.40		814.45
g. OCI Reserve						
- Remeasurement of employee benefits	(12.90)		(10.69)		(12.05)	
- Cash flow hedging reserve	3.83		(3.84)		13.58	
- Foreign currency translation reserve	(3.74)	(12.81)	0.19	(14.34)	-	1.53
Total		2,430.02		2,233.95		2,171.30

* The Board of Directors in their meeting held on May 28, 2017 have recommended a dividend of ₹ 1/- per equity share (previous year Nil) to be approved by the shareholders in the ensuing general meeting. On approval, this will result in an outflow of ₹15.19 crores including dividend tax.

Notes to financial statements as at and for the year ended March 31, 2017

12. Financial Liabilities - Borrowings

a) Long-term Borrowings - Secured

(₹ Crores)

Particulars		Non - Current Portion As at			Current Maturities as at		
		Mar 31, 2017	Mar 31, 2016	Apr 01, 2015	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
(i)	Debentures	-	4.99	9.98	4.99	4.99	4.98
(ii)	Foreign currency term loan	340.42	413.84	435.41	130.00	180.36	100.94
(iii)	Buyers credit	6.80	14.80	-	6.79	1.64	-
Total (a)		347.22	433.63	445.39	141.78	186.99	105.92

Details of above:-

(₹ Crores)

Sr. No.	Name of the Instruments/ Institutions	Non - Current Portion As at			Current Maturities as at		
		Mar 31, 2017	Mar 31, 2016	Apr 01, 2015	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
(i)	Debentures						
1	9.25% Secured Redeemable Non-Convertible Debentures	-	4.99	9.98	4.99	4.99	4.98
	Total (i)	-	4.99	9.98	4.99	4.99	4.98
(ii)	Foreign Currency Term Loans						
1	a) BNP PARIBAS, Singapore Branch	44.90	66.20	-	19.96	-	-
	b) BNP PARIBAS, Singapore Branch	-	-	62.35	-	66.26	-
2	DBS BANK, Singapore Branch	7.64	23.40	36.78	15.20	15.48	14.55
3	Barclays Bank PLC, London Branch	-	-	-	-	-	6.56
4	a) HSBC Bank Mauritius Ltd.	-	-	15.61	-	16.55	37.40
	b) HSBC Bank Mauritius Ltd.	14.31	44.03	62.27	28.87	22.09	-
	c) HSBC Bank Mauritius Ltd.	-	15.28	33.61	14.96	20.35	19.17
	d) HSBC Bank Mauritius Ltd.	40.49	74.41	101.30	32.33	33.00	23.26
	e) HSBC Bank Mauritius Ltd.	107.71	124.68	123.49	14.63	6.63	-
5	Standard Chartered Bank- London	60.80	-	-	4.05	-	-
6	United Overseas Bank Ltd.	64.57	65.84	-	-	-	-
	Total (ii)	340.42	413.84	435.41	130.00	180.36	100.94
(iii)	Buyers Credit						
1	Standard Chartered Bank	6.80	14.80	-	6.79	1.64	-
	Total (iii)	6.80	14.80	-	6.79	1.64	-
Total (i + ii + iii)		347.22	433.63	445.39	141.78	186.99	105.92

b) Long-term Borrowings - Unsecured

(i)	Buyers credit	4.52	50.64	53.31	44.93	11.07	-
Grand Total (a+b)		351.74	484.27	498.70	186.71	198.06	105.92

c) Details of securities and repayment terms of secured loans stated above

(i) Debentures

Secured by first mortgage and pari-passu charge over Company's office premises at Ahmedabad, Gujarat and first charge by way of equitable mortgage charge on immovable properties being land and building situated at Sejavata, Ratlam and Polo Ground, Indore, both in the state of Madhya Pradesh; Village Athal & Village Piparia (Silvassa); plot no.48, plot no.142-AB, plot no.123, plot no.125 & plot no.126ABCD at Kandivli Industrial Estate in Mumbai and at Dehradun in the state of Uttarakhand. Redeemable in 4 equal annual installments of ₹ 5.00 crores at the end of 2nd year, 3rd year, 4th year and 5th year from the date of issue i.e. December 12, 2012.

Notes to financial statements as at and for the year ended March 31, 2017

(ii) Foreign Currency Term Loans

1 BNP PARIBAS, Singapore Branch

- Secured by first pari passu charge by way of hypothecation of movable fixed assets both present and future Including Pithampur Plant(Indore).
Repayable in 13 equal quarterly instalments from June 30, 2017.
- Secured by first pari passu charge by way of hypothecation of movable fixed assets both present and future except on movable fixed assets at Pithampur, Indore.
Bullet repayment at the end of 5th year on October 07, 2016.

2 DBS BANK, Singapore Branch

Secured by first pari passu charge by way of hypothecation of all the movable fixed assets both present and future. Repayable in 17 equal quarterly instalments from September 16, 2014.

3 Barclays Bank PLC, London Branch

Secured by first pari passu charge on the plant & machinery of the Company except assets at Pithampur, Indore. Repayable in 13 quarterly instalments from May 31, 2012.

4 HSBC Bank Mauritius Ltd.

- Secured by first pari passu charge on the plant & machinery of the Company except assets at Pithampur, Indore. Repayable in 7 half yearly instalments from July 31, 2013.
- Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Pithampur, Indore and at Baroda.
Repayable in 9 equal quarterly instalments from September 26, 2016.
- Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Pithampur, Indore and at Baroda.
Repayable in 13 equal quarterly instalments from November 19, 2014.
- Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Pithampur, Indore and at Baroda.
Repayable in 16 equal quarterly instalments from September 30, 2015
- Secured by first pari-passu charge over current and future movable fixed assets of the Company except assets at Baroda(Gujarat).
Repayable in 11 half yearly un-equal instalments from December 08, 2016

5 Standard Chatered Bank- London

Secured by first pari-passu Charge on movable fixed assets at company's API plant at Baroda and Formulation plant at SEZ Pithampur and the specific and exclusive charge on the unit II at Sikkim.
Repayable in 16 quarterly equal instalments from February 15, 2018.

6 United Overseas Bank Ltd.

Secured by first pari passu charge by way of hypothecation on movable fixed assets both present and future Including Pithampur plant (Indore).
Repayable in 4 equal half yearly Instalments from June 29, 2018.

(iii) Buyer's Credit - Standard Chartered Bank

Exclusive Charge by way of hypothecation on specific movable fixed assets financed through this Buyers' Credit.
Repayable 10% at end of 12 months, 45% at end of 24 months and balance 45% at end of 36 months from the date of drawdown.

d) Maturity Profile of Borrowings other than Debentures is as per the original sanction terms without Ind AS effects.

(₹ Crores)			
Particulars	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
Instalment payable between 1 to 2 years	152.30	182.06	224.15
Instalment payable between 2 to 5 years	200.86	259.71	201.62
Instalment payable beyond 5 years	-	39.75	65.63
Total	353.16	481.52	491.40

e) The long term loans other than non convertible debentures are taken at the following rates.

Particulars	Interest Band
i) Foreign currency loan	Libor + 0.55% to 2.45%

Notes to financial statements as at and for the year ended March 31, 2017

13. Other Financial Liabilities

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Deposits from customers	-	1.07	-	1.10	-	1.33
Current maturities of long term debt	-	186.71	-	198.06	-	105.92
Interest accrued but not due on borrowings	-	1.71	-	2.73	-	2.62
Unpaid dividends	-	1.43	-	1.67	-	1.82
Amount payable on hedging transactions	-	0.02	-	3.84	-	1.27
Payable for capital goods	-	21.47	-	43.09	-	58.33
Others	-	0.05	0.06	0.10	0.15	0.10
Total	-	212.46	0.06	250.59	0.15	171.39

14. Provisions

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Gratuity	-	3.39	-	1.92	-	2.79
Provision for leave encashment	24.55	2.67	20.22	2.32	17.66	1.99
Provision for leave travel assistance (LTA)	-	5.66	-	4.84	-	4.17
Other employee related provision	-	2.16	-	5.74	-	1.31
Provision for breakage/damage	-	2.38	-	3.50	-	4.61
Provision for product expiry	-	43.46	-	37.28	-	34.12
Provision for sales return	-	6.35	-	6.62	-	6.34
Total	24.55	66.07	20.22	62.22	17.66	55.33

The disclosure of provisions movement as required by Ind AS 37 is as follows:-

(₹ Crores)

Particulars	Mar 31, 2017	Mar 31, 2016
i. Provision for breakage/damage		
Balance at the beginning of the period	3.50	4.61
Provisions made during the period	2.49	3.00
Utilisations during the period	(3.61)	(4.11)
Provision at the end of the period	2.38	3.50
ii. Provision for product expiry		
Balance at the beginning of the period	37.28	34.12
Provisions made during the period	30.79	26.24
Utilisations during the period	(24.61)	(23.08)
Provision at the end of the period	43.46	37.28
iii. Provision for sales return		
Balance at the beginning of the period	6.62	6.34
Provisions made during the period	17.81	16.18
Utilisations during the period	(18.08)	(15.90)
Provision at the end of the period	6.35	6.62
iv. Provision for wage arrears under negotiation		
Balance at the beginning of the period	5.74	1.32
Provisions made during the period	8.32	4.60
Utilisations during the period	(11.90)	(0.18)
Provision at the end of the period	2.16	5.74

Notes to financial statements as at and for the year ended March 31, 2017

v. Disclosure in accordance with Ind AS – 19 “Employee Benefits”, of the Companies (Indian Accounting Standards) Rules, 2015.

Gratuity

The company provides for gratuity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement/ termination is the employees last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service. The gratuity plan is a funded plan and the company makes contributions to recognised funds in India. The company does not fully fund the liability and maintains a target level of funding to be maintained over a period of time based on estimations of expected gratuity payments.

The following table summarizes the components of net benefit expense recognized in the Statement of Profit and Loss and the funded status and amounts recognized in the Balance Sheet.

	(₹ Crores)	
Particulars	As at Mar 31, 2017	As at Mar 31, 2016
Expense recognised in Statement of Profit & Loss		
Current Service cost	6.13	5.02
Interest expense	3.24	3.02
Expected Return on Plan Assets	(3.49)	(2.79)
Benefit paid but pending claim	-	2.29
Total	5.88	7.54
Expense recognised in Other Comprehensive Income		
Return on plan assets (Greater)/Less than Discount Rate	(0.17)	(0.54)
Actuarial (Gain)/Loss due to Experience on DBO	4.61	(1.16)
Total	4.44	(1.70)
Present value of funded defined benefit obligation	54.49	43.20
Fair value of Plan assets	(51.10)	(41.28)
Funded Status	3.39	1.92
Net defined benefit (Asset)	3.39	1.92
Movements in present value of defined benefit obligation		
Present value of defined benefit obligation at the beginning of the year	43.20	37.79
Current Service Cost	6.13	5.01
Interest Cost	3.24	3.02
Actuarial (Gain)/Loss	4.61	(1.16)
Benefits paid	(2.69)	(1.46)
Present value of defined benefit obligation at the end of the year	54.49	43.20
Movements in fair value of the plan assets are as follows.		
Opening fair value of plan assets	41.28	35.01
Expected returns on Plan Assets	3.49	2.79
Remeasurement (Gains)/Losses:		
Actuarial (Gain)/Loss on Plan assets	0.17	0.54
Contribution from Employer	8.85	6.69
Benefits paid	(2.69)	(1.46)
Benefit paid but pending claim	-	(2.29)
Closing fair value of the plan asset	51.10	41.28
Remeasurement effect recognised on Other Comprehensive Income		
Actuarial (Gain)/Loss arising from experience adjustments	4.61	(1.16)
Actuarial (Gain)/Loss on Plan assets	(0.17)	(0.54)
Total Actuarial (Gain)/Loss included in OCI	4.44	(1.70)

Notes to financial statements as at and for the year ended March 31, 2017

The principal assumptions used as at the balance sheet date are used for purpose of actuarial valuations were as follow

Particulars	As at Mar 31, 2017	As at Mar 31, 2016
Financial Assumptions		
Discount Rate	7.25%	8.00%
Salary Increase Rate	6.00%	6.00%
Demographic Assumptions		
Mortality Rate	IALM (2006-08) Ultimate	IALM (2006-08) Ultimate
Withdrawal Rate	5%	Age Based: Upto 30 years - 3% 31 to 45 years - 2% 46 years and above - 1%
Retirement age	58 Years	58 Years

The rate used to discount post-employment benefit obligations is determined by reference to market yields at the end of the reporting period on government bonds.

Significant actuarial assumptions for the determination of the defined obligation are discount rate, expected salary increase and mortality.

The sensitivity analyses below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of reporting period, while holding all other assumptions constant.

Defined Benefit Obligation		
Discount rate		
a. Discount rate - 100 basis points	60.75	47.78
b. Discount rate + 100 basis points	50.56	39.14
Salary increase rate		
a. Rate - 100 basis points	51.99	39.03
b. Rate + 100 basis points	58.74	47.83

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would clear in isolation of one another as some of the assumptions may be correlated.

Further more, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the Projected Credit Method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

15. Deferred Tax Liabilities (Net)

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
Deferred tax liabilities on account of Depreciation including on R&D Assets, Amortisation and impairment		228.38		212.11		183.88
Deferred tax asset on account of						
Leave encashment	9.42		7.80		6.80	
Bonus	2.42		2.77		0.69	
MAT Credit available	28.00		-		-	
Unabsorbed depreciation	-		28.48		-	
Provision for revenue and credit loss	18.06		16.60		15.88	
Other tax disallowance	0.01	57.91	-	55.65	2.10	25.47
Net deferred tax liability		170.47		156.46		158.41

Notes to financial statements as at and for the year ended March 31, 2017

16. Other Non-current liabilities

(₹ Crores)

Particulars	As at March 31, 2017		As at March 31, 2016		As at April 01, 2015	
	Non Current	Current	Non Current	Current	Non Current	Current
Security deposit	1.56	-	1.56	-	1.56	-
Revenue received in advance	-	9.85	-	20.43	-	21.75
Duties & taxes payable	-	22.73	-	22.58	-	40.30
Other payables	-	4.58	-	3.90	-	3.40
Total	1.56	37.16	1.56	46.91	1.56	65.45

17. Financial Liabilities - Borrowings

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
(i) Secured Loans:			
Working capital loan from banks *	167.30	116.00	518.61
Other loan from banks #	-	1.99	4.37
(ii) Unsecured Loans:			
Short term loans from banks	10.00	66.26	120.35
Short term loans from others	-	0.60	-
Total Short Term Borrowings (i)+(ii)	177.30	184.85	643.33

* Secured loans are secured by first charge by way of hypothecation of all the stocks, book debts and all other movable current assets of the Company and second charge by way of mortgage of the immovable properties of the Company and hypothecation of plant & machinery of the Company.

Secured by Collateral property being immovable property in USA, which is defined under the Loan agreement. Further, a Standby Letter of Credit from Citibank N.A., India Branch was submitted and which was also guaranteed by parent company Ipca Laboratories Limited.

18. Financial Liabilities - Trade Payables

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
(a) Trade Payables for goods and services:			
Total outstanding dues of Micro and small enterprises	2.63	3.67	2.51
Others	416.90	403.61	286.57
(b) Acceptances	38.14	13.83	16.88
Total	457.67	421.11	305.96

Trade payables and acceptances are non-interest bearing and are normally settled between 0-120 days.

Notes to financial statements as at and for the year ended March 31, 2017

Details of dues to micro and small enterprises as defined under MSME Act, 2006

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Principal amount due	2.63	3.67	2.51
Interest due on above	-	-	-
Amount paid in terms of Sec 16 of the Micro, Small and Medium Enterprise Development Act, 2006			
- Principal amount paid beyond appointed day	2.98	1.59	1.68
- Interest paid thereon	0.02	0.01	0.06
Amount of interest due and payable for the period of delay	-	-	-
Amount of interest accrued and remaining unpaid as at year end	0.02	0.01	0.01
Amount of further interest remaining due and payable in the succeeding year.	-	-	-

The company has compiled the above information based on written confirmations from suppliers and have been determined to the extent such parties have been identified on the basis of the information available with the company. This has been relied upon by the auditors.

19. Current Tax Liabilities (Net)

(₹ Crores)

Particulars	As at March 31, 2017	As at March 31, 2016	As at April 01, 2015
Provision for taxation (net of taxes paid)	5.27	4.27	10.28
Total	5.27	4.27	10.28

20. Revenue from Operations (Gross)

(₹ Crores)

Particulars	2016-17		2015-16	
Sale of products		3094.94		2,817.00
Sale of services		53.74		50.19
Other operating revenues				
Export incentives	47.03		26.98	
Sundry balances written back	2.51		2.72	
Bad debts recovered	0.68		0.85	
Miscellaneous income	11.74	61.96	8.77	39.32
Total		3,210.64		2,906.51

21. Other Income

(₹ Crores)

Particulars	2016-17	2015-16
Interest income	10.35	9.35
Interest income on financial asset at amortised cost	3.93	3.36
Dividend income - from current investments	-	0.03
Profit on sale of investments - non current (net)	-	1.36
Profit on sale of investments - current (net)	5.15	5.36
Net gain on financial asset through FVTPL	0.16	-
Remeasurement of Financial Assets	0.11	-
Profit on sale of property, plant & equipment	0.45	0.39
Miscellaneous income	2.42	2.36
Total	22.57	22.22

Notes to financial statements as at and for the year ended March 31, 2017

22. Cost of Materials Consumed

(₹ Crores)

Particulars	2016-17		2015-16	
Raw Materials Consumed				
Opening stock	294.90		331.89	
Add : Purchases (Net of discount)	808.62		690.43	
Add : Raw material conversion charges	11.42		10.53	
	1,114.94		1,032.85	
Less : Closing stock	331.86	783.08	294.90	737.95
Packing Materials Consumed				
Opening stock	32.68		39.39	
Add : Purchases (Net of discount)	187.89		167.07	
	220.57		206.46	
Less : Closing stock	31.25	189.32	32.68	173.78
Neutralisation of duties and taxes on inputs on exports - Drawback benefits		(18.53)		(18.42)
Total		953.87		893.31

23. Purchases of Traded Goods

(₹ Crores)

Particulars	2016-17	2015-16
Formulations	142.37	112.08
Active Pharmaceutical ingredients/ Intermediates	16.64	15.85
Others	2.83	11.31
Total	161.84	139.24

24. Changes in inventories of Finished Goods(FG), Work-in-progress(WIP) and Traded Goods

(₹ Crores)

Particulars	2016-17		2015-16	
Inventory Adjustments - WIP				
Stock at commencement	201.23		173.50	
Less: - Stock at closing	187.70	13.53	201.23	(27.73)
Inventory Adjustments - FG				
Stock at commencement	264.71		334.70	
Less : Stock at closing	273.08	(8.37)	264.71	69.99
Inventory Adjustments - Traded Goods				
Stock at commencement	31.12		33.85	
Less : Stock at closing	43.97	(12.85)	31.12	2.73
Variation in Excise duty on				
Closing stock of finished goods	24.21		22.04	
Less: Opening stock of finished goods	22.04	2.17	41.19	(19.15)
Total		(5.52)		25.85

25. Employee Benefits Expenses

(₹ Crores)

Particulars	2016-17	2015-16
Salaries , bonus , perquisites , etc.	615.36	554.57
Contribution to provident and other funds	35.09	31.94
Leave encashment	11.17	8.02
Leave travel assistance	3.86	3.34
Gratuity fund contributions	5.88	7.53
Staff welfare expenses	21.89	16.06
Recruitment & training	2.73	4.12
Total	695.98	625.58

Notes to financial statements as at and for the year ended March 31, 2017

26. Finance Cost

(₹ Crores)

Particulars	2016-17	2015-16
Interest expense	20.07	25.10
Other borrowing cost	3.01	6.80
Interest on Income tax	1.00	0.01
Total	24.08	31.91

27. Depreciation & Amortisation

(₹ Crores)

Particulars	2016-17	2015-16
Depreciation on tangible assets	161.62	154.11
Amortisation on intangible assets	11.33	9.15
Total	172.95	163.26

28. Other Expenses

(₹ Crores)

Particulars	2016-17	2015-16
Consumption of stores and spares	33.99	34.28
Power and fuel	145.67	136.38
Water charges	5.33	5.29
Freight, forwarding and transportation	76.22	74.81
Outside manufacturing charges	19.94	18.04
Repairs and maintenance	88.32	88.03
Loss on sale of property, plant & equipment	1.93	0.92
Property, plant & equipment scrapped	1.53	0.34
Commission on sales and brokerage	19.31	15.54
Field staff expenses	85.12	73.17
Sales and marketing expenses	164.18	123.19
Product information catalogue	19.24	25.55
Expenditure on scientific research	41.68	40.46
Laboratory expenses and analytical charges	31.27	33.16
Rent	19.49	18.49
Rates and taxes	17.31	16.36
Travelling expenses	32.50	27.73
Professional charges	38.91	28.65
Printing and stationery	7.77	7.55
Books, subscription and software	13.81	17.63
Product registration expenses	11.01	10.39
Excise duty	56.01	39.40
Communication expenses	6.52	7.09
Insurance	11.66	12.11
Intellectual property right expenses	1.83	4.13
Remuneration to auditors	0.62	0.56
Remuneration to components' auditors	0.13	0.14
Bank charges	2.83	2.65
Provision for doubtful debts/advances	0.51	(0.13)
Bad debts and other balance w/off	2.68	3.30
CSR expenses	4.28	4.80
Compensation towards failure to supply of goods/services	1.79	10.13
Loss on liquidation of subsidiary	-	0.68
Foreign exchange (gain)/Loss-net	(15.22)	40.59
Miscellaneous expenses (none of which individually forms more than 1% of the operating revenue)	11.52	11.53
Total	959.69	932.94

Notes to financial statements as at and for the year ended March 31, 2017

	(₹ Crores)	
Particulars	2016-17	2015-16
Details of:		
1 Repairs and Maintenance:		
- Building	13.62	17.12
- Machinery	73.11	69.77
- Others	1.59	1.14
	88.32	88.03
2 Remuneration To Auditors:		
- Audit fees including Limited Review	0.42	0.41
- Tax matters	0.10	0.06
- Certification and other services	0.07	0.06
- Out of pocket expenses	0.03	0.03
	0.62	0.56

29. Tax Expense

	(₹ Crores)	
Particulars	2016-17	2015-16
Current Tax	53.30	22.39
Tax expense of previous year	(0.04)	-
Deferred Tax	14.26	(1.95)
Total	67.52	20.44
(i) Reconciliation of current rate of tax and effective rate of tax:		
Profit before Income taxes	270.32	116.64
Enacted tax rates in India (%)	34.61%	34.61%
Computed expected tax expenses	93.56	40.37
Tax effect due to incentives	(1.93)	-
Accelerated Depreciation	(4.53)	(16.75)
Effect of exempt income	(2.98)	(0.49)
Effect of non- deductible expenses	10.99	24.77
Effect of differential overseas tax rates	(35.58)	1.38
Additional deduction on Research and development Expenses	(40.17)	(40.16)
Trading loss brought forward	(2.55)	(0.29)
Others	(16.81)	(8.08)
Income tax expenses - Net	-	0.75
Tax liability as per Minimum Alternate Tax on book profits		
Minimum Alternate Tax rate	21.34%	21.34%
Computed tax liability on book profits	55.10	23.79
Tax effect on adjustments:		
Provision for diminution disallowed	0.01	0.35
Adjustment of OCI	0.95	(0.36)
Others	(2.76)	(2.14)
Minimum Alternate Tax on Book Profit	53.30	21.64

Notes to financial statements as at and for the year ended March 31, 2017

30. Disclosure as required by Accounting Standard – Ind AS 33 “Earning Per Share” of the Companies (Indian Accounting Standards) Rules 2015.

The earning per share is calculated by dividing the profit after tax by weighted average number of shares outstanding for basic & diluted EPS.

(₹ Crores)				
Particulars	2016-17		2015-16	
(i) Profit after tax		194.54		93.14
(ii) Profit after tax and exceptional Items		194.54		93.14
(iii) Closing equity shares outstanding (Nos.)				
Opening equity shares outstanding (Nos.)	12,61,99,109		12,61,99,109	
Add:- issued during the year (Nos.)	-		-	
Closing equity shares outstanding (Nos.)		12,61,99,109		12,61,99,109
(iv) Weighted avg no. of shares outstanding (Nos.) (Basic)		12,61,99,109		12,61,99,109
(v) Weighted avg no. of shares outstanding (Nos.) (Diluted)		12,61,99,109		12,61,99,109
(vi) Nominal value of equity share (₹)		2.00		2.00
(vii) Basic EPS (i/iv) (₹)		15.42		7.38
(viii) Diluted EPS (i/v) (₹)		15.42		7.38

31. Disclosure in accordance with Ind AS – 17 “Leases”, of the Companies (Indian Accounting Standards) Rules, 2015.

- a) The Company has taken various residential/ godowns/ offices premises (including Furniture and Fittings if any) under leave and license agreements. These generally range between 11 months to 3 years under leave and license basis. These arrangements are renewable by mutual consent on mutually agreed terms. Under some of these arrangements the Company has given refundable security deposits. The lease payments are recognized in the Statement of Profit and Loss under Rent.
- b) The following operating lease payments are committed to be paid as under by subsidiaries :

(₹ Crores)		
	As at March 31, 2017	As at March 31, 2016
Expiring:		
Within one year	0.02	0.28
Between one and five years	0.91	0.85
Total	0.93	1.13

32. Segment Reporting**Disclosure as required by Ind AS 108 “Operating Segment”, of the Companies (Indian Accounting Standards) Rules, 2015.**

Based on the “management approach” as defined in Ind AS 108, the Chief Operating Decision Maker (CODM) evaluates the Company’s performance in accordance with Ind AS “Operating Segment”, the Company has only one reportable operating segment i.e. Pharmaceuticals.

Additional disclosure required as per Ind AS 108

(₹ Crores)		
Particulars	2016-17	2015-16
(i) The revenue from Geographical region		
India	1,594.92	1,398.75
Outside India	1,615.72	1,507.76
Total	3,210.64	2,906.51

Of the above, revenue from sales to United Kingdom amounts to ₹ 281.65 crores (previous year ₹ 285.72 crores)

The non-current assets attributable to any particular geographical segment is not material for disclosure.

- (ii) No single customer or customer group accounts for more than 10% of the revenue.

Notes to financial statements as at and for the year ended March 31, 2017

33. Disclosure in accordance with Ind AS - 24 "Related Party Disclosures", of the Companies (Indian Accounting Standards) Rules, 2015

A) List of related parties

Relationships	Country
(i) Entities where control exists	
Shareholders of Ipca Laboratories Ltd	
Kaygee Investments Pvt.Ltd.	India
(ii) Associates	
Trophic Wellness Pvt.Ltd.	India
Krebs Biochemicals & Industries Ltd.	India
(iii) Joint Venture	
Avik Pharmaceutical Ltd.	India
(iv) Key Management Personnel	
Mr. Premchand Godha	Chairman & Managing Director
Mr. Ajit Kumar Jain	Joint Managing Director & CFO
Mr. Pranay Godha	Executive Director
Mr. Prashant Godha	Executive Director
Mr. Babulal Jain	Independent Director
Mr. Anand T. Kusre	Independent Director
Mr. Dev Parkash Yadava	Independent Director
Dr. Ramakanta M. Panda	Independent Director
Mrs. Manisha Premnath	Independent Director
(v) Other Related Parties (Entities in which Directors or their relatives have significant influence)	
Nipra Industries Pvt.Ltd.	India
Nipra Packaging Pvt. Ltd.	India
Prabhat Foundation	India
Vandhara Resorts Pvt. Ltd.	India
Mexin Medicaments Pvt. Ltd.	India
Makers Laboratories Ltd.	India

Details of related party transaction are given in statement 1 attached to the financial statement.

34. CSR expenditure:

- a) Gross amount required to be spent by the Company during the year ₹ 7.14 crores (previous year ₹ 9.51 crores).
b) i) Amount spent by the Company during the year is as follows;

(₹ Crores)			
Particulars	Paid in cash	Yet to be paid in cash	Total
1 Eradication of poverty, promotion of healthcare, sanitation, drinking water etc.	0.38	-	0.38
2 Promotion of education, vocational training & skill enhancement etc.	3.67	-	3.67
3 Environmental sustainability, animal welfare, natural resource conservation etc.	0.01	-	0.01
4 Promoting of gender equality and empowering women	0.02	-	0.02
5 Promotion of rural sports	0.03	-	0.03
6 Rural development	0.17	-	0.17
Total	4.28	-	4.28

Notes to financial statements as at and for the year ended March 31, 2017

ii) Amount spent by the Company during the previous year is as follows;

		(₹ Crores)		
Particulars	Paid in cash	Yet to be paid in cash	Total	
1 Eradication of poverty, promotion of healthcare, sanitation, drinking water etc.	0.44	-	0.44	
2 Promotion of education, vocational training & skill enhancement etc.	4.08	-	4.08	
3 Environmental sustainability, animal welfare, natural resource conservation etc.	0.03	-	0.03	
4 Protection of national heritage, art, culture etc.	0.05	-	0.05	
5 Promotion of rural sports	0.06	-	0.06	
6 Rural development	0.14	-	0.14	
Total	4.80	-	4.80	

35. Contingent liabilities and Commitments

A) Contingent Liabilities

		(₹ Crores)	
Particulars	As at March 31, 2017	As at March 31, 2016	
Other moneys for which the Company is contingently liable for tax, excise, customs and other matters not accepted by the Company *	20.43	17.03	
Amount deposited under protest	(1.80)	(3.51)	
Claims against the Company not acknowledged as debts	13.25	13.22	
Corporate guarantee given to others	2.28	2.28	
Guarantees given by banks in favor of Govt. & others *	11.31	15.14	
Total	45.47	44.16	

*Note:- It includes ₹4.38 crores (Previous year ₹4.38 crores) towards interest and penalty demanded by excise department, Ankleshwar relating to erstwhile Tonira Pharma Limited since amalgamated with the Company and is not payable in accordance with the order passed by the Hon'ble Central Excise and Service Tax Appellate Tribunal (CESTAT), Ahmedabad. The Department had moved the Hon'ble Gujarat High Court against the said CESTAT order and as per the order of the said Hon'ble High Court, the Company has furnished a Bank Guarantee of ₹2.00 crores (Previous year ₹2.00 crores) to the Department.

B) Commitments

		(₹ Crores)	
Particulars	As at March 31, 2017	As at March 31, 2016	
(a) Estimated amount of contracts remaining to be executed on capital account and not provided for:			
Tangible Assets	15.46	41.08	
Intangible Assets	27.68	29.71	
	43.14	70.79	
(b) Uncalled liability on partly paid shares and other investment partly paid	-	3.40	
	-	3.40	
(c) Other Commitments			
Purchase orders backed by LC opened by bankers.	34.40	7.73	
	34.40	7.73	
Total	77.54	81.92	

36. Significant accounting judgments, estimates and assumptions

The financial statements require management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosures of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

a) Judgments

In the process of applying the company's accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognised in the separate financial statements.

b) Taxes

Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Significant management judgment is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

c) Defined benefit plans (gratuity benefits)

The cost of the defined benefit gratuity plan and the present value of the gratuity obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds in currencies consistent with the currencies of the post-employment benefit obligation. For plans operated outside India, the management considers the interest rates of high quality corporate bonds in currencies consistent with the currencies of the post-employment benefit obligation with at least an 'AA' rating or above, as set by an internationally acknowledged rating agency, and extrapolated as needed along the yield curve to correspond with the expected term of the defined benefit obligation. The underlying bonds are further reviewed for quality. Those having excessive credit spreads are excluded from the analysis of bonds on which the discount rate is based, on the basis that they do not represent high quality corporate bonds.

The mortality rate is based on publicly available mortality tables for the specific countries. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates for the respective countries.

37. First-time adoption of Ind AS

These financial statements, for the year ended March 31, 2017, are the first, the Company has prepared in accordance with Ind AS. For periods up to and including the year ended March 31, 2016, the Company prepared its financial statements in accordance with accounting standards notified under section 133 of the Companies Act, 2013 read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP).

Accordingly, the Company has prepared financial statements which comply with Ind AS applicable for periods ending on March 31, 2017, together with the comparative period data as at and for the year ended March 31, 2016, as described in the summary of significant accounting policies. In preparing these financial statements, the Company's opening balance sheet was prepared as at April 1, 2015, the Company's date of transition to Ind AS. This note explains the principal adjustments made by the Company in restating its previous GAAP financial statements, including the balance sheet as at April 1, 2015 and the financial statements as at and for the year ended March 31, 2016.

A Exemptions applied

Ind AS 101 allows first-time adopters certain exemptions from the retrospective application of certain requirements under Ind AS. The Company has applied the following exemptions:

- i) The Company has elected to apply the exemption for deemed cost of property, plant and equipment contained in D7AA of Ind AS 101 by considering the previous GAAP carrying values as deemed costs. Accordingly the Net block as at March 31, 2015 as per the previous GAAP have been considered as the deemed cost as at April 1, 2015 and are being depreciated over the residual useful life on a straight line basis.
- ii) Ind AS 101 permit cumulative translating gains and losses to be reset to zero at the transition date. This provides relief from determining cumulative currency translation difference in accordance with Ind AS 21.
- iii) The Company has designated unquoted equity instruments held at April 01, 2015 as fair value through P&L.

Notes to financial statements as at and for the year ended March 31, 2017

38. Reconciliation between previous GAAP and Ind AS

(₹ Crores)

A Effect of Ind AS adoption on the Balance Sheet as on March 31, 2016 and April 01, 2015

Particulars	Notes to first time adoption	As at 31st March, 2016 (End of Last Period presented under previous GAAP)			As at 1st April, 2015 (Date of Transition)		
		Previous GAAP	Effect of Transition to Ind AS	March 31, 2016	Previous GAAP	Effect of Transition to Ind AS	As per Ind AS Balance Sheet
ASSETS							
(1) Non-current assets							
(a) Property, plant and equipment		1,944.23	(2.34)	1,941.89	1,719.42	(2.46)	1,716.96
(b) Capital work-in-progress		93.80	(0.19)	93.61	236.29	(0.04)	236.25
(c) Goodwill on consolidation	xi	34.44	(10.85)	23.59	34.44	(10.85)	23.59
Goodwill on acquisition		15.12	8.49	23.61	23.61	-	23.61
(d) Other intangible assets		25.09	-	25.09	22.96	-	22.96
(e) Intangible assets under development		35.13	-	35.13	30.93	(0.27)	30.66
(f) Financial assets							
(i) Investments in subsidiary/ joint venture/ associate		21.77	4.00	25.77	12.81	3.56	16.37
(ii) Other investments	i	0.09	(0.04)	0.05	3.38	(0.50)	2.88
(iii) Loans	xii	80.20	(9.85)	70.35	60.98	(11.76)	49.22
(iv) Other financial assets		2.49	-	2.49	15.55	-	15.55
(g) Other non-current assets	xii	16.72	11.49	28.21	38.01	13.91	51.92
Total non-current assets		2,269.08	0.71	2,269.79	2,198.38	(8.41)	2,189.97
(2) Current assets							
(a) Inventories		843.70	(6.28)	837.42	926.56	(0.72)	925.84
(b) Financial assets							
(i) Investments		-	-	-	-	-	-
(ii) Trade receivables	ii	451.21	(5.34)	445.87	629.32	1.03	630.35
(iii) Cash and cash equivalents		169.80	(0.93)	168.87	140.33	(0.27)	140.06
(iv) Bank balances other than (iii) above		6.67	-	6.67	26.11	-	26.11
(v) Loans		1.75	-	1.75	6.88	(0.42)	6.46
(vi) Other financial assets		14.43	(0.14)	14.29	37.86	-	37.86
(c) Current tax assets (net)		-	-	-	-	-	-
(d) Other current assets	xii	144.14	2.91	147.05	164.89	3.22	168.11
Total current assets		1,631.70	(9.78)	1,621.92	1,931.95	2.84	1,934.79
Total assets		3,900.78	(9.07)	3,891.71	4,130.33	(5.57)	4,124.76
EQUITY AND LIABILITIES							
Equity							
(a) Equity share capital		25.24	-	25.24	25.24	-	25.24
(b) Other equity	xiii	2,258.57	(24.62)	2,233.95	2,183.19	(11.89)	2,171.30
Total equity		2,283.81	(24.62)	2,259.19	2,208.43	(11.89)	2,196.54
Liabilities							
(1) Non-current liabilities							
(a) Financial liabilities							
(i) Borrowings	v	488.29	(4.02)	484.27	503.21	(4.51)	498.70
(ii) Other financial liabilities		0.06	-	0.06	0.15	-	0.15
(b) Provisions		20.64	(0.42)	20.22	18.03	(0.37)	17.66
(c) Deferred tax liabilities (net)	vii	170.12	(13.66)	156.46	174.31	(15.90)	158.41
(d) Other non-current Liabilities		-	1.56	1.56	0.66	0.90	1.56
Total non-current liabilities		679.11	(16.54)	662.57	696.36	(19.88)	676.48

Notes to financial statements as at and for the year ended March 31, 2017

(2) Current liabilities							
(a) Financial liabilities							
(i) Borrowings	v	191.34	(6.49)	184.85	643.33	-	643.33
(ii) Trade payables		426.66	(5.55)	421.11	306.59	(0.63)	305.96
(iii) Other financial liabilities	v	252.87	(2.28)	250.59	173.78	(2.39)	171.39
(b) Other current liabilities		47.69	(0.78)	46.91	65.86	(0.41)	65.45
(c) Provisions	vi	15.01	47.21	62.22	25.67	29.66	55.33
(d) Current tax liabilities		4.29	(0.02)	4.27	10.31	(0.03)	10.28
Total current liabilities		937.86	32.09	969.95	1,225.54	26.20	1,251.74
Total liabilities		1,616.97	15.55	1,632.52	1,921.90	6.32	1,928.22
Total equity and liabilities		3,900.78	(9.07)	3,891.71	4,130.33	(5.57)	4,124.76

* The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

B Effect of Ind AS adoption on the Statement of Profit and Loss for the year ended March 31, 2016

(₹ Crores)

Particulars	Notes to first time adoption	Previous GAAP	Effect of Transition to Ind AS	2015-16
(I) Income				
Revenue from operations	vi & viii	2,883.28	23.23	2,906.51
Other income	xii	16.91	5.31	22.22
Total income		2,900.19	28.54	2,928.72
(II) Expenses				
Cost of materials consumed		904.49	(11.18)	893.31
Purchases of stock-in-trade		132.09	7.15	139.24
Change in inventories of work-in-progress, stock-in-trade and finished goods		21.14	4.71	25.85
Employee benefit expense	iii	626.96	(1.38)	625.58
Finance costs	v	29.85	2.06	31.91
Depreciation and amortisation expense	xi	172.21	(8.95)	163.26
Other expenses	xii	898.15	34.79	932.94
Total expenses		2,784.89	27.20	2,812.09
Profit before exceptional items and tax		115.30	1.34	116.64
Exceptional items		-	-	-
Profit before tax from continuing operations		115.30	1.34	116.64
Income tax expense				
- Current tax		22.75	(0.36)	22.39
- Deferred tax	vii	(4.18)	2.23	(1.95)
Total tax expense		18.57	1.87	20.44
Profit from continuing operations		96.73	(0.53)	96.20
Profit from discontinued operation		-	-	-
Share of (profits)/ loss from investments in associates and Joint ventures		3.46	(0.40)	3.06
Profit for the year		93.27	(0.13)	93.14
Other comprehensive income		-	(15.87)	(15.87)
Total comprehensive income		93.27	(16.00)	77.27

* The previous GAAP figures have been reclassified to conform to Ind AS presentation requirements for the purposes of this note.

Notes to financial statements as at and for the year ended March 31, 2017

C Reconciliation of total Equity as at March 31, 2016 and April 01, 2015

Particulars	Notes to first time adoption	March 31, 2016	April 01, 2015
Total equity (shareholder's funds) as per previous GAAP		2,283.81	2,208.43
Adjustments:			
FCTR transfer to retained earning	(iv)	0.42	-
Proposed dividend and tax on dividend	(x)	-	15.19
Exchange gain/ (loss)	(iv)	(0.90)	0.41
Depreciation and amortisation expense	(xi)	8.49	-
Effect of Ind AS 109		2.43	2.88
Effect of Ind AS 18	(vi)	(48.03)	(45.88)
Tax effects of adjustments	(vii)	13.66	15.88
Associate/JV share of profit due to Ind AS		(0.53)	(0.23)
Others		(0.16)	(0.14)
Total adjustments		(24.62)	(11.89)
Total equity as per Ind AS		2,259.19	2,196.54

D Notes to effect of first time adoption**i) FVTPL Financial assets**

Under Indian GAAP, the Company accounted for long term investments and mutual funds in unquoted and quoted equity shares as investment measured at cost less provision for other than temporary diminution in the value of investments. Under Ind AS, the Company has designated such investments other than investments in subsidiaries/ joint ventures and associates as FVTPL investments. Ind AS requires FVTPL investments to be measured at fair value. At the date of transition to Ind AS, difference between the instruments fair value and previous GAAP carrying amount has been recognised under retained earnings.

On account of this adjustment the retained earning increased by ₹ 0.46 crores as at March 31, 2016 and is decreased by ₹ 0.50 crores as at April 01, 2015.

ii) Trade Receivables

As per Ind AS 109, the Company is required to apply expected credit loss model for recognising the allowance for doubtful debts. As a result, the allowance for doubtful debts is ₹ (0.18) crores as at March 31, 2016 and ₹ 0.81 crores as at April 01, 2015.

iii) Defined benefit liabilities

Under Ind AS, re measurements i.e. actuarial gains and losses and the return on plan assets, excluding amounts included in the net interest expense on the net defined benefit liability are recognised in other comprehensive income instead of profit or loss. Accordingly ₹ (12.09) crores net of tax thereon has been adjusted in other comprehensive income from retained earnings as at April 01, 2015. The adjustment for the year ended March 31, 2016 is ₹ 1.36 crores net of the tax effect thereon. As a result of this change, the retained earnings as at April 01, 2015 and profit for the year ended March 31, 2016 has been adjusted. There is no impact on the total equity as at March 31, 2016.

iv) Foreign currency translation reserve

Under Indian GAAP, the Company recognised translation differences on foreign operations in a separate component of equity. Under Ind AS, the balance appearing in the foreign currency reserve has been reset to zero as at April 1, 2015 by transferring the same to retained earnings. Accordingly, foreign currency translation reserve balance under previous GAAP has been transferred to retained earnings. There is no impact on total equity as a result of this adjustment.

Notes to financial statements as at and for the year ended March 31, 2017

v) Borrowings

Ind AS 109 requires transaction costs incurred towards origination of borrowing to be deducted from carrying amount of borrowings on initial recognition. These cost are recognised in the profit and loss over the tenure of the borrowing as part of the interest expenses by applying the effective interest rate method.

Accordingly, the upfront fees has been amortised over the loan period as against charge to the profit and loss statement in the initial year. On account of this change, retained earnings as at April 01, 2015 has been increased by ₹ 3.22 crores with consequent adjustment of the upfront fees as prepaid expenses to be amortised over the period of the loan.

vi) Provisions for expiry, returns and breakage/damage.

The Company has estimated probable expiry, returns and breakage/ damage based on past trends and has made provision thereon as required by Ind AS 18 "Revenue recognition". On account of this change, the retained earnings as at April 01, 2015 has been decreased by ₹ 45.07 crores with consequent increase in provision. The impact for the year ended March 31, 2016 is ₹ 2.33 crores on the profit for the year with corresponding effect on the balance of provisions.

vii) Deferred tax

Consequent impact on deferred tax arising out of various adjustments under Ind AS has been given in accordance with Ind AS 12 "Income Taxes". On the date of transition the net impact of deferred tax is ₹ 15.88 crores which is adjusted against retained earnings. For the year ended March 31, 2016 the impact on profit arising out of deferred tax changes is ₹ 2.22 crores.

viii) Excise duty

Under Indian GAAP, sale of goods was presented as net of excise duty. However, under Ind AS, sale of goods includes excise duty. Excise duty on sale of goods is accounted as a cost under other expenses. Thus sale of goods under Ind AS has increased by ₹ 31.74 crores in March 2016 with a corresponding increase in other expense. There is no impact on total equity.

ix) Statement of cash flows

The transition from Indian GAAP to Ind AS has not had a material impact on the statement of cash flows.

x) Proposed Dividend

Under the previous GAAP, dividends proposed by the board of directors after the balance sheet date but before the approval of the financial statements were considered as adjusting events. Accordingly, provision for proposed dividend was recognised as a liability as at March 31, 2015. Under Ind AS, such dividends are recognised when the same is approved by the shareholders in the general meeting. Accordingly, the liability for proposed dividend of ₹ 12.62 crores and ₹ 2.57 crores tax liability as at March 31, 2015 has been reversed back to retained earnings. The same is charged to retained earnings during the year ended March 31, 2016 on approval by the shareholders. There is no impact on equity as at March 31, 2016.

xi) Goodwill

Under Ind AS goodwill on business acquisition is not required to be amortised but is to be tested for impairment. Accordingly, amortisation of goodwill during March 31, 2016 has been reversed and the goodwill is carried at April 01, 2015 values. On account of this, profit for the year March 31, 2016 is higher by ₹ 8.49 crores.

xii) Security deposits

Under the previous GAAP, interest free lease security deposits (that are refundable in cash on completion of the lease term) are recorded at their transaction value. Under Ind AS, all financial assets are required to be recognised at fair value. Accordingly, the group has fair valued these security deposits under Ind AS. Difference between the fair value and transaction value of the security deposit has been recognised as prepaid rent. Consequent to this change, the amount of security deposits increased by ₹ 0.80 crore as at March 31, 2016 and decreased by ₹ 18.45 crores as at April 01, 2015. The prepaid rent decreased by ₹ 1.76 crores as at March 31, 2016 and increased by ₹ 18.17 crores as at April 01, 2015. The net impact on retained earnings as at April 01, 2015 is decrease of ₹ 0.27 crore and the impact on profit for the year ended March 31, 2016 is decrease of ₹ 0.96 crore.

Notes to financial statements as at and for the year ended March 31, 2017**xiii) Retained earning**

Retained earnings as at April 1, 2015 has been adjusted consequent to the above Ind AS transition adjustments.

xiv) Joint Venture

Under the previous GAAP, as per AS 27 joint venture was accounted using proportionate consolidation method. However, as per Ind AS 28 the same is accounted using Equity method. For conversion to equity method share of net loss in the financial year 2014-15 of ₹ 1.75 crore of Avik Pharmaceuticals Limited (Joint venture) was reversed and revised net loss of ₹ 1.85 crore as per Ind AS was given effect in books of account. As a result of above effect the retained earnings reduced by ₹ 0.10 crores. During the financial year 2015-16 the IGAAP net profit of ₹ 0.71 crore was reversed and revised Ind AS profit of ₹ 0.60 crore was recorded using equity method, thus reducing net profit by ₹ 0.11 crore. The share of other comprehensive income of Avik Pharmaceutical Limited was ₹ 2.19 crores for the year 2015-16, the same was included in other comprehensive income of group, thus increasing equity of the group by ₹ 2.19 crores. The proportionate share of total assets of ₹ 8.16 crores for 2014-15 and ₹ 17.06 crores for 2015-16 and liabilities of ₹ 15.19 crores for 2014-15 and ₹ 23.09 crores for 2015-16 which were included in group assets were reversed for purpose of conversion to equity. Due to this, the assets of group were reduced by ₹ 8.16 crores and ₹ 17.06 crores and liabilities by ₹ 15.19 crores and ₹ 23.09 crores for the financial year 2014-15 and 2015-16 respectively. For the purpose of conversion to equity method, all inter group transactions with Avik Pharmaceuticals Limited which were previously eliminated were now reversed for the year 2014-15 and 2015-16.

xv) Associate

Under previous GAAP the share of Loss in associates during financial year 2015-16 was ₹ 3.46 crores which was revised to ₹ 3.64 crore due to transition effect of Ind AS. Due to this the net loss was increased by ₹ 0.18 crores.

39. Standards issued but not yet effective

In March 2017, the Ministry of Corporate Affairs issued the Companies (Indian Accounting Standards) (Amendments) Rules, 2017, notifying amendments to Ind AS 7, "Statement of cash flows" and Ind AS 102, "Share-based payment". These amendments are in accordance with the recent amendments made by International Accounting Standards Board (IASB) to IAS 7, "Statement of cash flows" and IFRS 2, "Share-based payment", respectively. The amendments are applicable to the group from April 1, 2017.

Amendment to Ind AS 7:

The amendment to Ind AS 7 requires the entities to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes, suggesting inclusion of a reconciliation between the opening and closing balances in the balance sheet for liabilities arising from financing activities, to meet the disclosure requirement.

The Company is currently evaluating the requirements of the amendment and has not yet determined the impact on the financial statements.

Amendment to Ind AS 102:

The amendment to Ind AS 102 provides specific guidance to measurement of cash-settled awards, modification of cash-settled awards and awards that include a net settlement feature in respect of withholding taxes.

It clarifies that the fair value of cash-settled awards is determined on a basis consistent with that used for equity-settled awards. Market-based performance conditions and non-vesting conditions are reflected in the 'fair values', but non-market performance conditions and service vesting conditions are reflected in the estimate of the number of awards expected to vest. Also, the amendment clarifies that if the terms and conditions of a cash-settled share-based payment transaction are modified with the result that it becomes an equity-settled share-based payment transaction, the transaction is accounted for as such from the date of the modification. Further, the amendment requires the award that include a net settlement feature in respect of withholding taxes to be treated as equity-settled in its entirety. The cash payment to the tax authority is treated as if it was part of an equity settlement.

The Company is currently evaluating the requirements of the amendment and has not yet determined the impact on the financial statements.

Notes to financial statements as at and for the year ended March 31, 2017

40. Financial Instruments

The carrying value and fair value of financial instruments by categories as at March 31, 2017, March 31, 2016 and April 1, 2015 is as follows:

Particulars	Carrying Value			Fair Value		
	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015	Mar 31, 2017	Mar 31, 2016	Apr 01, 2015
Financial assets						
Amortised Cost						
Investments						
- Equity Instruments	-	-	-	-	-	-
- Preference Shares	0.05	0.05	0.05	0.05	0.05	0.05
Loans	98.82	72.10	55.68	98.82	72.10	55.68
Others	19.95	13.46	32.84	19.95	13.46	32.84
Trade receivables	500.16	445.87	630.35	500.16	445.87	630.35
Cash and cash equivalents	35.85	175.54	166.17	35.85	175.54	166.17
FVTPL						
Equity Instruments	-	-	2.83	-	-	2.83
Mutual funds considered as Cash and cash equivalents	113.57	-	-	113.57	-	-
FVTOCI						
Derivative Assets	12.16	3.32	20.57	12.16	3.32	20.57
Total Financial Assets	780.56	710.34	908.49	780.56	710.34	908.49
Financial liabilities						
Amortised Cost						
Borrowings	529.04	669.12	1,142.03	529.04	669.12	1,142.03
Trade payables	457.67	421.11	305.96	457.67	421.11	305.96
Others	212.44	246.81	170.27	212.44	246.81	170.27
FVTOCI						
Derivative Liabilities	0.02	3.84	1.27	0.02	3.84	1.27
Total Financial Liabilities	1,199.17	1,340.88	1,619.53	1,199.17	1,340.88	1,619.53

The management assessed that fair value of cash and short-term deposits, trade receivables, trade payables, book overdrafts and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

41. Fair Value Hierarchy

This section explains the judgments and estimates made in determining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

Notes to financial statements as at and for the year ended March 31, 2017

(₹ Crores)

Particulars	Fair Value measurement using				
	Date of Valuation	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Financial assets measured at fair value					
Mutual funds - Growth plan	31/03/2017	113.57	-	-	113.57
Mutual funds - Dividend plan	31/03/2017	-	-	-	-
Derivatives designated as hedges	31/03/2017	-	12.16	-	12.16
Total financial assets		113.57	12.16	-	125.73
Financial liabilities					
Derivatives designated as hedges	31/03/2017	-	-	-	-
Derivative financial liabilities	31/03/2017	-	0.02	-	0.02
Total financial liabilities		-	0.02	-	0.02
Financial assets measured at fair value					
Listed Equity investments	31/03/2016	-	-	-	-
Derivative financial assets	31/03/2016	-	3.32	-	3.32
Total financial assets		-	3.32	-	3.32
Financial liabilities					
Derivative financial liabilities	31/03/2016	-	3.84	-	3.84
Total financial liabilities		-	3.84	-	3.84
Financial assets measured at fair value					
Listed Equity investments	01/04/2015	2.83	-	-	2.83
Derivative financial assets	01/04/2015	-	20.57	-	20.57
Total financial assets		2.83	20.57	-	23.40
Financial liabilities					
Derivative financial liabilities	01/04/2015	-	1.27	-	1.27
Total financial liabilities		-	1.27	-	1.27

42. Financial Risk Factors

The Company's business activities are exposed to a variety of financial risks: Market/Business risk, credit risk, Exchange risk, etc. The Company's focus is to foresee the unpredictability of financial and business risks and seek to minimize potential adverse effects of these risks on its business and financial performance.

(i) Business/Market Risk

The primary business/market risk to the Company is the price risk and its ability to pass on the same to its customers. The Company's operations extend to a number of countries across the globe and its products pricing competitiveness is a primary factor for the acceptability of Company's products in those markets. The Company has a robust procurement process, which ensures that its pricing power is not adversely affected by price changes in the market place for its raw-materials. The backward integration into manufacturing of several API's for its own use in the formulations manufacturing also works as a mitigating strategy for price risk faced by the Company. The other business risk is regulatory risk and regulatory audits of its manufacturing facilities by the regulators to ensure that the manufacturing facilities meet the current Good Manufacturing Practices (cGMP) requirements. The Company is already exposed to certain audit observations from the US FDA for 3 of its manufacturing plants and has taken the necessary corrective measures to redress those US FDA audit observations so as to be able to market all its products once again in the US market. While the stringent regulatory requirements and audits works as a business risk, the successful audit of its facilities by regulators coupled with price competitiveness results in higher business and margins for the Company. The Company's products are also subjected to product liability claims/litigations. To mitigate these risks, the Company has obtained adequate Product Liability Insurance.

Notes to financial statements as at and for the year ended March 31, 2017

The Company, however, has a reduced risk from dependence on any single customer as no single customer or customer group accounts for more than 10% of Company's annual revenue. The Company also continuously forays into different markets/countries to reduce its dependence on any particular country or customer group. The Company also has a diversified therapeutic product portfolio and therefore no single product account for more than 10% of Company's annual revenue.

(ii) Credit Risk

The Company has exposure to credit risks associated with sales to various developing markets/countries. To mitigate these credit risks arising out of this, the Company obtains credit insurance on a regular basis after evaluating the credit risk associated with a country/customer. Country/customer where no credit insurance is available, the Company monitors such risk by continuously monitoring its exposure to such country/customer. There was no historically significant credit risk in the domestic market for the Company. Based on the historical data, the Company has made adequate provisions for expected loss because of credit risk, which is neither significant nor material.

(iii) Interest Risk

The Company has borrowings mainly in foreign currencies which is linked to Libor. The Company mitigates these risks associated with floating Libor rates by entering into interest rate swaps to move them to fixed Libor rates. The domestic interest risk is exposed to the changes in the RBI bank rate. The Company manages this risk by managing its working capital effectively.

(iv) Foreign Currency Risk

The company continuously manages its risks associated with foreign currency by adopting various hedging strategies in consultation with internal and external experts. The Company has a system of regularly monitoring its currency wise exposures. The significant part of Company's receivables and borrowings are in US Dollars which operates as a natural hedge against each other. The Company has a policy not to borrow in a currency where it has no business exposure.

(v) The unhedged foreign currency exposure is as follows:

Particulars	Currency	Mar 31, 2017	Mar 31, 2017	Mar 31, 2016	Mar 31, 2016
		Amount in foreign currency (in millions)	Amount (₹ in crores)	Amount in foreign currency (in millions)	Amount (₹ in crores)
I) Unhedged foreign exchange liability					
a. ECB Term Loan & Interest	USD	72.91	472.86	90.28	598.22
b. Buyers Credit & Interest	USD	7.01	45.43	8.67	57.44
	EURO	2.64	18.27	2.86	21.56
c. Packing Credit & Interest	USD	1.00	6.49	6.24	41.37
	AUD	3.47	17.23	-	-
	GBP	2.00	16.19	-	-
d. FCNR Working Capital Loan	USD	-	-	10.01	66.36
e. Trade & Other Payables	USD	14.92	96.74	12.58	83.40
	EURO	0.09	0.65	0.22	1.69
	GBP	0.89	7.22	0.01	0.09
	NZD	0.00	0.01	-	-
	AUD	-	-	0.01	0.05
	JPY	0.14	0.01	-	-
	CAD	-	-	0.06	0.31
II) Unhedged receivables in foreign currency					
a. Trade & Other receivables	USD	41.71	270.51	37.94	251.38
	EURO	5.03	34.88	3.42	25.79
	GBP	4.43	35.87	3.06	29.20
	AUD	1.50	7.44	0.96	4.86
	CAD	0.44	2.15	0.62	3.15
	NZD	0.64	2.92	0.99	4.54
	COP	649.63	1.46	954.77	2.10
b. Unbilled Revenue	USD	1.79	11.59	0.65	4.30
	CAD	0.04	0.27	-	-

Notes to financial statements as at and for the year ended March 31, 2017

- III) The Company has entered into various derivatives transactions, which are not intended for trading or speculative purpose but to hedge the export receivables including future receivables and foreign currency loan interest rate risks. The Company has following derivatives instruments/ forward cover outstanding.

Type of transaction	Purpose	Amount Outstanding in millions	
		Mar 31, 2017	Mar 31, 2016
a. USD interest rate swap	To hedge the USD LIBOR risk by moving from Floating LIBOR rate to Fixed LIBOR Rate.	USD 49.20 Notional O/s	USD 68.38 O/s
b. Forward cover beyond six months	To hedge export receivables	STG 2.00	Nil

43. Capital Management

For the purpose of the Company's capital management, capital includes paid-up equity share capital, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Company's capital management is to maximise the shareholders' value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust its dividend payment ratio to shareholders, return capital to shareholders or issue fresh shares. The Company monitors capital using a gearing ratio, which is net debt divided by its total capital. The Company includes within its net debt the interest bearing loans and borrowings, trade and other payables less cash and cash equivalents.

Particulars	(₹ Crores)		
	As at Mar 31, 2017	As at Mar 31, 2016	As at April 01, 2015
Borrowings other than convertible preference shares	529.04	669.12	1,142.03
Trade payables	457.67	421.11	305.96
Other payables	212.46	250.65	171.54
Less: Cash and Cash Equivalents (C&CE)	(35.85)	(175.54)	(166.17)
Less: Investment in MF (part of C&CE)	(113.57)	-	-
Net debt	1,049.75	1,165.34	1,453.36
Total Equity	2,455.26	2,259.19	2,196.54
Capital and net debt	-	-	-
Gearing ratio	42.76%	51.58%	66.17%

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets the financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the lending institutions to immediately call back the loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

No changes were made in the objectives, policies or processes for managing the capital during the years ended March 31, 2017 and March 31, 2016.

44. Disclosure under Schedule III of the Companies Act, 2013 relating to consolidated financial statements are given in Statement 2 attached to the financial statements.
45. The figures of the subsidiaries including the step down subsidiaries are appropriately grouped along with the figures of the parent Ipca Laboratories Limited.
46. The Balance Sheet, Statement of Profit and Loss, Cash Flow Statement, Statement of change in equity, Statement of Significant accounting policies and the other explanatory notes forms an integral part of the financial statements of the Company for the year ended March 31, 2017.

As per our report of even date attached

For **Natvarlal Vepari & Co.**

Chartered Accountants

Firm Registration No. 106971W

N. Jayendran

Partner

M.No. 40441

Mumbai,

28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director (DIN 00012691)

Ajit Kumar Jain

Joint Managing Director & CFO (DIN 00012657)

Prashant Godha

Executive Director (DIN 00012759)

Harish P. Kamath

Company Secretary (ACS - 6792)

Statement 1 (refer Note No. 33)

Related Party Disclosure as required by Indian Accounting Standard – Ind AS 24 "Related Party Transactions" of the Companies (Indian Accounting Standards) Rule 2015.

Transactions with Related Parties

(₹ Crores)

Description	Key Management Personnel		Associates		Joint Venture		Other Related Parties		Total	
	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16
Purchase of goods and services										
Makers Laboratories Ltd.	-	-	-	-	-	-	8.18	13.12	8.18	13.12
Avik Pharmaceutical Ltd.	-	-	-	-	18.02	17.31	-	-	18.02	17.31
Krebs Biochemicals & Industries Limited	-	-	5.87	4.15	-	-	-	-	5.87	4.15
Others	-	-	-	-	-	-	5.76	5.51	5.76	5.51
TOTAL	-	-	5.87	4.15	18.02	17.31	13.94	18.63	37.83	40.09
Sales of goods and services										
Makers Laboratories Ltd.	-	-	-	-	-	-	2.52	2.24	2.52	2.24
Trophic Wellness Pvt. Ltd.	-	-	0.59	0.60	-	-	-	-	0.59	0.60
Avik Pharmaceutical Ltd.	-	-	-	-	0.81	16.07	-	-	0.81	16.07
Others	-	-	-	-	-	-	-	0.15	-	0.15
TOTAL	-	-	0.59	0.60	0.81	16.07	2.52	2.39	3.92	19.06
Rent income										
Avik Pharmaceutical Ltd.	-	-	-	-	0.41	0.46	-	-	0.41	0.46
Trophic Wellness Pvt. Ltd.	-	-	0.13	0.04	-	-	-	-	0.13	0.04
TOTAL	-	-	0.13	0.04	0.41	0.46	-	-	0.54	0.50
Interest income										
Avik Pharmaceutical Ltd.	-	-	-	-	1.78	1.58	-	-	1.78	1.58
Krebs Biochemicals & Industries Limited	-	-	6.20	4.01	-	-	-	-	6.20	4.01
TOTAL	-	-	6.20	4.01	1.78	1.58	-	-	7.98	5.59
Purchase of fixed assets										
Makers Laboratories Ltd.	-	-	-	-	-	-	-	0.06	-	0.06
TOTAL	-	-	-	-	-	-	-	0.06	-	0.06
Sale of fixed assets										
Trophic Wellness Pvt. Ltd.	-	-	0.33	-	-	-	-	-	0.33	-
Others	-	-	-	-	-	-	-	-	-	-
TOTAL	-	-	0.33	-	-	-	-	-	0.33	-
Rent and other expenses										
Avik Pharmaceutical Ltd.	-	-	-	-	(0.02)	(0.25)	-	-	(0.02)	(0.25)
Krebs Biochemicals & Industries Limited	-	-	5.58	5.23	-	-	-	-	5.58	5.23
Others	-	-	0.02	-	-	-	0.20	0.21	0.22	0.21
TOTAL	-	-	5.60	5.23	(0.02)	(0.25)	0.20	0.21	5.78	5.19
Excise duty Reimbursements										
Makers Laboratories Ltd.	-	-	-	-	-	-	0.65	0.30	0.65	0.30
Avik Pharmaceutical Ltd.	-	-	-	-	0.65	(0.68)	-	-	0.65	(0.68)
Krebs Biochemicals & Industries Limited	-	-	(0.75)	(0.51)	-	-	-	-	(0.75)	(0.51)
TOTAL	-	-	(0.75)	(0.51)	0.65	(0.68)	0.65	0.30	0.55	(0.89)
Net loans and advances given/(Recovered)										
Avik Pharmaceutical Ltd.	-	-	-	-	-	1.87	-	-	-	1.87
Krebs Biochemicals & Industries Limited	-	-	23.57	16.23	-	-	-	-	23.57	16.23
TOTAL	-	-	23.57	16.23	-	1.87	-	-	23.57	18.10
Deposit given										
Krebs Biochemicals & Industries Limited	-	-	-	5.56	-	-	-	-	-	5.56
TOTAL	-	-	-	5.56	-	-	-	-	-	5.56
Investments made										
Trophic Wellness Pvt. Ltd.	-	-	3.40	-	-	-	-	-	3.40	-
Krebs Biochemicals & Industries Limited	-	-	-	12.42	-	-	-	-	-	12.42
TOTAL	-	-	3.40	12.42	-	-	-	-	3.40	12.42

Notes to financial statements as at and for the year ended March 31, 2017

(₹ Crores)

Description	Key Management Personnel		Associates		Joint Venture		Other Related Parties		Total	
	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16	2016-17	2015-16
Remuneration to Directors										
Mr. Premchand Godha	5.21	4.48	-	-	-	-	-	-	5.21	4.48
Mr. Ajit Kumar Jain	2.56	2.32	-	-	-	-	-	-	2.56	2.32
Mr. Pranay Godha	1.19	1.11	-	-	-	-	-	-	1.19	1.11
Mr. Prashant Godha	1.08	0.76	-	-	-	-	-	-	1.08	0.76
TOTAL	10.04	8.67	-	-	-	-	-	-	10.04	8.67
Provident Fund to Directors										
Mr. Premchand Godha	0.44	0.40	-	-	-	-	-	-	0.44	0.40
Mr. Ajit Kumar Jain	0.16	0.14	-	-	-	-	-	-	0.16	0.14
Mr. Pranay Godha	0.08	0.07	-	-	-	-	-	-	0.08	0.07
Mr. Prashant Godha	0.07	0.05	-	-	-	-	-	-	0.07	0.05
TOTAL	0.75	0.66	-	-	-	-	-	-	0.75	0.66
Post employment benefits of Directors										
Mr. Ajit Kumar Jain	0.23	0.19	-	-	-	-	-	-	0.23	0.19
Mr. Pranay Godha	0.09	0.03	-	-	-	-	-	-	0.09	0.03
Mr. Prashant Godha	0.09	0.02	-	-	-	-	-	-	0.09	0.02
TOTAL	0.41	0.24	-	-	-	-	-	-	0.41	0.24
Sitting Fee to Non-executive Directors										
Mr. Anand T Kusre	0.05	0.05	-	-	-	-	-	-	0.05	0.05
Mr. Babulal Jain	0.05	0.06	-	-	-	-	-	-	0.05	0.06
Mr. Dev Prakash Yadava	0.05	0.06	-	-	-	-	-	-	0.05	0.06
Mrs. Manisha Premnath	0.02	0.02	-	-	-	-	-	-	0.02	0.02
Dr. Ramakanta M. Panda	0.02	0.03	-	-	-	-	-	-	0.02	0.03
TOTAL	0.19	0.22	-	-	-	-	-	-	0.19	0.22
Donation										
Prabhat Foundation	-	-	-	-	-	-	-	0.15	-	0.15
TOTAL	-	-	-	-	-	-	-	0.15	-	0.15
Balance at year end										
Receivables										
Avik Pharmaceutical Ltd.	-	-	-	-	15.18	17.74	-	-	15.18	17.74
Krebs Biochemicals & Industries Limited	-	-	56.69	58.06	-	-	-	-	56.69	58.06
Others	-	-	0.50	-	-	-	-	-	0.50	-
TOTAL	-	-	57.19	58.06	15.18	17.74	-	-	72.37	75.80
Payables										
Mr. Premchand Godha	0.89	0.51	-	-	-	-	-	-	0.89	0.51
Makers Laboratories Ltd.	-	-	-	-	-	-	1.89	5.22	1.89	5.22
Others	0.64	1.04	-	-	-	-	0.84	1.03	1.48	2.07
TOTAL	1.53	1.55	-	-	-	-	2.73	6.25	4.26	7.80

Statement 2 (refer Note No. 44)
Disclosure under Schedule III of the Companies Act, 2013 relating to consolidated financial statements.

Name of the entity in the	2016-17						2015-16						(₹ crores)					
	Net Assets, i.e. total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income		Share in total comprehensive income		Net Assets, i.e. total assets minus total liabilities		Share in profit or (loss)				Share in other comprehensive income		Share in total comprehensive income	
	As % of consolidated net assets	Amount	As % of consolidated profit or (loss)	Amount	As % of consolidated profit or (loss)	Amount	As % of consolidated profit or (loss)	Amount	As % of consolidated net assets	Amount	As % of consolidated profit or (loss)	Amount			As % of consolidated profit or (loss)	Amount	As % of consolidated profit or (loss)	Amount
Parent - Ipca Laboratories Limited	100.33	2,463.43	93.43	181.76	246.64	3.78	94.63	185.54	100.83	2,277.81	92.40	86.06	100.13	(15.89)	90.81	70.17		
Subsidiaries in India - Tonira Export Limited	-	0.02	(0.01)	(0.01)	-	-	(0.01)	(0.01)	-	0.03	0.01	0.01	-	-	0.01	0.01		
Subsidiaries out of India - Ipca Pharmaceuticals, Inc , USA	(0.29)	(7.06)	(2.16)	(4.21)	(11.74)	(0.18)	(2.24)	(4.39)	(0.12)	(2.67)	1.02	0.95	-	-	1.23	0.95		
- Ipca Laboratories (UK) Ltd.	(0.03)	(0.68)	7.31	14.23	(153.99)	(2.36)	6.05	11.87	(0.56)	(12.56)	7.66	7.13	-	-	9.23	7.13		
- Ipca Pharma (Australia) Pty. Ltd.	-	0.09	0.07	0.13	(1.30)	(0.02)	0.06	0.11	-	(0.03)	(0.07)	(0.06)	-	-	(0.08)	(0.06)		
- Ipca Pharma Nigeria Ltd.	0.52	12.84	5.62	10.93	(63.29)	(0.97)	5.08	9.96	0.13	2.90	2.90	2.70	-	-	3.49	2.70		
- Ipca Pharmaceuticals (Shanghai) Ltd.	-	-	-	-	-	-	-	-	-	-	0.07	0.06	-	-	0.08	0.06		
- Ipca Pharmaceuticals Ltd SA de CV , Mexico	(0.05)	(1.11)	(0.02)	(0.04)	(0.54)	(0.01)	(0.02)	(0.04)	(0.05)	(1.06)	(0.03)	(0.03)	-	-	(0.04)	(0.03)		
- National Druggists (Pty) Ltd, South Africa	-	-	-	-	-	-	-	-	-	0.05	(0.79)	(0.74)	-	-	(0.96)	(0.74)		
Associates (Investment as per the equity method)																		
Indian																		
- Trophic Wellness Pvt. Ltd.	0.20	4.89	(1.38)	(2.69)	0.06	-	(1.37)	(2.69)	0.34	7.59	1.60	1.49	-	-	1.92	1.49		
- Krebs Biochemicals & Industries Limited	(0.40)	(9.72)	(2.46)	(4.79)	88.09	1.35	(1.75)	(3.44)	(0.28)	(6.28)	(5.50)	(5.12)	-	-	(6.63)	(5.12)		
- Avik Pharmaceutical Ltd.	(0.31)	(7.49)	(0.40)	(0.77)	(3.91)	(0.06)	(0.42)	(0.83)	(0.29)	(6.66)	0.75	0.69	(0.13)	0.02	0.93	0.71		
Grand Total	100.00	2455.21	100.00	194.54	100.00	1.53	100.00	196.08	100.00	2259.13	100.00	93.14	100.00	(15.87)	100.00	77.27		

Form AOC-I

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures as at March 31, 2017

Part "A": Subsidiaries

Sr. No	Name of Subsidiary Company	Reporting Currency	Share Capital	Reserves & Surplus	Total Assets	Total Liabilities	Investments	Total Income/ Turnover	Profit/ (Loss) Before Taxation	Provision for Taxation	Profit After Taxation	Proposed Dividend	% of Shareholding
1	Ipca Pharma Nigeria Ltd., Nigeria	Nigerian Naira	188.94	178.30	1,131.33	1,131.33	-	1,488.14	(121.57)	5.11	(126.68)	-	100%
2	Ipca Pharmaceuticals, Inc. USA	USD	920.20	(213.12)	724.17	724.17	-	504.40	83.41	-	83.41	-	100%
3	Ipca Pharmaceuticals Ltd. SA de CV, Mexico	Mexican Peso	115.15	(110.48)	17.15	17.15	-	-	(3.56)	-	(3.56)	-	100%
4	Ipca Pharma (Australia) Pty. Ltd., Australia	Aus \$	12.98	53.86	76.38	76.38	-	49.25	17.26	(4.49)	12.77	-	100%
5	Ipca Pharma (NZ) Pty. Ltd., New Zealand	Aus \$	0.04	-	1.35	1.35	-	-	(0.02)	-	(0.02)	-	100%
6	Ipca Laboratories (UK) Ltd., UK	STG £	4,627.91	(556.90)	4,854.14	4,854.14	-	637.94	567.26	5.42	561.84	-	100%
7	Onyx Scientific Ltd., UK	STG £	249.63	2,646.36	3,877.29	3,877.29	-	4,936.16	830.45	(253.89)	1,084.34	-	100%
8	Tonira Exports Limited	INR	10.00	(5.49)	15.42	15.42	-	1.73	1.32	0.19	1.13	-	100%

1. Financial reporting period of all subsidiaries is March 31.

2. Exchange rate considered as on March 31 2017: 1 USD = ₹ 64.7236, 1 STG £ = ₹ 80.81772, 1 N (Nigerian Naira) = ₹ 0.2059, 1 Aus \$ = ₹ 49.4751, 1 MXN (Mexican Peso) = ₹ 3.4552.

3. The Company owns 100% interest in all the above subsidiaries.

4. Ipca Pharma (NZ) Pty. Ltd., New Zealand is a 100% subsidiary of Ipca Pharma (Australia) Pty. Ltd.

5. Onyx Scientific Ltd., UK is a wholly owned subsidiary of Ipca Laboratories (UK) Ltd., UK.

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director

Ajit Kumar Jain

Joint Managing Director

Prashant Godha

Executive Director

Harish P. Kamath

Company Secretary

Mumbai,

28th May, 2017

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

PARTICULARS	ASSOCIATE				JOINT VENTURE
	Name of Associate/ Joint Venture	Trophic Wellness Pvt. Ltd.	* CCPL Software Pvt. Ltd.	Krebs Biochemicals & Industries Ltd.	Avik Pharmaceutical Ltd.
1. Latest Audited Balance Sheet Date		March 31, 2017	-	March 31, 2017	March 31, 2017
2. Shares of the Associate/ Joint Venture held by Ipca Laboratories Limited as at 31 st March, 2017					
- Number of Shares		7,80,000	55,000	41,00,100	5,00,000
- Amount of Investment in Associates/ Joint Venture		₹ 1234 Lacs	*	₹ 2196 Lacs	₹ 651 Lacs
- Extent of Holding %		19.26 %	28.95 %	29.83%	49%
3. Description of how there is Significant Influence		Company promoted and managed with other promoters	Percentage of shareholding	Company under joint management control	Significant shareholding and joint management control
4. Reason why the associate/joint venture is not consolidated		-	-	-	-
5. Net worth attributable to Shareholding as per latest audited Balance Sheet		₹ 1016.30 Lacs	-	₹ 44.06 Lacs	(₹ 356.41 Lacs)
6. Profit/ (Loss) for the Year					
i. considered in consolidation		(₹ 269.43 Lacs)	*	(₹ 344 Lacs)	(₹ 83.73 Lacs)
ii. not considered in consolidation		-	-	-	-

* cost fully written off in books. No effect of share of loss/ profit from CCPL Software Pvt. Ltd. is taken since 01.04.2004, as the Company has no further commitment towards its share either of loss/ profit in this company.

Mumbai,

28th May, 2017

For and on behalf of the Board of Directors

Premchand Godha

Chairman & Managing Director

Ajit Kumar Jain

Joint Managing Director

Prashant Godha

Executive Director

Harish P. Kamath

Company Secretary

Notes

Notes

Ipca Laboratories Limited

Regd Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067; Phone: 022-6647 4444, Fax: 022-2868 6613
CIN: L24239MH1949PLC007837; Email: investors@ipca.com ; Website: www.ipca.com

**ATTENDANCE SLIP****67th ANNUAL GENERAL MEETING ON FRIDAY, 4TH AUGUST, 2017 AT 3.30 P.M.**

Folio/D.P. & Client I.D. No. :
Name :
Address :
Joint Holder (s) :
No. of Equity shares held :

I/ We hereby record my/ our presence at the 67TH ANNUAL GENERAL MEETING of the Company at Shri Bhaidas Maganlal Sabhagriha, Swami Bhaktivedanta Marg, J.V.P.D. Scheme, Vile Parle (W), Mumbai - 400056 on Friday, 4th August, 2017 at 3.30 p.m.

Member's/Proxy's name in Block Letters

Member's/Proxy's Signature

NOTE: Please complete and sign this Attendance Slip and hand it over at the attendance verification counter at the entrance of the meeting hall.

Ipca Laboratories Limited

Regd Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067; Phone: 022-6647 4444, Fax: 022-2868 6613
CIN: L24239MH1949PLC007837; Email: investors@ipca.com; Website: www.ipca.com

FORM NO. MGT -11
PROXY FORM

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the member (s) :
Registered address :
No. of Shares held :
Folio No/ DP Id & Client Id :
E-mail Id :

I/We being a member(s) of shares of the above named company hereby appoint:

1. Name Address
Email Id Signature or failing him;

2. Name Address
Email Id Signature or failing him;

3. Name Address
Email Id Signature

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 67th Annual General Meeting of the company to be held at Shri Bhaidas Maganlal Sabhagriha, Swami Bhaktivedanta Marg, J.V.P.D. Scheme, Vile Parle (W), Mumbai - 400056 on Friday, 4th August, 2017 at 3.30 p.m. and at any adjournment thereof in respect of such resolutions as are indicated below:

Item No.	Resolution	No. of Shares	I/We assent to the Resolution (FOR)	I/We dissent the Resolution (AGAINST)
Ordinary Business:				
1.	a) Adoption of Audited Financial Statements for the financial year ended 31 st March, 2017, Reports of the Board of Directors and Auditors thereon			
	b) Adoption of Audited Consolidated Financial Statements for the financial year ended on 31 st March, 2017 and Report of the Auditors thereon			
2.	Declaration of dividend on equity shares			
3.	Re-appointment of Mr. Prashant Godha (DIN 00012759), who retires by rotation, as a Director.			
4.	Re-appointment of Mr. Premchand Godha (DIN 00012691), who retires by rotation, as a Director.			
5.	Appointment of Auditors and fixing their remuneration.			
Special Business:				
6.	Remuneration payable to Cost Auditors.			

Signature of shareholder(s) Signed this day of, 2017

Signature of Proxy holder

Note:

- This form of proxy in order to be effective, should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.
- For the Resolutions, Explanatory Statement and Notes, please refer to the Notice of the 67th Annual General Meeting.



Ipcalaboratories Limited

Information as per Section 197 of the Companies Act 2013 and forming part of the Directors Report for the year ended 31st March, 2017

SR. NO.	NAME OF THE EMPLOYEE	DESIGNATION	AGE (YEARS)	QUALIFICATION	DATE OF JOINING	REMUNERATION [₹]	% OF EQUITY SHARES HELD	EXPERIENCE [YEARS]	LAST EMPLOYMENT HELD BEFORE JOINING THE COMPANY	PERIOD OF LAST EMPLOYMENT [YEARS]
A EMPLOYED THROUGHOUT THE YEAR										
1	Mr. Premchand Godha	Chairman & Managing Director	69	B.COM, A.C.A.	31/10/1975	5,19,83,775	2.13	44	Professional Practice	-
2	Mr. Ajit Kumar Jain	Jt. Managing Director	61	B.Sc, A.C.A.	02/04/1980	2,65,31,834	0.05	36	Industrial Oxygen Co. Pvt. Ltd. - Management Accountant	1
3	Mr. Pranay Godha	Executive Director	44	B SC, MBA	16/04/2003	1,22,46,944	0.65	19	-	-
4	Mr. Prashant Godha	Executive Director	42	B.COM, PGDBM	16/08/2011	1,15,48,209	0.60	18	Makers Laboratories Limited. - Executive Director	12
5	Dr. Sanjay U Kapadia	President - Corporate Quality Assurance	55	M.SC, PHD	10/08/2015	1,78,86,591	-	32	Apotex Research Pvt Ltd. - Head - Quality & Compliance	11
6	Mr. Jeevanlal Nagori	President - Projects	56	B.COM, A.C.A.	27/09/1983	1,58,71,077	0.05	33	Win Laboratories Pvt. Ltd. - Finance Manager	6
7	Dr. Anil Kumar Pareek	President - Medical Affairs & Clinical Research	60	MBBS, MD	11/09/2000	1,37,48,050	0.01	28	Biological E. Ltd. - VP - Medical Services	9
8	Mr. N Guhaprasad	President - International Marketing	53	B.SC, B.S.C (TECH), MMS	04/05/2005	1,21,92,080	0.04	28	Wockhardt Ltd - VP - Pharma Business	1
9	Dr. Ashok Kumar	President - R&D (Chemicals)	63	M.SC, PHD	06/09/2000	1,17,01,881	0.04	34	Lupin Lab. Ltd. - Deputy Director	6
10	Mr. Pabitra Kumar Bhattacharya	President - Operations (API)	48	B SC, B TECH (CHEM)	23/05/2013	1,01,39,113	-	23	Sun Pharma - VP - API Operations & Process Engineering	19
B EMPLOYED FOR THE PART OF THE YEAR										
1	Dr. R Buchi Reddy	Executive Vice President- R&D (Chemicals)	59	M.SC PH D PGDIPR	21/01/2014	69,51,807	-	28	Orchid Pharma - Executive Vice President R & D	25
2	Dr. Goutam Muhuri	President - R&D (Formulations)	58	M PHARM, PGDBM PHD	01/02/2017	38,70,945	-	33	Aviva Biopharma	1
3	Mr. Vishnu Saran Singh Kushwaha	Vice President - Technical	50	M PHARM, MFA, LLB	22/06/2000	38,35,351	-	25	Lyka Labs Ltd.	1
4	Mr. Kamal S Mehta	Sr. Vice President - R&D (Formulations)	46	M PHARM	02/03/2015	27,64,077	-	22	Glenmark Pharma Ltd. - VP Formulations Development	20



Notes:

1. All the employees have adequate experience to discharge the responsibilities assigned to them.
2. Nature of employment is contractual for all employees.
3. Except Mr. Premchand Godha, Mr. Pranay Godha and Mr. Prashant Godha, Directors who are related to each other, none of the other employees are related to any Director of the company.
4. Remuneration includes Salary, Commission, Allowances, Leave Travel Assistance, Ex-Gratia, Leave Encashment, Medical Reimbursement, Gratuity, Company's contribution to the employees' Provident Fund, National pension scheme, Family Pension Fund and Superannuation Funds.
5. Perquisites are valued as per Income Tax Rules.


Mumbai
28th May, 2017

For and on behalf of the Board
Premchand Godha
Chairman & Managing Director


Total Income 2016-17 ₹ 3,178.87 Crores




Domestic Income 2016-17 ₹ 1,617.13 Crores




Continent Wise Exports (%)



Export Income 2016-17 ₹ 1,561.74 Crores



Distribution of Shareholding as on 31st March, 2017



International Subsidiaries

Australia

Ipca Pharma (Australia) Pty. Ltd.
6, Morotai Avenue, Ashburton
VIC 3147, Melbourne, Australia
T: + 613 98856172
F: + 613 98856173
E: ipca.australia@ipca.com

Nigeria

Ipca Pharma Nigeria Ltd.
17, Osolo Way, Ajao Estate
Isolo, Lagos, Nigeria
T: + 2341 7926460 / 4528738
F: + 2341 4521146
E: ipca.nigeria@ipca.com

UK

Onyx Scientific Ltd.
Silverbriar
Sunderland Enterprise Park East
Sunderland SR5 2TQ, UK
T: + 44 191 516 6 516
F: + 44 191 516 6 526
E: info@onyxipca.com

Mexico

Ipca Pharmaceuticals Ltd. SA de CV
Presa La Angostura 116, Colonia Irrigación
Delegación Miguel Hidalgo, C. P. 11500
Alvaro Obregon, Mexico D. F.
T: + 52 55 53952590
E: ipca.mexico@ipca.com

UK

Ipca Laboratories (UK) Ltd.
Units 97-98, Silverbriar
Sunderland Enterprise Park East
Sunderland SR5 2TQ, UK
T: + 44 191 516 6 517
F: + 44 191 516 6 526
E: ipca.uk@ipca.com

USA

Ipca Pharmaceuticals, Inc.
51, Cragwood Road, Suite No. 307
South Plainfield, NJ 07080, USA
T: + 1 908 412 6561/63
F: + 1 908 412 6564
E: ipca.usa@ipca.com

New Zealand

Ipca Pharma (NZ) Pty. Ltd.
3-A, St. Oswalds Road
Greenlane
Auckland 1061, New Zealand
T: + 64 2136 0880
E: ipca.newzealand@ipca.com



Ipca Laboratories Ltd.

www.ipca.com

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India

T: +91 22 6647 4444 F: +91 22 2868 6613 E: investors@ipca.com

CIN: L24239MH1949PLC007837